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ABSTRACT 
Annexin 1 (ANXA1) is an important mediator of the regulatory effects of 
glucocorticoids (GCs) within the neuroendocrine and host defence systems.  Recent 
data suggest that it acts via a formyl peptide receptor (FPR) as a mediator of the 
negative feedback effects of GCs on adrenocorticotrophic hormone (ACTH) release.  
In the present study, in vitro and in vivo methods were used to detect and explore 
further the function of these receptors within the hypothalamo-pituitary-adrenocortical 
(HPA) axis.  Lipopolysaccharide (LPS), given intra-peritoneally (i.p.) or centrally 
(i.c.v.), increased expression of mRNAs for ANXA1 and Fpr1, Fpr2 and Fpr3 in the 
spleen, pituitary and adrenal gland, but not in the brain.  Given i.p., it also caused 
inflammatory cell infiltration in the adrenal gland, but not the pituitary, together with 
decreased vacuolation in the steroidogenic cells, increases in serum pro-inflammatory 
cytokines and corticosterone (CORT) and a subsequent loss of sensitivity to ACTH. 
The increases in ANXA1, Fpr1 and Fpr3 expression were dependent on inflammatory 
cell infiltration (predominantly eosinophils) but those of Fpr2 were not.  The decrease 
in vacuolation was also independent of the inflammatory cell infiltration but was 
severely compromised by deletion of the genes encoding ANXA1 and Fpr2.  
Pharmacological studies on isolated adrenal cells in vitro suggest that ANXA1 may 
act via Fpr2 to inhibit ACTH-stimulated CORT release but that Fpr1 effects a tonic 
stimulatory effect on ACTH-driven steroidogenesis.  These data suggest that ANXA1 
and the FPRs play an important role within the adrenal in mediating the HPA 
responses to endotoxin and provide new evidence to suggest that infiltrating 
leukocytes are also important in this regard. 
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CHAPTER 1         
INTRODUCTION 
1.1 Neuroendocrine system and stress 
Stress arises when homeostasis is threatened and may be either physical (e.g. 
infection) or emotional (e.g. bereavement).  The response to acute stress can be 
considered a natural homeostatic response for most people, leading to an increase in 
awareness and a response to an adverse situation (such as the fright-flight response, 
Figure 1.1).  However, if the stress is sustained, for example, if an individual is in a 
condition of unpredictable or uncontrollable stress, this can lead to a failure of 
homeostasis which can contribute or lead to the manifestation of disease, e.g. 
depression or hypertension (Buckingham, 2006).  Hans Selye was considered one of 
the lead endocrinologists in the field of stress with his work on the general adaptation 
syndrome, and defined stress as: 
 
―Stress is the nonspecific response of the body to any demand. A stressor is an 
agent that produces stress at any time.  The general adaptation syndrome 
represents the chronologic development of the response to stressors when their 
action is prolonged.  It consists of three phases: the alarm reaction, the stage of 
resistance and the stage of exhaustion.”   Hans Selye (1976) 
 
Glucocorticoids (GCs) are released in response to stress and enhance the 
physiological response by mobilising energy stores through gluconeogenesis; 
proteolysis; and lipolysis; increasing glucose delivery to the central nervous system 
(CNS).  They also increase cardiac contractility, cardiac output and vascular 
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contractility by augmenting sensitivity to catecholamines, and increasing work 
capacity of skeletal muscles (Buckingham, 2006).   
 
GCs, principally cortisol (man) and corticosterone (CORT, rodents), are hormones 
that influence or regulate a variety of metabolic, cardiovascular, immunologic and 
homeostatic mechanisms.  They are used clinically for the treatment of chronic 
inflammatory and autoimmune diseases.  However, although highly effective in 
alleviating disease symptoms, they are not without side-effects that are attributed to 
their inherent functional ubiquity.  The consequences of excessive oversecretion or 
undersecretion of GCs (Cushing‘s syndrome or Addison‘s disease, respectively) are 
well recognised.  In recent years it has become apparent that more subtle changes in 
GC levels or activity may be an important contributory factor in the aetiology of 
diseases such as hypertension, obesity, type II diabetes and various mental health and 
neurological disorders, e.g. depression and Alzheimer‘s disease (Buckingham, 2006). 
 
GCs exert their effects through both genomic and non-genomic mechanisms. It has 
been proposed that approximately 10% of the genome might be modulated by GCs 
(Buckingham, 2006).  However, GC effects do not solely occur through receptor-
mediated alterations in gene transcription.  GCs mediate their actions through GC and 
mineralocorticoid receptors (GR and MR respectively) which have differing activity 
and affinity for GCs.  Mineralocorticoid‘s (principally aldosterone) primary function 
is considered to be the control of electrolyte balance, but MRs bind both 
mineralocorticoids and GCs with high affinity, and show a close homology with GRs 
(Hu & Funder, 2006).  MRs are found in both Na
+
 transporting epithelia (e.g. 
kidneys), where they are protected from GCs by the enzyme type 2 11β-
hydroxysteroid dehydrogenase (11βHSD2), and non-epithelial tissues [e.g. brain  
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(Funder, 2005)].  By contrast, GRs have a high specificity but relatively low affinity 
for GCs and are activated principally when GC levels are raised, for example in stress 
or at the peak of the circadian rhythm, and those MRs that are not protected by 11β-
HSD2 are saturated.  GRs are thus considered to be responsible for the biological 
efficacy of GCs in stress (Buckingham, 2006).  The GR belongs to the type 1 nuclear 
receptor superfamily that constitutes a class of transcription factors regulated by small 
lipophilic ligands of which there are two isoforms (GRα and GRβ).  GRα is 
considered the predominantly biologically active form, and in the absence of GC, 
GRα resides in the cytoplasm in an inactive state.  Upon activation of GRα by GC, the 
receptor binds GC response elements in the promoter region of target genes, and 
activates or inhibits transcription through transcription factors such as activator 
protein 1 and nuclear factor kappa B (NF-κB).  The role of GRβ has not yet been 
clearly elucidated and it may have a dominant-negative effect on GRα transcription 
activity (Sionov et al., 2008). 
 
Taking into consideration the multitude of effects that GCs can assert over many 
physiological functions, investigating the various pathways that control feedback 
mechanisms could significantly contribute to help the understanding and the potential 
development of novel treatments in specific GC-associated diseases. 
Chapter 1 
 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Overview of acute and chronic stress.  A simplified overview of the 
central and peripheral components involved in acute and chronic stress and their 
principle functional feedback relationships. ACTH: adrenocorticotrophic hormone, 
CRH: corticotrophin releasing hormone, AVP: Arginine vasopressin, Ө negative 
feedback loop. (NAPS Buss, unpublished). 
 
 
1.2 Hypothalamic pituitary adrenal (HPA) axis 
1.2.1 The hypothalamus 
The major region of the brain associated with co-ordinating GC release and 
homeostasis is the hypothalamus, which is an area of the brain that lies beneath the 
thalamus and links the endocrine, autonomic and limbic systems (Figure 1.2).  The 
non-endocrine roles of the hypothalamus include: temperature regulation; memory; 
sleep; cardiovascular; respiratory and gastro-intestinal functions.  The hypothalamus 
is one of the most complicated areas of the brain based on its functionality and 
number of chemical neurotransmitters located within a small amount of tissue that 
comprises hypothalamic nerve cells, fibre systems, glial cells and blood vessels.  The 
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neuroactive substances acetylcholine, amines, amino acids and many neuropeptides 
are found within their neurons.  In terms of connectivity, the hypothalamus has both 
afferent and efferent pathways to the major regions of the brain, which form an 
integral part of homeostatic control.  Efferent neurons from the hypothalamus project 
to the posterior pituitary gland or to the portal vessels which transport neurohormones 
from the hypothalamus to the anterior pituitary gland.  Neurons also project to other 
areas both within and external to the hypothalamus and release chemicals which 
function as neurotransmitters or neuromodulators.  Therefore, the hypothalamus acts 
as a centre that integrates endocrine, autonomic and higher brain functions (Swaab, 
2004). 
 
The hypothalamus comprises four major rostrocaudally organised regions (preoptic, 
anterior, middle and posterior hypothalamus) which can be further divided into medial 
and lateral hypothalamic areas (Figure 1.2).  From a neuroendocrine perspective, the 
hypothalamus can be further separated into the magnocellular and parvocellular 
system.  The magnocellular system is located principally in the supraoptic nucleus 
(SON) and paraventricular nucleus (PVN) of the hypothalamus (Figure 1.2) and 
projects to the posterior pituitary gland.  The magnocellular neuroendocrine cells are 
primarily responsible for the release of oxytocin (promotes milk secretion and smooth 
muscle contraction) and arginine vasopressin (AVP, an antidiuretic hormone and 
potent vasoconstrictor) directly into the venous circulation of the posterior pituitary 
gland.  This is facilitated by long unmyelinated axons that travel through the median 
eminence to the posterior pituitary gland.  AVP and oxytocin release is regulated by 
the electrical activities of the relevant magnocellular neurons and modulated by 
various local factors within the posterior pituitary gland (Lightman, 1988).   
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The magnocellular neuroendocrine system is considered highly plastic as it is subject 
to sudden morphological changes with varying physiological conditions which alter 
the excitability of the cells (Tasker et al., 2002).  Whilst GC feedbacks primarily to 
the hippocampus, pituitary and amygdala, GCs also have inhibitory actions on the 
magnocellular neuroendocrine cells of the PVN and SON, suppressing oxytocin and 
AVP release.  It has been proposed that the combined actions of GCs on 
magnocellular neurons is facilitated through GC-mediated release of 
endocannabinoids that suppress glutamate release and that GCs cause rapid 
facilitation of γ-aminobutyric acid (GABA) mediated inhibitory synaptic inputs to 
magnocellular neurons.  By this mechanism, GCs can mediate a rapid feedback 
inhibition of the secretion of oxytocin and AVP that is seen during stress (Di & 
Tasker, 2008). 
 
The parvocellular system has projections that terminate in the median eminence, brain 
stem and spinal cord.  These neurons release small amounts of stimulating or 
inhibiting releasing hormones (or factors) that are delivered to the anterior pituitary 
gland, released into the primary capillary plexus in the median eminence and 
transported via the hypophyseal portal vessels to their target cells (Lightman, 1988).  
The principal releasing hormones are: corticotrophin releasing hormone (CRH); AVP; 
thyrotrophin releasing hormone (TRH); gonadotrophin releasing hormone (GnRH); 
growth hormone releasing hormone (GHRH); growth hormone inhibiting hormone (or 
somatostatin, SS) and dopamine (DA, Figure 1.3).  There are also many other 
signalling molecules that include neuropeptides, neurotransmitters, growth factors, 
cytokines and tissue factors (Denef, 2008).   
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Figure 1.2: A schematic of the hypothalamus and pituitary gland.  A simplified 
overview of the principal components of the hypothalamus and pituitary gland (NAPS 
Buss, unpublished).  
 
Adrenocorticotrophic hormone (ACTH) release is mediated primarily through release 
of CRH and AVP into the portal blood from parvocellular neurons of the PVN.  CRH 
is a peptide which acts via two mammalian G-protein coupled receptor (GPCR) sub-
types designated CRH-R1 and CRH-R2.  Of these receptors, CRH-R1 is widely 
distributed in the CNS and anterior pituitary gland demonstrating increased selectivity 
for CRH over CRH-R2 (Hauger et al., 2003).  CRH-R1 mediates the ACTH responses 
to stress, whereas CRH-R2 functions include anxiolysis and de-arousal (Hsu & 
Hsueh, 2001).  Although CRH is considered the major ACTH secretagogue, 
administration of AVP also has an important role in stimulating ACTH release in man 
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and experimental animals (Salata et al., 1988).  Synergism between the two peptides 
has been identified both in vitro and in vivo and these synergistic actions are thought 
to be critical to the regulation of ACTH release (Hashimoto et al., 1988).  AVP also 
exerts multiple physiological actions, including; pressor and anti-diuretic functions; 
platelet aggregation; hepatic glycogenolysis; uterine contraction and atrial natriuretic 
peptide secretion by the heart (Hashimoto et al., 1988).  These actions are mediated 
through three GPCR sub-types designated V1a, V1b and V2 (Guillon et al., 2004).  
Of these, the V1b receptor has been localised to the anterior pituitary gland, where it 
mediates AVP-stimulated ACTH secretion.  It is also widely distributed in the CNS, 
including the septum, cortex and hippocampus (Shimazaki et al., 2006). 
 
Whilst the role of CRH in regulation of the hypothalamic-pituitary-adrenal (HPA) 
axis is relatively well known, the functional roles of the related urocortin (UCN) 
peptides (UCN1, UCN1 and UCN3) are less well understood.  CRH and UCN1 have 
an equal affinity for CRH-R1, but UCN1 is more potent than CRH for CRH-R2, and 
both CRH and UCN also binding to the endogenous pseudo-receptor, CRH-binding 
protein [CRH-BP, (Simopoulos et al., 2009)].  When bound to CRH-BP, the 
biological activity of CRH and the UCNs are greatly reduced as it prevents binding to 
CRH receptors and thus acts as an inhibitor of functionality (Tsatsanis et al., 2007).  
With respect to HPA-function, it is considered that endogenous UCN1 may play a 
role in the control of ACTH secretion, as UCN induced the release of ACTH, likely 
through CRH-R1, from cultured rat anterior pituitary cells (Oki & Sasano, 2004) and 
infusion of UCN1 in healthy human males caused an increase in plasma ACTH and 
cortisol (Davis et al., 2004).  Recent findings have demonstrated that UCN2 and 
UCN3 may act as autocrine and/or paracrine regulators of glucose homeostasis 
through modulation of insulin secretion in the pancreas and as peripheral modulators 
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of glucose utilisation and insulin sensitivity in skeletal muscle (Kuperman & Chen, 
2008).   
 
A key link between the CNS and the endocrine system is the pituitary gland, often 
referred to as the ‗master gland‘ that exerts control over all other endocrine tissue.  
 
1.2.2 The pituitary gland 
Anatomically, the pituitary is divided into two different structures, the anterior 
pituitary gland or adenohypophysis (consisting of the pars distalis, pars intermedia 
and pars tuberalis) and the posterior pituitary gland or neurohypophysis [median 
eminence, hypophyseal stalk, and the pars nervosa, (Thapar et al., 2001)].  As 
previously mentioned, the neurohypophysis is considered an extension of the 
hypothalamus as neurons from the SON and PVN secrete oxytocin and AVP 
systemically from axons that extend to the pars nervosa. 
 
The anterior pituitary gland is composed of granular (endocrine) and agranular (non-
endocrine) secretory cells.  Within the pars distalis there are five secretory cell types; 
somatotrophs, lactotrophs, corticotrophs, thyrotrophs and gonadotrophs that produce 
the pituitary hormones related to the stress response, metabolism, growth, 
reproduction and the immune response (Figure 1.3) and is considered the main site of 
adenohypophysial hormone synthesis and discharge.  The pars intermedia contains 
corticotrophs and melanotrophs (producing melanocyte stimulating hormone, MSH) 
and in humans, unlike rodents, is very small or absent in adulthood.  Melanotrophs 
also synthesise proopiomelanocortin (POMC) a major precursor protein for ACTH, 
endorphins and MSH.  The pars intermedia also has many nerve terminals containing 
DA, noradrenaline, GABA and serotonin.  The pars tuberalis, the upward extension of 
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the adenohypophysis, surrounds two sides of the hypophyseal stalk and consists of 
adenohypophysial cells, primarily gonadotrophs and thyrotrophs interdispersed with 
few corticotrophs.  The thyrotrophs within the pars tuberalis are slightly unique as 
they express a high density of melatonin receptors which are associated with the 
action of melatonin in seasonal rhythmicity of prolactin (PRL) by the pars distalis 
(Thapar et al., 2001).  Furthermore, the pars tuberalis rhythmically expresses a range 
of ‗clock genes‘ known to act on neural and endocrine pathways to regulate circadian 
rhythm (Dardente, 2007). 
 
The major agranular cells within the parenchymal tissue of the anterior pituitary gland 
are the folliculo-stellate cells.  Folliculo-stellate cells have a characteristic star-like 
morphology, total 5-10% of all pituitary cells and play an important role in inter-
cellular communication as well as scavenging and supporting activity within the 
pituitary gland (Devnath & Inoue, 2008).  This is also structurally evident as the 
cytoplasmic processes of folliculo-stellate cells extend to and entwine the hormonal 
cells so as to maintain a close contact.  Signalling molecules include nitric oxide 
(NO), fibroblast growth factor-2, transforming growth factor-β1, leukaemia-inhibitory 
factor, metalloproteinase inhibitor, interleukin (IL)-6, vascular endothelial growth 
factor, leptin, follistatin and annexin A1 (ANXA1).  Other non hormonal cells include 
dendritic cells, macrophages, endothelial cells, pericytes, fibroblasts, transferrin-
positive, colony forming and nestin-positive cells (Denef, 2008).   
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Figure 1.3: Overview of anterior pituitary 
gland function.  A simplified overview of 
the hypothalamic-pituitary axis and the 
releasing (→) or inhibitory (┤) releasing 
hormones and how they act on the five 
secretory cell types and folliculo-stellate cell 
(FS) within the anterior pituitary gland. CRH, 
corticotrophin releasing hormone; ACTH, 
adrenocorticotrophic hormone; AVP, 
arginine vasopressin; GnRH, gonadotrophin 
releasing hormone; LH, leutenising hormone; 
FSH, follicle stimulating hormone; DA, 
dopamine; PRL, prolactin; GH, growth 
hormone; GHIH, growth hormone inhibiting 
hormone; GHRH, growth hormone releasing 
hormone; TSH, thyroid stimulating hormone; 
TRH, thyrotrophin releasing hormone; 
CART, cocaine and amphetamine regulated 
transcript; POMC, pro-opiomelanocortin; 
LPS, lipopolysaccharide; IL-1, Interleukin-1; 
TNFα, Tumour necrosis factor alpha; PCAP, 
pituitary adenylate cyclase-activating 
peptide; VIP, vasointestinal peptide; GCs, 
glucocorticoids; IL-6, Interleukin-6; iNOS, 
inducible nitric oxide synthase; NO, nitric 
oxide; ET, endothelin; 5HT, 5-
hydroxytryptamine; adapted from Denef, 
2008. 
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The principal trigger to GC synthesis and release is ACTH, derived from the larger 
pre-cursor POMC in corticotrophs in the anterior pituitary gland.  Its primary action is 
to promote steroidogenesis, increasing the synthesis and secretion of GCs and 
androgenic steroids of the adrenal cortex; and in addition, in certain situations, it may 
also augment the secretion of the mineralocorticoid, aldosterone (Buckingham, 2006). 
 
1.2.3 The adrenal glands  
GCs are synthesised in, and released from, the adrenal cortex into the systemic 
circulation.  Their pattern of release follows a circadian rhythm, is sensitive to stress 
and subject to negative feedback control.  The adrenal glands are paired organs that 
are located to the upper pole of the kidneys and comprise two functionally distinct 
endocrine tissues: the cortex (zona glomerulosa, zona fasciculata and zona reticularis) 
and the medulla [Figure 1.4, (Greaves, 2000b)].  The adrenal gland receives a rich 
innervation and many different transmitter substances have been identified in the 
nerves supplying both the cortex and medulla, including catecholamines and other 
neuropeptides (Whitworth et al., 2003).  
 
The adrenal medulla comprises 10% of the total adrenal volume and is primarily 
responsible for secretion of the catecholamines: adrenaline and noradrenaline.  The 
cells of the adrenal medulla, termed chromaffin cells contain secretory vesicles and 
are considered part of the sympathetic nervous system (Greaves, 2000b). 
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Figure 1.4:  Haematoxylin and eosin (H&E) staining of adrenal glands from 
C57Bl/6 mice. Anatomy and physiology of an adrenal gland from C57Bl/6 mice 
stained with H&E (NAPS Buss, unpublished). 
 
Within the cortex and lying beneath the adrenal capsule, the zona glomerulosa is 
responsible for aldosterone secretion and constitutes about 5% of the cortex.  Under 
light microscopy, the adrenocortical cells are small with a dense nucleus, high 
nuclear/cytoplasmic ratio and relatively low cytoplasmic lipid content.  The cells 
within the zona fasciculata and reticularis can both secrete GCs and androgens 
through steroidogenesis (Figure 1.5).  Histologically, the zona fasciculata comprises 
approximately 70% of the cortex and consists of columns of cells extending from the 
capsule
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inner reticularis zone to the glomerulosa.  The cells are large, with a low 
nuclear/cytoplasmic ratio and abundant cytoplasmic lipid content, giving a vacuolated 
appearance (termed ‗clear cells‘) under microscopic evaluation (as fixation removes 
the lipid droplets). The zona reticularis comprises the inner 25% of the cortex and the 
cells vary widely in size and contain densely granular cytoplasm and sparse lipid 
(referred to as ‗compact‘ cells).  The blood supply of the adrenal gland flows inwardly 
from the capsule, which creates a gradient of increasing steroid hormone 
concentration from the outer to the inner cortex (Greaves, 2000b).  The varying 
concentrations may modulate the relative activities of the steroidogenic enzymes and 
as a consequence the medullary cells are bathed in steroid rich blood (Vinson et al., 
1985).  The adrenal cortex secretes a range of steroid hormones that are catalysed 
mainly by cytochrome P450 enzymes in the process called steroidogenesis.  The 
enzymes and pathways are well reviewed (Miller, 2007a), and are summarised in 
Figure 1.5. 
 
The substrate for steroidogenesis is cholesterol that is derived predominantly by the 
dietary intake of low-density lipoproteins, although the adrenal gland can synthesise 
cholesterol de novo from acetyl coenzyme A.  The amount of steroid a steroidogenic 
cell stores is much less than those cells that produce peptide hormones.  Therefore, 
when there is a rapid steroidogenic response, such as an increase in ACTH stimulating 
GC release, there is a requirement for rapid synthesis of GCs.  The rate limiting step 
in this synthesis is the movement of insoluble cholesterol from the outer to the inner 
mitochondrial membrane for its subsequent conversion to soluble pregnenolone, a 
steroidal precursor in steroidogenesis (Miller, 2007b).   
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Figure 1.5: Principle pathways of steroidogenesis.  The adrenal cortex secretes a 
range of steroid hormones that are catalysed mainly by cytochrome P450 enzymes 
(CYP) in the process called steroidogenesis. Products of steroidogenesis include: 
androgens (testosterone), oestrogens, progesterone, glucocorticoids and aldosterone. 
High density lipids (HDL); low density lipids (LDL); steroidogenic acute regulatory 
protein (StAR); dehydroepiandrosterone (DHEA); 17-OH progesterone (17OH Prog); 
17-OH pregnenolone (17OH Preg); deoxycorticosterone (DOC); 3-beta 
hydroxysteroid dehydrogenase (3βHSD); 17-beta hydroxysteroid dehydrogenase 
(17βHSD, NAPS Buss, unpublished). 
 
 
The protein that controls this rate limiting step is the 37-kDa steroidogenic acute 
regulatory (StAR) protein.  This was identified as a mitochondrial phosphoprotein in 
adrenal cells that were stimulated with ACTH, whose appearance could be blocked by 
cycloheximide, an inhibitor of protein biosynthesis (Pon et al., 1986).  The 
transcription rate of the StAR gene is a primary determinant of steroidogenesis, 
however the mechanism by which StAR mediates cholesterol transport across the 
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mitochondrial membrane is not yet known (Christenson & Strauss, 2001).  In chronic 
regulation of steroidogenesis, the transcription of genes encoding steroidogenic 
enzymes are considered to determine the steroidogenic capacity of a cell as 
conversion of cholesterol to pregnenolone is very slow (Miller, 2008b).  
 
GCs are the end product of stress-induced HPA-activation and are considered potent 
anti-inflammatory hormones in the body that restrain innate immune responses during 
infection and other forms of immune activation.  This activation of the innate immune 
response and inflammatory signalling has led to the link between stress and illness, 
especially as inflammation is increasingly recognised as a common mechanism of 
diseases such as cardiovascular disease, diabetes and cancer (Miller, 2008a). 
 
1.3 Stress and inflammation 
Inflammation is the physiological response to infection or tissue injury with the 
principal signs being redness, an increase in temperature, swelling, pain and loss of 
surrounding tissue function (Tracy, 2006).  Inflammation, both acute and chronic 
involves a highly orchestrated interaction of cells and soluble mediators that can be 
divided into three stages; (i) dilation of microcirculation to increase blood flow, (ii) 
microvascular structural changes with escape of plasma proteins and (iii) movements 
of leukocytes through the endothelium and accumulation at the site of injury (Gilroy, 
2004).  All leukocytes (lymphocytes, polymorphonuclear leukocytes, PMNs, 
monocytes and macrophages) play important roles in the initiation and progression of 
inflammation and differ depending on the initiation factor (Lawrence & Gilroy, 2007).  
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Lymphocytes mediate the immune response to antigens and are considered either 
large (natural killer cells; NK cells) or small (T and B cells) lymphocytes that form 
part of both the innate (NK cells) and adaptive (T and B cells) immune system. B cell 
lymphocytes differentiate into antibody-secreting plasma cells that express surface 
immunoglobulins and can present surface antigen. T cell lymphocytes have many 
functional and phenotypic sub-populations including the cytokine releasing T helper 
(TH) subsets.  As lymphocytes differentiate into their functional populations they 
acquire cell-surface molecules defining the phenotype, referred to as cluster of 
differentiation [CD, (Chaplin, 2010)].  CD nomenclature is commonly used when 
referring to leukocyte surface molecules and antibodies against them (Zola et al., 
2007). 
 
PMNs were first identified by staining of the lobulated nucleus and the granules 
which differentiate them into neutrophils, eosinophils and basophils (Borregaard & 
Cowland, 1997).  Neutrophils are an essential component of the innate immune 
response and a major contributor to inflammation.  They are essential for host 
protection against bacterial and fungal pathogens.  Their lifespan is short and 
following phagocytosis, undergo apoptosis and elimination from the inflammatory 
site by macrophages; this is considered a key step in the resolution of inflammation 
(Kantari et al., 2008).  Eosinophils mediate cytotoxic and inflammatory processes by 
the release (degranulation) of their proteins and numerous cytokines, chemokines, 
growth factors, reactive oxygen species and pro-inflammatory lipid mediators (Hogan 
et al., 2008).  Their primary role is generally considered to be associated with host 
protection against parasites, but more recently they are considered to be 
multifunctional leukocytes involved in both the innate and adaptive immune systems 
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(Hogan et al., 2008).  Basophils are circulating granulocytes that support the 
secondary immune response and are associated with allergies and found at low levels 
in healthy animals.  They are activated by cytokines, immunoglobulins, proteases and 
parasite-associated antigens that support T-cells, produce chemotactic factors to 
recruit eosinophils and neutrophils and release effector molecules such as histamine 
and leukotrienes (Min, 2008).   
 
Monocytes are considered the pre-cursors to macrophages and are released by the 
bone marrow into the blood to replenish tissue-specific macrophages of the bone 
(osteoclasts), alveoli, CNS (microglial cells), connective tissue (histiocytes), gastro-
intestinal tract, liver (Kupfer cells), spleen and peritoneum (Gordon & Taylor, 2005).  
In mice, monocytes have been classified as either inflammatory or resident 
monocytes, depending on the amount of time spent in the blood prior to migration and 
are differentiated by expression of cell surface markers that differ from those relevant 
to man.  Inflammatory monocytes are classified as: CCR2
+
 (cc-chemokine receptor 
2); CX3CR1 (CX3C-chemokine receptor 1) and GR1
+
; resident monocytes as 
CCR2-CX3CR1
hi
GR1
-
 (Mosser & Edwards, 2008).   
 
Macrophages are phagocytic cells and are present in virtually all tissues.  Mosser et 
al., (2008) recently proposed the division into classically activated macrophages, 
wound healing macrophages and regulatory macrophages with a high degree of 
plasticity (Mosser & Edwards, 2008).  Classically activated macrophages are 
stimulated by interferon gamma (IFNγ) that is produced during an adaptive response 
by T helper 1 or CD8+ T cells.  During an innate immune response, classically 
activated macrophages are stimulated by NK-cells or tumour necrosis factor (TNF) 
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produced by dendritic cells (antigen-presenting cells) and are considered toll-like 
receptor (TLR) mediated.  Wound healing macrophages are produced in response to 
IL-4 which can be released from granulocytes during an adaptive response by TH2 
cells or during an innate response.  Regulatory macrophages are generated in response 
to various stimuli immune complexes such as: prostaglandins; GPCRs; ligands; GCs, 
apoptotic cells; or IL-10 to suppress immune responses (Mosser & Edwards, 2008).   
 
An important aspect of cellular signalling for leukocytes are the cytokines.  Cytokines 
are regulatory proteins (simple polypeptides or glycoproteins) secreted by cells 
(predominantly leukocytes) that have numerous paracrine or autocrine effects on cells 
of the immune system (occasionally endocrine as well).  Cytokines are highly specific 
and the majority of their activity on the target cells leads to an altered pattern of gene 
expression.  The family of cytokines include ILs, interferons, chemokines, colony 
stimulating factors and transforming growth factors (Oppenheim, 2001).   
 
Part of the inflammatory process involves the movement of leukocytes through the 
endothelium and into the target tissue.  PMN recruitment, lymphocyte recirculation 
and monocyte trafficking all require adhesion and transmigration through blood 
vessels.  The leukocyte adhesion cascade has recently been updated to include 
capture, rolling, slow rolling, arrest, adhesion strengthening, intravascular crawling 
and transmigration.  Transmigration was also differentiated to either paracellular or 
transcellular transmigration  (Ley et al., 2007).   
 
Rolling is mediated through a family of cell adhesion molecules (CAM) called 
selectins.  L-selectin is expressed by most leukocytes and both P-selectin and 
Chapter 1 
 
 35 
E-selectin are expressed by activated endothelial cells.  These CAMs interact with 
P-selectin glycoprotein ligand 1 and other glycosylated ligands (Ley et al., 2007). 
Rolling slows down circulating leukocytes, bringing them into close proximity with 
the endothelium allowing the binding of chemokines on the target endothelium to 
bind through their specific chemokine receptors on the leukocytes.  Slow rolling to 
arrest not only requires selectin signalling, but also engagement of β2-integrins, 
specifically lymphocyte function associated antigen 1 or macrophage receptor 1 
[MAC1, (Ley et al., 2007)].  The activation of the chemokine receptors triggers 
intracellular pathways that activate leukocyte integrins (Weber et al., 2007).  The 
interaction between integrins and their endothelial immunoglobulin ligands mediate 
the firm adhesion of leukocytes such as intracellular adhesion molecule 1 (ICAM1) 
and vascular cell adhesion molecule 1 (VCAM-1).  Before transmigration, leukocytes 
crawl along the blood vessels in a MAC1 and ICAM1-dependent manner to identify 
the preferred site of transmigration (Ley et al., 2007).  The leukocytes then 
transmigrate through the endothelium to the exogenous chemoattractant [e.g. IL-8 or 
N-formyl-methionyl-leucyl-phenylalanine, fMLP or fMLF (Smith et al., 1991)] to 
complete their action (Ley et al., 2007).  Leukocytes transmigrate via junction 
adhesion molecules and can go either through or between endothelial cells.  
Paracellular transmigration, where leukocytes pass through the endothelial cells is the 
movement of leukocytes through endothelial-cell junctions.  Activated endothelial 
cells can redistribute junctional molecules in a way that favours transendothelial cell 
migration.  Some endothelial junction molecules from the immunoglobulin 
superfamily members (platelet-endothelial cell adhesion molecule-1, ICAM 1 & 2, 
junction adhesion molecules A to C and endothelial cell-selective adhesion molecule) 
are considered to actively mediate leukocyte transendothelial migration.  More 
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recently, and of great interest, is the discovery of the ability of leukocytes to 
transmigrate through the endothelial cells, which may be more relevant in tissue such 
as the CNS and other various inflammatory scenarios.  Transcellular migration occurs 
through ‗thin‘ parts of the endothelium, being the shortest distance to the target. 
ICAM1-containing caveolae link together forming vesiculo-vacuolar organelles that 
form an intracellular channel through which a leukocyte can migrate (Ley et al., 
2007). 
 
In the case of acute inflammation, once the initiating foreign materials are removed 
via phagocytosis, the inflammatory reaction must be resolved to prevent the 
progression into a disease state.  This is referred to as resolution of inflammation 
which is a regulated process that facilitates the return to normal homeostasis.  The 
process of resolution is rapidly initiated by cellular pathways that actively 
biosynthesise local, specialised, dual-acting anti-inflammatory and pro-resolution 
lipid mediators, such as the lipoxins, resolvins and protectins (Ariel & Serhan, 2007).  
Chronic inflammation can occur from excessive and/or unresolved inflammatory 
responses, and arachidonic acid (AA) derived lipid mediators (e.g. prostaglandins and 
leukotrienes) can amplify this process (Serhan et al., 2008).   
 
In each of the different cellular signalling mechanisms associated with inflammation, 
NF-κB was identified as a key mediator of inducible transcription in the immune 
system (Ghosh et al., 1998).  Through the activation of NF-κB there is an up-
regulation of adhesion molecules and chemokines by the vascular endothelial cells 
and surrounding tissue.  Subsequently, there is recruitment and activation of effector 
cells, initially neutrophils and then macrophages and other leukocytes (Ghosh & 
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Hayden, 2008).  NF-κB is generally considered to play a pro-inflammatory role 
during the course of inflammation.  However, in an inflammatory model (rat 
carrageenin pleurisy model), inhibition of NF-κB during the resolution of 
inflammation prevented apoptosis in leukocytes and prolonged the inflammatory 
response, suggesting it also has an anti-inflammatory role (Lawrence et al., 2001).   
 
NF-κB is activated by numerous extracellular stimuli that include cytokines (e.g. 
TNFα or IL-1β), viruses and other factors that lead to an immune response.  
Activation of cell-surface receptors leads to phosphorylation of receptor-associated 
kinases (IκB) that phosphorylate the inhibitors of NF-κB kinase (Bladh et al., 2008). 
Phosphorylation of IκB leads to the phosphorylation of the NF-κB cytoplasmic 
inhibitor (IκBα), which enables degradation of IκBα. This degradation precipitates the 
release of NF-κB from its inactive state, enabling nuclear translocation and binding to 
specific deoxyribonucleic acid (DNA) response elements within the regulatory 
regions of responsive genes (Bladh et al., 2008).  Inhibition of NF-κB by GCs occurs 
through repression of transcription by the GR, which up-regulates the inhibitory 
protein, IκBα that may lead to retention of NF-κB in the cytoplasm (Bladh et al., 
2008).  GCs can also inhibit the activity of the mitogen-activated protein kinase 
(MAPK) signaling cascades, including the extracellular signal-regulated kinase 1 and 
2 (ERK1/2) pathway (Bladh et al., 2008). The MAPK cascade, including the two 
isoforms ERK1/2, are involved in various cellular functions, including cell 
proliferation, differentiation and migration that can be activated by growth factors and 
environmental stressors (Nishimoto & Nishida, 2006).   
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The inflammatory process is mediated by the increased expression of inflammatory 
proteins (including cytokines, chemokines, adhesion molecules and their receptors) 
which are regulated by increased gene transcription that are controlled by 
pro-inflammatory transcription factors such as NF-κB.  It is clear that GCs play an 
important role in the regulating the immune
 
response, from initial activation to 
eventual suppression and
 
restoration of homeostasis. 
 
1.4 Glucocorticoids and disease 
The role of GCs in disease is considered to be well known, yet due to the subtle 
complexities of its role in each disease, to most scientists it is still poorly understood.  
It is considered that both dramatic and subtle changes in GCs contribute to diseases 
such as inflammatory (e.g. allergy or autoimmune disease) and neurological (e.g. 
depression or Alzheimer‘s disease) disorders (Buckingham, 2006).  In 2003, a 
longitudinal study conducted by the United Kingdom (UK) Office for National 
Statistics indicated that approximately 21% of British citizens suffer some kind of 
diagnosable mental disorder (Singleton, 2003).  Mental disorders are also common in 
the United States (US) and internationally, with an estimated 26% of US adults 
suffering from a diagnosable mental disorder (Kessler et al., 2005).  Mental disorders 
are generally sub-divided, based in clusters of symptomology, consisting of: mood 
disorders; schizophrenia; anxiety disorder; eating disorder; attention deficit 
hyperactivity disorder; autism; and Alzheimer‘s disease, amongst others.  Therefore, 
psychiatric illnesses encompass 20% of the population and any area of research that 
could help develop new medicines to treat these relatively unmet therapeutic areas 
will have a significant impact on improving the overall morbidity and wellbeing of the 
population. 
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Neuroendocrine research suggests an intimate link between neurohormonal functional 
activity and major components of mood disorders (major depressive disorder and 
bipolar disorders), particularly with regard to the HPA axis.  Patients with major 
depression exhibit impaired GC feedback and elevations of CRH concentration in the 
cerebro-spinal fluid when compared to that of controls (Nemeroff et al., 1984).  
Furthermore, post mortem studies have demonstrated increased CRH messenger 
ribonucleic acid (mRNA) expression and an increased number of CRH-containing 
neurons in the PVN of depressed patients versus controls (Raadsheer et al., 1994; 
Raadsheer et al., 1995).  These and other data have led to modulators of CRH and GC 
activity being identified as potential new avenues for therapeutic intervention in 
depression (Arborelius et al., 1999).  Further interest in the GCs has been triggered by 
increasing evidence that these steroid hormones contribute the pathogenesis of 
neurodegenerative conditions, such as Alzheimer‘s disease, particularly in those 
instances where there is evidence of dysregulation of cortisol secretion (Swaab et al., 
2005). 
 
Evidence for the involvement of GCs in Alzheimer‘s disease can be considered from 
two perspectives.  Firstly, in patients with Alzheimer‘s disease, the hippocampal 
neurons, which are highly sensitive to the GCs, are among the first to degenerate 
(Behl et al., 1997).  Secondly, a neuroinflammatory process, triggered by amyloid β 
peptide (Aβ), plays a central role in the neurodegenerative process.  The presence of 
Aβ and deposition in the brain is considered to contribute to the pathogenesis of 
Alzheimer‘s disease (Weisman et al., 2006).  However, stress-associated hormones 
are not the only hormones to be implicated in the pathogenesis of Alzheimer‘s 
Chapter 1 
 
 40 
disease, for example epidemiological data suggest and associate with gonadotrophins 
(Bowen et al., 2000; Short et al., 2001; Webber et al., 2005; Casadesus et al., 2005; 
Chen et al., 2006; Roberts et al., 2006).   
 
The hippocampus is considered one region of the adult brain which undergoes 
continuous neurogenesis (Gould et al., 1999) and studies in animals have indicated 
that stress is associated with changes in hippocampal structure and function, 
manifested through reduced neurogenesis (Bremner, 2006).  In the study by Sapolsky 
et al., (1985) chronic GC treatment (3 months) caused a reduction in hippocampal GR 
expression, which was not reversed 4 months after drug withdrawal.  These changes 
were associated with a loss of GC-concentrating cells predominantly in the Cornu 
Ammonis 3 (CA3) field and analysis of the size distributions of hippocampal cell 
bodies were comparable between treated and aged (non-treated) animals indicating 
that GCs may contribute to an age-related loss of neurons in the hippocampus 
(Sapolsky et al., 1985).  Reductions in GCs were shown to reduce hippocampal 
damage (Landfield et al., 1981a), however, adrenalectomy resulted in damage to the 
dentate gyrus (Conrad & Roy, 1995) suggesting that homeostasis of GCs at 
physiological relevant levels is important for maintenance of neurons within the 
hippocampus.  This and other research provides evidence that the effects of chronic 
stress (and concomitant increases in GCs) affect the hippocampus, leading to 
disruption of hippocampal function.  In addition, hippocampal dysfunction would also 
be expected to disrupt HPA function as the hippocampus is a major site of GC 
feedback.  For example, hippocampal lesions or severing of the fornix (the pathway 
between hippocampus and hypothalamus) leads to dexamethasone resistance and 
hypersecretion of GCs, ACTH, CRH, AVP and oxytocin during basal stress and post-
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stress conditions (Sapolsky & Plotsky, 1990).  Furthermore, the disruption of GC 
feedback in rats subjected to continuous stressors (water immersion and restraint) 
have been attributed to impairment of the actions of GCs in the pre-frontal cortex and 
hippocampus (Mizoguchi et al., 2003). 
 
In a clinical investigation, the molar ratio of cortisol to dehydroepiandrosterone 
sulphate (the sulphated precursor of testosterone and oestrogen), was significantly 
higher in demented patients and changes in adrenal secretory pattern corresponded 
with a decline in hippocampal volumes, as assessed by magnetic resonance imaging 
(Magri et al., 2006).  The hippocampal impairment may therefore be associated with a 
perturbance of the HPA axis and associated hormones, thus re-iterating the important 
role of the hippocampus with respect to regulation of GCs.  
 
GCs have potent anti-inflammatory and immunosuppressive properties and influence 
circulation of leukocytes and immune accessory cells.  Synthetic GCs are widely used 
clinically for these properties, in the treatment of inflammatory, autoimmune and 
allergic diseases as well as following organ transplantation.  For example 
dexamethasone is used to reduce inflammation (swelling, heat, redness and pain) in 
arthritis and intestinal disorders (Liberman et al., 2007).  They inhibit the immune 
activation of these cells, production of cytokines, other mediators of inflammation and 
cause resistance to cytokines (Chrousos, 1995).  The downside to this suppression is 
that it may affect the response to infection, inhibiting eicosanoid and glycolipid 
synthesis, bradykinin action, histamine and pro-inflammatory cytokines [TNFα, IL-1, 
and IL-6 secretion, (Almawi et al., 1996)].  The influence on the circulation of 
leukocytes includes lymphocytopenia, monocytopenia, neutropenia and eosinopenia 
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and by activating the apoptosis pathway through GC receptor-mediated effects 
(Cidlowski et al., 1996).  However, caution should be given in the assumption that 
GCs have solely an anti-inflammatory effect as they also induce pro-inflammatory 
effects.  GCs increase the migration of leukocytes to the site of inflammation, increase 
and potentiate the release of pro-inflammatory cytokines as well as NF-κB (Sorrells & 
Sapolsky, 2010).  With respect to Alzheimer‘s disease, the neuroinflammatory process 
involves microglia, astrocytes, the induction of pro-inflammatory molecules and 
related signalling pathways leading to neurodegenerative changes (Weisman et al., 
2006).  It has been proposed that the neuronal cell death caused by Aβ peptide and 
glutamate (potential oxidative stressors) is enhanced by GCs.  Rodent hippocampal 
cell lines were pre-treated with either dexamethasone or CORT, followed by Aβ and 
glutamate challenge, which was blocked following mifepristone (a synthetic steroid 
with anti-progestagenic and anti-GC effects) challenge.  The results demonstrated a 
GR-mediated interaction and that this vulnerability was associated with a suppression 
of protective genetic programs via the block of the activity for the transcription factor 
NF-κB (Behl et al., 1997).     
 
Therefore, acute and chronic stress effects on the neuroendocrine, neural and immune 
responses are considered to be involved in the pathophysiology of many common 
health issues and understanding the mechanisms that regulate the secretion and 
activity of GCs could contribute significantly to advances in medical research. 
 
1.5 Annexin A1 - a mediator of the feedback actions of GCs in the HPA axis 
Response to stress is not just a behavioural adaptation and a change to homeostasis, 
but also a response within the HPA axis and its interactions with the immune system.  
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As previously described, principal control of GCs are considered to be through 
mediation of CRH and AVP.  However the feedback actions of GCs are also critically 
important in this regard.  GCs act at several levels and via multiple molecular 
mechanisms within the HPA to suppress the release of ACTH.  Thus they suppress 
directly and indirectly the expression of the gene encoding ACTH and CRH/AVP.  In 
addition, over a shorter time frame, they induce the formation of second messenger 
proteins which inhibit the release of preformed ACTH and CRH/AVP from their 
secretory granules.  ANXA1, also referred to as lipocortin 1, is one such second 
messenger and has been shown in the anterior pituitary gland to be a cell-cell 
mediator of the inhibitory effects of GCs on the secretion of ACTH and to act via a 
similar mechanism within the hypothalamus to suppress the release of CRH (John et 
al., 2004).  As well as being a mediator of GCs in the neuroendocrine system, 
ANXA1 is also a regulator of cell-growth regulation (Croxtall et al., 2003), 
differentiation (Violette et al., 1990) and apoptosis (Solito et al., 2003a), neutrophil 
migration (Perretti & Flower, 2004) and the generation/activity of eicosanoids and 
other pro-inflammatory mediators (Parente & Solito, 2004).  Within the CNS, 
ANXA1 is neuroprotective and suppresses the generation of pro-inflammatory 
cytokines, as it does in the periphery (Rothwell & Luheshi, 1994). 
 
The annexins are a family of highly conserved proteins widely distributed in tissues 
that are known to bind to phospholipids in a Ca
2+
 dependent way.  Currently thirteen 
annexins have been identified, each composed of two principal domains.  The 
N-terminal domain of each annexin is unique in sequence and is considered the ‗head‘ 
which defines the biological specificity of each annexin.  The COOH-terminal protein 
core is highly conserved and comprises of up to eight repeated sequences of 70 amino 
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acids [(Gerke & Moss, 2002), Figure 1.6].  The N-terminal domain of ANXA1 
comprises 44 amino acids which includes sites for protein kinase C and tyrosine 
kinase phosphorylation and for glycosylation, acetylation and proteolysis 
(Buckingham, 1996).  Local changes in Ca
2+
 concentration may alter the confirmation 
of the molecule in such a way that the N-terminal domain is exposed which, in turn, 
may influence the biological activity of the protein (Rosengarth & Luecke, 2003).   
 
Figure 1.6: Ribbon diagram of one monomer of full-length ANXA1. Full length 
ANXA1 (N-terminal domain is shown in yellow) and structure is presented in the 
absence of calcium ions (Rosengarth & Luecke, 2003). 
 
From an endocrine perspective, ANXA1 protein is abundant in the anterior pituitary 
gland [and to a lesser extent in the posterior pituitary, (Ozawa et al., 2002; John et al., 
2004)], and also found within hypothalamus (particularly the median eminence and 
ependymal cells surrounding the third ventricle (Johnson et al., 1989; John et al., 
2004), adrenal cortex (Davies et al., 2007), pancreas (Ohnishi et al., 1994), testis 
(Cover et al., 2002), ovary (Tsao et al., 1995), thyroid (El Btaouri et al., 1996), 
thymus (Fava et al., 1989) and placenta (Fava et al., 1989; Tsao et al., 1995). 
 
Functional studies performed in vivo and in vitro using ANXA1-peptides, neutralising 
anti-ANXA1 antisera and anti-ANXA1 mRNA oligonucleotides have provided 
evidence that ANXA1 plays a key role in regulating the early (evident within 2h of a 
steroid challenge) inhibitory effects of GCs on the secretion of ACTH and CRH from 
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the anterior pituitary gland and hypothalamus, respectively, and that other pituitary 
hormones, such as PRL are similarly regulated (Morris et al., 2002).  Exposure of 
dispersed pituitary cells to an oligodeoxynucleotide for ANXA1 mRNA or anti-
ANXA1 antisera effectively reversed the inhibitory effects of dexamethasone on the 
concentration-dependent increases in ACTH release induced by CRH-41, forskolin 
(used to raise levels of cyclic adenosine monophosphate, cAMP), and BAYK8644 (L-
Ca
2+
 channel opener) with concentration-dependent increases in the release of 
immunoreactive ACTH (Taylor et al., 1993; John et al., 2002).  Central or peripheral 
administration of ANXA1 to rats inhibited the increase in plasma ACTH 
concentration induced by co-injection with CRH and reversed the feedback induced 
reduction in rat hypothalamic immuno-reactive CRH content caused by co-
administration of sauvagine (a non-selective CRF agonist) indicating that ANXA1 can 
suppress HPA activity (Sudlow et al., 1996).  Similarly, central administration of 
ANXA1 peptides mimicked, while anti-ANXA1 antisera attenuated, the inhibitory 
effects of natural and synthetic GCs on the cytokine-induced release of ACTH 
(Loxley et al., 1993; Taylor et al., 1995; Philip et al., 2001).  More recent data suggest 
that ANXA1 may fulfil a role at the adrenal level (Davies et al., 2007).  ANXA1 
mRNA and protein are expressed in the adrenal gland, mainly the cortex and capsule, 
ANXA1 was produced and externalised in the CORT secreting cells, whilst 
aldosterone remained unchanged in these ANXA1-null adrenal cells or following 
challenge with the ANXA1 N-terminal peptide ANXA1Ac2-26.  Furthermore, 
functional and morphometric studies on ANXA1 null adrenal glands revealed that 
ANXA1 gene deletion causes an increase in ACTH-induced steroidogenesis but a 
reduction in gland size (Davies et al., 2007). 
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ANXA1 is localised to three predominant compartments, the cytoplasm, within 
membrane structures and attached to the outer surface of the cellular membrane by a 
Ca
2+
 dependent mechanism (John et al., 2004).  Increased levels of ANXA1 are seen 
on the outer surface of cells from the cortex, hippocampus, hypothalamus and 
pituitary gland following in vitro and in vivo treatment with dexamethasone (Taylor et 
al., 1993; Loxley et al., 1993; Philip et al., 1998).  However, the intra-cellular levels 
of ANXA1 are either reduced or unchanged, suggesting that GCs promote ANXA1 
from intra-cellular to peri-cellular sites (Philip et al., 1997). 
 
ANXA1 is now considered to serve as a paracrine or juxtacrine mediator of GC action 
in the neuroendocrine system (John et al., 2007).  In support of this argument, 
ANXA1 is expressed by the non-secretory folliculo-stellate cells in the anterior 
pituitary gland (Traverso et al., 1999), is promptly exported from the cells following 
exposure to GCs (Christian et al., 1997) and corticotrophs express specific ANXA1 
binding sites (Tierney et al., 2003).  To support this hypothesis, Tierney et al., (2003) 
used co-cultures of two murine cell lines (the murine corticotroph cell line, AtT20, 
and the murine folliculo-stellate cell line, TtT/GF) to investigate the paracrine and 
juxtacrine interactions following ANXA1-dependent GC actions between these two 
cell lines, mimicking the relationship between corticotrophs and folliculo-stellate cells 
(Tierney et al., 2003).  By co-culturing and challenging with dexamethasone and 
N-terminal ANXA1 fragments (peptide ANXA1Ac2-26 and ANXA11-188), ANXA1 was 
shown to mimic the effects of dexamethasone inhibition of ACTH release and was 
reversed by mifepristone and by an antisense oligodeoxynucleotide to ANXA1, the 
oligodeoxynucleotide also blocked dexamethasone induced externalisation of ANXA1 
from the folliculo-stellate cell line (Tierney et al., 2003).  Critically, when cultured 
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alone, the AtT20 cells were shown to be unresponsive to GCs over the time course of 
the study, thus demonstrating an essential role for the folliculo-stellate cells in 
mediating the actions of the steroid (Tierney et al., 2003). 
 
As well as non-clinical evidence for the involvement of ANXA1 and the HPA axis, 
clinical studies have been shown to support this following therapeutic doses of 
hydrocortisone which induced rapid changes in the concentration of ANXA1 
(Goulding et al., 1990) and that in vitro studies using a human cell line (U-937 cells) 
showed that ANXA1 translocated from the cytosol to the cell surface following 
exposure of cells to dexamethasone (Solito et al., 1994). 
 
From an inflammatory perspective, it is considered that ANXA1 is regulated by GCs 
that affect the ANXA1 pathway in cells of both the innate and adaptive immune 
system (Perretti & D'Acquisto, 2009).  Neutrophils, macrophages and monocytes 
contain high levels of ANXA1 and following activation by an immune stressor, 
ANXA1 is mobilised to the cell surface and secreted (Perretti & D'Acquisto, 2009).  
Much experimental data has been generated which shows clearly that when ANXA1 
is administered to mice there is potent inhibition of neutrophil infiltration through a 
reduction in neutrophil adherence (Perretti & D'Acquisto, 2009).  The relationship 
between ANXA1 and GCs was demonstrated as GCs mediated an increase in ANXA1 
within leukocytes studied in post-capillary venules of the hamster cheek pouch 
(Mancuso et al., 1995).   
 
Unlike the folliculo-stellate cells that require phosphorylation of ANXA1 for 
externalisation (Solito et al., 2006), leukocytes, such as macrophages are considered 
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to mobilise ANXA1 through the adenosine triphosphate (ATP) binding cassette 
transporter system (Wein et al., 2004).  Following externalisation of ANXA1 to the 
outer layer of the cell membrane, where it is bound in a Ca
2+
 dependant manner, 
changes in extracellular Ca
2+
 concentration expose the N-terminal domain which, in 
turn, influences the biological activity of ANXA1 (Rosengarth & Luecke, 2003).  As 
the biological activity of ANXA1 is Ca
2+
 dependent, the role of Ca
2+ 
channels should 
be discussed.  Ca
2+ 
channels are classified into six subtypes (L-, B-, P-, Q-, R- and T-
type) based on their electrophysiological and pharmacological properties (Takahara, 
2009).  The T-type Ca
2+
 channels are considered low-voltage activated channels that 
activate and deactivate slowly, whilst the other five subtypes of Ca
2+
 channels are all 
high-voltage activated which depolarise rapidly (Takahara, 2009).  Of particular 
interest are the Ca
2+ 
release activated Ca
2+ 
(CRAC) channels.  In non-excitable cells, 
when Ca
2+
 is depleted from the major stores, e.g. the endoplasmic reticulum, CRAC 
channels are activated to slowly replenish the stores.  Decreases of intra-cellular stores 
of Ca
2+
 subsequently activates plasma membrane Ca
2+
 channels and the influx of Ca
2+
 
is termed store operated Ca
2+ 
entry and in non-excitable cells is considered the major 
route of regulated Ca
2+ 
influx and signal transduction (Cahalan et al., 2007).  As a 
second messenger, Ca
2+
 entry can induce both short-term (e.g. degranulation from 
mast cells) and long-term (gene transcription) cellular responses (Vig & Kinet, 2007).  
It is clear that the downstream consequences of CRAC channel activation are still 
poorly understood and it is not known whether these channels are associated with 
ANXA1.  When human recombinant ANXA1 was given to a macrophage cell line 
(RAW264.7), it was shown to suppress intracellular Ca
2+
 concentrations induced 
using the endotoxin lipopolysaccharide (LPS) and was considered to be independent 
of the NF-κB pathway (Xu et al., 2009b).  Furthermore, it was proposed that the 
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influence of ANXA1 on CRAC channels is mediated through formyl peptide receptor 
(FPR) 2 (Li et al., 2008).  Using both electrophysiology and imaging techniques FPR2 
agonists were shown induce Ca
2+
 release from the endoplasmic reticulum.  FPR2 
agonists evoked CRAC channel-like currents displaying fast inactivation in the 
presence and absence of this receptor using ribonucleic acid (RNA) interference of 
FPR2 on HEK293 cells and these experiments indicated the association of FPR2 with 
CRAC channels, and that one of these agonists utilised was ANXA1 (Li et al., 2008).  
 
Of particular recent interest was this identification of a specific GPCR, FPR2 
(formerly formyl peptide like 1 receptor, FPRL1 and also referred to as lipoxin A4 
receptor, ALX) that interacts with ANXA1 not only in experiments investigating 
CRAC channels, but on the cell surface of activated neutrophils (Perretti et al., 2002).  
Lipoxins are eicosanoids generated from AA and are considered mediators involved 
in the resolution of the inflammatory response that has been associated with the anti-
inflammatory actions of GCs (Hashimoto et al., 2007).  In a model of mouse 
peritonitis, FPR antagonists [Boc1 (N-t-butoxycarbonyl-MLP) and Boc2 (N-t-
butoxycarbonyl-PLPLP)] antagonised the anti-migratory effects of peptides 
ANXA1Ac2-26 and ANXA1Ac2-12 (Perretti et al., 2001).  Additionally, binding of 
ANXA1 to circulating leukocytes was lower in FPR Knock Out (KO) mice indicating 
a functional role for FPR in the anti-migratory effects of ANXA1 and derived 
peptides (Perretti et al., 2001). 
 
1.6 Formyl peptide receptors – targets for annexin A1 
FPRs were originally identified as chemoattractant receptors that have already been 
implicated with potential therapeutic benefits for diseases of high morbidity and 
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mortality, including the human immunodeficiency virus type-1 (HIV-1) and 
neurodegenerative disorders (Le et al., 2002).   
 
N-formyl methionyl receptors were originally identified in 1975 as bacterial 
chemoattractant receptors on the basis of their affinity for peptides with an amino 
terminal formylation, as occurs in peptides derived from certain bacterial and 
mitochondrial proteins (Schiffman et al., 1975).  The N-formyl peptide 
chemoattractant receptor was shown to direct leukocytes after bacterial or cell 
destruction (Le et al., 2002).  Structural-activity relationships were investigated using 
synthetic peptides as chemotactic factors with rabbit neutrophils.  These studies 
showed that, of the N-formyl methionyl peptide series tested, fMLP was the most 
potent based of its ability to stimulate movement in a Boyden chamber (two 
compartments used to test for chemotaxis that are separated by a filter).  This high 
activity was attributed to the position of the phenylalanine in the carboxyl terminal, as 
little or no effect on the activity was shown when this residue was located as the 
second amino acid from the NH2 terminal.  The high specificity of the structure 
indicated that the interaction between the peptide and neutrophils was likely to be 
associated with a stereospecific receptor on the neutrophils surface (Showell et al., 
1976).  From this data, fMLP became a prototype for the study of neutrophil 
activation by chemoattractants. 
 
This work led to identification of the formyl peptide chemotactic receptor on human 
neutrophil membranes using covalent affinity labelling (Niedel et al., 1980).  
Association of these receptors as GPCRs was indicated by observations that both a 
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high affinity guanine nucleotide binding protein and guanosine 5'-triphosphate 
enzyme are closely associated with a neutrophil FPR (Hyslop et al., 1984). 
 
In 1990, isolation of a human FPR from cloned complementary deoxyribonucleic acid 
(cDNA) revealed evidence that this receptor shares the seven transmembrane domain 
structure characteristic of the GPCR superfamily (Boulay et al., 1990).  GPCRs are 
generally considered one of the largest and most diverse group of cell surface 
receptors and the majority of drugs active at these receptors have a broad range of 
diverse therapeutic indications (Drews, 2000).  A comprehensive analysis of the drug 
targets in 1996 showed that GPCRs constitute a subgroup of drug targets, representing 
some 45% of all targets of the 500 molecular targets addressed (Drews, 2000), which 
in 2009 comprises approximately 27% of all Food and Drug Administration (FDA) 
approved drugs (Williams & Hill, 2009), clearly demonstrating that the technology 
and capability to develop drugs that target the FPRs is available. 
 
Following isolation of a human FPR1 from cloned cDNA (Boulay et al., 1990), two 
variants of the human FPR1 were isolated from a eukaryotic expression vector 
(CDM8) library prepared from mRNA of human promyelocytic leukaemia cells (HL-
60) differentiated to the granulocyte phenotype with dibutyryl adenosine
 
3':5'-cyclic 
monophosphate [Bt2cAMP, (Boulay et al., 1990)].  Thus, it became apparent that the 
human FPR subfamily includes three members FPR1, FPR2 and FPR3.   
 
FPR2 was initially identified through screening of a HL-60 neutrophil cDNA library 
with an FPR cDNA probe.  The cDNAs of both were found to cross-hybridise with a 
third gene which was designated FPR3 [FPRL2, (Murphy et al., 1992)].  Evidence 
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supporting this was identified at the same time when genes encoding the receptors for 
FPR were mapped to chromosome 19 (Bao et al., 1992).  From this, two structural 
homologues of the FPR (FPR2 and FPR3) were identified, which also map to 
chromosome 19 and these homologues did not recognise the ligand fMLP (Bao et al., 
1992).  Further molecular cloning indicated that FPR1 may be the only gene that is 
expressed by neutrophils that encodes a receptor capable of binding prototypic N-
formyl peptides (Murphy et al., 1992), indicating a functional divergence of these 
receptors.  However, FPR2 is now considered to be a low-affinity receptor for these 
peptides as in vitro activation occurred at very high concentrations whilst FPR3 does 
not bind or respond to N-formyl peptides (Ye et al., 1992).  Also, FPR3 does share 
some non-formylated chemotactic peptides identified as ligands for FPR2 (Christophe 
et al., 2001). 
 
Since their initial identification, it has become apparent that the FPR family also 
respond to a range of non-formylated peptides (e.g. HIV envelop proteins, serum 
amyloid, β-amyloid1-42, ANXA1) and also to certain lipid mediators (lipoxin A4, 
LXA4) which are specifically associated with disease processes and/or the body‘s 
defence of them.  The cyclooxygenase (COX) and lipoxygenase pathways are two 
major routes by which AA is oxygenated, leading to the production of eicosanoids.  
Products of the COX pathway include prostaglandins and thromboxanes, whilst the 
lipoxygenase pathway generates leukotrienes and hydroxyeicosataetranoic acids 
(HETE).  Eicosanoids are important modulators of many important physiologic 
activities such as immunoregulation and inflammation, as well as carbohydrate 
metabolism, lipolysis, bone resorption and reproductive physiology (Becker, 2001).  
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Hence, these receptors may well have greater functional significance than was 
originally envisaged.   
 
The eicosanoid GPCR, ALX, was cloned in 1992 by Murphy et al. (1992) who 
identified that this receptor has a high sequence homology to FPR1 (Murphy et al., 
1992) and later referred to this as FPR2 (Ye et al., 1992). Although FPR2 shares 
~70% homology with FPR1, FPR2 has a low affinity to fMLP and is selective for 
LXA4 by three orders of magnitude (Ye et al., 2009).  In human neutrophils, LXA4 
was identified as the first endogenous ligand for FPR2 (Fiore et al., 1994).  In 
functional experiments, LXA4 was shown to possess anti-inflammatory properties, 
inhibiting neutrophil infiltration (Takano et al., 1998) that was perceived to be 
through induction of NO production, thus suppressing leukocyte-endothelial cell 
interaction (Ye et al., 2009).  The anti-inflammatory properties of LXA4 include 
suppression of pro-inflammatory cytokines (Wu et al., 2005), inhibition of NF-κB 
(Wu et al., 2008) and stimulation of IL-10 (Souza et al., 2007), an anti-inflammatory 
cytokine.  The intracellular signalling cascades for FPR2 appear specific and selective 
for different cell types.  LXA4 stimulated rapid lipid remodelling and release of AA 
(Grandordy et al., 1990), blocked intracellular generation of inositol 1, 4, 5-
triphosphate as well as Ca
2+
 mobilisation (Lee et al., 1989) in human PMNs, however 
in human monocytes, LXA4 triggers intracellular Ca
2+
 release (Romano et al., 1996; 
Maddox et al., 1997).  This data suggests that LXA4, through FPR2, acts on different 
cell specific signalling pathways and is tissue dependent.        
 
In the mouse, eight different members of the FPR family have been identified to date.  
These are designated Fpr1, Fpr-related sequences (Fpr-rs) 1-7 (Ye et al., 2009).  
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Initial work characterised six different receptors using probes for the three human 
genes, which form a cluster on chromosome 17 in a region of conserved synteny with 
human chromosome 19 (Ye et al., 2009).  Fpr1 is considered the orthologue of FPR1 
and shows higher affinity for fMLP than the other murine receptors, whilst Fpr-rs1 
and Fpr-rs2 are viewed as orthologues of the human ALX [FPR2, (Gao et al., 1998)].  
Very little is known of the biology of Fpr-rs3, Fpr-rs4 and Fpr-rs5 which do not 
encode full length receptors.  Fpr-rs6 to Fpr-rs7 do however appear to represent 
classical GPCRs, although as yet nothing is known of their physiological ligands 
(Wang & Ye, 2002).  Therefore, the FPR gene cluster has undergone differential 
expansion in mammals with Fpr-rs1-7 arising after divergence of human and mouse 
(Figure 1.7).  The structural relationships between FPR1, FPR2 and FPR3 may lead 
one to the hypothesis that there could be a potential evolutionary drift in the 
functional role of these receptors.   
 
More recently, the nomenclature of the FPRs has been amended to an International 
Union of Basic and Clinical Pharmacology-recommended nomenclature  (Ye et al., 
2009).  In essence, murine Fpr1 is considered the orthologue to human FPR1 in which 
they share a sequence identity of 77%.  For Fpr-rs1 and Fpr-rs2 the orthology and lack 
of understanding is more complex.  Fpr-rs2 is referred to as murine Fpr2 (Ye et al., 
2009), whilst National Centre for Biotechnology Information (NCBI) database refer to 
Fpr-rs1 as murine Fpr3 (Fpr3).  Fpr2 shares a sequence identity of 76% with FPR2, 
yet Fpr3 shares a sequence identity of 60% with FPR3 and 73% with FPR2.  Indeed, it 
is presently difficult to understand whether the gene product of Fpr3 or Fpr2 is the 
ortholog of FPR2/ALX, because both receptors are able to detect and respond to 
LXA4.  It is hoped that the work included in this thesis will contribute to the 
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differentiation of these receptors.  Therefore, for the rest of this thesis, murine FPRs 
will be referred to as Fpr1, Fpr2 and Fpr3 for Fpr1, Fpr-rs2 and Fpr-rs1, respectively. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Structural relationships among members of FPR gene cluster. 
Dendogram representing structural similarities between human and mouse FPR-
related amino acid sequences (Ye et al., 2009). 
 
To assist with the understanding of the potential relevance of each receptor, a 
summary of our current knowledge of the expression profile and ligands of the FPRs 
is provided in Tables 1.1-6.   
FPR1 (man) 
Fpr2 (mouse)
Fpr3 (mouse)
FPR3 (man)
FPR2 (man)
Fpr-rs 3 (mouse)
Fpr-rs 4 (mouse)
Fpr-rs 5 (mouse)
Fpr-rs 6 (mouse)
Fpr-rs 7 (mouse)
Fpr1 (mouse) 
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Human FPR1 Mouse Fpr1 
Tissues 
adrenal glands 
autonomic nervous 
system 
bone marrow 
colon 
central nervous 
system 
eye 
heart 
kidney 
liver 
lung 
spleen 
uterus 
ovary 
placenta 
stomach 
thyroid  
 
Cell types 
adrenal cortical cells 
astrocytes 
endothelial cells 
epithelial cells 
fibroblasts 
hepatocytes 
immature dendritic cells 
Kupfer cells  
microglial cells 
monocytes/macrophages  
platelets 
PMNs 
smooth muscle cells 
thyroid follicular cells 
U937 cells 
vascular smooth muscle cells 
 
Tissues 
adrenal gland 
anterior pituitary 
hippocampus 
hypothalamus 
liver 
lung 
spleen 
 
Cell types 
dendritic cells 
PMNs 
mononuclear cells 
microglial cells 
 
 
 
 
Table 1.1: Tissue and cellular distribution for FPR1 in human and mouse.  A 
summary of the currently established cell types or tissue distribution for FPR1, 
adapted from (Le et al., 2002; Migeotte et al., 2006; John et al., 2007; Rabiet et al., 
2007; Mandal & Hamilton, 2007; John et al., 2008).  PMNs, polymorphonuclear 
leukocytes. 
 
 
Human FPR2 Mouse Fpr2 
Tissues 
brain 
bone marrow 
lung 
placenta 
spleen 
testis 
Cell types 
astrocytes 
B/T lymphocytes 
endothelial cells 
epithelial cells 
fibroblasts 
hepatocytes 
immature dendritic cells  
microglial cells 
monocytes/macrophages 
PMNs 
Tissues 
anterior pituitary  
adrenal gland 
hippocampus 
hypothalamus 
lung 
spleen 
 
Cell types 
microglia 
PMNs 
 
Table 1.2: Tissue and cellular distribution for FPR2 in human and mouse.  A 
summary of the currently established cell types or tissue distribution for the FPR2, 
adapted from (Le et al., 2002; Migeotte et al., 2006; John et al., 2007; Rabiet et al., 
2007; Mandal & Hamilton, 2007; John et al., 2008).  PMNs, polymorphonuclear 
leukocytes. 
 
 
Chapter 1 
 
 57 
 
Human FPR3 Mouse Fpr3 
Tissues 
adrenal gland 
liver 
lung 
lymph nodes 
placenta  
small intestine 
spleen 
trachea 
 
Cell types 
dendritic cells 
HL-60 cells 
monocytes/macrophages 
 
Tissues 
adrenal gland  
anterior pituitary 
heart 
hippocampus 
hypothalamus 
liver 
lung  
spleen 
 
Cell types 
microglia 
leukocytes 
 
 
Table 1.3: Tissue and cellular distribution for FPR3 in human and mouse.  A 
summary of the currently established cell types or tissue distribution for the FPR3, 
adapted from (Le et al., 2002; Migeotte et al., 2006; John et al., 2007; Rabiet et al., 
2007; Mandal & Hamilton, 2007; John et al., 2008).  PMNs, polymorphonuclear 
leukocytes. Note: murine Fpr-rs3-7 not included. 
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FPR1 
Agonist Antagonist 
Bacterial peptides 
fMLP 
formylated peptides 
 
Viral peptides 
HIV-1 T20 (DP178) 
HIV-1 T21 (DP107) 
HIV gp41 
HSV gG-2p20 
 
Peptide derived 
WKYMVm peptide 
WKYMVM 
 
Host derived 
ANXA1 
ANXA1Ac2-26 
ANXA1Ac2-12 
ANXA1Ac9-25 
Cathepsin G 
LL-37 
SRSRY 
 
Bacterial peptide 
Chemotaxis inhibitory protein of S. 
aureus (ChIPS) 
 
Viral peptides 
Coronavirus 229E peptides 
Coronavirus (SARs) peptides 
Coronavirus OC43 peptides 
Ebola peptides  
HIV-2 peptides 
 
Compound 
Boc1 
Boc2 
Cyclosporin A 
Cyclosporin H 
 
Host derived 
Chenodeoxycholic acid 
Deoxycholic acid  
Spinorphin 
 
 
 
 
Table 1.4: Summary of FPR1 ligands. A summary of the currently established 
ligands for FPR1 based on current literature combining murine and human data (Le et 
al., 2002; Gargiulo et al., 2005; Haas et al., 2005; Migeotte et al., 2006; Mills, 2006; 
Rabiet et al., 2007; Stenfeldt et al., 2007; John et al., 2008).  
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FPR2 
Agonist Antagonist 
Bacterial peptides 
fMLP 
formylated peptides 
Helicobacter pylori derived peptide 
Hp(2-20) 
 
Viral peptides 
domain F 
HIV-1 T21 (DP107) 
 
Peptide derived 
MMK-1 
N36 (synthetic peptide derived 
from HIV-1) 
V3 (synthetic peptide derived from 
HIV-1) 
WKYMVM 
WKYMVm 
 
Host derived 
Aβ42 
Annexin A1 
ANXA1Ac2-26 
ANXA1Ac2-12 
CRAMP 
D2D388-274 
Humanin 
LL-37 
LXA4 
Major histocompatibility complex 
binding peptide 
PACAP27 
PrP106-126 
sCKβ8-1 
Serum amyloid A 
uPAR84-95 
 
Viral peptides 
Coronavirus 229E peptides 
 
Compound 
Boc1 
Boc2 
 
Host derived 
Chenodeoxycholic acid 
Deoxycholic acid  
PBP10 
Spinorphin
1
 
 
Peptide derived 
WRW
4
 
 
 
Table 1.5: Summary of FPR2 ligands. A summary of the currently established 
ligands for FPR1 based on current literature combining murine and human data (Le et 
al., 2002; De Paulis et al., 2004; Harada et al., 2004; Migeotte et al., 2006; Rabiet et 
al., 2007; Tsuruki et al., 2007; John et al., 2008).  (1) spinorphin is an antagonist and 
was incorrectly labeled agonist by Migeotte et al., (2006).  
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FPR3 
Agonist Antagonist 
Bacterial peptides 
Hp(2-20) 
 
Peptide derived 
WKYMVm  
WKYMVM 
 
Host derived 
ANXA1Ac1-25 
ANXA1Ac2-26 
F2L (FPRL2 ligand) 
Humanin 
LXA4 
uPAR84-95 
 
Viral peptides 
ETYIKPWWWVWL (derived from 
coronavirus 229E  
 
Compound 
Boc1 
Boc2 
 
Peptide derived 
WRW
4
 
 
 
Table 1.6: Summary of FPR3 ligands.  A summary of the currently established 
ligands for FPR1 based on current literature combining murine and human data (Le et 
al., 2002; De Paulis et al., 2004; Harada et al., 2004; Migeotte et al., 2006; Rabiet et 
al., 2007; Tsuruki et al., 2007; John et al., 2008). 
 
Functional studies indicate that FPR1 is a key contributor to host defence against 
pathogens, allowing phagocytic cells to recognise the presence of bacteria (Migeotte 
et al., 2006).  This receptor also responds to certain virus particles, in particular from 
HIV-1, a synthetically derived version of the peptide segment T20/DP178 of the HIV-
1 envelope protein gp41, which mediates fusion with human host cells, bind to FPRs 
(Su et al., 1999).  Furthermore, FPR1 appears to mediate the chemoattractant activity 
of a synthetic version of herpes simplex virus type 2 glycoprotein G (gG-2p20) and its 
ability to induce the release of reactive oxygen from monocytes and neutrophils 
(Bellner et al., 2005).  In addition, peptides derived from HIV-2, Coronavirus 229 E, 
severe acute respiratory syndrome coronavirus and Ebola virus were all potent 
antagonists of the FPRs in Chinese hamster ovary (CHO) cells (Mills, 2006).  This 
clearly highlights that the role of FPRs in host defence is important and may offer new 
therapeutic areas for treatment of these pathogens. 
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The presence of FPR and FPR2/ALX in microglial cells (Migeotte et al., 2006) gives 
a potential indication for the role of FPRs in diseases of the CNS.  Microglial cells are 
those generally considered most relevant to the immune response of the CNS and are 
considered closely associated with macrophages.  Like macrophages, microglial cells 
are believed to be derived from monocytes or other precursors that originate in the 
bone marrow during embryonic development and then migrate to the CNS to 
differentiate (Chew et al., 2006).  Microglial cells are considered to play a key role in 
the pathogenesis of neuroinflammatory and neurodegenerative disease, for example 
Alzheimer‘s disease (Turner, 2006) and are readily activated by brain injury 
(Kreutzberg, 1996).  In the Alzheimer‘s disease brain, microglial cells accumulate at 
the sites of Aβ peptide deposition and FPR2/ALX has been shown both to be 
expressed by activated microglial cells and to mediate the chemotactic activity of 
Aβ42.  In addition, FPR2/ALX participates in Aβ42 internalization in macrophages 
and its cytotoxicity for neuronal cells (Iribarren et al., 2005).  Whilst the interaction of 
ANXA1 and the HPA axis is the focus of this research project, an interesting 
association is that ANXA1 has been seen in microglial cells and it has been proposed 
that ANXA1 may offer a neuroprotective action by limiting microglial activation 
(Minghetti et al., 1999) and this could be associated with its affinity to FPRs.  Whilst 
the causes of Alzheimer‘s disease are not known and are likely to involve many 
complex pathways, advances in our understanding of the role of FPRs in Alzheimer‘s 
disease and other neurodegenerative disease may assist in development of novel 
therapies. 
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1.7 Formyl peptide receptors and the neuroendocrine system 
As discussed previously, evidence is accumulating that the FPR family are targets for 
ANXA1 and peptides derived from it in the host defence system.  Thus, for example 
in a model of mouse peritonitis, FPR antagonists Boc1 and Boc2 quenched the anti-
migratory effects of peptides ANXA1Ac2-26 and ANXA1Ac2-12 (Perretti et al., 2001).  
Additionally, binding of ANXA1 to circulating leukocytes was lower in Fpr1-null 
mice indicating a functional role for FPR1 in the anti-migratory effects of ANXA1 
and derived peptides (Perretti et al., 2001).   
 
A recent study has provided novel evidence the FPR family in mediating the actions 
of ANXA1 in the anterior pituitary gland (John et al., 2007).  Reverse transcription-
polymerase chain reaction (RT-PCR) analysis demonstrated expression of mRNAs for 
four members of the FPR family in the murine pituitary gland, Fpr2, Fpr3, Fpr-rs6 
and Fpr-rs7, although not for Fpr1.  Functional studies performed by John et al., 
(2007) showed that, like GCs, ANXA1 and two derived peptides (ANXA11-188 and 
ANXA1Ac2-12) inhibit ACTH release from the anterior pituitary tissue in vitro (John et 
al., 2007).  Similar responses occurred in tissue from FPR1 KO mice, suggesting in 
line with the expression profile, that FPR1 does not mediate the effects of ANXA1 at 
the pituitary level.  However, the effects of GCs and the ANXA1 peptides in wild-
type (WT) mice were reversed by a high but not a low concentration of the pan FPR 
antagonist, Boc1, suggesting that other FPR family members may be important in this 
regard (John et al., 2007).  Furthermore, the inhibitory effects of GCs and ANXA1 on 
ACTH release were mimicked by high concentrations of fMLP and LXA4, and the 
actions of both fMLP and LXA4 were also overcome by Boc1.  Taken together, these 
data suggest that the effects of ANXA1 in the pituitary gland are independent of Fpr1, 
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but may involve other FPR family members, in particular Fpr2 or Fpr3 and provides 
interesting evidence for the role of the FPR family in the regulation of neuroendocrine 
function [(John et al., 2007), Figure 1.8]. 
 
1.8 Experimental models of stress 
The neuroendocrine and immune systems interact to maintain physiological 
homoeostasis during inflammatory stress.  The stress model used in this project, to 
characterise and understand the mechanisms for ANXA1 and the FPRs, was 
administration of LPS to mice.  LPS is an endotoxin that acts as an immunological 
stressor eliciting a prolonged activation of the HPA axis after administration (Loum-
Ribot et al., 2006). 
This is best exemplified by the significantly reduced survival rate of adrenalectomised 
rodents following administration of LPS, which show increased tolerability following 
co-administration of GCs  (Webster & Sternberg, 2004).  Administration of LPS 
activates the HPA axis through release of cytokines from stimulated immune cells, 
primarily IL-1, IL-6 and TNFα.  These cytokines promote the release of ACTH, either 
centrally by indirect mechanisms or peripherally by acting directly on the pituitary 
gland.  The exact mechanism of ACTH release is still unclear as elevations were seen 
in animals even after removal of the medial hypothalamus (Stark et al., 1973).  
Elevation of plasma GCs leads to an immunosuppressive effect on these cytokines as 
well as up-regulation of other cytokines such as IL-4 and IL-10 (Loum-Ribot et al., 
2006).   
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Figure 1.8: Proposed role of ANXA1 and FPRs. A growing body of data suggests that the actions of ANXA1 in both systems are mediated, at 
least in part, through actions on FPRs, a family of GPCRs first characterised by their ability to respond to formylated bacterial peptides, e.g. 
fMLP (John et al., 2007).  
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GCs inhibit cytokine production indirectly through inhibition of pro-inflammatory 
transcription factors such as NF-κB which increases the expression of many genes 
including those for cytokines, enzymes and adhesion molecules (Beishuizen & Thijs, 
2003).  IL-1 and its related family members are pro-inflammatory cytokines that 
stimulate the expression of genes associated with inflammation, such as: COX type 2 
(COX-2); type 2 phospholipase A; inducible nitric oxide synthase (iNOS); and 
adhesion molecules such as VCAM-1.  The two principle IL-1 cytokines are IL-1α 
and IL-1β, and both are produced by macrophages, monocytes and dendritic cells.  
Studies with LPS in IL-1β KO mice showed similar responses to that seen in WT 
mice with no differences in plasma elevations of GCs, indicating that it is not IL-1β 
that is required for activation of the HPA axis during endotoxaemia and that IL-1β 
plays a more relevant role in the induction of fever (Fantuzzi et al., 1996).  More 
recently IL-18, that is structurally associated with the IL-1 family that has pro-
inflammatory, pro-apoptotic and pro-atherogenic activities, may also contribute in the 
regulation of the HPA axis (Sugama & Conti, 2008).  IL-18 has been observed in the 
adrenal and pituitary glands during stress and IL-18 null mice show reduced basal and 
stress-induced levels of CORT (Seino et al., 2007) indicating that IL-18 may actually 
contribute to CORT synthesis.  It has also been shown that, unlike IL-1β (Tsagarakis 
et al., 1989), IL-18 inhibits CRH release (Tringali et al., 2005).   
IL-6 stimulates ACTH, either through release of CRH and AVP or directly by acting 
on the corticotrophs, and stimulates PRL, growth hormone (GH) and leuteinising 
hormone (LH).  IL-6 is a pleiotropic cytokine produced by both lymphoid and non-
lymphoid cells and regulates immune reactivity, the acute phase response, 
inflammation, oncogenesis and haematopoesis (Beishuizen & Thijs, 2003).  
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Interestingly, when LPS was administered to IL-6 KO mice, a similar endotoxic 
response to WTs was observed, showing that under these conditions, IL-6 function is 
dispensable (Fattori et al., 1994).  IL-6 KO mice produced three times more TNFα 
that WT controls, which suggests that an increase in TNFα production might be one 
of the compensatory mechanisms through which a normal response to LPS is 
achieved in the absence of IL-6 (Fattori et al., 1994).  Whilst it was considered that 
the elevation in TNFα was a compensatory mechanism through which a normal 
response to LPS was achieved, it should be noted that TNFα expression can be 
suppressed by IL-6 as well as GCs, and that this elevation may just have been due to a 
break in the feedback loop of homeostasis.  Interestingly, IL-6 KO mice showed 
comparable increases in GCs following administration of LPS, indicating an increase 
in IL-6 may not be required for activation of the HPA axis (Fattori et al., 1994).  
TNFα was originally identified as an anti-tumour agent that induced necrotic cell 
death in sarcomas.  Whilst high levels of TNFα play a pivotal role in tissue injury, low 
levels may be beneficial in repair and regeneration of damaged tissue, including CNS 
tissue as it may play a central role in promoting neurogenesis and brain repair in 
response to brain injury and infection (Bernardino et al., 2008).  TNFα has also been 
shown to activate the HPA axis, via a dual mechanism, inhibiting the release of 
ACTH at the pituitary level, and stimulating the release of CRH at the hypothalamic 
level (Turnbull & Rivier, 1999).   
As yet, little is known of the extent to which stressful stimuli such as LPS that 
activate the HPA axis influence the expression and function of ANXA1 and FPRs 
within the brain-neuroendocrine system.  ANXA1 is an important mediator of the 
regulatory effects of GCs and recent data suggests its actions are mediated via FPRs.  
In the present study, in vitro and in vivo methods have been used to determine the 
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presence and function of these receptors in response to LPS.  Accordingly, the effects 
of LPS treatment were examined on (a) the expression of mRNAs for ANXA1 and 
FPRs within the HPA axis (b) serum CORT and plasma cytokines (c) general 
histology, immunohistochemical markers of tissues from WT, Fpr2
-/-
, ANXA1
-/-
, 
PMN depleted mice and (d) the functional activity of dispersed adrenal cells taken 
from WT mice.  Therefore, the aim of this thesis is to understand further the role of 
the FPR family and their interaction with ANXA1 and other ligands, in mediating the 
adaptive responses of the HPA axis to LPS.  
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CHAPTER 2         
MATERIAL AND METHODS 
2.1 Animals 
All animal work was performed under licence according to Home Office regulations 
[guidance on the operation on animals was from the Animals (Scientific Procedures) 
act 1986] and in compliance with the Italian national legislation (DL 116/92) and 
European Directive 86/609. 
 
2.1.1 Maintenance 
Animals were housed according to treatment group and sex (3-6 per cage) and 
acclimatised to local housing conditions for at least 5 days prior to each experiment.  
Animals were maintained on a standard chow pellet diet and had free access to water.  
The environmental controls were set to maintain temperature within the range 
21 to 23C and relative humidity within the range 45 to 65%; with an approximate 
12-hour light and 12-hour dark cycle (lights on 08:00 – 20:00h).  Experiments were 
always started between 09.00 - 10.00h to minimise complications associated with 
circadian rhythms.   
 
2.1.2 Wild type mice (C57Bl/6) 
Male C57Bl/6 mice, referred to as WT within this thesis, were purchased from either 
Charles River [Calco (Lecco), Italy or Manston, UK], or Banton and Kingsman (Hull, 
Humberside, UK).  All animals weighed approximately 20 – 30 grammes (g) at the 
start of each experiment.    
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2.1.3 Fpr2 null mice 
A colony of Fpr2 null mice (Fpr2
-/-
) was bred on site.  Breeding pairs were kindly 
donated by Professor Flower of the William Harvey Research Institute (WHRI) at 
Barts and The London School of Medicine and Dentistry.  These mice were derived 
from C57Bl/6 mice in which Fpr2 was ‗knocked out‘ using the method of 
homologous recombination/gene targeting (Capecchi, 1989) and green fluorescent 
protein (GFP) was ‗knocked in‘ as a ‗reporter‘ gene. All animals weighed 
approximately 20 – 30g at the start of each experiment.  As these mice are a new 
colony and have been backcrossed for less than 6 generations, it was necessary to use 
Fpr2 littermate controls (Fpr2
+/+
) in the experiments and genotype using polymerase 
chain reaction (PCR, see Section 2.3.3).   
 
2.1.4 ANXA1 null mice 
A colony of ANXA1 null mice (ANXA1
-/-
) was bred on site.  Adult male ANXA1
-/-
 
mice (approximately 20 - 30g), previously generated (Hannon et al., 2003), have been 
back-crossed with C57Bl/6 for more than twelve generations, thus, C57Bl/6 were 
used as controls (WT). 
 
2.2 In vivo experiments 
2.2.1 Intra-peritoneal administration of LPS 
Adult male mice (WT, ANXA1
-/-
, Fpr2
-/-
 or Fpr2
+/+
) were injected (i.p.) with LPS 
[extracted from Escherichia Coli serotype O111:B4 (Sigma-Aldrich, Cat L3024) at 
500µg/kg] or vehicle (saline, both at 2.5 ml/kg). 
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2.2.2 Intra-cerebroventricular administration of LPS or saline 
Adult male mice (C57Bl/6) were anaesthetised using a mixture of Hypnorm 
(2.5mg/ml fluanisone/0.079mg/ml fentanyl citrate, Janssen Animal Health) and 
1.25mg/ml midazolam (Roche) in sterile water (mixed 1:1:2) at 10ml/kg i.p.  Mice 
were then placed in a stereotactic surgical frame for intra-cerebroventricular (i.c.v.) 
administration of LPS (50µg/kg) or saline (both at 50µl/kg).  The injection co-
ordinates were -0.2mm caudal, 1.0mm lateral and 2.2mm ventral with respect to 
bregma (Paxinos & Franklin, 2004).  A hole was drilled at these co-ordinates so that 
LPS could be administered i.c.v. using a 28-gauge Hamilton syringe at an infusion 
rate of 0.5µl/min and left in situ for 2min after infusion to prevent reflux along the 
injection tract.  The needle was removed, the aperture dusted with anti-bacterial 
powder, animals sutured and placed in a warming box for recovery.  Following 
recovery, animals were housed as specified in Section 2.1.1.  
 
2.2.3 Polymorphonuclear leukocyte depletion in mice 
Male C57Bl/6 mice were purchased from Charles River (Calco (Lecco), Italy) and 
weighed approximately 20 - 30g at the start of each experiment.  PMN depletion was 
induced by injection (10ml/kg, intra-peritoneally, i.p.) of anti-mouse PMN serum 
(diluted in sterile saline 1:10, Accurate Chemical & Scientific Corp, Product Number: 
AIA31140) or control immunoglobulin G (IgG) isotype matched serum (Accurate 
Chemical & Scientific Corp, Product Number: AIS403) daily for two days prior to the 
specified experiment.  PMN depletion was determined 48h after anti-mouse PMN 
serum by counting of total white blood cells (WBC) on blood diluted 1:20 in Turk's 
solution using a haemocytometer. WBC differential counts were obtained from blood 
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smears stained with Wright-Giemsa (Sigma, Cat: WG128).  These counts were 
compared with samples taken prior to administration of anti-mouse PMN serum. 
 
As administration of hyperimmune serum at high doses can lead to overt toxicity, and 
subsequently death, a small dose-range finding study was performed where two 
groups of mice (n=3) were given a 1:10 dilution of anti-PMN at the recommended 
doses of 10-20ml/kg (i.p., as specified by supplier in Accu-Spec Sheet).  Following 
two daily doses, animals were killed and a white cell count was performed.  A further 
two animals were given two daily doses of 20ml/kg (i.p.), the maximum tolerated 
dose (as specified by supplier in Accu-Spec Sheet), followed by LPS (500µg/kg; 
2.5ml/kg i.p.), 24h after the last dose and killed after 6h to assess tolerability to LPS.  
PMNs were depleted by >80% when compared to historical control data and there 
were no mortalities.  Therefore a dose of 10ml/kg was selected for the main 
experiment.  
 
2.2.4 Tissue sampling 
A number of different in-vitro tests (Section 2.3) were performed, so tissue and blood 
samples were collected from mice in different ways, according to the experimental 
requirements.  
 
A) In situ hybridisation 
Adult male WT mice were anaesthetised with 100mg/ml chloral hydrate (Sigma-
Aldrich, Cat C8383) at 4ml/kg i.p.  The heart was incannulated through the left 
ventricle and all blood was removed through the right auricle using saline perfusion.  
The brain and spleen were removed and placed into pre-stirred isopentane (Sigma-
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Aldrich, Cat M32631) at approximately -25°C for 2min and then stored frozen at 
-80°C before subsequent analysis. 
 
B) Enzyme-linked immunosorbent assay/Enzyme immunoassay/Luminex 
Blood was collected by cardiac puncture immediately after terminal anaesthesia 
(5mg/kg sodium pentobarbitone; 200mg/ml) into either chilled heparinised or non-
heparinised tubes for the separation of plasma or serum, respectively.  The blood 
samples were then centrifuged (2000g, 10min, 4ºC) and the supernatant fluid 
collected and stored at -20°C. 
 
C) Quantitative real time polymerase chain reaction 
Adult male WT mice were anaesthetised with 5mg/kg sodium pentobarbitone 
(200mg/ml), the heart incannulated through the left ventricle and all blood removed 
through the right auricle using saline perfusion.  The pituitary gland, adrenal glands, 
spleen, hippocampus and hypothalamus (dissected from brain) were immediately 
collected, placed into ribonuclease (RNase) free Eppendorf tubes with the appropriate 
volume of RNAlater (Ambion) and stored overnight at 4ºC.  The following day, 
excess RNAlater was removed and samples were stored at -80°C. 
 
D) Histology 
Adult male mice (WT, ANXA1
-/-
, Fpr2
-/-
 or Fpr2
+/+
) were anaesthetised with 5mg/kg 
sodium pentobarbitone (200mg/ml), the heart incannulated through the left ventricle 
and all blood removed through the right auricle using saline perfusion.  The brain, 
thymus, spleen, pituitary and adrenal glands were immediately collected.  Tissues 
were stored in 10% neutral buffered formalin (Sigma). 
Chapter 2 
 
 73 
E) Static incubation of primary adrenal cells 
Adult male mice (WT) were killed by carbon dioxide asphyxiation followed by 
cervical dislocation and the adrenal glands removed and placed in Earle‘s Balanced 
Salt Solution (EBSS) for static incubation experiments. 
 
2.3 Tissue analysis 
2.3.1 In situ hybridisation  
Detection of mRNA by in situ hybridisation (ISH) of labelled oligonucleotides was 
performed based on published methods (Tacconi et al., 2001), as described in the 
following section.   
 
2.3.1.1 Probe design  
The sequence of mRNA for each receptor was retrieved from the NCBI database 
(http://www.ncbi.nlm.nih.gov/, 2006).  Multiple antisense oligonucleotide probes for 
each receptor comprising approximately 45 base pairs and 50% GC ratio were ordered 
(Table 2.1, Sigma-Proligo).  The specificity of the probes was evaluated using the 
public domain programme, Basic Local Alignment Search Tool (BLAST), which 
finds regions of local similarity between sequences 
(http://www.ncbi.nlm.nih.gov/BLAST/).  As well as multiple antisense probes, a 
sense probe was ordered to act as an additional control.  For CRH-R1, a validated 
murine oligonucleotide was kindly donated by the Department of Biology, 
GlaxoSmithKline, Verona, Italy.   
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Murine 
Receptor 
Accession 
Number 
Probe Sequence (antisense) 
CRH-R1 NM_007762 Probe A: ACCACGTGGCGTTGCGCAGGATGAAAGCCGAGATGAGGTTCCAGTG 
V1b NM_011924 Probe A:  AGCAGCTCAGAGCGTTTTATGCTCTTGGATTCCTAGTCCAGAGGC 
Probe B:  GGAGAGAGTAGCCGTTTCTAAGTTGTCTTGAAGGTGAGGTCCAGG 
Probe C:  GGGTGTTAATATGGGAAGGTTGGAGGAGGTTGGAAGTGGGGGCTT 
Fpr1 NM_013521 Probe A: CTCCTGAACTTTCCAACAGCTCTGGACAGATCTACAGCTGATCTC 
Probe B: GCAATGTAAAATGGCAAAGTGGAAGTGAAGCAAAAGTCAGCAATG 
Probe C: TCACGGACTTGGATTGTGGATATGAGGGCCACTACTTGAAATGGG 
Fpr2 NM_008039 Probe A: GCACAACCAGCTGAGGTCTCCTTCTTACACTCTTCGGTTCCTGTG 
Probe B: ACAACCACCATTGAGAGGATCCACAGAACTCTGGAGATGGTAGAA 
Probe C: ACAAATGCAGCGGTCCAAGGCAATGAGAGCAATCAAGAAGACACT 
Probe D: CACTCTTCGGTTCCTGTGGTGTAAATGAAGTACTTGGCTCTCACT 
Probe E: GGAGACAACCACCATTGAGAGGATCCACAGAACTCTGGAGATGGT 
Fpr3 NM_008042 Probe A
1: CAACCAGCTGAGGTCTCCTTCTTACACTCTTCGGTTCCTGTGGTG  
 
Probe B: CAGATCACTAGTCCATTGCCCAGCACACCAAGGAAGAAAGTGATG 
 
 
Table 2.1: Oligonucleotide sequences used for in situ hybridisation.  For detection 
of mRNA by in situ hybridisation, oligonucleotide probes were designed based on the 
target mRNA sequence (NCBI database).  
1
Note: Further BLAST (2008) analysis of 
sequence Fpr3 probe A showed homology to Fpr2, therefore, will be referred to in 
results section as Fpr2. 
 
2.3.1.2 Tissue preparation  
Frozen coronal sections (3 sections/slide) of brain from untreated WT mice were 
prepared focusing on the hypothalamic area (Paxinos & Franklin, 2004).  Sections 
were cut with a thickness of 14µm using a microtome at approximately -20°C, then 
stored frozen at -20°C. 
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2.3.1.3 Probe labelling 
A) Non-radioactive 
ISH was initially performed using biotin hyperlabelled probes for CRH-R1 
(GeneDetect, Auckland, New Zealand) in an attempt to validate a non-radioactive 
method for detection of mRNA that could be used for quantitative analysis in future 
experiments.   
 
Frozen sections were removed from storage at -20°C and placed into cold (4°C) 4% 
paraformaldehyde (PFA, Sigma) in 0.1M phosphate buffered saline (PBS) for 
10 - 15min.  The slides were washed 3x5min in 0.1M PBS and incubated in 0.3% 
hydrogen peroxide (Sigma) in PBS for 30min at room temperature so as to inhibit 
endogenous peroxidase activity (quenching step).  This was followed by a further 
3x5min washes with 0.1M PBS, after which the slides were placed in 100% ethanol 
for 5min and then dried at room temperature.   
 
The CRH-R1 probe was added to the hybridisation buffer at concentrations between 
100 - 1000ng/ml, mixed well and placed onto the slides (400µl/slide) prior to 
incubation for at least 18h at 37°C in sealed chambers at high humidity.  The slides 
were removed and washed using different concentrations of standard saline citrate 
buffer (SSC, Invitrogen): 
1X SSC  Room temperature 5min 
1X SSC  Room temperature 5min 
1X SSC  55°C 20min 
1X SSC  55°C 20min 
0.5X SSC  55°C 20min 
0.5X SSC  55°C 20min 
0.5X SSC  Room temperature 5min 
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Detection of the biotin labelled probes was performed using the VECTASTAIN ABC 
kit (Vector Laboratories) and counterstained with diaminobenzidine (DAB, Sigma). 
 
B) Radioactive (
33
P) 
Radioactive labelled probes were used for CRH-R1, V1b, Fpr1, Fpr2 and Fpr3 for 
detection of mRNA in brain using 
33
phosphorous (
33
P) labelled oligonucleotide 
probes.   
 
The 
33P was bound to the oligonucleotides using the 3‘ tailing kit (GE Healthcare Life 
Sciences).  The following were added to an Eppendorf: 2µl 5‘ terminal transferase 
buffer (GE Healthcare Life Sciences), 1.2µl oligonucleotide (150ng/µl, Sigma-
Proligo), 6.4µl 
33
P (PerkinElmer) and 0.4µl terminal transferase (GE Healthcare Life 
Sciences) and incubated for 2h at 37ºC.  Unincorporated nucleotides were removed 
from the labelled nucleotides using a mini quick spin column (Roche) and made to a 
final volume of 25µl with double distilled water (ddH2O).  Three aliquots (1µl) of the 
labelled probes were diluted into 4ml of fluoro-pico marker (Sigma) to measure the 
strength of radioactivity as counts per minute (cpm).  The hybridisation buffer was 
diluted to a concentration of 5000cpm.  
 
The 
33
P bound oligonucleotides and/or hybridisation buffer were added (400µl) to 
each slide and incubated for at least 18h at 37°C in sealed chambers at high humidity.  
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Slides were then washed: 
2X SSC  Room temperature 5min 
2X SSC  Room temperature 5min 
0.5X SSC  55°C 20min 
0.5X SSC  55°C 20min 
0.5X SSC  55°C 20min 
1X SSC  Room temperature 5min 
70% Ethanol Room temperature 1min 
95% Ethanol Room temperature 1min 
100% Ethanol Room temperature 1min 
 
Imaging films (BAS-TR2025, Fuji Imaging Plate) were erased (IP Eraser BCS, 
Fujifilm) and slides were placed in the cassettes, covered with an image film and left 
to develop in a sealed lead cabinet, protected from light, for 10 to 14 days.  Variations 
in the duration of exposure were tested in attempt to improve signal and/or reduce 
background noise, dependent on probe used.  Films were removed and analysed 
(Fujifilm, BAS-500) with MCID Basic V7.0 (Imaging Research Inc.).   
 
Two control procedures were included in this experiment.  The first was the use of a 
sense probe (complementary to antisense probes; Table 2.1) to determine whether the 
observed labelling pattern was specific to the target sequence.  The second control 
procedure was the use of multiple probes for the same gene sequence (Table 2.1).  
 
To confirm stereotaxic co-ordinates, the slides were stained with cresyl violet acetate 
(0.1g in 100ml sterile water, Sigma) following ISH and examined by light 
microscopy. 
 
2.3.2 Quantitative real time polymerase chain reaction  
Quantitative real time polymerase chain reaction (qRT-PCR) is based on the 
principles established by Kary Mullis in 1986 (Mullis et al., 1986) which are 
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summarised (Bustin, 2000; Peirson et al., 2003).   
 
QRT-PCR provides an accurate method for determination of levels of specific DNA 
and RNA sequences in tissue samples.  It is considered one of the most sensitive and 
accurate quantification methods (Wang & Brown, 1999).  PCR entails the use of 
primers (approximately 20 nucleotides) that are complementary to a defined sequence 
on each of the two strands of the DNA (Mullis et al., 1986).  The primers are 
extended by a DNA polymerase (to synthesise an oligonucleotide that is hybridised to 
the target amplicon) so that the designated sequence is replicated.  Following this, the 
primers are ‗re-used‘ and copies of both sequences (original and copy) are made.  In 
order to repeat the amplification process the temperature must be increased to separate 
the two strands of the double strand DNA in each round.  As DNA polymerase are 
sensitive to heat, the use of Taq polymerase (a thermo stable DNA polymerase 
isolated from Thermus aquaticus) allowing the process to be replicated without the 
repeated addition of DNA polymerase.  So as to measure mRNA the method was 
further developed using reverse transcriptase to convert mRNA into cDNA which is 
then amplified and is useful to characterise changes in RNA expression under 
different conditions.  Real time PCR was developed to quantify differences in mRNA 
expression, previously quantifiable by northern blotting, ribonuclease protection 
assays, in situ hybridisation and PCR, PCR being the most sensitive of these. 
 
The method used is based on these principles and was optimised for the purpose of 
this investigation and is summarised in Figure 2.1. 
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Figure 2.1: A summary of qRT-PCR.  A basic overview of the key steps required to 
perform qRT-PCR.  These include sample collection (into an RNA stabilising reagent, 
RNAlater), RNA isolation, cDNA preparation in presence of absence of reverse 
transcriptase (RT), plating followed by polymerase chain reaction (PCR). 
 
1) Tissue Collection
2) RNA Isolation
3) cDNA Preparation
4) Plating
5) PCR
Hippocampus
Hypothalamus
Pituitary gland
Adrenal gland
Spleen
RNA Later 
(-80ºC)
Homogenised
RT+ RT-
Sample
collection
Primers and 
probes
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2.3.2.1 RNA collection 
All procedures performed with RNA were done so using materials and reagents that 
were either RNase free (e.g. RNase free Eppendorfs and pipette tips) or had been 
cleaned with 70% ethanol followed by RNase Zap (Ambion): 
 
A) Homogenisation  
The tissues selected for each experiment collected for qRT-PCR were removed from 
-80ºC storage and kept on dry ice prior to homogenisation.  Tissues were removed, 
placed into 175µl ice-cold RNA lysis buffer [4M guanidine thiocyanate, 0.01M Tris 
(pH 7.5) and 0.97% β-Mercaptoethanol] and homogenised using either an Ultra 
Turrax (IKA) tissue disruptor for large tissue or a TissueLyser (Qiagen) for smaller 
tissue until a homogenous and clear solute was achieved.  Samples were maintained 
on wet-ice, and on occasion kept on wet-ice for brief periods during homogenization, 
to maintain a low temperature required for RNA stability. 
 
B) RNA isolation  
RNA isolation was performed using reagents from the SV Total RNA Isolation 
System (Promega) and a modification of its protocol, as described.   
 
Following homogenisation, samples were pulsed at a low speed in a centrifuge and 
immediately placed on ice.  350µl RNA dilution buffer (10X PBS, Promega) was 
added to the lysate and mixed by inversion.  Samples were denatured on a heating 
block at 70°C for 3min and then centrifuged at 13000g for 10min.  The supernatant 
fluid was removed and placed into a new Eppendorf with 200µl ethanol (95%) which 
was mixed by gentle pipetting.  The mixture was transferred to the spin column 
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assembly, centrifuged at 13000g for 1min and the liquid in the collection tube was 
discarded.  600µl of RNA Wash Solution (162.8mM potassium acetate, 27.1mM Tris-
HCL, pH 7.5, Promega) was added to the spin column assembly and centrifuged at 
13000g for 1min, and the liquid was discarded.  50µl deoxyribonuclease (DNase, 
Promega) was placed onto the spin column membrane and incubated for 15min at 
room temperature followed by 200µl DNase stop solution (5M guanidine thiocyanate, 
0.01M Tris-hydrochloric acid, HCL, pH 7.5, Promega).  Two cycles of RNA wash 
(600µl at 13000g for 1min and 250µl at 13000g for 2min) were performed and the 
spin column transferred to a fresh collection tube.  100µl nuclease-free water was 
placed on the membrane and the column spun at 13000g for 1min only.  The spin 
basket was removed, discarded and the purified RNA was stored at -70°C.   
 
Due to the generally low RNA yield for the hippocampus, hypothalamus, pituitary 
and adrenal glands, 50µl nuclease-free water was placed on the membrane and the 
column spun at 13000g for 1min.  The eluate was then re-applied to the membrane for 
15min, before being spun at 13000g for 1min.  
 
If a low yield of RNA was obtained (as determined by quantification), samples were 
placed in a vacuum centrifuge to increase the concentration.  During this procedure, 
care was taken to maintain low temperature and also to ensure that RNA was gently 
mixed using a pipette.  If this was required, quantification and qualification was 
repeated.  For the pituitary gland, the RNA yield was too poor to conduct qRT-PCR, 
therefore samples were ‗amplified‘ as detailed below. 
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2.3.2.2 RNA amplification 
As tissues that generally yield a very low concentration of RNA (<5000ng) were 
being evaluated (i.e. mouse pituitary gland), a further step was necessary to enable 
evaluation of this tissue.  This was based on isothermal RNA amplification (Van 
Gelder et al., 1990) which amplifies mRNA from small starting quantities of total 
RNA.  Briefly, total RNA is converted into first strand cDNA, followed by second 
strand synthesis and purification.  In vitro transcription of the double stranded cDNA 
allows for amplification of all the RNA.  When this method was required, it was 
applied to all samples from the specific time-point and saline-control group so as to 
reduce bias on any analysis.  The reagents used in this amplification system were 
supplied by Invitrogen (Cat. L1016-01) and it is summarised in Figure 2.2. 
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Figure 2.2: A basic summary of RNA amplification.  A basic overview of the key 
steps required to amplify RNA from low yields of RNA.  These include first strand 
cDNA synthesis, second strand cDNA synthesis and in vitro transcription. ATP, 
adenosine triphosphate; CTP, cytidine triphosphate; GTP, guanosine triphosphate; 
UTP, uridine triphosphate. 
 
A) First strand cDNA synthesis 
RNA isolated from the tissues as previously described was initially converted into 
first strand cDNA by reverse transcription.  100-500ng total RNA was added to 1µl of 
T7-Oligo (dT) Primer and made to a final volume of 10µl with deionised, 
diethylpyrocarbonate (DEPC) treated water and incubated at 70ºC for 1min and then 
placed on wet-ice and reagents for first strand cDNA synthesis were added.  Samples 
were mixed, contents collected and incubated at 46ºC for 2h, followed by 70ºC for 
10mins and 4ºC until contents collected and placed on wet-ice for second strand 
synthesis. 
1) RNA
2) First strand cDNA
synthesis
3) Second strand cDNA
synthesis and 
purification
4) In vitro transcription 
and purification
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B) Second strand cDNA synthesis 
Second strand synthesis uses the combined activities of RNase H and DNA 
polymerase I to catalyze second strand cDNA synthesis from an mRNA-cDNA hybrid 
by RNA primed nick translation and includes DNA ligase to seal any nicks in the 
nick-translated second-strand cDNA (D'Alessio & Gerard, 1988).  Samples on wet-ice 
from the first strand cDNA were mixed and the reagents for second strand synthesis 
were added. The incubation mixture was mixed, contents collected and incubated at 
16ºC for 2h.  The second strand cDNA was stored at -20ºC until cDNA purification. 
 
C) cDNA purification 
Prior to in vitro transcription, the cDNA was purified and 500µl cDNA loading buffer 
was added to the sample from the second strand synthesis.  Samples were mixed 
gently, placed onto the spin cartridge, centrifuged at 12000g for 1min and the flow 
through discarded.  700µl cDNA wash buffer was added, the column centrifuged at 
12000g for 4min and the flow through discarded. 100µl of DEPC-treated water was 
added to the centre of the spin column membrane, centrifuged at 12000g for 1min and 
the purified cDNA collected. 
 
D) In vitro transcription 
In vitro transcription transcribes antisense RNA (aRNA) molecules complementary to 
the original mRNA targets for use in qRT-PCR.   
 
The purified cDNA (at a final volume of 23µl with DEPC-treated water) was mixed 
with 1.5µl 100mM adenosine triphosphate (ATP), cytidine triphosphate (CTP), 
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guanosine triphosphate (GTP) and uridine triphosphate (UTP) along with 10X T7 
reaction buffer (4µl) and T7 enzyme mix (7µl).  Contents were mixed carefully, 
collected and incubated at 37ºC for 12 to 16h.  160µl aRNA binding buffer was added 
to the sample of aRNA with 100µl 100% ethanol and mixed gently.  The sample was 
then loaded onto the spin cartridge and centrifuged at 12000g for 15sec, the flow 
through discarded.   
 
500µl aRNA wash buffer was added and the sample centrifuged at 12000g for 15sec, 
the flow through discarded. This wash procedure was repeated.  The spin cartridge 
was then centrifuged at the same speed for a further 2min to dry the column.  The spin 
cartridge was placed into a collection tube and 100µl DEPC-treated water was added 
to the centre of the spin cartridge and incubated at room temperature for 1min, then 
centrifuged at 12000g for 2min to collect the aRNA and stored at -80ºC. 
 
2.3.2.3 Total RNA quantification  
The concentration, yield and purity of each total RNA sample was determined using 
ultraviolet (UV) spectrophotometry.  Either the Spectramax 190 UV Microtitre Plate 
Reader (Molecular Devices) or NanoDrop ND-1000 UV (NanoDrop Technologies) 
spectrophotometers were used for measuring UV absorbance of total RNA samples.  
 
The absorbance of each total RNA sample (at an appropriate dilution in molecular 
grade water (5 Prime, Cat 2500010) at 260nm (peak nucleic acid absorbance) and 
280nm (peak protein absorbance) was measured and the A260/A280 ratio determined 
to indicate the level of protein contamination. Total RNA samples with an A260/A280 
ratio of 1.8 to 2.1 were considered of acceptable quality.  
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The total RNA concentration was derived using the following formula: 
 RNA concentration in μg/μl = [(A260 x 40*) x dilution factor]/1000 
 *Where 40 = the RNA extinction coefficient 
 
2.3.2.4 Total RNA quality control 
Total RNA was assessed for quality using an Agilent 2100 Bioanalyser for an 
assessment of 28S and 18S ribosomal RNA (which represents the majority of total 
RNA) to determine quality.  This electrophoretic assay utilise the same principles of 
gel electrophoresis, but requires a low sample volume requirement and provides 
automated qualification (as well as quantification if required).  Within the chip, 12 
sample wells (as well as ladder, with components of known sizes) receive an electrical 
charge (from a 16-pin electrode) and RNA, intercalated with dye molecules, is 
electrophoretically driven by a voltage gradient and the molecules are separated by 
size, similar to gel electrophoresis, and the data is digitally translated into 
electropherograms or gel images. 
 
550μl RNA 6000 Nano gel matrix was placed into a Spin Filter and centrifuged at 
1,500g for 10min.  A 65μl aliquot of filtered RNA 6000 Nano gel matrix was 
transferred to an RNase free Eppendorf tube and 1μl RNA Nano 6000 dye concentrate 
added (gel-dye matrix).  The gel-dye matrix was mixed by vortexing and centrifuged 
at 13000g for 10min at room temperature.  An RNA 6000 Nano Labchip was placed 
on the priming station (Agilent) and 9μl gel-dye matrix was carefully pipetted into the 
‗priming well‘.  The plunger of the priming station was positioned at the 1ml 
graduation and the manifold closed firmly over the Labchip.  The plunger was firmly 
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depressed until it was held by the clip and priming allowed to proceed for 30sec, after 
which the clip was released. The plunger allowed to recoil for 5sec and then pulled 
back to the 1ml graduation.  The priming station was opened, the Labchip removed 
and 9μl gel-dye matrix carefully pipetted into each of the three ‗gel‘ wells. Labchip 
priming was completed by adding 5μl RNA 6000 Nano Marker Buffer to wells 1-12 
and the ‗ladder‘ well.  2μl RNA Nano 6000 Ladder and RNA sample were transferred 
to a 0.5ml RNase free Eppendorf tube and heat denatured at 70ºC for 2min.  For 
tissues of high RNA concentration (e.g. spleen), the sample was diluted 1:10 with 
DEPC-treated water so as not to overload the Labchip.  The tubes were immediately 
chilled on wet-ice and the contents briefly centrifuged to collect contents.  1μl heat 
denatured sample was added to each sample well; the same volume of heat denatured 
sample was added to each sample well; the same volume of heat denatured RNA 
Nano 6000 Ladder was added to the well labelled with a ladder symbol.  The RNA 
Nano 6000 Labchip was run on the 2100 Bioanalyser within 5min. The lid of the 2100 
Bioanalyser was opened and a chip specifically for cleaning the electrodes was 
placed, first with RNase, then replaced with a chip containing molecular grade water 
(less <30sec).  The chip was then replaced with Labchip and the lid closed.  The 
‗Nano 6000 Assay‘ protocol was selected within the 2100 Expert Software version 
B.02.02 (Agilent) and electrophoresis commenced by pressing ‗Start‘.  Once the 
electrophoresis was complete the results file was saved and the size profiles of each 
RNA sample inspected visually (Figure 2.3). 
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Figure 2.3: Representative Agilent gel from isolated RNA.  Following RNA 
isolation, the quality of RNA was checked using the Agilent 2100 Bioanalyser for an 
assessment of 28S and 18S ribosomal RNA (which represents majority of total RNA) 
to determine quality.  A successful total RNA run are 1 marker peak (25nt), 2 
ribosomal peaks (18S at approximately 4000nt and 28S at approximately 2000nt).  
Note: mammalian 28S and 18S are approximately 5kb and 2kb in size. Nt, 
nucleotides. 
 
2.3.2.5 cDNA preparation 
cDNA for qRT-PCR was prepared from the mRNA by synthesis of first strand cDNA 
with random primers and removal of remaining RNA (Invitrogen, Cat 11904-018).  
RNA was removed from storage at -80ºC, thawed on wet-ice and pulsed gently in a 
centrifuge to collect contents.  The following were added to a 0.5ml Eppendorf: 1µg 
RNA (calculated from total yield/µl), 1µl random hexamers, 1µl 10mM dNTP (10mM 
each dATP, dCTP, dGTP and dTTP) to a final volume of 10µl (DEPC-treated water), 
mixed gently, contents collected, incubated at 65ºC for 5min and placed on wet-ice 
and the reagents for reverse transcription were added.  Samples were mixed gently 
and collected by brief centrifugation.  A preparation of each sample in the absence of 
reverse transcriptase (RT-) was made to allow for assessment of genomic 
contamination in the reverse transcriptase positive (RT+) preparation.  A 
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thermocycler was used to incubate samples at 25ºC for 10min, 42ºC for 50min and 
70ºC for 15min and then kept at 4ºC.  Samples were then collected by brief 
centrifugation and 1µl RNase H was added to each tube, mixed, contents collected by 
brief centrifugation and incubated at 37ºC for 20min.  Samples were then chilled on 
wet-ice, contents collected by brief centrifugation and frozen at -20ºC. 
 
2.3.2.6 Analysis 
For this experiment, detection of amplified cDNA utilises Taqman® (Applied 
Biosystems) which allow detection of a fluorescent signal from the probe.  Taqman 
probes depend on the 5‘-nuclease activity of the DNA polymerase, and Taqman 
probes are oligonucleotides that have a fluorescent reporter dye attached to the 5‘ end 
and a quencher moiety coupled to the 3‘ end.  In the unhybridised state, the proximity 
of the fluor and the quench molecules prevent the detection of the fluorescent signal 
from the probe.  During the reaction, when the DNA polymerase replicates a template 
on which a Taqman probe is bound, the 5‘ nuclease activity of the polymerase cleaves 
the probe.  This decouples the fluorescent and quenching dyes and FRET (Förster 
resonance energy transfer) no longer occurs.  Thus fluorescence increases in each 
cycle, proportional to the amount of probe cleavage.  Quantification of the amount of 
cDNA in the original sample must be done where the amplification is logarithmic, 
which is at the very beginning of the upturn of the curve and not in what appears to 
the linear region of the curve. In real time PCR, the cycle number at which the 
increase in fluorescence (and therefore cDNA) is logarithmic.  The point at which the 
fluorescence crosses the threshold is called the Ct.   
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2.3.2.7 Primer and probe design 
Initially, primers and probe were designed to the gene of interest using Applied 
Biosystems Primer Express software (Table 2.2).  This software provides a selection 
of primers and probes that can be selected based on the requirements and mRNA 
sequence (NCBI) entered.  For primers and probes, the designs were based on general 
guidance on the principles of qRT-PCR practice (Bustin, 2000; Peirson et al., 2003).  
In this experiment, either a Taqman probe [Fpr2, 18S, Beta actin (β-actin), Beta 2 
microglobulin, (ß-2M) and glyceraldehyde 3-phosphate dehydrogenase, GAPDH) or a 
minor groove binder (MGB) probe (Fpr1, Fpr3, ANXA1 and V1b) were used.  The 
Taqman fluorescent probe (an oligonucleotide) includes a 5‘ fluorogenic dye and a 
quencher moiety at the 3′ end.  After hybridisation to the complementary DNA 
template it is degraded by the 5′–3′ exonuclease activity of the Taq polymerase during 
extension, thus releasing the fluorescence of the reporter dye.  The MGB probe (a 
slightly shorter oligonucleotide than the Taqman probe) incorporates a 5′ reporter dye 
and a 3′ non-fluorescent quencher, and it is the non-fluorescent quencher that reduces 
the background signal offering a more accurate quantification (Yao et al., 2006). 
 
ß-actin and GAPDH were ordered as a TaqMan endogenous control (FAM™ 
Dye/MGB Probe, Non-Primer Limited) kit from Applied Biosystems (Cat 4352933E 
and Cat 4352932E, respectively). 
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Murine 
Receptor 
Accession 
Number 
Primer Sequence Probe 
V1b NM_011924 F: AATATCTACAGGTGCTCAGCATGTTT 
R: GGTACCGGTCCAGCGTCAT 
MGB 
CTTCCACTTACATGCTGC 
Fpr1 NM_013521 F: TGTTGTGGCTGCCTTTTTCC 
R: ATTGTGGATATGAGGGCCACTACT 
MGB 
CTGGTGCCCATTTC 
Fpr2 NM_008039 F: TGCATTTGTGTTCTGCATCCA 
R: CCACCTTCCTAGCCAGGCTC 
TaqMan 
TGGGCTCAGAACCACCGCACTG 
Fpr3 NM_008042 F: TCCGGATGCCACACACTGT 
R: AAAGAGAAGTCAGCCAATGCTAGA 
MGB 
ACCACTATCTGGTATCTGA 
Fpr3_Rep NM_008042 F: GGTTGAACACAGCTATCACGTTTG 
R: TGGGCAAGCTGAAGCTAACA 
MGB 
ACAACTAGAGGGATCATC 
ANXA1  (NM_010730) F: GGAGGTTGTTTTGGCTATGCTAA 
R: TGGCACCACGGAGTTCATC 
MGB 
CTCCAGCTCAGTTTGAT 
ß-2M NM_009735 F: TCAAGTATACTCACGCCACCCAC 
R: CAGCATTTGGATTTCAATGTGAGG 
TaqMan 
TCAGTATGTTCGGCTTCCCATTCTCCG 
18S RNA NR_003278.1 F: TTTTGTTGGTTTTCGGAACTGA 
R: CGGCGCAATACGAATGC 
TaqMan 
CCGGCCGTCCCTCTTAATCATGG 
 
Key: 
V1b: Arginine Vasopressin receptor 1b 
Fpr: Formyl peptide receptor 
MGB: Minor groove binder 
ANXA1: Annexin A1 
ß-2M: Beta 2 microglobulin 
Rep: Repeat 
 
Table 2.2 Primers and probes for qRT-PCR: Detection of cDNA by qRT-PCR 
utilised primers and probes that were designed based on the target mRNA sequence 
(NCBI database). 
 
As the primers and probes were designed specifically for these experiments, all 
custom designed primers underwent a dissociation curve analysis to check for non-
specific amplification with primers or if there were primer dimers.  If there is a high 
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background signal, large amounts of primer dimers may alter the Ct of the 
experimental samples and change the expression level interpretation.  For each 
dissociation curve analysis, the following reagents were added to a 1.5ml Eppendorf 
tube: 15μl 2X SybrMan Universal Mastermix (Applied Biosystems, Cat 4309155), 
5μl (100nM forward and reverse primers), 5μl molecular grade water and 5μl cDNA.  
The dissociation curve cycling profile was tagged onto the end of the normal thermal 
cycling profile (Section 2.3.2.10).  The dissociation curve cycling parameters are; 1) 
95ºC for 15sec, 2) 60ºC for 15sec and 3) 95ºC for 15sec.  On the last cycle, between 
number 2 and 3, the ramping time was increased to its maximum of 19.59 minutes to 
allow a full dissociation curve to be captured.  All primers were considered acceptable 
for use as no primer dimers were detected. 
 
2.3.2.8 Standard plate preparation and evaluation 
For small qRT-PCR experiments, 96-well optically clear microtitre plates (Applied 
Biosystems, Cat 4306737) were used and designed according to each experiment.  A 
master mix for each cDNA sample was prepared on the day of use.  For each PCR 
reaction to be run the following reagents were prepared for each well of the 96-well 
plate: 15μl TaqMan mastermix (Applied Biosystems) and 5μl template solution 
(primers and probe).  The quantity was adjusted dependent on the number of 
preparations required for each experiment (plus 10% overage).  For each reaction, 5μl 
of sample cDNA (RT+ and RT-) was added to each well.  For experiments with 
standard plating, a standard curve and non template control (NTC) at the same volume 
were included.  Plates were placed in a 7900HT Fast Real Time PCR machine 
(Applied Biosystems) and samples were run at default running conditions; 1) 50ºC for 
2min, 2) 95ºC for 10min, 3) 95ºC for 15sec and 60ºC for 1min for 40 cycles. 
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Preliminary experiments conducted using standard plating and probes and primers for 
Fpr2 showed a very high variability between tissues which meant the current 
experimental design was not adequate for the proposed investigations.  As the number 
of animals, time-points, tissues and target mRNA of interest meant nearly one 
hundred 96-well plates would be required, the experimental design had to be 
optimised to reduce variability and further validation was required. 
 
2.3.2.9 Method validation 
To validate the gene expression studies, the spleen from two animals (#1 and #2) was 
taken, divided into three pieces, homogenised for RNA extraction from each piece 
(labelled A, B and C).  For cDNA synthesis, two preparations were made from each 
RNA sample in the presence and absence of reverse transcriptase to allow for 
assessment of genomic contamination in the reverse transcriptase positive preparation.  
cDNA preparations were randomly assigned to wells and plates so as to mimic 
experimental conditions where large numbers of samples are analysed.  In addition, 
three separate 7900HT fast real time PCR systems (Applied Biosystems) were used.  
For the standard curve, a pool of 5µg RNA was reverse transcribed to cDNA from the 
spleen, and assigned an arbitrary copy number of 1x10
7
 copies/µl and a range of 
concentrations were prepared from this stock.  The number of copies of Fpr2 or 
endogenous controls was calculated manually based on the log number of copies 
versus Ct number as calculated by the standard curve.  As shown in Figure 2.4, the 
expression of mRNA for Fpr2 showed low inter-animal variability when normalised 
for GAPDH, β-actin and ß-2M confirming the technique was suitable for larger 
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experiments.  A further consideration was that all probes and primers were to be 
optimised to further reduce the variability.   
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Expression of Fpr2 mRNA in three samples of the same spleen from 
untreated WT mice.  Gene expression quantified by qRT-PCR (mean adjusted to 
GAPDH, β-actin, β-μglobulin, β-2M, ± standard error of means, SEM) of Fpr2 
mRNA in three sections of spleen (separated at sampling) and processed separately 
and analysed on three different analysers to assess variability (n=2/group). 
 
2.3.2.10 Probe and primer optimisation 
Prior to running the final experiments, the probes and primers were tested at different 
combinations of concentrations with cDNA from the spleen (three replicates) so as to 
provide an optimal reaction mixture for qRT-PCR.  Primer and probe optimisation 
was performed for Fpr1, Fpr2, Fpr3, V1b and ANXA1.  For 18s primer and probe 
concentrations had been optimised previously by GlaxoSmithKline (unpublished 
data).    
The following combinations were tested for forward and reverse primers: 
 Forward/Reverse concentration (nM): 200/200, 200/400, 200/600, 
400/200, 400/400, 400/600, 600/200, 600/400 and 600/600. 
0
1
2
3
4
1 1 12 2 2
Animal number
A
d
ju
s
te
d
 m
e
a
n GAPDH
β-actin
β-µglobulin
A
d
ju
s
te
d
 m
e
a
n
Chapter 2 
 
 95 
The following concentrations were tested with the optimised forward/reverse primer 
concentration: 
 100, 150, 200, 225, 250, 275, 300, 325 and 350nM 
The amplification plot and Ct values were used to select the optimal concentrations 
that were used in the experiments (Figures 2.5-6). 
 
 Concentration (nM) 
Murine Receptor Forward Primer Reverse Primer Probe 
Fpr1 200 200 200 
Fpr2 400 600 200 
Fpr3 400 600 200 
Fpr3_Rep 200 200 200 
ANXA1 600 400 350 
V1b 200 200 300 
18s 100 100 50 
Key: 
Fpr: Formyl peptide receptor 
ANXA1: Annexin A1 
V1b: Arginine Vasopressin Receptor 1b 
Rep: Repeat 
 
Table 2.3: Optimised concentrations for primers and probes used in qRT-PCR.   
 
  96 
                (A)  (B) 
 
 
 
 
 
 
 
 
 
Figure 2.5: Amplification plot for primer optimisation of Fpr2: To further enhance the amplification efficiency, a range of primer 
concentrations (at set probe concentration of 200 nM) were investigated to further reduce the variability and improve the reproducibility.  (A) 
Primers were tested with cDNA from the spleen at final concentrations of (as forward/reverse primer) 200/200, 200/400, 200/600, 400/200, 
400/400, 400/600, 600/200, 600/400 and 600/600nM.  (B) Optimal primer concentration for Fpr2 was considered 400/600nM. 
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 (A)  (B) 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Amplification plot for probe optimisation of Fpr2: The optimised primer concentrations (400/600) were tested using cDNA from 
spleen at (A) increasing probe concentrations (100, 150, 200, 225, 250, 275, 300, 325 and 350nM) and (B) probe concentration of 200nM was 
considered optimal. 
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2.3.2.11 Reverse plate preparation and evaluation 
As a total of approximately 300 tissues and 550 cDNA preparations (run twice) meant 
that a total of approximately 100 plates was required, a reverse plate layout was used.  
This randomly assigned the cDNA preparations over all the plates, with each gene 
represented on each plate for each cDNA preparation.  An inter-plate control (IPC) 
was used where one cDNA was run across all plates to monitor for plate variability 
(not used for normalisation) with primers and a probe for 18s (Table 2.2).  A standard 
curve plate was run separately for each gene of interest (Figure 2.8).   
 
Samples (both RT+ and RT-) were run in duplicate and randomly across the 96-well 
plates.  Each sample occupied a single column that contained a well for each target of 
interest (Figure 2.7). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 Fpr1 18sIPC 
B Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3 Fpr3  
C Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2 Fpr2  
D ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1 ANXA1  
E V1b V1b V1b V1b V1b V1b V1b V1b V1b V1b V1b  
F ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M ß-2M  
G GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH GAPDH  
H ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin ß-actin  
 
Figure 2.7: Example of master plate layout. The layout of each 96-well plate 
showing primers and probes of interest were plated in rows, whilst samples were 
randomly allocated to columns, with no two samples of RT+ or RT- on the same 
plate. Fpr, formyl peptide receptor; ANXA1, annexin A1; V1b, arginine vasopressin 
receptor 1b; β-2M, beta 2 microglobulin; GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase; β-actin, beta actin; RT, reverse transcriptase; IPC, inter-plate control.  
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For each target of interest, primers and probes were prepared at optimised 
concentrations as specified in (Table 2.3) to a final volume of 5µl/well (template 
solution). 
 
A) Master plate stamping 
The template solution was then dispensed into 0.75ml screen mate (Matrix 
Corporation, Cat 4273) tubes housed within a latch rack (Matrix Corporation) master 
plate (according to the configuration outlined in Figure 2.7).  The master plate was 
used to produce replicate plates by dispensing 5μl of each template solution into the 
96-well optically clear microtitre plates with a Plate Mate Plus™ (Matrix 
Corporation).  These pre-dispensed plates were referred to as the ‗Master Plates‘.  
Plates were temporarily sealed with a plastic optical cover (ABGene) and stored at 
-20ºC.  18S RNA probe and primers were prepared as above (for 100 reactions) as an 
IPC. 
 
B) Plating 
For each PCR reaction, the following reagents were added to a 1.5ml Eppendorf tube: 
15μl TaqMan Mastermix, 5μl molecular grade water and 5μl sample (20 reactions 
were accounted for each sample; total volume 500μl).  For the IPC enough genomic 
DNA (gDNA) for 100 (2000µl) reactions was prepared.  Each sample preparation was 
carefully mixed and then transferred to a 0.75ml screen mate tube and placed within a 
latch rack for dispensing into the master plates.  The template master mix latch rack 
was placed on a BioMek FX (Beckman Coulter), along with an appropriate master 
plates, and the master mixes dispensed.  Plates were sealed with a plastic optical cover 
(ABGene) and spun in a microtitre plate centrifuge at 1000rpm for 30sec. 
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C) Data capture 
Plates were placed in one of four 7900HT fast real time PCR machine (Applied 
Biosystems) using an automated loader (Zymark Twister Microplate Handler, 
Zymark).  Samples were run at default running conditions; 1) 50ºC for 2min, 2) 95ºC 
for 10min, 95ºC for 15sec and 60ºC for 1min for 40 cycles. 
 
Ct values were exported as tab-delimited text files for each plate for downstream 
analysis. 
 
2.3.2.12 Standard curve 
Quantification of mRNA was done using a pool of 5µg RNA that was reverse 
transcribed to cDNA from the spleen, and assigned an arbitrary copy number of 1x10
7 
copies/µl and a range of concentrations were prepared from this stock.  The number of 
copies for all targets of interest, including endogenous controls was calculated 
manually based on the log number of copies versus Ct number as calculated by the 
standard curve (Figure 2.8). 
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Figure 2.8: Standard curve from genomic cDNA. Standard curve plotted for (A) 
Fpr1, (B) Fpr3, (C) Fpr2, (D) ANXA1, (E) V1b and (F) GAPDH using a pool of 5µg 
RNA from an untreated homogenate of 3 spleens and reverse transcribed to cDNA 
and given arbitrary copy number of 1x10
7
 copies/µl, then serial diluted to 1x10
3
 
copies/µl.  The standard curve was used to calculate the number of copies based on 
log number of copies versus Ct number. 
 
2.3.3 Genotyping of Fpr2
-/-
 and Fpr2
+/+
 mice 
Animals from the Fpr2
-/-
 colony were genotyped using PCR collected from DNA 
obtained from ear clips. 
 
A) DNA extraction 
DNA was extracted using the Nucleospin DNA extraction kit (Macherey-Nagel; Art-
Nr: 740952.250).  Samples were pre-lysed in a waterbath overnight at 56ºC in 
proteinase K (25µl) in lysis buffer (180µl).  The following day lysis buffer (200µl) 
was added to the sample, heated at 70ºC for 10min and then 210µl of 70% ethanol 
was added to adjust the DNA binding conditions and added to the column and 
centrifuged at 11000g for 1min.  The column was then washed twice with wash 
buffers (spun for 1min at 11000g after each wash), the contents discarded and then 
dried at 11000g for a further 1min.  The DNA was eluted by adding the supplied 
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elution buffer and quantified using the NanoDrop ND-1000 UV (NanoDrop 
Technologies) spectrophotometer for measuring UV absorbance of total DNA 
samples.  
 
B) Polymerase chain reaction 
PCR was used to amplify the sequence of Fpr2 with using primers complementary to 
the target region of Fpr2, Fpr3 and GAPDH (NCBI) using Primer-BLAST 
(www.ncbi.nlm.nih.gov) and specified in Table 2.4. 
 
Murine 
Receptor 
Accession 
Number 
Tm ºC Primer Sequence 
Fpr2 NM_008039 60 
60 
F: ACTGTGAGCCTGGCTAGGAA 
R: CAGACTTCATGGGGCCTTTA 
Fpr3 NM_008042 60 
60 
F: GAAATGTGGTTGTTGGGTCC 
R: GAGAATTGGATTGAGGCAGC 
GAPDH NM_008084 68 
72 
F: AAGGTGAAGGTCGGAGTCAACG 
R: GGCAGAGATGATGACCCTTTTGGC 
Key:  
Tm: Melting temperature 
Fpr2: Formyl peptide receptor 2 
Fpr3: Formyl peptide receptor 3 
GAPDH: glyceraldehyde-3-phosphate dehydrogenase 
 
Table 2.4 PCR primers used for genotyping 
 
All primers were diluted to a concentration of 100µM with molecular grade water 
upon arrival and stored at -20ºC.  On the day of PCR, a stock concentration of 10µM 
was prepared for each primer in molecular grade water.  The following were then 
added for each reaction, with a final volume of 50µl: 
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Forward Primer 2µl 
Reverse Primer 2µl 
Template Xµl  
(0.1-1µg) 
Amplitaq Gold PCR Mastermix (Part number: 4327058) 25µl 
Total volume to 50μl using molecular grade water Xμl 
 
Samples were mixed gently and collected by brief centrifugation.  Using a 
thermocycler, samples were then incubated at 95ºC for 5min, followed by 30 cycles of 
1) 95ºC for 30sec, 2) 55ºC for 30sec and 3) 72ºC for 60sec.  Upon completion of the 
last cycle, samples were incubated at 70ºC for 7min then kept at 4ºC using a 
thermocycler. 
 
C) Electrophoresis 
Pre-prepared 1% agarose gel (10mg/ml of ethidium bromide) was poured into a gel 
tank, bubbles removed using a disposable tip and the comb inserted, then left to set.  
0.5x tris-borate-ethylenediaminetetraacetic acid (TBE) buffer was poured into the gel 
tank to submerge the gel to 2-5mm depth (this is running buffer).  5µl sample was 
placed into a separate micro-eppendorf and 1µl loading buffer (bromophenol blue, 
Sigma) so as monitor the DNA during electrophoresis and 2µl each sample with 
buffer was added to each respective lane.  2µl DNA ladder (1-1000kb) was loaded on 
each side of the gel to assist in visualisation.  The gel-tank is then closed and 
electrodes attached and run at 140v for 40min.  The gel was then evaluated in an UV 
light box and the image captured digitally.  A representative gel used for genotyping 
is shown in Figure 2.9. 
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Figure 2.9: Representative gel of PCR products from genotyping.  Ear clips were 
collected from Fpr2
+/+
, Fpr
-/-
 and WT mice, DNA extracted and PCR for Fpr2, Fpr3 
and GAPDH conducted.  PCR product and loading buffer were placed in each lane 
and run at 140v for 40min.  The absence of staining indicated gene deletion and all 
samples were run blind. 
 
2.3.4 Enzyme-linked immunosorbent assay  
Determination of cytokines in the plasma from mice was performed using DuoSet 
ELISA Development kits (R&D Systems) for IL-1α (DY400) and IL-1β (DY401), 
IL-6 (Cat DY406) and TNFα (DY410).  Unless otherwise stated all reagents were 
obtained from R&D Systems. 
 
Working concentrations of each capture antibody were prepared in 1X PBS at 2µg/ml 
(IL-1α and IL-6), 4µg/ml (IL-1β) or 0.8µg/ml (TNFα).  Then 100µl capture antibody 
was placed into each well of a 96-well optically clear microtitre plate and incubated 
overnight at room temperature.  The contents of each well were emptied and washed 
with approximately 400µl wash buffer (0.05% Tween 20 in 1X PBS, pH 7.2-7.4, Cat 
WA126).  The plates were then emptied (by inversion) and blotted on a clean paper 
towel.  The wash step was repeated for a total number of 3 washes and all proceeding 
washes were performed in this way.  Plates were blocked by adding 300µl reagent 
L
a
d
d
e
r 
1
0
0
b
p
B
la
n
k
G
A
P
D
H
F
p
r2
F
p
r3
Fpr2-/-
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
L
a
d
d
e
r 
1
0
0
b
p
F
p
r2
F
p
r3
Fpr2-/- Fpr2+/+ Fpr2-/- WT H2OL
a
d
d
e
r 
1
0
0
b
p
B
la
n
k
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
G
A
P
D
H
F
p
r2
F
p
r3
L
a
d
d
e
r 
1
0
0
b
p
F
p
r2
F
p
r3
Chapter 2 
 
 105 
diluent (1% bovine serum albumin, BSA in PBS, pH 7.2 - 7.4, Cat DY995) for IL-1α, 
IL-6 and TNFα.  For IL-1β the reagent diluent consisted 0.1% BSA, 0.05% Tween 20 
in Tris-buffered saline (20 mM Trizma base, 150 mM NaCl in ddH2O, Sigma) pH 7.2-
7.4.  Following addition of the reagent diluent, plates were incubated at room 
temperature for 1h, and washed three times with wash buffer.  A standard curve was 
prepared using 2-fold serial dilutions in reagent diluent with a high standard of 
1000pg/ml for IL-1α, IL-1β, IL-6 and 2000pg/ml for TNFα.  Samples of plasma from 
each animal were diluted 1:5 in the appropriate reagent diluent and 100µl added to 
each well in duplicate.  Concentrations of standard curve were added in triplicate 
(100µl) to each well.  Plates were covered and incubated for 2h at room temperature.  
Plates were then washed and 100µl of the detection antibody prepared in 1X PBS at 
50ng/ml (IL-1α), 600ng/ml (IL-1β) or 200ng/ml (IL-6 and TNFα) in respective 
reagent diluent.  Plates were covered and incubated at room temperature for 2h and 
washed.  100µl of streptavidin conjugated to horseradish-peroxidase (at suppliers 
concentration) was added to each well and incubated at room temperature for 20min, 
protected from light.  Plates were washed and 100µl substrate solution (1:1 mixture of 
hydrogen peroxide, H2O2 and tetramethylbenzidine, Cat DY999) added and then 
incubated at room temperature for 20min, protected from light.  50µl stop solution 
(2M sulphuric acid, H2SO4, Cat DY994) was added to each well.  The optical density 
of each well at 450nm absorbance (reference 570nm) was measured using a 
microplate reader.  The values of the mean absorbance for each standard 
concentration were plotted on a log axis and from this, the sample value calculated 
(Figure 2.10). 
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Figure 2.10: Typical standard curve from mouse cytokine ELISA. A 
representative standard curve from the mouse cytokine (taken from IL-6) DuoSet 
ELISA.  The log values of the mean absorbance for each standard concentration are 
plotted and the sample value calculated.   
 
2.3.5 Luminex assay  
Plasma cytokines for TNFα, IL-1β, IL-6, IL-10, IL-4, vascular endothelial growth 
factor (VEGF), regulated upon activation, normal T cell expressed and secreted 
(RANTES), INFγ, IL-17 and eotaxin (Millipore Cat: MPXMCYTO-70K-10) were 
evaluated using the Luminex xMap immunoassay.  Briefly, Luminex® uses 
techniques to internally color-code microspheres with two fluorescent dyes which 
enable distinctly coloured beads (up to 100) for each specific capture antibody.  After 
an analyte from a test sample is captured by the bead, a biotinylated detection 
antibody is introduced.  The reaction mixture is then incubated with Streptavidin-
Phycoerythrin (PE) conjugate, the reporter molecule, to complete the reaction on the 
surface of each microsphere.  The 96-well plate is then placed in a Luminex 100 IS 
system which measure the concentrations bound to the microspheres by passing 
rapidly through a laser which excites the internal dyes marking the microsphere set. A 
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second laser excites PE, the fluorescent dye on the reporter molecule.  Finally, high-
speed digital-signal processors identify each individual microsphere and quantify the 
result of its bioassay based on fluorescent reporter signals.  The capability of adding 
multiple conjugated beads to each sample results in the ability to obtain multiple 
results from each sample, thus increasing the number of cytokines/chemokines that 
can be analysed from 25µl of plasma, and reducing the number of animals 
required/experiment.    
 
First, the preparation of the antibody-immobilised beads (individual vials of beads) 
were sonicated and vortexed, then 60µl of each antibody bead vial was added to a 
single mixing bottle and brought to a final volume of 3.0ml with assay buffer, then 
vortexed.  Each quality control was mixed with 250µl deionised water and mixed.  
The standard curve was prepared with a mouse cytokine standard (10,000pg/ml) and 
diluted 1:5 for six concentrations (to 3.2pg/ml). The filter plate was placed on a 
specific plate holder at all times during reagent dispensing and incubation steps so that 
the bottom of the plate does not touch any surface.  The plate was pre-wet (200µl into 
each well) with wash buffer, sealed and mixed (on a plate shaker) for 10min at room 
temperature and the wash buffer removed by vacuum (<100 millimetre of mercury, 
mmHg). Each standard, control or sample (diluted 1:2) were added to the designated 
well (in duplicate) with 25µl of assay buffer or serum matrix, followed by 25µl of the 
mixed beads, then sealed, and shaken over night at 4ºC. The following day, the fluid 
was removed by vacuum as before, washed three times and 25µl of detection 
antibodies added to each well, sealed, shaken for 1h at room temperature.  Following 
this, 25µl of Streptavidin-PE was added to each well and incubated with agitation for 
30min at room temperature.  The plate was then washed twice followed by 150µl of 
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sheath fluid, shaken and then evaluated on the Luminex 100 IS system.  The median 
fluorescent intensity data using a 5-parameter logistic or spline curve fitting method 
for calculating cytokine/chemokines concentrations was analysed for each sample, 
taking into consideration the dilution factor (Figures 2.11-12). 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Standard curve from mouse cytokine Luminex xMAP assay for 
IL-4, IL-17, RANTES, TNFα and VEGF. A standard curve from the mouse 
cytokine Luminex xMAP assay for IL-4, IL-17, RANTES, TNFα and VEGF.  The log 
values of the median fluorescence intensity for each standard concentration are used 
to calculate the sample value.   
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Figure 2.12: Standard curve from mouse cytokine Luminex xMAP assay for 
IL-6, IL-10, eotaxin, IFNγ and IL-1β.  A standard curve from the mouse cytokine 
Luminex xMAP assay for IL-6, IL-10, eotaxin, IFNγ and IL-1β.  The log values of the 
median fluorescence intensity for each standard concentration are used to calculate the 
sample value. 
 
2.3.6 Determination of corticosterone 
Determination of CORT in the serum from mice and cell culture supernates from 
dispersed mouse adrenals was performed using an enzyme immunoassay (EIA, IDS, 
UK, Cat AC-14F1) which superseded previous classical measurement of CORT by 
radioimmunoassay, offering the benefit of being non-radioactive. 
 
Samples and concentrations for the standard curve were run in duplicate.  Samples of 
serum were diluted 1:10, whilst cell culture supernates were diluted 1:5 with the 
sample diluent provided (PBS containing horse serum).  100µl of each standard curve 
concentration or sample were then added to each antibody coated well of the 
microplate along with 100µl of enzyme conjugate.  Plates were covered with an 
adhesive plate sealer and incubated at 2-8ºC for 16-24h.  The contents of each well 
were emptied and washed with approximately 250µl of wash buffer provided.  The 
plates were then emptied (by inversion) and blotted on a clean paper towel.  Plates 
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were washed with three times.  200µl of tetramethylbenzidine and hydrogen peroxide 
(TMB) substrate and incubated at room temperature for 30min.  100µl of stop solution 
(HCL) was added to each well and the absorbance of each well at 450nm (reference 
650nm) was measured immediately using a microplate reader.  Concentrations of the 
sample were taken from the calibration curve by plotting B/Bo% [(mean 
absorbance/means absorbance for ‗0‘ calibrator) X 100] against the B/B0% for five 
known CORT concentrations, ranging from 1.7 to 188ng/ml (Figure 2.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Typical calibration curve from CORT EIA. A representative 
calibration curve from the CORT EIA.  The percent binding (B/Bo%) is plotted 
against the concentration of CORT provided for the standard curve.  The B/Bo% for 
each unknown sample is calculated and the concentration is taken from the calibration 
curve.   
 
2.3.7 Microscopic examination 
2.3.7.1 Tissue processing 
Tissues were placed into a tissue cassette and embedded in paraffin wax at 
approximately 60ºC, cooled, block removed and sections cut at 3µm (haematoxylin 
and eosin, H&E) or 5µm (immunohistochemistry, IHC) using a microtome. 
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2.3.7.2 Haematoxylin and eosin staining 
Slides were placed in an oven at 37ºC for 20min, and placed in xylene for 
deparaffinization for 5min.  Slides were then placed in the rack of an automatic stainer 
(Sakura, DRS2000) and reagents loaded.  The following protocol was followed: 
xylene for 2min (X3), 100% ethanol for 2min, 95% ethanol for 2min, 70% ethanol for 
2min; washed in distilled water for 3min, Mayer‘s haematoxylin for 2min, running 
water for 10min, Eosin Y (5wt.% in water) for 2min, running water for 4secs, 
dehydrated in 95% ethanol for 30secs (X2), 100% ethanol for 30secs (X2), xylene for 
1min (X2) and mounted with Entellan.  Cytoplasm is varying shades of pink, nuclei 
are blue/black, red blood cells orange/red and fibrin deep pink.  Slides were evaluated 
using a light microscope and peer reviewed with a histopathologist. 
 
The above protocol was modified to differentiate between neutrophils and eosinophils 
by improving the eosinophilic appearance of PMNs.  The above protocol was 
modified by adding acetic acid (~2-3 drops/200ml, Sigma) to the Eosin Y (more/less 
acetic acid may have been required as the endpoint was a colour change from dark red 
to brilliant red) and extending the time in eosin from 2min to 4min. 
 
2.3.7.3 Immunohistochemistry 
IHC is a technique that allows the recognition of individual antigens in tissues and 
cells.  In principle, sections are treated with an antibody, and the sites of binding are 
identified by a marker, e.g. fluorescent dye.  This can be done by either binding the 
marker to the primary antibody, or by binding a biotinylated secondary antibody 
coupled with streptavidin-horseradish peroxidase and counterstained with 
diaminobenzidine.  
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2.3.7.4 Green fluorescent protein 
Frozen sections of tissues were prepared using a microtome at approximately -20°C at 
10-14µm, air dried and then stored at -80°C.  Tissues from the Fpr2
-/-
 mice were 
examined for the presence of GFP that had been genetically inserted using 
immunofluorescence microscopy. 
 
Slides were removed, air dried, fixed in acetone for 10min, dried and washed in 
ddH20.  Slides were labelled then a PAP pen was used around the sections to create a 
hydrophobic barrier.  Sections were then washed in autowash buffer (Dako, Cat 
S3006) and 400µl of 5% goat serum in PBS (blocking step) was added and sections 
incubated for an hour.  Sections were also blocked using an avidin/biotin blocking kit 
(Vector Labs, Cat SP-2001) prior to the addition of the primary antibody.  Sections 
were washed in autowash buffer and 400µl of anti-GFP primary antibody (ab290, 
Abcam) diluted 1:1000 in autowash buffer was added, sections were then incubated 
overnight at room temperature, protected from light.  Negative control sections were 
prepared with omission of primary antibody.  The following day, sections were 
washed with autowash buffer and 400µl of biotinylated anti-rabbit (Dako, Cat E0353) 
diluted 1:500 in autowash buffer was added and sections incubated for 2h, protected 
from light.  Sections were washed in autowash buffer and treated with 400µl of 
Streptavidin-Alexa 488 conjugate (Invitrogen, Cat 32354) diluted 1:500 in autowash 
buffer for 2h, protected from light.  Sections were then washed in autowash buffer, 
distilled water, dehydrated in industrial methylated spirit (X3) and cleared with xylene 
(X3).  Slides were then mounted using Entellan and viewed under blue light using a 
fluorescent microscope (Nikon). 
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A fluorophore labelled anti-GFP (anti-green fluorescent protein, rabbit IgG fraction, 
Alexa Fluor 488 conjugate, Invitrogen, Cat A21311) diluted 1:500 or 1:1000 was also 
used.  This was inserted into the above protocol (instead or primary antibody), 
incubated overnight, washed, dehydrated and mounted as described.  
 
2.3.7.5 Anterior pituitary gland hormones 
Sections of pituitary gland, embedded in paraffin wax and cut at 5µm were stained 
with a rabbit polyclonal anti-mouse anti-bodies for ACTH (Cat No: BP5035; diluted 
1:1000), PRL (Cat No.: 7770-2949; diluted 1:2000), follicle stimulating hormone 
(FSH, Cat No: 4561-6959; diluted 1:1500), LH (Cat No: 5720-6609; diluted 1:3000), 
thyroid stimulating hormone (TSH, Cat No: 8922-6009) and were diluted in autowash 
buffer (Dako) for 1h at room temperature.  Using an automated (Dako) 
immunostaining instrument, EnVision
TM
 (as secondary antibody, Dako) was added for 
30min, followed by diaminobenzidine for 5min and counter stained with Mayer‘s 
haematoxylin for 2min.  Omission of the primary-antibody was used as a negative 
control.  The protocol was previously validated by GlaxoSmithKline (unpublished 
data).  
 
2.3.8 Static incubation of primary adrenal cells 
The method used was a modification of that described previously (Cover et al., 2001) 
in which administration of ACTH in the presence or absence of agonists and 
antagonists to primary adrenal cells enables the evaluation of a CORT response. 
 
Adult male WT mice were killed by carbon dioxide asphyxiation followed by cervical 
dislocation, adrenal glands removed and placed into 3ml of EBSS (Sigma, 
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Cat E7510).  The adrenals were cut using a scalpel in a glass Petri-dish, bathed in 
EBSS, excess EBSS removed and then segments were collected with a 1000µl pipette 
(the tip was cut to allow for collection of segments) into 5ml EBSS containing 
2mg/ml collagenase from Clostridium histolyticum (Sigma, Cat C2674).  The medium 
was incubated at 37ºC with a minimal flow of 95% O2/ 5% CO2 for 60min.  During 
the incubation period, the cells were gently dispersed every 10min using a 1000µl 
pipette with the tip end removed.  Large pieces of tissue were then removed by 
filtering through a piece of 100μm gauze placed over a falcon tube.  The cell 
suspension was then centrifuged at 100g for 15min.  The supernatant was removed 
and 5ml (dependent on number of adrenals used) EBSS added and mixed gently with 
a pipette and this step was repeated a further two times.  1ml of cell suspension was 
removed into a 1.5ml Eppendorf, and then mixed gently by pipetting and 100µl cell 
suspension removed and stained with trypan blue (Sigma).  The remaining cell 
suspension was returned to the sample.  A cell count was performed with a 
haemocytometer and automated counter.  Trypan blue was used to stain any dead cells 
(cells looking faint or dark blue) within the grid.  Cell viability was calculated as 
follows: 
 Live cell count  x 100 = percentage viability 
  Total cell count  
 
The target cell count was 1x10
6
 cells/ml (later increased to 2x10
6
 cells/ml to improve 
CORT yield) and the volume of the cell suspension was adjusted accordingly with 
EBSS.  150µl of cell suspension was aliquoted into a 96 well plate and incubated (pre-
incubation) in a humid atmosphere with a flow of 95% O2/ 5% CO2 for 60min.  The 
number of wells/treatment was dependent on cell numbers obtained, with 5 
wells/treatment considered optimum.  If a low yield was obtained, the number of 
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wells/concentration was adjusted in real-time (always >3 wells/treatment) to ensure 
that the quality of the experiment was not affected.  Plates were removed, covered and 
centrifuged at 2000g for 10sec, and the supernatant discarded.   
 
Drug solutions +/-ACTH (1nM, Sigma or tetracosactide) were prepared towards the 
end of the pre-incubation period (pH 7.4) and kept on ice until used.  EBSS +/- drugs 
at the pre-prepared concentrations were added at a final volume of 200µl to each well 
and incubated as before for 2h (3-5 wells/concentration).  Plates were removed, 
covered and centrifuged at 2000g for 10sec, and the supernatant was either analysed 
immediately or stored frozen (-80ºC) until analysis of CORT EIA. 
 
The following drugs were assessed; ACTH (0.001-100nM), ANXA1Ac2-26 (3, 10 or 
30µM), BOC2 (1, 3 or 10µM), fMLP (1, 10 and 100µM) or H-Trp-Arg-Trp-Trp-Trp-
Trp-CONH2 (WRW4, 0.1, 1 and 10µM) with/without 0.1nM ACTH in EBSS.  EBSS 
only was included as a negative control.   
 
2.4 Statistical analysis 
A) qRT-PCR 
Within Microsoft Excel, standard curve data was plotted for each gene and copy 
numbers for individual cDNA samples derived.  The corresponding RT- copy number 
was subtracted from each RT+ copy number and an average copy number derived 
from these two values.  Adjusted means, copy numbers and group mean fold changes 
in gene expression for each gene were derived in relation to the control group data and 
reported as mean ± standard error of the mean (SEM) of n number of samples per 
group using TaqMan Toolkit (Brian Bond, GSK R&D).  The TaqMan Toolkit is a 
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software specifically designed for qRT-PCR and is a collection of univariate and 
multivariate statistical routines for the analysis of data from TaqMan fluorogenic 
probes.  Statistical analysis for each gene of interest were derived to the time-matched 
saline control group data and significance determined by carrying out an analysis of 
covariance (ANCOVA) and post-hoc Dunnet's test.  GAPDH, ß2M and β-actin 
expression data was used as the covariant for data analysis (endogenous control gene).  
The Covariance Efficiency Factor (CEF) was also assessed for each endogenous 
control (covariate) to ensure that there were no effects of treatment on the endogenous 
controls.   
 
B) ELISA, EIA and Luminex xMAP 
For ELISA, EIA and Luminex xMAP experiments data is reported as mean ±SEM of 
n number of samples per group.  All data was tested for normal distribution.  
Statistical differences were analysed by analysis of variance, using the software 
GraphPad Prism
TM
.  If the pre-test was successful in identifying normal distribution, 
the analysis was continued.  Statistical analysis was assessed by one-way or two-way 
analysis of variance (ANOVA) with Dunnett‘s or Bonfferoni post-hoc test, 
respectively.  Where there was an n of 3 or 4 in the assessment of CORT from 
dispersed adrenal cells, a non-parametric Kruskal-Wallace with Dunn‘s post-hoc test 
was performed.  In all cases a threshold value of ‗P‘ less than 0.05 was considered 
significant to reject the null hypothesis, and differences were considered significant.  
 
C) PMN depletion 
For an assessment of PMNs, data is reported as mean ±SEM of n number of samples 
per group.  All data was tested for normal distribution. Statistical differences were 
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analysed by Students t test to compare the means of two groups, using the software 
GraphPad Prism
TM.  A threshold value of ‗P‘ less than 0.05 was considered significant 
to reject the null hypothesis, and differences were considered significant.  
 
2.5 Reagents 
2.5.1 In situ hybridisation 
A) Non-radioactive hybridisation buffer  
Hybridisation buffer (final volume 100ml) was prepared comprising:  
20X standard saline citrate buffer (SSC, Invitrogen) 30ml 
dextran sulphate (Sigma) 10g 
deionised formamide (Sigma) 50ml 
single stranded DNA (10mg/ml, Roche) 5ml 
transfer RNA (10mg/ml, Sigma) 1ml 
1M dithiothreitel (DTT, Sigma) 5ml 
50X Denhart (Sigma) 2ml 
double distilled (dd) H20 7ml 
 
B) Radioactive hybridisation buffer 
Hybridisation buffer (final volume 100ml) was prepared comprising:  
20X standard saline citrate buffer (SSC, Invitrogen) 20ml 
deionised formamide (Sigma) 50ml 
50X Denhart (Sigma) 2ml 
10X PBS 10ml 
transfer RNA (25mg/ml, Sigma) 1ml 
4M dithiothreitel (DTT, Sigma) 5ml 
dextran sulphate (Sigma) 10g 
0.5M Ethylene-(2, 2)-diamine-tetracetic acid 
(EDTA, pH 8.0) 
2ml 
Sarcosyl (Sigma) 1g 
ddH20 5ml 
single stranded DNA (10mg/ml, Roche) 5ml 
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2.5.2 qRT-PCR 
A) RNA amplification  
For first strand synthesis the following were added to each sample:  
5X first strand buffer (250mM Tris-HCl, pH 8.3; 375mM KCl; 15mM 
MgCl2) 
4µl 
0.1M DTT 2µl 
10mM dNTP Mix (dATP, dGTP, dCTP and dTTP) 1µl 
RNaseOUT
TM
 recombinant ribonuclease inhibitor (40U/µl) 1µl 
SuperScript
TM
 III reverse transcriptase (200U/µl) 2µl 
 
For second strand synthesis the following were added to each sample: 
DEPC-treated water 91µl 
5X second strand buffer (100mM Tris-HCl, pH 6.9; 450mM KCl; 23mM 
MgCl2; 50mM (NH4)2SO4) 
30µl 
10mM dNTP mix 3µl 
E.Coli DNA polymerase I (10units/µl) 4µl 
E.Coli DNA ligase (10units/µl) 1µl 
E.Coli RNase H (2units/µl) 1µl 
 
B) cDNA preparation 
cDNA was prepared by reverse transcription and the following were added to each 
sample: 
10X RT buffer 2µl 
25mM MgCl2 4µl 
0.1M DTT 2µl 
RNaseOUT
TM
 recombinant ribonuclease inhibitor 1µl 
SuperScript
TM
 II reverse transcriptase 1μl 
 
2.5.3 PCR 
A) 10X TBE buffer 
10XTBE buffer was prepared to a final volume of 2L using: 
Tris base (Sigma) 218g 
Boric acid (Sigma) 110g 
EDTA (Sigma)  9.3g 
 
10XTBE buffer was pH adjusted to 8.3 using NaOH. 
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B) Electrophoresis gel 
2g of agarose (Sigma) was weighed into a conical flask and 200ml of 0.5X TBE was 
added and mixed by gentle swirling.  The conical flask was microwaved for 
approximately 2-5min until the agarose was dissolved and then cooled to 
approximately 60ºC.  4µl of ethidium bromide was added (10mg/ml) and mixed by 
swirling the conical flask and poured into the gel tank. 
 
 
2.6 Drugs 
A) N-terminal peptide ANXA1Ac2-26 
The N-terminal peptide ANXA1Ac2-26 (Ac-AMVSEFLKQAWFIENEEQEYVQTVK, 
custom-made by Dr. Ian Moss, Advanced Biotechnology Centre, Imperial College 
London; purity of the product was verified by mass spectrometry and high 
performance liquid chromatography, HPLC) was first dissolved in small amounts of 
1M NH4HCO3 and then diluted in medium (the final concentration of NH4HCO3 
never exceeded 20mM).  Dispersed adrenal cells were incubated at 0, 3, 10, 30µM 
ANXA1Ac2-26 with/without 1nM ACTH in EBSS. 
 
B) Boc2 
N-tert-butyloxy-carbonyl-phenyalanine-leucyl-phenyalanine-leucyl-phenyalanine 
(Boc2, MP Biomedicals, USA, Cat 0215276005) was first dissolved in small amounts 
of dimethyl sulfoxide (DMSO) and then diluted in medium (the final concentration of 
DMSO never exceeded 1%).  Dispersed adrenal cells were incubated at 0, 1, 3 and 
10µM Boc2 with/without 1nM ACTH in EBSS. 
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C) fMLP 
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, Sigma, Cat F3506)) was 
first dissolved in small amounts of DMSO and then diluted in medium (<1%).  
Dispersed adrenal cells were incubated at 0, 1, 10 and 100µM fMLP with/without 
1nM ACTH in EBSS.   
 
D) WRW4 
H-Trp-Arg-Trp-Trp-Trp-Trp-CONH2 (WRW4, Calbiochem, Darmstadt, Germany, 
Cat 344220) was first dissolved in small amounts of DMSO and then diluted in 
medium (<1%).  Dispersed adrenal cells were incubated at 0, 0.1, 1 and 10µM WRW4 
with/without 1nM ACTH in EBSS. 
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CHAPTER 3         
FORMYL PEPTIDE RECEPTOR TRANSCRIPTOMICS 
3.1 Introduction and Methods 
Prior to the start of this study, data from our group showed expression of mRNAs for 
five FPR family members in the mouse hypothalamus using RT-PCR [Figure 3.1, 
(John et al., 2007)].   
 
 
 
 
 
   
Figure 3.1: RT-PCR analysis of the expression of mRNAs for FPR family 
members in mouse hypothalamic tissue.  RT-PCR with primers for murine Fpr1 
(NM_013521), Fpr3 (Fpr-rs1, NM_008038), Fpr2 (Fpr-rs2, NM_008039), Fpr-rs6 
(NM_177316), Fpr-rs7 (NM_177317) and GAPDH was performed on untreated WT 
mice using 30 cycles of amplification, taken from (John et al., 2007).     
 
As the aim of my project was to understand the role of FPRs within the HPA axis, my 
initial investigation focused on the hypothalamus.  The hypothesis to be tested was 
that the FPR family plays an essential role in mediating the regulatory effects of 
ANXA1 on HPA function at the hypothalamic level in the mouse, and that is 
mediated through an FPR.  As mRNAs for murine Fpr1, Fpr2 and Fpr3 had been 
identified in the murine hypothalamus (John et al., 2007), a natural progression of the 
work was to elucidate the hypothalamic distribution of these mRNAs in normal WT 
mice.  Fpr2 and Fpr3 were selected as the available data indicated that the effects of 
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ANXA1 in the anterior pituitary gland may be mediated through one or both of these 
receptors.  Fpr1 was included as it showed weak expression in the hypothalamus 
(John et al., 2007) and along with Fpr2 and Fpr3, has close structural similarity with 
human FPRs (Gao et al., 1998; John et al., 2007).  Whilst mRNAs for Fpr-rs6 and 7 
were also detected in the hypothalamus (John et al., 2007), their high sequence 
homology indicate that these may be splice variants and due to their lack of human 
orthologues (Wang & Ye, 2002), these receptors were omitted from this investigation. 
 
Because no antibodies were available for detection and localisation of the murine FPR 
family by IHC, and a strong signal for mouse Fpr2 mRNA had previously reported in 
the hypothalamus (John et al., 2007), ISH was used initially in an attempt to localise 
mRNA expression in the brain.  This technique enables the detection and localisation 
of specific mRNAs within the tissues by using target specific antisense probes that 
‗hybridise‘ with the target mRNA sequence in situ; sense probes are used as controls 
to provide an indication of specificity (Nouri-Aria, 2008).  Synthetic oligonucleotide 
probes were used as complementary sequences to known mRNA sequences as these 
can easily be synthesised by an automated apparatus (Lewis et al., 1988).  These 
probes are short (40-50bps) and, thus, penetrate target cells/tissues easily, are resistant 
to RNases and are extremely cost effective.  In the absence of published data, this 
approach allows for the use of multiple target probes to be synthesised that cover the 
5‘-end, middle and 3‘-end of a target mRNA sequence.  If multiple probes show 
identical binding, this is considered to provide firm evidence for expression of the 
target mRNA.  Thus, for the initial investigations, more than one antisense 
probe/target sequence of mRNA was used together with the corresponding sense 
probes to detect non-specific binding. 
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Following the use of ISH to examine the distribution of mRNAs for the FPRs, 
CRH-R1 and V1b in the brain of WT mice, a further more sensitive method, 
qRT-PCR, was used to quantify gene expression.  qRT-PCR permits accurate  
determination of specific RNAs in tissue samples and is a highly sensitive method of 
quantification (Wang & Brown, 1999).  Thus, by developing a robust qRT-PCR 
protocol, it was possible to quantify receptor mRNA expression in the brain.  This 
subsequently allowed us to explore quantitative changes in gene expression following 
pharmacological manipulations.  Measurements of mRNAs for murine Fpr1, Fpr2 and 
Fpr3 were made in the hippocampus, hypothalamus, pituitary and adrenal glands.  The 
spleen was also included as a positive control as it is known to express the FPR 
receptors (Le et al., 2002).  Murine ANXA1 mRNA expression was also determined 
as ANXA1 is considered to be a putative ligand for the FPRs (John et al., 2008).  It 
was not assessed by ISH as previous studies have shown that expression of the protein 
in the brain is modest (Smith et al., 1993).  In all gene expression studies (ISH and 
qRT-PCR), V1b was studied as an additional positive control based on its close 
association with the HPA axis.  AVP is an important ACTH secretagogue and acts via 
the V1b on anterior corticotrophs to potentiate the secretory responses to CRH 
(Papadimitriou & Priftis, 2009) and is considered to be an important mediator of the 
HPA axis response to chronic stress (Guillon et al., 2004).   
 
The HPA axis was activated by treating adult WT mice with a small dose of LPS, 
given either peripherally (500µg/kg, i.p.) or centrally (50µg/kg, i.c.v.) and assessed 
changes in gene expression over the 24h period that followed.  Control animals 
received a corresponding volume (2.5ml/kg, i.p. or 1µl/kg, i.c.v.) of the vehicle 
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(saline).  The animals were perfused with saline at autopsy and the following tissues 
collected for analysis: spleen, hippocampus, hypothalamus, pituitary and adrenal 
glands.  Expression of mRNAs for murine Fpr1, Fpr2, Fpr3, ANXA1 and V1b as well 
as endogenous controls (GAPDH, β-actin and β-2M) was determined by qRT-PCR 
2h, 4h, 8h and 24h after treatment as described previously. 
  
In animals given LPS peripherally, changes in the plasma concentrations of cytokines 
and the serum concentrations of CORT were also assessed.  Plasma for the 
determination of TNFα, IL-1α, IL-1β and IL-6 by ELISA was collected 2h, 4h and 
24h after treatment with LPS or saline.  Plasma for evaluation of IL-10, IL-4, VEGF, 
RANTES, IFNγ, IL-17 and eotaxin using the Luminex xMap immunoassay was 
collected 2h after treatment.  Serum for evaluation of CORT by EIA was collected 2h 
and 4h after treatment to assess HPA activation (i.e. an elevation in CORT). 
 
3.2 Results 
3.2.1 Detection and localisation of mRNAs for the FPRs, ANXA1, CRH-R1 and 
V1b in the mouse brain 
As previous studies based on RT-PCR identified strong bands for Fpr2 mRNA and 
weaker signals for Fpr3 mRNA in the hypothalamus of WT mice (John et al., 2007), 
receptor expression was examined by ISH in brains from untreated WT mice in the 
current study.  Prior to evaluating the expression of FPRs, the possibility of using 
non-radioactive (biotin) vs. radiolabelled probes was explored as biotin would enable 
a more detailed assessment and offered the potential to counter-stain.  Greenstar 
(Genedetect) biotin labelled mouse CRH-R1 probes were therefore compared with 
radiolabelled probes.  No signal was detected with the non-radioactive (biotin) probes 
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and when the concentration of probe was increased, the level of background and non-
specific staining increased to an unacceptable level.  By contrast the radioactive 
probes for CRH-R1 mRNA provided a clear and specific signal vs. the controls.  
Therefore, for this investigation all probes for the target mRNAs of interest were 
radiolabelled with 
33
P.  ISH was performed according to published methods (Tacconi 
et al., 2001), and the CRH-R1 probe was kindly donated by GlaxoSmithKline, having 
been previously validated (GlaxoSmithKline, unpublished).   
 
A) 
33
P-labelled CRH-R1 oligonucleotide probes 
Figure 3.2 shows representative images from coronal sections of brain from untreated 
WT mice following ISH with 
33
P-labelled antisense probe for murine CRH-R1 or the 
corresponding sense probe.  The pattern and distribution of CRH-R1 mRNA 
expression is summarised in Table 3.1.  Strong signals were detected in the 
hippocampus, lateral hypothalamus, cortex, cerebellum and mammillary tract.  No 
notable differences were seen between sections and animals evaluated.   
(A) CRH-R1 antisense   (B) CRH-R1 sense 
    
Figure 3.2 Photomicrographs of coronal sections of WT mouse brain with 
33
P-labelled CRH-R1 oligonucleotide probes.  Representative image films of (A) 
33
P-labelled CRH-R1 antisense probe showing detection of CRH-R1 mRNA in the 
hippocampus (Hi), cortex (Co), mammillary tract (Mt) and lateral hypothalamus 
(LaH) and (B) 
33
P labelled CRH-R1 sense probe (bregma -1.94 to -2.30mm). n = 6 
animals/probe and minimum of 3 sections per animal.  Scale Bar=2mm. 
 
 Hi 
Co 
Mt LaH 
2mm 2mm
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B) ISH using 
33
P-labelled V1b oligonucleotide probes 
For mouse V1b mRNA, a strong signal (visual assessment of intensity) was observed 
in coronal sections of brain from untreated WT mice following ISH with 
33
P-labelled 
antisense probe for V1b (Figure 3.3).  Specific staining was observed mainly in the 
hippocampus (most likely the oriens layer of CA3) with three separate probes (Figure 
3.3). 
 
(A) V1b antisense    (B) V1b sense 
   
 
 
 
 
 
 
Figure 3.3: Photomicrographs of coronal section of WT mouse brain with 
33
P-labelled V1b oligonucleotide probes. Representative image films of (A) 
33
P-labelled V1b antisense probes showing detection of V1b mRNA in the 
hippocampus (Hi) and (B) 
33
P-labelled V1b equivalent sense probe (bregma -1.94 to -
2.30mm), n = 6 animals/probe and a minimum of 3 sections per animal.  Scale 
Bar=2mm. 
 
C) 
33
P-labelled Fpr1 oligonucleotide probes 
For Fpr1, no specific signal was observed with any of the probes used in sections 
from any of the animals evaluated (Figure 3.4, Table 3.1).  
 
 
Hi 
2mm 2mm
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(A) Fpr1 antisense    (B) Fpr1 sense 
  
Figure 3.4: Photomicrographs of coronal sections of WT mouse brain with 
33
P-labelled Fpr1 oligonucleotide probes. Representative image films of (A) 
33
P-labelled Fpr1 antisense probe A, bregma -1.06-1.70mm and (B) of 
33
P-labelled 
Fpr1 sense probe A bregma -2.18-2.70mm, n = 6 animals/probe and a minimum of 3 
sections per animal.  Scale Bar=2mm.  
 
D) 
33
P-labelled Fpr2 oligonucleotide probes 
Of the 5 probes tested initially for murine Fpr2 mRNA, only one showed a consistent 
signal in coronal sections of untreated WT mouse brain and in all animals tested.  
Interestingly, a probe originally designed for Fpr3 mRNA which was later found to be 
specific for Fpr2 mRNA when the GenBank database was updated, showed a similar 
signal.  Therefore 2/6 probes for Fpr2 mRNA showed a weak signal in the dentate 
gyrus (dg), hippocampus (CA1 and CA2) and cerebellum (Figures 3.5-7, Table 3.1).  
Of the other four probes, two showed significant non-specific staining (perhaps 
because the GC content was higher, thus making the probe ‗sticky‘) and two showed 
no binding.  Hippocampal and cerebellar expression was confirmed with sagittal 
sections.   
 
Additional sections were prepared from the spleen of a limited number of animals 
(n = 2) as a positive control tissue for Fpr2 mRNA (Probe A).  This probe detected 
Fpr2 mRNA in the white pulp (lymphoid tissue, Figure 3.8).  However the signal was 
2mm 2mm
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weak, possibly because the ISH protocol was developed and optimised for the brain, a 
lipid-rich tissue, unlike the spleen. 
(A) Fpr2 antisense    (B) Fpr2 sense 
  
 
Figure 3.5: Photomicrographs of coronal sections of WT mouse brain with 
33
P-labelled Fpr2 oligonucleotide probes.  Representative image films of (A) 
33
P-labelled Fpr2 antisense Probe A showing detection of Fpr2 mRNA in the 
hippocampus (Hi) and dentate gyrus (dg; bregma -2.18-2.30mm) and (B) 
33
P-labelled 
Fpr2 sense Probe A (bregma -2.54mm).  n = 6 animals/probe and 3 sections per 
animal.  Scale Bar=2mm. 
 
(A) Fpr2 antisense    (B) Fpr2 sense 
  
 
 
 
 
 
 
 
 
 
Figure 3.6: Photomicrographs of coronal sections of WT mouse brain with 
33
P-labelled Fpr2 oligonucleotide probes.  Representative image films of (A) 
33
P-labelled Fpr2 antisense Probe A showing detection of Fpr2 mRNA in the 
hippocampus (Hi) and dentate gyrus (dg; bregma –6.72mm) and (B) 33P-labelled Fpr2 
sense Probe A (bregma -6.84mm).  n = 6 animals/probe and 3 sections per animal.  
Scale Bar=2mm. 
 
dg 
2mm 2mm
Hi 
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(A) Fpr2 antisense  
 
 
 
 
 
 
 
 
 
 
 
 
(B) Fpr2 sense  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Photomicrographs of sagittal sections of WT mouse brain with 
33
P-labelled Fpr2 oligonucleotide probes.  Representative image films of (A) 
33
P-labelled Fpr2 antisense Probe A showing detection of Fpr2 mRNA in the 
hippocampus (Hi) and cerebellum (Ce) and (B) 
33
P-labelled Fpr2 sense Probe A.  n = 
3 animals (Probe A only) and 3 sections per animal.  Scale Bar=3mm. 
 
(A) Fpr2 antisense (B) Fpr2 antisense (C) Fpr2 sense 
   
Figure 3.8: Photomicrographs of cross sections of WT mouse spleen with 
33
P-labelled Fpr2 oligonucleotide probes.  Representative image films of (A and B) 
33
P-labelled Fpr2 antisense Probe A detected Fpr2 mRNA in white pulp (WP) and (C) 
33
P-labelled Fpr2 sense Probe A. n = 2 animals/probe and 3 sections per animal.  
Scale Bar=500μm. 
500µm 500µm 500µm
WP 
WP 
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E) 
33
P-labelled Fpr3 oligonucleotide probes 
For Fpr3 mRNA, no signal was observed in any sections from any of the animals 
evaluated (Figure 3.9, Table 3.1).  Initially, two probes for Fpr3 mRNA were selected, 
however, following an update of the GenBank database (2008), Probe A was deemed 
to be selective to Fpr2 only and the data are therefore reported in Section D.  An 
additional probe was not tested, as by this stage, probes and primers for qRT-PCR had 
been validated and were being used for further gene expression investigations. 
 
(A) Fpr3 antisense    (B) Fpr3 sense 
  
Figure 3.9: Photomicrographs of coronal sections of WT mouse brain with 
33
P-labelled Fpr3 oligonucleotide probes.  Representative image films of (A) 
33
P-labelled Fpr3 antisense Probe B and (B) 
33
P-labelled Fpr3 sense Probe B (bregma 
-1.06-1.94mm), n = 3 animals and a minimum of 3 sections per animal.  Scale 
Bar=2mm. 
 
2mm 2mm
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 Mouse Receptor Distribution 
Region CRH-R1 V1b Fpr1 Fpr2 Fpr3 
Cortex + - - - - 
Cerebellum + - - + - 
Hippocampus + + - + - 
Hypothalamus + - - - - 
Mammillary Tract + - - - - 
Dentate gyrus - - - + - 
Key:  
+ = Present 
- = Not detected 
 
Table 3.1: Qualitative analysis of hybridisation signal of mRNA for CRH-R1, 
V1b, Fpr1, Fpr2 and Fpr3 in brain of untreated WT mice.  Distribution of mRNA 
for the receptors for CRH-R1, V1b, Fpr1, Fpr2 and Fpr3 in untreated WT mice using 
mRNA specific 
33
P-labelled oligonucleotides, n = 6 animals/probe and 3 sections per 
animal.      
 
3.2.2 Assessment of gene expression in tissues from untreated WT mice by 
qRT-PCR 
Tissues (spleen, hippocampus, hypothalamus, pituitary and adrenal glands) were 
collected from untreated WT mice and analysed by qRT-PCR.  Expression of mRNAs 
for murine Fpr1, Fpr2, Fpr3 and ANXA1 as well as endogenous ‗housekeeping genes‘ 
(GAPDH, β-actin and β-2M as controls) was detected in all tissues studied.  The rank 
order of expression is shown for Fpr1, Fpr2, Fpr3 and ANXA1 in Figure 3.10. 
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(A)  Fpr1     (B) Fpr2 
 
 
 
 
 
 
 (C) Fpr3     (D)  ANXA1 
 
 
 
 
 
     
 
(E) V1b 
 
 
 
 
 
Figure 3.10:  Expression of Fpr1, Fpr2, Fpr3, ANXA1 and V1b mRNAs in tissues 
from untreated WT mice.  Gene expression was quantified by qRT-PCR (mean 
adjusted to GAPDH ± SEM) of (A) Fpr1, (B) Fpr2, (C) Fpr3, (D) ANXA1 and (E) 
V1b mRNA in the hippocampus (Hi), hypothalamus (Hy), pituitary gland (Pi), 
adrenal glands (Ad) and spleen (Sp) from untreated WT mice (n = 6/group). 
**P<0.01, *P<0.05 (ANCOVA followed by Dunnett‘s test after log transformation). 
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Using qRT-PCR to assess mRNA for murine Fpr1, Fpr2, Fpr3, ANXA1 and V1b in 
the hippocampus, HPA axis and spleen the rank order of mRNA expression in 
untreated WT mice were: 
  Fpr1: spleen>hypothalamus>hippocampus>adrenal>pituitary 
  Fpr2: spleen>hypothalamus>adrenal>hippocampus> pituitary 
  Fpr3: spleen>hypothalamus>hippocampus>adrenal>pituitary 
  ANXA1: spleen>adrenal>hypothalamus>hippocampus>pituitary 
V1b: hippocampus>spleen>hypothalamus>adrenal>pituitary 
 
3.2.3 Circadian rhythm of expression of mRNAs for the FPRs, ANXA1 and V1b 
In gene expression studies that investigated the effects of an immune stressor on the 
expression of mRNAs for the murine FPRs, ANXA1 and V1b over a 24h period, 
time-matched controls were included, so that any potential effects of both the 
injection stress and circadian rhythm could be excluded.  Data from the studies 
involved the injection of saline (i.p.) which also allowed us an insight to the circadian 
rhythm of gene expression for the genes of interest (Figure 3.11). 
 
For Fpr1, there was no evidence of a circadian pattern of gene expression in the 
hypothalamus, pituitary or adrenal gland. 
 
In hypothalamus, Fpr2 mRNA was at its greatest just after lights on at 09:00h and 
then decreased during the day being at its lowest between 13:00h and 17:00h.  
Contrary to this for the pituitary gland, Fpr2 mRNA was at its lowest just after lights 
on at 09:00h and then increased during the day until a peak at the last time-point, 
13:00h (approximately 3-fold, P<0.01). 
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Fpr3 mRNA was at its lowest in the morning at 09:00h in both the hypothalamus and 
pituitary, but steadily increased during the day, being maximal in the afternoon, at 
13:00h and 17:00h for the pituitary and hypothalamus, respectively.  Contrary to this 
in the adrenal gland, Fpr3 mRNA was maximal in the morning (09:00h) and declined 
during the day, being at its lowest in the afternoon (17:00h).  
 
There were no changes over the time-course with mRNA of ANXA1 in the spleen, 
hippocampus, hypothalamus, pituitary and adrenal glands. 
 
By contrast, expression of V1b mRNA in the spleen, hypothalamus, pituitary and 
adrenal glands did not vary over 24h, although in the hippocampus a reduction in V1b 
mRNA was evident in the afternoon (17:00h) when compared to the morning. 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
Figure 3.11: Assessment of circadian rhythm in expression of the mRNAs for 
mouse FPRs and V1b in the hippocampus, hypothalamus, pituitary and adrenal 
glands.  Saline was administered i.p. to WT mice (n = 6/group) and (A) hippocampus, 
(B) hypothalamus, (C) pituitary and (D) adrenal gland removed at various time-points 
over 24h.  V1b, Fpr1, Fpr2 and Fpr3 mRNAs were quantified by qRT-PCR (mean 
adjusted to GAPDH ± SEM). Note: 24h value assumed to be same as 0h.  **P<0.01 
vs. 24h saline control (ANCOVA followed by Dunnett‘s test after log transformation 
of normalised data). 
 
 
3.2.4 Studies on the effects of LPS on gene expression, corticosterone secretion 
and the plasma cytokine profile 
A) Effects of peripheral (i.p.) administration of LPS  
Administration of LPS (500µg/kg, 2.5ml/kg, i.p.) caused time-dependent significant 
increases in the serum CORT concentration both 2h (3.1-fold P<0.01) and 4h (9.5-
fold, P<0.01) after treatment (Figure 3.12) when compared to saline treated controls.   
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Figure 3.12:  Effects of LPS administration on the serum CORT concentration in 
male WT mice.  Serum samples were collected by cardiac puncture 2h and 4h after 
the administration of LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) for the analysis 
of CORT by enzyme immunoassay.  Values are mean ± SEM of n = 6 mice per group.  
**P<0.01 vs. saline-treated (one way ANOVA followed by Dunnett‘s test).  
 
LPS also caused marked changes in the plasma cytokine profile within 2h of injection 
(Figure 3.13-14).  Significant increases in the plasma concentrations of TNFα (1.86-
fold, P<0.01, Figure 3.13A), IL-1α (1.41-fold, P<0.05, Figure 3.13B), IL-1β (1.20-
fold, P<0.01, Figure 3.13C) and IL-6 (34-fold, P<0.01, Figure 3.13D) vs. saline 
controls were observed 2h after injection of LPS.  However the apparent increases in 
TNFα (1.20-fold, P>0.05, Figure 3.13A), IL-1α (1.10-fold, P>0.05, Figure 3.13B), 
IL-1β (1.09-fold, P>0.05, Figure 3.13C) and IL-6 (10-fold, P>0.05, Figure 3.13D) 
observed at 4h did not reach significance.  Similarly the apparent increase (21-fold, 
P>0.05) in IL-6 observed at 24h was not significant (Figure 3.13D). 
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(A) TNFα (B) IL-1 α 
 
 
 
  
 
 
(C) IL-1β (D) IL-6 
 
 
 
 
 
 
Figure 3.13:  Effects of LPS administration on the plasma concentrations of 
TNFα, IL-1α, IL-1β and IL-6 in male WT mice.  Plasma samples were collected by 
cardiac puncture 2h, 4h and 24h after LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) 
for the analysis of (A) TNFα, (B) IL-1α, (C) IL-1β or (D) IL-6 by enzyme-linked 
immunosorbent assay.  Values are mean ± SEM of n = 6 mice per group.  
**P<0.01,*P<0.05 vs. saline-treated (one-way ANOVA followed by Dunnett‘s test). 
NS, not significant.  
 
Significant increases in plasma concentrations of IL-10 (247-fold, P<0.01, Figure 
3.14A) and RANTES (>49-fold, P<0.01, Figure 3.14C) were seen 2h after the 
administration of LPS compared to time-matched saline control.  No changes in IL-4, 
IFNγ (Figure 3.14B), IL-17, VEGF or eotaxin (Figure 3.14D) were evident at this 
time-point. 
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(A) IL-10 (B) IFNγ 
 
 
 
 
 
 
(C) RANTES (D) Eotaxin 
  
 
 
 
 
Figure 3.14:  Effects of LPS administration on the plasma concentrations of 
IL-10, IFNγ, RANTES and eotaxin in male WT mice.  Plasma samples were 
collected by cardiac puncture before (untreated) or 2h after injection of LPS 
(500µg/kg) or saline (both at 2.5ml/kg, i.p.) for the analysis of (A) IL-10, (B) IFNγ, 
(C) RANTES or (D) eotaxin using the Luminex xMap immunoassay.  Values are 
mean ±SEM of n = 6 mice per group.  **P<0.01,*P<0.05 vs. saline-treated (one-way 
ANOVA followed by Dunnett‘s test).  NS, not significant. 
 
B) Changes in gene expression following treatment with LPS or Saline (i.p.) 
LPS (500µg/kg) or saline (2.5ml/kg) were given (i.p.) to WT mice.  After perfusion at 
autopsy, tissues (spleen, hippocampus, hypothalamus, pituitary and adrenal glands) 
were collected for qRT-PCR analysis.  Expression of mRNAs for murine Fpr1, Fpr2, 
Fpr3 and ANXA1 as well as endogenous control genes (GAPDH, β2M and β-actin) 
were assessed 2h, 4h, 8h (except pituitary gland) and 24h after treatment.  The 
pituitary gland was sampled from a separate experiment as in the first experiment the 
samples were ‗pooled‘ together to increase RNA yield, and thus gave an n=1 only.  
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Therefore, a new technique of RNA amplification was used in which small quantities 
of RNA were amplified from each pituitary gland to yield enough cDNA to quantify 
the genes of interest, whilst maintaining an n=6.  In the repeat experiment, no samples 
were taken at 8h to minimise animal usage.  The amplification technique was also 
used in successive experiments investigating gene expression in the pituitary gland. 
 
All endogenous housekeeping genes were studied in order to assess independence 
from treatment using the CEF (Product).  GAPDH was considered the most suitable 
over all time-points (Figure 3.15) and was used as the normaliser and covariate for 
statistical analysis by ANCOVA.  
  140 
 
Figure 3.15:  Covariate Efficiency Factors (CEF) for GAPDH mRNA and target genes following i.p. administration of LPS.  The CEF 
(Product) for the endogenous control GAPDH with (A) Fpr1, (B) Fpr2, (C) Fpr3, (D) ANXA1 and (E) V1b mRNA over all time-points 
following administration of LPS (500µg/kg, 2.5ml/kg, i.p.).  CEF (Product) was >1, thus proving independence from treatment. 
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Figures 3.16–19 demonstrate the time-dependent effects of LPS vs. saline on the 
expression of mRNAs for murine Fpr1, Fpr2, Fpr3 and ANXA1 in the hippocampus, 
hypothalamus, pituitary gland, adrenal gland and spleen.  Administration of LPS 
(500µg/kg, i.p. in 2.5ml/kg saline) to WT mice caused significant increases in the 
expression of mRNAs for Fpr1, Fpr2, Fpr3 and ANXA1 in the pituitary and adrenal 
glands but not in the hippocampus or hypothalamus.  For Fpr1 (Figure 3.16E), Fpr2 
(Figure 3.17E) and Fpr3 (Figure 3.18E) significant LPS-induced increases in mRNA 
were also seen in the spleen but only after 4h (1.16-fold, 1.15-fold and 1.27-fold, 
respectively, P<0.01), vs. time-matched saline controls; in general the expression of 
all the FPRs tested was higher in the spleen than in the other tissues studied.  In the 
pituitary gland Fpr1 (Figure 3.16C) and Fpr2 (Figure 3.17C) mRNAs were increased 
after 2h (6.9-fold and 3.8-fold, respectively, P<0.01) and 4h (3.3-fold and 5.7-fold, 
respectively, P<0.01) compared to time-matched saline-treated controls.  By contrast, 
increases in Fpr3 (Figure 3.18C) mRNA were seen after 2h (3.6-fold, P<0.01) only, 
compared to time-matched saline control.  A small but statistically significant increase 
in the mRNA for ANXA1 (Figure 3.19C) was also observed at this time point 
(1.13-fold, P<0.05, vs. time-matched saline-treated control).  In the adrenal glands, 
striking statistically significant increases were seen in the levels of mRNAs for 
murine FPRs.  For Fpr1 (Figure 3.16D), Fpr2 (Figure 3.17D) and Fpr3 (Figure 3.18D) 
significant increases (P<0.01) were evident at 2h (1.53-fold, 1.60-fold and 1.51-fold, 
respectively), 4h (1.70-fold, 2.1-fold and 1.80-fold, respectively) and 8h (1.52-fold, 
1.80-fold and 1.68-fold, respectively) after the administration of LPS.  By 24h, 
expression had declined to values that did not differ significantly from those of the 
corresponding saline-treated controls.  Increases in ANXA1 mRNA (Figure 3.19D) 
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were also observed in the adrenal gland, 2h (1.08-fold, P<0.01) and 4h (1.11-fold, 
P<0.05) after the administration of LPS vs. the time-matched saline-treated control.  It 
must be noted that these increases were not as large as those seen with the FPRs in the 
adrenal. 
 
No increases in V1b mRNA (Figure 3.20) occurred in the spleen, hypothalamus or 
pituitary gland after administration of LPS, i.p.  However, the hippocampus showed a 
significant decrease in V1b mRNA (Figure 3.20A) after 2h (0.81-fold, P<0.05) 
compared with the time-matched saline-treated controls.  Furthermore, a pronounced 
decrease in V1b mRNA was evident in the adrenal gland 4h after injection of LPS 
(0.14-fold, P<0.05, Figure 3.20D) compared to time-matched saline-treated controls.  
Notably the overall levels of V1b mRNA in this tissue were low in both LPS- and 
saline-treated mice, raising the possibility that this change may reflect the very small 
amounts of message rather than a treatment-related change. 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
   (E) Spleen 
 
 
 
 
 
Figure 3.16:  Effect of i.p. administration of LPS on the expression of Fpr1 
mRNA in the hippocampus, hypothalamus, pituitary gland, adrenal gland and 
spleen.  LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) were administered to WT 
mice and (A) hippocampus, (B) hypothalamus, (C) pituitary gland (D) adrenal glands 
and (E) spleen removed at various time-points over 24h.  Fpr1 mRNA was quantified 
by qRT-PCR (n = 6/group, mean adjusted to GAPDH ± SEM).  **P<0.01 vs. 
time-matched saline control (ANCOVA followed by Dunnett‘s test after log 
transformation). 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
   (E) Spleen 
 
 
 
 
 
Figure 3.17:  Effect of i.p. administration of LPS on the expression of Fpr2 
mRNA in the hippocampus, hypothalamus, pituitary gland, adrenal gland and 
spleen.  LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) were administered to WT 
mice and (A) hippocampus, (B) hypothalamus, (C) pituitary gland (D) adrenal glands 
and (E) spleen removed at various time-points over 24h.  Fpr2 mRNA was quantified 
by qRT-PCR (n = 6/group, mean adjusted to GAPDH ± SEM).  **P<0.01 vs. 
time-matched saline control (ANCOVA followed by Dunnett‘s test after log 
transformation). 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
   (E) Spleen 
 
 
 
 
 
Figure 3.18:  Effect of i.p. administration of LPS on the expression of Fpr3 
mRNA in the hippocampus, hypothalamus, pituitary gland, adrenal gland and 
spleen.  LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) were administered to WT 
mice and (A) hippocampus, (B) hypothalamus, (C) pituitary gland (D) adrenal glands 
and (E) spleen removed at various time-points over 24h.  Fpr3 mRNA was quantified 
by qRT-PCR (n = 6/group, mean adjusted to GAPDH ± SEM).  **P<0.01 vs. 
time-matched saline control (ANCOVA followed by Dunnett‘s test after log 
transformation). 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
   (E) Spleen 
 
 
 
 
 
Figure 3.19:  Effect of i.p. administration of LPS on the expression of ANXA1 
mRNA in the hippocampus, hypothalamus, pituitary gland, adrenal gland and 
spleen.  LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) were administered to WT 
mice and (A) hippocampus, (B) hypothalamus, (C) pituitary gland (D) adrenal glands 
and (E) spleen removed at various time-points over 24h.  ANXA1 mRNA was 
quantified by qRT-PCR (n = 6/group, mean adjusted to GAPDH ± SEM).  *P<0.05, 
**P<0.01 vs. time-matched saline control (ANCOVA followed by Dunnett‘s test after 
log transformation). 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
   (E) Spleen 
 
 
 
 
 
Figure 3.20:  Effect of i.p. administration of LPS on the expression of V1b 
mRNA in the hippocampus, hypothalamus, pituitary gland, adrenal gland and 
spleen.  LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.) were administered to WT 
mice and (A) hippocampus, (B) hypothalamus, (C) pituitary gland (D) adrenal glands 
and (E) spleen removed at various time-points over 24h.  V1b mRNA was quantified 
by qRT-PCR (n = 6/group, mean adjusted to GAPDH ± SEM).  *P<0.05 vs. 
time-matched saline control (ANCOVA followed by Dunnett‘s test after log 
transformation). 
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B) Effects of central (i.c.v.) administration of LPS 
All endogenous controls used were assessed for independence from treatment by 
calculating the CEF (Product), of which GAPDH was considered the most suitable 
over all time-points (Figure 3.21).  The actual CEF was adjusted for CEF (Product) 
and was >1, thus proving independence from treatment.  Therefore, GAPDH was used 
as the normaliser and gene expression data were statistically evaluated by ANCOVA, 
considering the expression of GAPDH as a covariate. 
 
Expression of Fpr1 mRNA in the hippocampus was unaffected by LPS treatment, but 
in the hypothalamus a small but significant increase in Fpr1 mRNA (Figure 3.22B) 
was apparent (1.11-fold) 8h after LPS injection (p<0.05) when compared to time-
matched saline-treated control.  LPS-induced changes in murine Fpr1 mRNA were 
also seen in the pituitary (Figure 3.22C) and adrenal glands (Figure 3.22D) whilst 
changes in the mRNAs for Fpr2, Fpr3 and ANXA1 were evident only in the pituitary 
(Figures 3.23C-25C) and adrenal glands (Figures 3.23D-25D), compared with time-
matched saline-treated controls.   
 
In the pituitary gland, statistically significant increases in Fpr1 mRNA (Figure 3.22C) 
were seen 4h (1.73-fold, P<0.05) and 8h (1.21-fold, P<0.01) after i.c.v. administration 
of LPS but the values returned to control levels by 24h.  In the adrenal glands 
statistically significant increases in Fpr1 mRNA (Figure 3.22D) were evident 2h 
(1.23-fold, P<0.01), 4h (1.31-fold, P<0.01) and 8h (1.47-fold, P<0.05) after i.c.v. 
treatment with LPS, when compared to time-matched saline-treated controls.   
  149 
 
 
Figure 3.21:  Covariate Efficiency Factors (CEF) for GAPDH mRNA and target genes following i.c.v. administration of LPS.  The CEF 
(Product) for the endogenous control GAPDH with (A) Fpr1, (B) Fpr2, (C) Fpr3, (D) ANXA1 and (E) V1b mRNA over all time-points 
following administration of LPS (50µg/kg, 1µg/µl, i.c.v., n = 6/group).  CEF (Product) was >1, thus proving independence from treatment. 
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Similar trends in the pattern of Fpr2 and Fpr3 gene expression were observed in LPS-
treated animals, as shown in Figures 3.23-24.  No significant changes in mRNA for 
Fpr2 or Fpr3 were evident in the hippocampus or hypothalamus of LPS-treated 
animals.  However, in the pituitary gland, significant increases in mRNA for Fpr2 
(Figure 3.23C) and Fpr3 (Figure 3.24C) were seen after 4h (2.4-fold and 1.41-fold, 
respectively, P<0.05) and 8h (1.43-fold and 1.24-fold, respectively, P<0.01) 
compared with time-matched saline-treated controls, but the values returned to normal 
by 24h.  Pronounced increases in mRNA for Fpr2 (Figure 3.23D) and Fpr3 (Figure 
3.24D) were also observed in the adrenal glands, 2h (2.7-fold and 1.27-fold, 
respectively, P<0.05), 4h (3.8-fold and 1.51-fold, respectively, P<0.01) and 8h 
(1.71-fold, P<0.01) after LPS treatment vs. time-matched saline-treated controls.   
 
There were no changes in the expression of mRNA for ANXA1 in the hippocampus, 
hypothalamus and adrenal gland after central LPS treatment (Figure 3.25).  Minimal, 
yet statistical (after log transformation) increases in mRNA for ANXA1 (Figure 
3.25C) were observed in the anterior pituitary gland at 2h (1.07-fold, P<0.05) and 8h 
(1.02-fold, P<0.05) after LPS treatment, when compared to time-matched saline 
treated controls.   
 
Central administration of LPS also failed to influence V1b receptor mRNA expression 
in the hypothalamus, anterior pituitary and adrenal glands (Figure 3.26).  It did 
however cause a significant increase in V1b mRNA in the hippocampus at 2h (1.22-
fold, P<0.05, Figure 3.26A) vs. time-matched saline-treated controls, but not at any 
other time points examined. 
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(A) Hippocampus    (B) Hypothalamus 
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland 
 
 
 
 
 
 
Figure 3.22: Effect of i.c.v. administration of LPS on the expression of Fpr1 
mRNA in the hippocampus, hypothalamus, pituitary and adrenal glands.  LPS 
(50µg/kg) or saline (both at 1µg/µl, i.c.v.) were administered to WT mice (n = 
6/group) and (A) hippocampus, (B) hypothalamus, (C) pituitary and (D) adrenal gland 
were removed at various time-points over 24h (except hypothalamus and adrenal 
gland which were collected up to 8h).  Fpr1 mRNA was quantified by qRT-PCR 
(mean adjusted to GAPDH ± SEM).  *P<0.05, **P<0.01 vs. time-matched saline 
control (ANCOVA followed by Dunnett‘s test after log transformation of normalised 
data, except for adrenal gland). 
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(A) Hippocampus    (B) Hypothalamus  
 
 
 
 
 
 
(C) Pituitary gland     (D) Adrenal gland  
 
    
 
   
 
 
Figure 3.23: Effect of i.c.v. administration of LPS on the expression of Fpr2 
mRNA in the hippocampus, hypothalamus, pituitary and adrenal glands.  LPS 
(50µg/kg) or saline (both at 1µg/µl, i.c.v.) were administered to WT mice (n = 
6/group) and (A) hippocampus, (B) hypothalamus, (C) pituitary and (D) adrenal gland 
were removed at various time-points over 24h (except hypothalamus and adrenal 
gland which were collected up to 8h).  Fpr2 mRNA was quantified by qRT-PCR 
(mean adjusted to GAPDH ± SEM).  *P<0.05, **P<0.01 vs. time-matched saline 
control (ANCOVA followed by Dunnett‘s test after log transformation of normalised 
data). 
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(A) Hippocampus    (B) Hypothalamus  
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland  
 
    
 
   
 
 
Figure 3.24: Effect of i.c.v. administration of LPS on the expression of Fpr3 
mRNA in the hippocampus, hypothalamus, pituitary and adrenal glands.  LPS 
(50µg/kg) or saline (both at 1µg/µl, i.c.v.) were administered to WT mice (n = 
6/group) and (A) hippocampus, (B) hypothalamus, (C) pituitary and (D) adrenal gland 
were removed at various time-points over 24h (except hypothalamus and adrenal 
gland which were collected up to 8h).  Fpr3 mRNA was quantified by qRT-PCR 
(mean adjusted to GAPDH ± SEM).  *P<0.05, **P<0.01 vs. time-matched saline 
control (ANCOVA followed by Dunnett‘s test after log transformation of normalised 
data, except for adrenal gland). 
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(A) Hippocampus    (B) Hypothalamus  
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland  
 
    
 
   
 
 
Figure 3.25: Effect of i.c.v. administration of LPS on the expression of ANXA1 
mRNA in the hippocampus, hypothalamus, pituitary and adrenal glands.  LPS 
(50µg/kg) or saline (both at 1µg/µl, i.c.v.) were administered to WT mice (n = 
6/group) and (A) hippocampus, (B) hypothalamus, (C) pituitary and (D) adrenal gland 
were removed at various time-points over 24h (except hypothalamus and adrenal 
gland which were collected up to 8h).  ANXA1 mRNA was quantified by qRT-PCR 
(mean adjusted to GAPDH ± SEM).  *P<0.05 vs. time-matched saline control 
(ANCOVA followed by Dunnett‘s test after log transformation of normalised data, 
except for adrenal gland). 
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(A) Hippocampus    (B) Hypothalamus  
 
 
 
 
 
 
(C) Pituitary gland    (D) Adrenal gland  
 
    
 
   
 
 
Figure 3.26: Effect of i.c.v. administration of LPS on the expression of V1b 
mRNAs in the hippocampus, hypothalamus, pituitary and adrenal glands.  LPS 
(50µg/kg) or saline (both at 1µg/µl, i.c.v.) were administered to WT mice (n = 
6/group) and (A) hippocampus, (B) hypothalamus, (C) pituitary and (D) adrenal gland 
were removed at various time-points over 24h (except hypothalamus and adrenal 
gland which were collected up to 8h).  V1b mRNA was quantified by qRT-PCR 
(mean adjusted to GAPDH ± SEM).  *P<0.05 vs. time-matched saline control 
(ANCOVA followed by Dunnett‘s test after log transformation of normalised data, 
except for adrenal gland). 
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3.2.5 Additional FPR3 mRNA data 
During a review of the sequences used for both ISH and qRT-PCR, it was noted that 
the primers and probes used for Fpr3 in the qRT-PCR experiments showed a degree 
of homology with Fpr2.  Therefore, a set of specific primers and probe for Fpr3 were 
selected, optimised (termed Fpr3_Rep) and evaluated.  In this experiment, WT mice 
were given LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.), the spleen and adrenal 
glands collected for qRT-PCR, 4h after injection.  Expression of mRNAs for Fpr2 and 
Fpr3 as well as endogenous controls (GAPDH, β-actin and β-2M) was assessed.  As 
before, all endogenous controls were assessed for independence from treatment 
[calculating the CEF (Product)], of which GAPDH was >1, thus proving 
independence from treatment.  Therefore, GAPDH was used as the normaliser and 
gene expression data were statistically evaluated by ANCOVA, considering the 
expression of GAPDH as a covariate.    
 
Changes in mRNA for Fpr2 (Figure 3.27A) were seen in the spleen (1.27-fold, 
P<0.01) and adrenal glands (2.9-fold, P<0.01), 4h after treatment with LPS, when 
compared to saline-treated controls (Figure 3.27).  For both sets of primers and probes 
for Fpr3 (Fpr3 and Fpr3_Rep) there was a statistically significant increase in Fpr3 
(Figure 3.27B-C) in the adrenal glands (Fpr3 was 2.4-fold, P<0.01 and Fpr3_Rep was 
from an adjusted mean value of 0.1 to 2.7, P<0.01) 4h after administration of LPS, 
confirming that LPS does increase Fpr3 mRNA within the adrenal gland.  However, 
for Fpr3 (Figure 3.27B) in the spleen, the first probe and primers used showed a 
statistically significant increase in mRNA for Fpr3 (1.26-fold, P<0.01) that was not 
seen with Fpr3_Rep (1.17-fold, P>0.05, Figure 3.27C), suggesting that the initial Fpr3 
primers and probes may well be detecting both Fpr2 and Fpr3.  However, the data 
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does confirm that mRNA for Fpr3 is increased in the adrenal gland following 
LPS-treatment compared to saline-treated controls.  These primers and probes 
(Fpr3_Rep) would be used for all further experiments that investigated changes in the 
expression of mRNA for Fpr3. 
(A) Fpr2    (B) Fpr3 
 
 
 
 
 
 
 
  (C) Fpr3_Rep 
 
 
 
 
 
 
 
 
Figure 3.27: Effect of i.p. administration of LPS on the expression of Fpr2 and 
Fpr3 mRNA in the spleen and adrenal glands.  LPS (500µg/kg) or saline (both at 
2.5ml/kg, i.p.) were administered to WT mice and spleen and adrenal glands collected 
4h after treatment.  (A) Fpr2, (B) Fpr3 and (C) Fpr3_Rep primers and probes were 
used to quantify mRNA by qRT-PCR for Fpr2 and Fpr3 (n = 6/group, mean adjusted 
to GAPDH ± SEM).  **P<0.01 vs. time-matched saline control (ANCOVA followed 
by Dunnett‘s test after log transformation).  Fpr3 showed homology for Fpr2, 
however Fpr3_Rep showed no homology to Fpr2. 
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3.3 Discussion 
The murine FPR family comprises a group of seven transmembrane GPCRs originally 
identified in 1975 as chemoattractant receptors which are sensitive to formylated 
peptides derived from bacteria (Schiffman et al., 1975).  Knowledge of the FPR 
family has since developed substantially and it is now apparent that these receptors 
are more promiscuous in their ligand binding than was originally envisaged and that 
they respond to a variety of non-formylated peptides such as ANXA1.  Indeed, the 
early nomenclature for the FPR family does not reflect the family‘s diverse and 
complex role in the regulation of physiological/patho-physiological processes, as 
initially considered following identification in 1975 (John et al., 2008). 
 
With respect to the role of the FPR family within the HPA axis, data from our group 
have previously described expression of mRNAs for five FPR family members in the 
hypothalamus and anterior pituitary gland of untreated mice (John et al., 2007).  In an 
oral communication at ―New Developments in Stress Physiology – from gene to man‖ 
at the University of Bristol, December 2006, Buckingham et al., presented data to 
further support that the actions of ANXA1 in the anterior pituitary gland are 
independent of Fpr1 but may involve other FPR family members, in particular Fpr2 or 
Fpr3, and that this was the first evidence of a role for the FPR family in the regulation 
of neuroendocrine function.  Published studies on the functionality of the FPR family 
within the HPA axis have focused on the anterior pituitary gland and, other than the 
detection of FPR mRNAs in the hypothalamus (John et al., 2007), the potential role of 
the FPR family in other parts of the HPA axis has not been explored to date.  
Therefore, building on the evidence of a strong signal for expression of mRNAs for 
murine Fpr1, Fpr2 and Fpr3 (as well as Fpr-rs6 and 7) mRNA in the hypothalamus 
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(John et al., 2007), we attempted to understand further the role of this receptor family 
in the HPA axis by examining the expression profile of the receptors before and after 
stress.   
 
Two methods of detection were employed, ISH and qRT-PCR.  The latter is highly 
sensitive and allows accurate quantification of low levels of specific mRNAs in tissue 
extracts.  It does not however provide detailed insight to the localisation of the 
mRNAs within the tissues.  ISH by contrast allows the distribution to be mapped and 
can be adapted to allow quantification at the single cell level (Nouri-Aria, 2008).  
However, it lacks the sensitivity of qRT-PCR even when techniques for amplifying 
the signal are employed.   
 
For ISH, coronal and some sagittal sections were taken, using stereotaxic co-ordinates 
that ensured inclusion of the hypothalamus (Paxinos & Franklin, 2004).  Two mRNA 
transcripts, CRH-R1 and V1b, were used as positive controls on the basis that ISH has 
been used previously to map the distribution of both in the murine brain.  Positive 
staining for CRH-R1 mRNA was detected with the 
33
P-labelled CRH-R1 probe in the 
hippocampus, cortex, lateral hypothalamus, mammillary tract and cerebellum.  These 
data generally confer with previous reports which identified the major brain areas 
expressing CRH-R1 mRNA in the mouse as the cerebral cortex, hippocampus, dorsal 
part of the lateral septal nucleus, medial septal nucleus, olfactory bulb, globus 
pallidus, red nucleus, principal sensory nucleus V, pontine gray, cerebellum, 
subthalamic nucleus, substantia nigra pars compacta and pedunculopontine nucleus 
(King & Bishop, 2002; Korosi et al., 2006).  The more extensive distribution 
described in these references may be associated with different experimental protocols, 
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different environmental condition and/or the source of animals. 
 
A strong signal for V1b mRNA was detected in hippocampus and localised 
specifically to the CA1 and CA2 regions.  This finding correlates with previous data 
which identified expression of V1b predominantly in the CA2 area of the mouse 
hippocampus (Young et al., 2006).  However, interestingly these data differ from 
those obtained using riboprobes for V1b in the rat which identified V1b expression in 
regions including the olfactory bulb, supraoptic, suprachiasmatic,
 
and dorsomedial 
hypothalamic nuclei, piriform and entorhinal
 
cortices, hippocampus, substantia nigra, 
and dorsal motor nucleus
 
of the vagus (Vaccari et al., 1998).  However, the riboprobe 
also showed some homology with the V1a and oxytocin receptors, and may therefore 
lack specificity.  Our finding that two diverse probes identified a strong signal for 
V1b mRNA in the hippocampus suggests the staining is specific and the apparent lack 
of staining in other areas is a likely limitation of the sensitivity of ISH.  Further 
evidence for expression of V1b mRNA in the hippocampus is provided by our qRT-
PCR data.  However, unlike ISH, qRT-PCR also identified levels of V1b mRNA in 
the hypothalamus similar to those in the hippocampus.  This difference may reflect 
the distribution profile in the hypothalamus which may be more diffuse than that of 
the hippocampus.   
 
3.3.1 Expression of mRNAs for FPRs and ANXA1 in untreated control animals 
In the present study, mRNAs for Fpr1 and Fpr3 were not detected by ISH in any of 
the sections of brain taken from untreated WT mice.  This may reflect the low level of 
mRNA and the limited sensitivity of the method used, as Fpr1 and Fpr3 mRNAs have 
previously been detected by RT-PCR analysis in the murine hypothalamus (John et 
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al., 2007).  Furthermore, in the present study, expression of both mRNAs was readily 
detected in the hypothalamus and hippocampus by qRT-PCR. 
 
By contrast, ISH revealed signals for Fpr2 mRNA with two probes in the cerebellum, 
dentate gyrus and hippocampus (CA1/2) of untreated WT mice.  Further evidence of 
expression of Fpr2 mRNA in the hippocampus was provided by qRT-PCR analysis 
which also identified expression in the hypothalamus.  Our inability to detect Fpr2 
mRNA by ISH in the hypothalamus may reflect a diffused distribution of message 
with no specific areas having sufficient mRNA for detection by this method which is 
less sensitive than qRT-PCR.  Specificity of the signal detected by ISH was confirmed 
by the positive staining for Fpr2 in the white pulp of the spleen, a tissue known to 
show expression of Fpr2 (Gao et al., 1998; Le et al., 2002).  However, the signal in 
the spleen was only weak, perhaps because our protocol was optimised for brain, not 
spleen.       
 
In our studies, the presence of mRNA for Fpr2 in the hippocampus was detected.  The 
hippocampus is considered essential for acquiring episodic and declarative memories 
(Gluck et al., 2003) and in particular the dentate gyrus generates new neurons 
continuously, even in adult animals, in a process referred to as neurogenesis (Gould et 
al., 1999).  Neurogenesis in the adult hippocampus is of particular interest because of 
the importance in maintaining normal learning and memory function and its 
dysfunction in diseases such as Alzheimer‘s disease (Behl et al., 1997).  It is not 
known whether ANXA1 and FPR2 are involved in these processes, however, it is 
worth noting that ANXA1 is strongly implicated in the processes controlling cell 
growth and differentiation in other tissues (Croxtall & Flower, 1994).   
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Whilst Fpr2 has not been well described previously in the mouse hippocampus, its 
ligand ANXA1, has been identified in the rat hippocampus by western blotting (Smith 
et al., 1993) and by IHC which localised staining to the neuronal cell bodies in the 
dentate gyrus, Ammon‘s horn and in glia of the hippocampus in human brain 
(Eberhard et al., 1994).  More recent studies have challenged the specificity of the 
antibodies used in this study (McKanna & Zhang, 1997), and argued that, aside from 
the cerebellum (Young et al., 1999), ANXA1 is not expressed in neuronal cells in the 
brain and found only in microglia (McKanna, 1993; McKanna & Zhang, 1997), the 
ependymal cells that line the ventricles and activated astrocytes  (Johnson et al., 1989; 
Smith et al., 1993; McKanna, 1993; McKanna & Zhang, 1997).  Nonetheless, there is 
good evidence that low levels of ANXA1 are expressed in the microglia through the 
brain and that, following tissue injury, expression in the cells is up-regulated.  
Whether ANXA1 is expressed by resting astrocytes is still under debate (Johnson et 
al., 1989; Eberhard et al., 1994; McKanna & Zhang, 1997; Dreier et al., 1998; 
Savchenko et al., 2000), although it is accepted that ANXA1 protein expression is 
absent from oligodendrocytes (McKanna & Zhang, 1997).  Studies on human brains 
at autopsy have shown that either acute CNS damage or chronic degeneration is 
associated with strong expression of ANXA1 in reactive astrocytes (Eberhard et al., 
1994).  
 
The protective effect of ANXA1 in stroke was first demonstrated in the early 1990s 
by Relton et al., (1991) who, using a middle cerebral artery occlusion (MCAO) model 
in the rat, showed that i.c.v. administration of ANXA1 (ANXA11-188) reduced infarct 
size (60%) and cerebral oedema (46%), as measured 2h post MCAO (Relton et al., 
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1991).  Conversely, a neutralizing anti-ANXA1 fragment antiserum increased both 
infarct size and oedema, suggesting a role for endogenous ANXA1 in cerebro-
protection in stroke (Relton et al., 1991).  More recently, Gavins et al., (2007) 
investigated the molecular mechanism(s) underlying the protective mechanism of 
action of ANXA1 using MCAO as a model of murine cerebral ischaemia and 
intravital fluorescence microscopy to visualise pial vessels and monitor the leukocyte 
cascade (Gavins et al., 2007).  They showed that lesion-induced leukocyte adhesion 
and infarct size are enhanced by ANXA1 gene deletion while the neurological score is 
worsened.  These detrimental effects were rescued by administration of ANXA1 and 
the peptide ANXA1Ac2-26.  Following identification of mRNA for Fpr1 and Fpr2 (not 
Fpr3) in brain tissue extracts, HEK293 cells, stably transfected with FPR1 and FPR2, 
were able to show that both cold (non-radioactive) ANXA1Ac2-26 and Boc2 displaced 
the radiolabelled tracer peptide ANXA1Ac2-26, suggesting this was an FPR-mediated 
effect (Gavins et al., 2007).  Furthermore, in the murine cerebral ischaemia model 
there were no differences between WT and Fpr1
-/-
 mice in the parameters (i.e. rolling 
and adhesion) assessed by intravital fluorescence microscopy following 
administration of ANXA1Ac2-26.  This suggests that the beneficial effects of ANXA1 
were mediated through Fpr2 and that ANXA1 and other Fpr2 ligands may have 
therapeutic potential for the treatment of stroke (Gavins et al., 2007). 
 
The presence of mRNA for Fpr2 in the mouse cerebellum is interesting and to the best 
of our knowledge, it is the first time it has been described.  However, the cerebellum 
is rich in both ANXA1 (Mullens et al., 1994; Young et al., 1999) and GRs (Aronsson 
et al., 1988).  GRs are widely distributed in the brain, and, in addition to the 
cerebellum are abundant in the cerebral cortex, hippocampus, thalamus and 
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hypothalamus (Aronsson et al., 1988).  MRs are less ubiquitous and are localised 
mainly to the hippocampus and dorsolateral septum (Reul et al., 2000). 
ANXA1-immunoreactivity has been detected by ELISA and IHC in the cerebellum, 
the latter technique localising the protein in particular to the Purkinje cell bodies and 
molecular layer interneurons in frozen brain from untreated rats (Young et al., 1999).  
In line with these findings, administration of kainic acid (which activates presynaptic 
kainate receptors to release glutamate leading to neuronal necrosis) to slices of rat 
cerebellum in vitro causes up-regulation of ANXA1 in activated microglia and, at 
later time-points, in activated astrocytes (Young et al., 1999).  ANXA1 protein 
expression in the cerebellum is also increased by treatment with kainic acid (Young et 
al., 1999).  ANXA1 possesses immunosuppressive (Perretti & Gavins, 2003) and 
neuroprotective properties (Relton et al., 1991) and may exert protective effects 
following damage to the CNS.  Our finding that murine Fpr2 is expressed together 
with data regarding ANXA1 (Mullens et al., 1994; Young et al., 1999) in the 
cerebellum raise the possibility that the effects of ANXA1 may be mediated through 
FPR2, and this warrants further investigation. 
  
3.3.2 Circadian rhythm 
The physiology of most organisms follows a 24h cycle, which is entrained by the 
light-dark cycle and, for any particular organism, will depend upon whether its active 
phase is at night (nocturnal, e.g. rodents) or during the day (diurnal, e.g. man).  These 
patterns concur with changes in the environment (e.g. lighting conditions, temperature 
and food availability) and result in a spectrum of changes in biological activity [e.g. 
thermoregulation, olfactory sensitivity, hormone secretion and glucose metabolism, 
(Dickmeis, 2009)].  The influence of the day-night cycle is the prominent driver for 
Chapter 3 
 
 165 
the circadian rhythm, with the major components that drive the rhythmic activity 
being transmission of information from the light-sensitive cells in the retina to the 
suprachiasmatic nucleus (SCN) in the hypothalamus (Stehle et al., 2003) and the 
release of melatonin from the pineal gland.  Melatonin also acts on the pituitary gland 
(Stehle et al., 2003) to inhibit GnRH-induced LH and FSH release from neonatal, but 
not adult pituitary tissue (Vanecek, 1999), and has been suggested to contribute to the 
seasonal control of PRL, as shown in rams in which the hypothalamic-pituitary link is 
surgically disconnected (Lincoln & Clarke, 1994; Lincoln & Clarke, 1995).  The 
SCN, sometimes called the ‗body clock‘, is the primary controller of the circadian 
rhythm (Hastings, 1998), although ‗clocks‘ in other tissues have recently been 
described and may play a role in e.g. metabolic changes.  The identification of clock 
genes has provided important new insights to the regulation of circadian periodicity.  
These genes are transcriptional regulators that regulate molecular feedback loops 
associated with the circadian rhythm at the cellular level (Lowrey & Takahashi, 
2004).  Clock gene expression is principally regulated by the light-dark cycle and is 
correlated with the sleep-wake cycle, highlighting the strong relationship between 
circadian rhythmicity, energy metabolism and sleep regulation (Franken & Dijk, 
2009). 
 
The HPA axis exhibits a clear circadian periodicity with GC secretion being highest 
just before waking (i.e. early morning in man and late afternoon in rodents).  In an 
elegant series of experiments on gene expression and the rat HPA axis, Girotti et al., 
(2007) showed that immediate early genes, a family of proto-oncogene transcription 
factors, display different diurnal expression patterns (e.g. c-fos) over the 24h period 
(Girotti et al., 2007).  They also showed that the pattern of clock gene expression over 
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24h (per1, per2 and bmal) is similar in the anterior pituitary and adrenal cortex but 
different from that of the PVN (Girotti et al., 2009).   
 
The responsiveness of tissues to GCs and the expression of GRs varies over 24h.  In 
the hippocampus expression of GR and MR mRNA is higher in the morning than the 
evening (Holmes et al., 1995).  The sensitivity of blood cells to GCs changes across 
the diurnal cycle (Gratsias et al., 2000), perhaps because of the profile of cell types 
present in the circulation (e.g. the number of circulating leukocytes) in the rat alters 
over the 24h cycle and is inversely correlated with the serum CORT concentration; 
the circadian periodicity of the leukocyte count is abolished by chronic treatment with 
GCs (House et al., 1997).  House et al., (1997) also showed in rats that CORT alters 
leukocyte-endothelium interactions throughout the day.  These diurnal differences 
may influence diseases such as acute myocardial infarction and stroke that have 
highest occurrence between 6AM and noon (Pepine, 1991).  While the significance of 
periodicity within the HPA axis is unclear, disorders of it are associated with a feeling 
of ‗poor wellbeing‘ and typically occur in depression and other mental health 
disorders (e.g. anorexia nervosa) where they have been linked with disorders of GC 
feedback (Buckingham, 2006). 
 
Since ANXA1 and Fpr2 are implicated in mediating the aspects of GC feedback 
within the HPA axis, it seemed pertinent to examine the expression of these genes, 
and also Fpr1 and Fpr3, within the HPA axis over the 24h cycle.  To achieve this aim, 
tissue was taken from animals given an injection (i.p.) of saline at 09:00h and killed at 
intervals thereafter (2h, 4h, 8h and 24h later).  While this design is not ideal as the 
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saline injection may itself have had an effect, it obviated the need to use a large 
number of untreated animals for this study. 
 
While the data revealed some potential trends (see Figure 3.11), no significant 
changes in murine Fpr1, Fpr2 or ANXA1 gene expression were observed in the 
hippocampus, hypothalamus, pituitary or adrenal glands.  There was however a 
striking and highly significant (P<0.01) rise in Fpr3 mRNA in the pituitary gland at 
13:00h.  A similar profile in Fpr3 mRNA was evident in the hypothalamus, although 
in this case the changes did not reach significance.  Conversely, in the adrenal gland 
Fpr3 mRNA expression appeared lower at 13:00h and 17:00h vs. 09:00h, although 
again this did not reach significance.  As yet, very little is known of the factors which 
regulate Fpr3 expression and it is possible that the rise observed in the pituitary gland 
after mid-day is secondary to a number of physiological factors.  Similarly, the 
functional significance of these rhythmic changes in expression is unclear.  
Nonetheless, the observation is interesting and merits further investigation. 
 
3.3.3 Effects of peripheral and central administration of LPS on FPR and 
ANXA1 gene expression in HPA axis  
Experimental models 
Gene expression in most cell types is dependent on extracellular stimuli, and therefore 
the expression of a gene, as assessed by mRNA evaluation, may be low or 
undetectable in the absence, or even excess, of such stimuli.  The HPA axis is a highly 
integrated system which, in normal conditions, is primed to respond to stress, be it 
physical or emotional, with a subsequent increased release of CRH/AVP and ACTH 
from preformed stores in the hypothalamus and pituitary gland, respectively, and 
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consequent adrenal steroidogenesis and release of GCs into the systemic circulation.  
The responses to incoming stimuli are tempered by the negative feedback effects of 
GCs which effectively attenuate both the magnitude and the duration of the response. 
Hans Selye described the initiation of a stress response as the ―alarm reaction‖ (Selye, 
1976).  Therefore, when evaluating changes associated with stress, it might be argued 
that relevant changes are unlikely to be apparent in the absence of the ―alarm 
reaction‖.  In support of this argument, increases in e.g. CRH mRNA occur in the 
hypothalamus after a stressor (Makino et al., 2005).  We hypothesised that in a 
normal physiological state, the levels of mRNAs for ANXA1 and certain members of 
the FPR family within the HPA axis may be low in the absence of stress but may 
increase markedly when the animal is then challenged with a noxious stimulus.  
Therefore, we chose to model mild infection as a stressor by administering a low dose 
of LPS either intra-peritoneally so as to induce systemic inflammation (Loum-Ribot et 
al., 2006) or centrally to induce local neuroinflammation (Tyagi et al., 2008).   
 
Intra-peritoneal (i.p.) injection of LPS is well known to cause a rise in the circulating 
levels of pro-inflammatory cytokines, particularly TNFα, IL-1β and IL-6, and 
eicosanoids that activate the HPA axis.  When LPS is given peripherally into the 
peritoneum (i.p.) there is activation of the innate immune system as phagocytic cells 
within the peritoneal cavity (predominantly peritoneal macrophages) act to clear, in 
this case the endotoxin, from the host peritoneum (Anand et al., 2007).  LPS is 
opsonised by lipopolysaccharide binding (LBP) protein and the complex is recognised 
by the opsonic receptor CD14, on the macrophages‘ surface.  The LPS-LBP-CD14 
ternary complex subsequently activates the TLR group of pattern recognition 
receptors and activates subsequent signalling pathways through adaptor protein 
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MyD88 and serine kinase interleukin-1 receptor-associated kinase [IRAK, (Aderem & 
Ulevitch, 2000)].  Activation of the IRAK pathway leads to subsequent activation of 
NF-κB through IκB kinases required for transcription of immune response genes as 
well as MAPKs leading to activation of the Jun/Fos transcription factors (Aderem & 
Ulevitch, 2000) responsible for the regulation of physiological cellular processes 
(Vesely et al., 2009).  In the leukocytes, IRAK undergoes rapid degradation following 
LPS stimulation and this in turn may down-regulate the IL-1R/TLR-mediated 
signaling and cytokine gene transcription, acting as a negative feedback mechanism 
(Hu et al., 2002).  Consideration should also be given to the fact that IRAK plays an 
essential role in IκB degradation, and NF-κB nuclear translocation (Liu et al., 2008).  
Once activated through these pattern recognition receptors, macrophage actions 
include phagocytosis, migration of macrophages, secretion of cytokines and 
production of chemical mediators such as eicosanoids, nitric oxide and reactive 
oxygen species (Tajima et al., 2008) which are also responsible for local tissue injury.  
In this model, of particular interest were the effects of both cytokines and eicosanoids.  
Eicosanoids are a family of oxygenated metabolites of eicosapolyenoic fatty acids, 
such as AA, formed by three oxygenation enzymatic pathways, cyclooxygenases, 
epoxygenases, and lipoxygenases.  Eicosanoids include prostaglandins, thromboxanes 
and leukotrienes that play a key role in inflammation (Khanapure et al., 2007).   
 
The release of the pro-inflammatory cytokines and eicosanoids is triggered via LPS 
activation of TLRs mainly on cells (particularly macrophages) in the peritoneum 
(Anand et al., 2007) but also on circulating leukocytes following entry of LPS to the 
blood stream (Salomao et al., 2002). 
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The production of eicosanoids and proinflammatory cytokines by the peritoneal 
macrophages stimulates the release of CRH/AVP through local activation of the 
abdominal vagal afferents (Gaykema et al., 1995; Ek et al., 1998; Turnbull & Rivier, 
1999; Blatteis et al., 2000).  Early studies demonstrated that cytokines released in the 
peritoneum (e.g. IL-1,), may activate the ventral noradrenergic tract (which sends 
projections from the nucleus tractus solitarius to the parvocellular region of the PVN), 
by local sensory afferent fibres stimulation (Laye et al., 1995).  Activation of the 
vagal afferents leads to central activation of the vagal nuclei, which subsequently 
activates the ventral noradrenergic bundle which conveys catecholaminergic 
innervation to the PVN and SCN (Szafarczyk et al., 1985) and subsequently 
activation of the HPA-axis (Gaykema et al., 1995).  Furthermore, lesions to the 
hypothalamic catecholaminergic innervation, in particular to the ventral noradrenergic 
bundle, inhibited ACTH and subsequently CORT release (Szafarczyk et al., 1985).  
Electrical stimulation of these noradrenergic inputs activates the PVN to release CRH, 
that can be blocked by α1-adrenoceptor antagonists (Plotsky, 1987) or stimulated after 
i.c.v. injection of noradrenaline or α1-adrenoceptor agonists, as well as causing an 
increase in CRH mRNA expression in the PVN (Lookingland et al., 1991; Gunion et 
al., 1992; Itoi et al., 1994).   
 
Therefore, through release of either eicosanoids or pro-inflammatory cytokines such 
as IL-1β, macrophages in the peritoneum activate the vagal afferent pathway, leading 
to stimulation of the ventral noradrenergic bundle and stimulate the hypothalamus to 
release CRH and subsequently ACTH and CORT (Gaykema et al., 1995).   
 
Chapter 3 
 
 171 
In addition to the activation of afferent neuronal pathways, LPS can cause cardiac 
depression (Stein et al., 1996; Liu et al., 2007) possibly through the release of 
acetylcholine from vagal efferent fibres that binds to the α7-subunit-containing 
nicotinic acetylcholine receptors that are expressed on macrophages (Borovikova et 
al., 2000; Matsunaga et al., 2001; Wang et al., 2003).  This subsequent drop in blood 
pressure will lead to homeostatic disturbance that will lead to an increase in GCs, so 
as to compensate the change in blood pressure (Scheuer et al., 2004). 
 
Intra-peritoneal injection will also lead to leakage of LPS into the blood and 
subsequent release of cytokines (TNFα, IL-1α. IL-1β and IL-6) that transfer an 
inflammatory signal to the brain (Thompson et al., 2008).  Several studies have 
suggested that systemic administration of LPS is dependent on cytokine driven 
prostanoid generation by endothelial cells or adjacent leukocytes (Coceani et al., 
1988; Katsuura et al., 1988; Navarra et al., 1992; Cunningham, Jr. & De Souza, 
1993).  Cytokines themselves do not readily cross the blood brain barrier (BBB), 
however, they are able to cross this unique barrier via fenestrated capillary 
endothelium of the circumventricular organs; sites of high BBB permeability (e.g. as 
seen in local inflammation and disease states such as stroke); and via specific 
transport systems.  Cytokines may also activate perivascular cells of the BBB, which 
can lead to the release of e.g. eicosanoids and other soluble mediators.  It is important 
to note that the modulation of the HPA axis by eicosanoids can also be independent of 
cytokines e.g. in chronic inflammation or infection, peripheral immune cells release 
eicosanoids into the systemic circulation which may target the hypothalamus and 
pituitary gland directly  (Turnbull & Rivier, 1999; Mulla & Buckingham, 1999; John 
& Buckingham, 2003).  Also, in septic shock, leukocytes release phospholipase 2 
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(PLA2) into the blood (Vadas & Hay, 1983; Glaser et al., 1993), which increases 
eicosanoid production both within the periphery and in the brain.  When in the 
systemic circulation, LPS may act on the pituitary gland, directly affecting the 
folliculo-stellate cells through TLR4, which through the NF-κB signalling pathway 
stimulates the release of IL-6 and other cytokines, e.g. leukaemia inhibitory factor 
(LIF), that acts in a paracrine way on the corticotrophs potentiating the actions of 
CRH in the release of ACTH (John & Buckingham, 2003).  At the adrenal level, 
exposure to endotoxin increases the expression of mRNA for IL-1β (Nazarloo et al., 
2003), IL-6 (Muramami et al., 1993) and COX-2 (Cover et al., 2001), while COX-2 
inhibitors have an inhibitory effect on ACTH stimulated steroidogenesis, suggesting 
that eicosanoids have a functional role within the adrenal during immune stimulation 
(Cover et al., 2001). 
 
Central administration of LPS activates microglia (resident macrophages of the CNS) 
and astrocytes in the brain that release pro-inflammatory cytokines [TNFα and IL-1β, 
(Tyagi et al., 2008)] and eicosanoids (prostaglandins) which contribute to a 
neuroinflammatory response (Chao et al., 1995; Brugg et al., 1995; Szczepanik et al., 
1996; Montero-Menei et al., 1996).  Within the brain, both eicosanoids and cytokines 
activate the noradrenergic input to the hypothalamus leading to release of CRH and 
subsequently ACTH (Turnbull & Rivier, 1999).  Centrally injected LPS may also leak 
into the peripheral circulation, possibly through altering the permeability of the BBB 
(Verma et al., 2006; Jaeger et al., 2009) and thereby induce a mild systemic 
inflammatory response which may be sufficient to stimulate the HPA axis via the 
mechanisms described above.   
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Cytokine and CORT profiles in LPS-treated mice 
IL-1α, IL-1β and TNFα were all increased 2h and 4h after intra-peritoneal injection of 
LPS, but returned to normal by 24h.  Serum CORT was raised 2h and still further at 
4h after LPS injection, thus confirming HPA activation.  The production of TNFα in 
response to bacterial products, such as LPS, is mediated by NF-κB, which translocates 
to the nucleus following degradation of the NF-κB inhibitory protein, IκB, and 
enhances the expression of TNFα (Chen et al., 2009).  The return of TNFα to baseline 
values after 4h, may be associated with the elevation in GCs, which up-regulate IκBα 
and thereby facilitate retention of NF-κB in the cytoplasm (Bladh et al., 2008).  Other 
mechanisms may also contribute to the restoration of TNFα levels, for example TNFα 
negatively regulates its own release (Lockett et al., 2008).  The LPS-induced release 
of TNFα leads to a cytokine cascade characterised by the release  of IL-1α, IL-1β and 
IL-6 (Fong et al., 1989).  In baboons, intravenous (i.v.) administration of LPS causes 
sequential time-dependent increases in plasma TNFα (maximal at 1.5h post injection), 
IL-1β (maximal at 3h post injection) and IL-6 (increased after peak IL-1β).  However, 
pretreatment with a neutralising TNFα antibody, prevents the rises in IL-1β and IL-6 
(Fong et al., 1989).  In mice, maximal levels of TNFα occur within 90min of LPS 
injection (i.v.) and precede the maximal circulating levels of IL-1 and IL6 (Amiot et 
al., 1997).  These data indicate that LPS initiates a cytokine cascade whereby TNFα 
production and associated signalling pathways are required for the IL-1β and IL-6 
release.   
 
In the present study, increases in TNFα, IL-1α, IL-1β and IL-6 were observed 2h after 
injection (i.p.) of LPS.  Earlier sampling time-points would be required to assess if the 
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data of Amiot et al., (1997) translates to the mouse.  Whilst injection of TNFα 
increased the circulating levels of IL-1 and IL-6, Amiot et al., (1997) showed that 
LPS also increases IL-1α, IL-1β and IL-6 release independently to TNFα and that the 
presence of TNFα amplifies the response of these cytokines to LPS (S. typhimurium 
derived) injection (Amiot et al., 1997).  The magnitude of the cytokine response and 
the finding that the levels attained of TNFα, IL-1α, IL-1β and IL-6 were maximal 
within 2h but declined to base-line levels by 4h indicates that the inflammatory 
response was probably mild.      
 
Our data also show an increase in plasma IL-10, 2h after peripheral injection (i.p.) of 
LPS to WT mice.  IL-10 decreases the production and secretion of pro-inflammatory 
mediators such as TNFα (Bogdan et al., 1992).  Hence the observed increase in IL-10 
may serve to counter the rise in plasma TNFα and may itself be affected by the 
increase in circulating GCs.  Interestingly, administration of methylprednisolone (a 
synthetic GC) to asthmatic patients down-regulates IL-10 receptor expression on 
monocytes, lymphocytes, NK cells and neutrophils (Moniuszko et al., 2009).   
 
RANTES, a member of the CC chemokine subfamily (also referred to as CCL5), was 
also significantly increased 2h after administration of LPS (i.p.).  RANTES, an 
inducer of leukocyte migration, is secreted from different cell types including 
platelets, macrophages, endothelial cells, some epithelial cells, antigen specific CD4+ 
TH cells and effector CD8+ T cells, producing a signalling cascade through CCR1, 
CCR3, CCR4 and CCR5.  RANTES is a chemoattractant for monocytes, T cells, 
basophils, eosinophils, and mast cells but not neutrophils.  It is also an activator of 
basophils, mast cells (inducing histamine release) and eosinophils [leading to the 
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release of inflammatory mediators and up-regulation of adhesion molecules, 
(Castellani et al., 2007)].  It is likely that the powerful effect of GCs on resolution of 
inflammation is effected in part by blockade of RANTES secretion, as pre-treatment 
with dexamethasone reduces serum RANTES concentration in LPS treated rats, when 
compared to PBS-treated animals (Castellani et al., 2007).   
 
Eotaxin, a chemokine that co-ordinates the recruitment of inflammatory cells, in 
particular eosinophils, to sites of allergic inflammation, was not affected by LPS 
treatment.  It is produced by a variety of cell types including lung fibroblasts, smooth 
muscle cells, endothelial cells, alveolar macrophages, eosinophils, lymphocytes and 
dermal fibroblasts (Pease & Williams, 2001).  Interestingly, eotaxin signals 
exclusively through CC chemokine receptor 3 (CCR3), which is present on the 
surface of eosinophils, basophils and TH2 lymphocytes.  Administration of LPS intra-
thoracically has been previously shown to induce the
 
early expression of the 
eosinophil chemokines, eotaxin and RANTES (Penido et al., 2001).  However, at the 
time-point assessed (2h) there was no increase in eotaxin.  A full profile for this 
chemoattractant over 24h as well as tissue concentrations could elucidate the role of 
eotaxin during the inflammatory process. 
 
The plasma levels of IL-17, VEGF or IFNγ in WT mice were also unchanged 2h after 
administration of LPS.  IL-17, produced by T cells, is associated with a recently 
identified TH cell subset involved in the generation of autoimmunity (Gaffen et al., 
2006).  IL-17 also exhibits pro-inflammatory activities similar to innate immune 
cytokines (i.e. IL-1β and TNFα) in the regulation of granulocytes in vivo (Gaffen et 
al., 2006).  VEGF plays an important role in mediating the process of angiogenesis 
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and is considered a potent proangiogenic growth factor.  It would be interesting to 
evaluate the effect of LPS administration over a time-course, as an increase in VEGF 
has been associated with changes in vascular permeability, causing increased vascular 
leakage, more potent than histamine, and in studies on the effect on microvascular 
permeability of skin and cremasteric muscle, capillary endothelial cells were 
fenestrated within 10min of VEGF application (Roberts & Palade, 1995).  It is 
possible that the minimal increase in VEGF induced by higher doses of LPS 
(Leypoldt et al., 2007) may act to increase the permeability of the BBB, as in cerebral 
ischaemia, brain injury and brain tumours, VEGF expression in endothelial cells of 
the BBB is elevated.  Elevated VEGF levels may contribute directly to the increased 
BBB permeability in these disorders (Ay et al., 2008), as inhibition of VEGF 
signalling reverses the phenomenon (Van Bruggen et al., 1999).  There is also an 
interesting perspective that hippocampal neurogenesis is also regulated by VEGF (Lee 
& Son, 2009), and that changes in astrocyte derived VEGF-A contributes to BBB 
breakdown (Argaw et al., 2009).   
 
Initiation of an immune response, leads to IFNγ secretion from NK cells and TH1 cells 
at the site of inflammation.  Macrophage recognition of IFNγ potentiates the secretion 
from NK or T cells and affects macrophage function, activities include the 
up-regulation of pathogen recognition and antigen processing and presentation 
capabilities, induction of an antiviral state, inhibition of cellular proliferation and 
modulation of apoptosis, acquisition of microbicidal effector functions, alterations in 
macrophage immunomodulatory function and changes in macrophage trafficking 
(Schroder et al., 2004).  The fact that we did not see any increases in IFNγ may be 
associated to the time-point sampled, as when LPS was injected into mice (albeit 
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different strain and dose), increases in TNFα were seen at 1.5h after dosing (not 
present from 3h after treatment) and IFNγ was increased at 6.5h and 10h after 
treatment, suggesting that the time-point analysed was unlikely to identify changes in 
IFNγ and that this would be observed at a later time-point (Amiot et al., 1997).     
 
In these experiments, samples for evaluation of CORT and cytokines were collected 
from animals given LPS peripherally only (i.p.).  Blood samples were not collected 
from animals given LPS centrally (i.c.v.) due to the complex surgery and requirement 
for a sample prior to autopsy, where animals were perfused. 
 
Expression of FPRs and ANXA1 mRNAs in LPS-treated mice 
Evaluation of FPR and ANXA1 gene expression within the HPA axis following 
central or peripheral administration of LPS revealed major changes in both the 
pituitary and adrenal glands that support the growing evidence that the FPRs and 
ANXA1 contribute to the regulation of HPA axis. 
 
Peripheral injection of LPS: With regard to peripheral administration of LPS, no 
changes in FPR or ANXA1 gene expression were seen in the brain at any time-point 
studied, a finding that concurred with a previous report which showed no change in 
ANXA1 protein expression in the brain of LPS-treated rats (Buckingham, 1996). 
However, expression of Fpr1, Fpr2, Fpr3 and ANXA1 in the pituitary gland, adrenal 
glands and spleen were all increased by the treatment.  The changes in ANXA1 
mRNA were relatively modest but concur with a previous report that LPS induces 
ANXA1 expression in the rat anterior pituitary gland, apparently by a GC-dependent 
mechanism (Buckingham, 1996).   
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An epithelial cell line derived from human lung adenocarcinoma (A549 cell line) 
transfected with a construct expressing a reporter gene (luciferase) under the control 
of the ANXA1 promoter showed that a unique region of the ANXA1 promoter 
confers sensitivity to the GC, dexamethasone.  Specificity of the response was 
confirmed by the finding that it was reversed by a GR-antagonist (Solito et al., 
1998a).  This experiment also showed that the response to dexamethasone is slow and 
it was suggested that it might be indirect and dependent on induction of mediator 
proteins, perhaps involving CCAAT/enhancer binding protein beta [C/EBP-β, (Solito 
et al., 1998a)].  Functional studies on static incubates of the anterior pituitary tissue 
showed that the acute inhibitory actions of GCs and ANXA1 on ACTH release in 
vitro are mimicked by LXA4 (0.02-2µM) and by high concentrations of fMLP (1-
100µM).  When a non selective FPR antagonist (Boc1) was given at 100µM, the 
inhibitory effects of dexamethasone, ANXA11-188, ANXA1Ac2-26, fMLP and LXA4 on 
ACTH release were effectively antagonised  (John et al., 2007).  The suppressive 
effects of dexamethasone and ANXA1Ac2–26 on ACTH release are not affected by 
Fpr1 gene deletion and may involve other FPR family members, in particular Fpr2 or 
Fpr3 (John et al., 2007; John et al., 2008).  This suggests that increases in mRNA for 
ANXA1 seen in the pituitary gland may after 2h be a reflection of an earlier increase 
in GCs.  However, in the current study, no increase in expression of ANXA1 was seen 
at 4h after LPS treatment, when CORT levels were maximal and Solito et al., (1998a) 
suggest that the ANXA1 promoter was a slow responder to dexamethasone (Solito et 
al., 1998a).  Taylor et al., (1993) exposed, in vitro, rat anterior pituitary segments to 
dexamethasone which over a 1.5h period caused a progressive increase in the 
externalisation of ANXA1 to the outer surface of the cell that were unaffected by 
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inhibitors of RNA or protein synthesis indicating a non-genomic effect of GCs 
(Taylor et al., 1993).  Philip et al., (1997) showed that by extending the contact time 
(3h) of anterior pituitary gland segments to dexamethasone, there were no effects on 
the intracellular stores of ANXA1, unlike Taylor et al., (1993), and suggest that there 
were two phases of GC action, an initial non-genomic effect which causes 
externalisation and an effect that was slow in onset causing de novo ANXA1 
synthesis (Philip et al., 1997).  This suggests that the increase in mRNA for ANXA1 
is a genomic response acting to replenish the intracellular stores of ANXA1 through 
transcription of this protein.     
 
In the experiments using the A549 cell line and luciferase promoter, Solito et al., 
(1998b) assessed the effects of the inflammatory cytokines (TNFα, IL-1β and IL-6) on 
ANXA1 regulation at the transcriptional and translational levels.  In these elegant 
experiments assessing the promoter region for ANXA1, neither TNFα nor IL-1β 
influenced promoter function, whilst the effects of IL-6 were quite remarkable.  IL-6 
increased intracellular ANXA1 and caused translocation of ANXA1 to the cell 
surface; these effects were independent of dexamethasone (Solito et al., 1998b).  In 
our studies, IL-6 was increased at 2h only which corresponds with the increase in 
expression of mRNA for ANXA1, however the time-course over which increases in 
serum IL-6 influence ANXA1 expression is unclear.  Nonetheless, the up-regulation 
of ANXA1 may reflect direct effects of IL-6 on the promoter region of the ANXA1 
gene, involving a transcription factor that appears C/EBP-β-like (Solito et al., 1998b).  
In a study on lung fibroblast cell lines derived from ANXA1
-/-
 mice, the effects of 
dexamethasone and/or IL-1 on IL-6 mRNA and protein were assessed (Yang et al., 
2006).  The data revealed that ANXA1
-/-
 cells show increased basal IL-6, but are less 
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sensitive to dexamethasone inhibition of IL-6 than their WT counterparts, suggesting 
that ANXA1 exerts a powerful tonic inhibitory effect on IL-6 expression and that 
ANXA1 is required for GC inhibition of IL-6 (Yang et al., 2006).  Yang et al., (2006) 
also showed that MAPK phosphatase 1, a GC-induced negative regulator of MAPK 
activation, is up-regulated by dexamethasone in WT cells, but decreased in ANXA1
-/-
 
cells.  Co-administration with ANXA1Ac2-26 restored MAPK phosphatase 1 expression 
and inhibited p38 MAPK activity, suggesting that ANXA1 is an endogenous inhibitor 
of MAPK activation and IL-6 expression (Yang et al., 2006).  A study on colon 
adenocarcinoma cells suggested that basal ANXA1 expression is controlled by a 
functional cooperation between p53 and NF-Y and that induction of ANXA1 
expression by butyrate (a class I and II histone deacetylase inhibitor) is dependent on 
p38 MAPK activation, that has a key role in the differentiation pathway, indicating 
the role of ANXA1 in this process (Lecona et al., 2008).  In vitro data from the rat 
adrenal gland have shown that IL-6 stimulates GC-release (Salas et al., 1990).  
Furthermore, IL-6 and its receptor are expressed in the adrenal gland, predominantly 
the zona reticularis and the zona fasciculata (Path et al., 1997).  In an alternative 
model of inflammation based on IL-1 induced PMN infiltration into a mouse 6-day 
old air pouch, ANXA1 inhibited PMN infiltration in a dose dependent manner as did 
dexamethasone (Perretti & Flower, 1993).   
 
ANXA1
-/-
 mice that express LacZ under the control of ANXA1 promoter offer the 
opportunity for measurement of a reporter gene as a surrogate for ANXA1 (Hannon et 
al., 2003).  LacZ was detected in many tissues from ANXA1 null mice (stomach, 
lung, spleen, ovary, uterus, kidney, thymus and heart), but not in the brain (mainly 
cortex), liver or adrenal gland (Hannon et al., 2003).  Furthermore, Hannon et al., 
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(2003) showed an overexpression of cytosolic PLA2 (cPLA2) and COX2 in some 
tissues, but not PGE2 in ANXA1
-/-
 mice, compared to WT (Hannon et al., 2003).  By 
contrast, using RT-PCR and western blotting, Davies et al., (2007) showed expression 
of mRNA and protein for ANXA1 in the adrenal gland of WT mice which using 
immunofluorescence staining was localised in the capsule and outer cortical cell 
layers of the adrenal gland (Davies et al., 2007).  This was further supported in 
ANXA1
-/-
 mice, derived from the same colony as Hannon et al., (2003) but back 
crossed against a C57Bl/6 background, where a strong immunofluorescent staining 
for β-galactosidase in the capsule and outer cortical cell layers was observed in the 
adrenal gland (Davies et al., 2007).  Davies et al., (2007) also detected mRNA for 
ANXA1 in the thymus, spleen and brain of WT mice, with the thymus showing the 
strongest and the brain showing the least expression of mRNA for ANXA1 using this 
method of detection (Davies et al., 2007).   
 
In carrageenin or zymosan-induced inflammation, dexamethasone effectively inhibits 
leukocyte emigration and IL-1β generation in WT mice, but not in mice lacking the 
ANXA1 gene (Hannon et al., 2003).  ANXA1
-/-
 mice also show a higher degree of 
PMN recruitment compared to WT mice in the zymosan peritonitis model (Chatterjee 
et al., 2005).  Together, these data showed that ANXA1
-/-
 mice have an altered 
inflammatory response and are resistant to the anti-inflammatory effects of GCs.  At 
the pituitary level, corticotrophs from ANXA1
-/-
 mice showed a gender specific 
change in corticotroph number and structure, with males exhibiting a 4-fold increase 
in corticotroph number vs. WT.  In both sexes of ANXA1
-/-
 mice, the corticotrophs 
appeared smaller with a reduced number of secretory granules.  Interestingly, IL-6 
pituitary content was increased in male, yet decreased in female ANXA1
-/-
 mice, 
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indicating some element of sexual dimorphism in these mice.  Furthermore, the 
regulatory effects of GCs on ACTH release in vitro and in vivo were unaffected by 
ANXA1 gene deletion, as also was the ability of the ANXA1-null mice to respond to 
stress, suggesting that compensation has occurred (John, Cover and Buckingham, 
unpublished). 
 
When LPS is given at a higher dose (10mg/kg, i.p.) than that used in our experiment 
(500μg/kg, i.p.), the cellular and cytokine responses were altered in ANXA1-null 
mice vs. WTs and leukocyte adhesion in the microcirculation was increased (Damazo 
et al., 2005).  In ANXA1
-/-
 mice, TNFα was still increased at both 6h and 24h as too 
was IL-6 at 24h, whereas in the WTs, TNFα and IL-6 returned to baseline values at 6h 
and 24h, respectively.  In addition, there was an increase in activated PMNs (as 
measured by CD11b expression) at both 6h and 24h, whilst monocytes were increased 
at 24h, compared to WT controls.  Furthermore, macrophage TLR4 expression was 
down-regulated 2h after LPS treatment in ANXA1
-/-
 mice compared to WTs (Damazo 
et al., 2005).  Together, these data suggest that ANXA1 plays a protective role in 
endotoxaemia.  Our data shows that LPS, albeit at a lower dose, up-regulates ANXA1 
expression in the pituitary and adrenal gland within 2h.  They thus concur with reports 
that LPS up-regulates ANXA1 expression in a pituitary folliculo-stellate cell line 
(Solito et al., 2006) and, like GCs, LPS causes serine-phosphorylation and 
translocation of the protein to the cell membrane (Solito et al., 2003b).  In fact, LPS 
has been shown to activate ANXA1 gene expression in other cell types including 
epithelial cells, neutrophils and macrophages (Damazo et al., 2005).  The functional 
significance of the later ANXA1 expression in the pituitary and adrenal glands is 
unclear, but one possibility is that it serves to enhance the negative feedback effects of 
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the GCs and, thus, to ensure that the HPA response to endotoxaemia is contained 
(Solito et al., 2006).  Our finding that LPS induced the expression of Fprs would 
facilitate ANXA1-dependent GC feedback and is thus consistent with this view.    
 
Whilst research into ANXA1 and the development of a transgenic colony for 
ANXA1
-/-
 mice has enabled the role of ANXA1 to be further elucidated, work on the 
role of FPRs in transgenic mice is limited mainly to Fpr1 and its role in the immune 
system.  Fpr1
-/-
 mice appear healthy and do not develop spontaneous infections (Gao 
et al., 1999). However, when infected with L.monocytogenes, they show accelerated 
mortality and increased bacterial burden in the liver and spleen (Gao et al., 1999).  In 
addition, the ability of fMLP to induce superoxide production in neutrophils is 
reduced (Lavigne et al., 2002).  Using these mice in a model of ischaemia reperfusion 
injury in the heart, Gavins et al., (2005) indicated that the cardioprotective effects of 
ANXA1 are mediated through an alternative receptor(s), possible Fpr2 (ALX) as the 
responses of WT mice and Fpr1
-/-
 mice to ANXA1Ac2-26 are indistinguishable.  More 
recently, an Fpr2
-/-
 mouse colony has been developed containing a GFP in-frame 
insertion within the promoter region (Dufton et al., 2009; Dufton et al., 2010).  In two 
inflammatory models (inflamed mesenteries and carrageenin-induced paw oedema) 
Fpr2
-/-
 mice show increased oedema, cell adhesion and emigration, but not leukocyte 
rolling velocity (intravital microscopy) in the mesentery vs. WTs, suggesting that the 
inflammatory response in Fpr2
-/-
 differs from that of WTs (Brancaleone et al., 2009).  
In studies on a different colony of FPR2-null mice, Gao et al., (unpublished) showed 
that neutrophils from these mice do not respond to F2L (an endogenous 
chemoattractant peptide), suggesting F2L is specific to FPR2; however, no additional 
data are available from this colony (Gao et al., 2007).  Devchand et al., (2003) studies 
Chapter 3 
 
 184 
a transgenic mouse in which the human ALX was selectively expressed in myeloid 
cells.  In a model of dermal ear inflammation, neutrophil infiltration was reduced in 
the transgenic mice, vs. WTs, following treatment with the combination of leukotriene
 
B4 (LTB4) and prostaglandin E2 (PGE2).  Similarly, in zymosan-induced peritonitis, 
PMN infiltration into the peritoneum was reduced in the transgenic mice (Devchand 
et al., 2003).  However, because the functional properties of mouse equivalent of 
ALX are contained in murine Fpr2 and Fpr3, development of a specific mouse ALX 
knockout has proved challenging and characterisation of the Fpr2-null mouse 
described by Dufton et al., (2010), will prove invaluable into further understanding of 
this receptor.       
 
Using HL-60 cells, Perez et al., (1992) were able to clone and express the gene coding 
for a human FPR1 (originally referred to as FPR, subsequent BLAST analysis of 
sequences used show specificity to FPR1) and identified potential binding sites for 
activator protein 1 (AP-1) and GR upstream of the promoter region (Perez et al., 
1992a).  Furthermore, they showed that FPR gene expression could be up-regulated 
by dexamethasone and hypothesised that this was through a GC regulatory element 
(Perez et al., 1992a; Perez et al., 1992b).  Further work where Chinese hamster ovary 
(CHO) cells were transfected with the same orphan receptor cDNA (pINF114) 
displayed specific 
3
H-LXA4 high affinity binding (Fiore et al., 1994), perhaps 
suggesting that the FPR identified by Perez et al., (1992) was FPR2, and that this 
receptor could be up-regulated by a GC regulatory element (Perez et al., 1992b). 
 
The LPS-induced increase in ANXA1 in the pituitary gland, whether initiated by GCs 
and/or LPS, is timely as it provides opportunity for the ANXA1-dependent inhibitory 
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effects of the GCs to manifest themselves and thereby contain the ACTH and CORT 
responses to LPS.  Similarly, at the adrenal level, there is evidence that GCs exert a 
local ANXA1-dependent inhibitory action on GC release (Davies et al., 2007).  The 
finding that the FPRs are also elevated in these tissues is both interesting and original.  
The limited data available suggest that ANXA1 may act via Fpr2 in the pituitary 
gland (John et al., 2007) to suppress ACTH release and, hence, the up-regulation of 
Fpr2 in the pituitary gland may serve to reinforce these actions of ANXA1.  However, 
the roles of Fpr1 and Fpr3 in this tissue are unknown, as too is the role of this receptor 
family in the adrenal gland.   
 
Central administration of LPS: Central administration of LPS also failed to modify 
expression of ANXA1 or the FPRs in the hypothalamus or hippocampus but produced 
significant changes in the pituitary gland and adrenal which were similar, but not 
identical to those induced by peripheral injection of the toxin.  It is therefore tempting 
to speculate that they were triggered by similar mechanisms.  In support of this 
argument, 70% of LPS injected i.c.v. enters the peripheral circulation within 4h 
treatment (Chen et al., 2000), thus providing opportunity for LPS to directly regulate 
peripheral gene expression.  However, if LPS has a direct regulatory effect on 
ANXA1 and FPR gene expression, it is surprising that expression of these genes in 
the brain was unaffected by i.c.v. injection of LPS.  Certainly, central injection of LPS 
elicits a centrally mediated cytokine response and induces a centrally-mediated 
activation of the HPA axis (Conde et al., 1999) and, as in the periphery, these effects 
are mediated via TLRs (Zhou et al., 2006).  Furthermore, there is widespread 
evidence that both expression of ANXA1 and members of the FPR family is up-
regulated in the brain following tissue injury (Le et al., 2002; Cui et al., 2002; Solito 
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et al., 2008).  One possibility is that the central response is delayed and dependent on 
the activation and proliferation of microglia and astrocytes.  While microglial 
activation is rapid, astrocyte proliferation occurs more slowly and is considered to be 
the major locus of ANXA1 expression in neural injury (Eberhard et al., 1994; Knott et 
al., 2000; Probst-Cousin et al., 2002).  Whilst i.c.v. administration of LPS is likely to 
elicit stimulation of the HPA axis through the hypothalamus, HPA-activation is also 
likely to be effected by appearance in peripheral blood of LPS, cytokines and 
eicosanoids as previously described.  This occurs through brain to blood transfer of 
these cytokines that are synthesised within the brain [astrocytes, microglia, 
endothelia, ependymal cells and possibly neurons, (Chen et al., 2000)] and also 
through the peripheral effects of LPS.  It is likely that central administration of LPS 
leads to activation of the noradrenergic input of the hypothalamus (De Simoni & 
Imeri, 1998), then at 8h, peripheral stimulation occurs from leakage (Chen et al., 
2000) of LPS into the periphery and a ‗secondary‘ activation as described above for 
peripheral administration of LPS.   
 
Whilst low levels of the mRNAs for Fpr1, Fpr2 and Fpr3 were detected in the 
hippocampus by qRT-PCR, expression of these receptors was unaffected by i.p. or 
i.c.v. administration of LPS up to 24h post injection.  The lack of response following 
i.p. administration is not unexpected assuming that LPS did not cross the BBB, 
however a lack of response following i.c.v. injection of LPS was surprising.  
Administration of LPS i.c.v. elicits local release of pro-inflammatory mediators (e.g. 
eicosanoids, cytokines) and, hence, neuroinflammation together with activation of the 
HPA axis.  Our finding that the hippocampal expression of mRNAs for Fpr1, Fpr2 
and Fpr3 was unaffected by central LPS administration suggests that the expression 
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profiles of these receptors is not affected by mild acute stress or mild acute CNS 
inflammation, although is of course feasible that changes might be observed at a later 
time-point.  In a study on primary murine microglial cells, Fpr1 and Fpr2 expression 
was observed; Fpr2 but not Fpr1 activation was induced by LPS treatment indicating 
that Fpr2 may have an active role in promoting the brain host response in 
inflammatory diseases (Cui et al., 2002).  Further studies using time-points up to 7 
days are recommended to determine whether the FPRs are indeed associated with 
neuroinflammation and neurodegeneration as previously suggested (Cui et al., 2002).   
 
From these gene expression studies, the data further support the growing evidence 
that FPRs and ANXA1 contribute to the regulation of HPA axis in conditions of 
stress, and in particular as mediators of GC regulation and feedback within the 
anterior pituitary and adrenal glands. 
 
Administration of LPS by i.p. or i.c.v. to WT mice elicited changes in the HPA axis 
for mRNA of ANXA1 and the FPRs that support the growing evidence that they 
contribute to the regulation of HPA axis condition of stress.  The inflammatory 
component of this experiment must be explored to understand whether these changes 
were GC-mediated, part of the innate immune response following an endotoxin 
challenge or both. 
 
3.3.4 Assessment of V1b mRNA expression within the HPA axis 
Whilst the remit of this thesis was to elucidate the role of FPRs within the HPA axis, 
V1b expression was used as a positive control in our studies using both ISH (brain) 
and qRT-PCR (brain, pituitary gland, spleen and adrenal glands) as methods for 
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detection of gene expression. 
 
V1b mRNA was detected in the brain (hippocampus and hypothalamus), pituitary 
gland, spleen and adrenal glands from untreated WT mice by qRT-PCR and in the 
hippocampus by ISH.  As discussed earlier, these findings are consistent with, but not 
identical to, those reported previously (Lolait et al., 1995; Gallo-Payet & Guillon, 
1998).   
 
No changes in the expression of V1b mRNA were seen within the hypothalamus or 
pituitary gland following either peripheral or central administration of LPS.  As 
described previously, AVP and CRH are the two main hypothalamic neuropeptides 
regulating the HPA axis, synergistically stimulating the release of ACTH from the 
anterior pituitary gland (Spiga et al., 2009).  The effects of AVP on the corticotrophs 
are mediated via the V1b receptor (Gillies et al., 1982; Jard et al., 1987) and, given 
the importance of this receptor in the pituitary gland, it is perhaps surprising that the 
expression levels were lower than those of the other tissues examined.  This finding 
may be explained by the facts that (a) expression is localised mainly to corticotrophs 
which represent only 5-10% of the pituitary cell population and (b) not all 
corticotrophs express this receptor (Jia et al., 1991).  Current evidence suggests that, 
while AVP is released in response to certain stressors [e.g. IL-1β, IL6, (Loxley et al., 
1993)], it plays a particularly important role in regulating ACTH release in conditions 
of repeated or chronic stress whereas CRH is the primary driver of ACTH release in 
acute stress (Spiga et al., 2009).  However, in V1b-null mice, the plasma ACTH and 
CORT concentrations are reduced vs. WT controls, suggesting that V1b receptor may 
also play an important role in regulating HPA activity under basal conditions (Tanoue 
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et al., 2004).  Furthermore, data from mice lacking CRH-R1 suggest that the 
vasopressinergic system provides a compensatory mechanism to maintain HPA-
activity, when CRH/CRH-R1 system is impaired (Muller et al., 2000).  These findings 
are consistent with reports that AVP mRNA but not CRH mRNA increased in some 
models of chronic stress (Chowdrey et al., 1995).  On the other hand, acute stress (1h 
immobilisation) causes a biphasic change in V1b mRNA expression in the rat 
pituitary with a decrease after 2h but increase after 4h (Rabadan-Diehl et al., 1995), 
suggesting that a rapid activation of V1b receptor gene transcription is required to 
restore V1b mRNA levels (Volpi et al., 2006).  Sequence analysis of the V1b 
promoter region has revealed potential binding sites for GCs, AP-1 and cAMP 
(Rabadan-Diehl et al., 2000) and suggested that interaction of a pituitary nuclear
 
protein complex with GAGA repeats located close to the transcription start point 
(inverted GAGA box) is required for transcription (Volpi et al., 2002).  Whilst AVP 
was not measured in our study, LPS treatment (i.p.) has been shown to increase 
plasma AVP in rats (Kasting et al., 1985).  Volpi et al., (2006) also suggest that AVP 
regulates its own receptor based on AVP induced GAGA binding activation leading to 
transcription of V1b during stress (Volpi et al., 2004) and later showed that AVP 
increases the binding activity (by phosphorylation) of nuclear proteins close to the 
promoter region through activation of the MEK MAP kinase pathway (Volpi et al., 
2006).  When GCs are given to rats there is an up-regulation of mRNA for V1b 
(Rabadan-Diehl et al., 1997; Rabadan-Diehl & Aguilera, 1998) and a decrease in 
vasopressin binding (Rabadan-Diehl & Aguilera, 1998).  A decrease in GCs (through 
adrenalectomy) reduces pituitary vasopressin binding (Antoni et al., 1985; Lutz-
Bucher et al., 1986) and causes a small reduction in V1b mRNA, that returns to 
normal by 3 days (Rabadan-Diehl et al., 1997).  These data suggests that whilst GCs 
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stimulate transcription and decrease receptor number at the translational or post-
translational levels, transcription is also under the control of other factors (Aguilera & 
Rabadan-Diehl, 2000).     
 
By contrast V1b mRNA expression in the hippocampus was sensitive to LPS, being 
down-regulated 2h after a peripheral injection but up-regulated 2h after a central LPS 
injection; with no changes observed at any other time point studied.  V1b mRNA is 
detectable (ISH and RT-PCR) within the hippocampus from untreated rodents (mice 
and rats) and humans [with no known neurological disease, (Young et al., 2006)], but 
direct innervation of the tissue by vasopressinergic neurons has not been described 
and the role of AVP within the hippocampus is still unclear.  The hippocampus 
undergoes continuous neurogenesis in adulthood (Gould et al., 1999) and studies in 
animals have indicated that stress is associated with changes in hippocampal structure 
and function, manifested through reduced neurogenesis (Armstrong et al., 1993).  In a 
study by Sapolsky et al., (1985), chronic GC treatment (3 months) caused a reduction 
in hippocampal GR expression, which was not reversed 4 months after drug 
withdrawal.  These changes were associated with a loss of GC-concentrating cells 
predominantly in the CA3 field; the size and distribution of hippocampal cell bodies 
were comparable in GC-treated and aged (non-treated) animals indicating that GCs 
may contribute to an age-related loss of neurons in the hippocampus (Sapolsky et al., 
1985).  Reductions in GC levels were shown to reduce hippocampal damage 
(Landfield et al., 1981b), however, adrenalectomy resulted in damage to the dentate 
gyrus (Landfield et al., 1981b) suggesting that homeostasis of GCs at physiological 
relevant levels is important for maintenance of neurons within the hippocampus.  This 
and other research provides evidence that the effects of chronic stress (and 
Chapter 3 
 
 191 
concomitant increases in GCs) affect the hippocampus leading to disruption of 
hippocampal function.  In addition, hippocampal dysfunction would also be expected 
to disrupt HPA function as the hippocampus is a major site of GC feedback.  For 
example, hippocampal lesions or severing of the fornix (mediator between 
hippocampus and hypothalamus) leads to dexamethasone resistance and 
hypersecretion of GCs, ACTH, CRF, AVP and oxytocin during basal stress and post-
stress conditions (Sapolsky & Plotsky, 1990).  Furthermore, the disruption of GC 
feedback in rats subjected to continuous stressors (water immersion and restraint) 
have been attributed to impairment of the actions of GCs in the pre-frontal cortex and 
hippocampus (Mizoguchi et al., 2003).  In a clinical study, GC disturbance was 
described in demented patients as an increase in the cortisol:dehydroepiandrosterone 
sulphate ratio correlating with a decline in hippocampal volumes (Magri et al., 2006).  
Furthermore, hippocampal lesions increase serum CORT and AVP and CRH mRNAs 
in the PVN, suggesting that the hippocampus tonically suppresses the synthetic 
activity of neurons issuing the primary ACTH secretagogues (Herman et al., 1989).  
The decrease in hippocampal V1b mRNA 2h after an i.p. injection of LPS parallels 
the decreases seen in the pituitary 2h after an acute stressor (Rabadan-Diehl et al., 
1995).  The latter has been attributed in part with a direct effect of elevated GCs 
(increases in CORT) or AVP (Kasting et al., 1985) on transcription of this receptor 
(Rabadan-Diehl et al., 1997; Rabadan-Diehl & Aguilera, 1998) as an acute stressor in 
the pituitary (restraint stress) also leads to an initial decrease in mRNA for V1b 
followed by recovery or elevation above the basal levels by 4h (Rabadan-Diehl et al., 
1995).  The changes in gene expression for the V1b receptor in response to LPS 
support a role for AVP in the hippocampus in response to stressful stimuli.   
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De Wied et al., (1971 & 1976) proposed that AVP may be involved in neuronal 
communication and memory processes (De Wied, 1971; De Wied et al., 1976).  AVP 
has been shown to improve learning and memory related performance in experimental 
animals (Engelmann & Landgraf, 1994; Bernstein et al., 1994; Vawter et al., 1997; 
Dietrich et al., 2001)  and been associated with facilitation of hippocampal long term 
potentiation (Chepkova et al., 2001; Dubrovsky et al., 2003).  Conversely, AVP 
deficiency is linked with deficits of spatial working memory performance (Aarde & 
Jentsch, 2006).  Mice that lack the V1b gene have been shown to exhibit decreased 
levels of aggression and modestly impaired social recognition (Wersinger et al., 
2002), further suggesting a role for AVP and, specifically the V1b receptor, in the 
regulation of cognition/behaviour.  Interestingly, in the light of the LPS-induced 
changes in V1b mRNA expression described here and the association of AVP with 
long-term potentiation and cognitions, pro-inflammatory cytokines have been shown 
to inhibit long-term potentiation (Tancredi et al., 2000; Vereker et al., 2000; Curran & 
O'Connor, 2003; Butler et al., 2004) and induce performance deficits in hippocampal-
mediated cognitive tests (Pugh et al., 1998; Sparkman et al., 2005a; Sparkman et al., 
2005b).  The changes in V1b mRNA observed in the hippocampus following LPS 
treatment may thus contribute to the cognitive changes evident in endotoxaemia.  
They may also effect the cognitive responses to high levels of GCs, which have been 
shown to affect different memory phases such as consolidation and memory retrieval 
(Roozendaal, 2002).  It is widely considered that GCs enhance memory consolidation 
as adrenalectomy impairs spatial memory performance (Paul & Havlena, 1962; Oitzl 
& de Kloet, 1992; Vaher et al., 1994; Roozendaal et al., 1996), an effect which is 
reversed by post-training injections of dexamethasone (Roozendaal et al., 1996) and 
suggest that memory consolidation depend on activation of GC-sensitive pathways 
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(Roozendaal, 2002).  However, elevated GCs can have a detrimental effect on 
memory retrieval.  In rats trained to locate a submerged platform in a water maze, an 
acute stressor (foot shock) just prior to performing the task led to rats being unable to 
locate the platform during peak (30min post stressor) plasma CORT levels, suggesting 
that CORT affects memory recall, as rats were able to locate the platform at earlier 
(2min) or later (4h) time-points (De Quervain et al., 1998).  An assessment of 
retention testing impaired hippocampal-dependent free recall of previously learned 
words in man was impaired following treatment with cortisone (De Quervain et al., 
2000).  The behavioural data collected for GCs suggest that GCs block hippocampal-
dependent influences on memory retrieval (Roozendaal, 2002).  Therefore, the 
changes in V1b expression observed in our experiments coupled with a strong but 
highly localised signals detected by us and others (Devito et al., 2009) in the 
hippocampus by ISH suggest that this receptor has an important role in the 
hippocampus but that its expression is highly plastic and sensitive to stress-induced 
changes in the local milieu. 
 
As well as the hippocampus, there was a statistically significant decrease in mRNA 
for V1b 4h after administration of LPS in the adrenal gland.  AVP has been detected 
in the rat adrenal cortex and medulla and may directly modulate adrenal 
steroidogenesis through a V1a-dependent paracrine mechanism (Perraudin et al., 
1993; Guillon et al., 1998).  Other data suggest that AVP may act via V1b in the 
medulla to stimulate catecholamine secretion in both acute and chronic stress 
(Grazzini et al., 1998).  In conscious rats intravenous administration of E.coli causes 
increases in plasma noradrenaline and adrenaline together with tachycardia within 
30min of injection while blood pressure falls within 1h and 2h (Jones et al., 1988).  
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Therefore, the down-regulation of V1b within the adrenal glands may reflect changes 
within the adrenal medulla perhaps as a response to the reduced blood pressure seen 
initially after administration of an endotoxin (Jones et al., 1988) and supports data 
generated by Grazzini et al., (1998).   
 
The functional relevance of our finding that the levels of V1b mRNA expressed in the 
spleen are higher than those found in the hypothalamus, anterior pituitary and adrenal 
glands is unclear but may indicate a role in mediating the reported effects of 
vasopressin on immune function (Kumamoto et al., 1995). 
 
The opposing changes in hippocampal V1b receptor expression following peripheral 
and central administration of LPS suggest that this V1b receptor population may 
particularly plastic in conditions of stress.  In view of the importance of the 
hippocampus in regulating the HPA responses to stress and then growing interest in 
the development of V1b antagonists for the treatment of depression and other CNS 
disorders associated with HPA dysfunction, these data merit further investigation.  
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CHAPTER 4         
EFFECTS OF LPS ON THE CELLULAR MORPHOLOGY 
OF THE BRAIN, PITUITARY GLAND, ADRENAL 
GLAND, SPLEEN AND THYMUS IN WILD TYPE, Fpr2
-/-
 
AND ANXA1
-/-
 MICE 
4.1 Introduction and Methods 
The previous chapter described the pattern of gene expression for the FPRs and 
ANXA1 in the brain, pituitary gland, adrenal gland and spleen.  Furthermore, when 
LPS was given either centrally or peripherally there was an up-regulation of these 
mRNAs in the pituitary and adrenal glands, but not brain.  Whilst this supports the 
growing evidence that the FPRs and ANXA1 contribute to the regulation of HPA axis 
in conditions of stress, the data did not provide any indication as to whether the 
changes in gene expression were associated with morphological changes in the tissue.  
To address this question, histological examination of the spleen, thymus, brain, 
pituitary and adrenal glands was performed 4h after i.p. administration of LPS to WT 
mice.  Parallel studies were performed in Fpr2
-/-
 and ANXA1
-/-
 animals to explore the 
impact of deletion of these genes. 
 
Histological examination of the tissues using H&E, which is regarded as the ‗gold 
standard‘ stain by histologists, enabled characterisation of any morphological changes 
that are associated with a treatment, gene deletion or LPS administration.  
Haematoxylin is a basic compound that binds with the acidic cell components, such as 
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cell nuclei, whilst eosin is acidic and binds to the basic components of the cell and 
extracellular matrix, such as proteins.   
 
Male WT, ANXA1
-/-
 or Fpr2
-/-
 mice were pre-treated with LPS (500µg/kg) or the 
sterile physiological saline vehicle (both at 2.5ml/kg, i.p.).  They were then killed 4h 
later (when transcription of FPRs was maximal) and following tissue perfusion (see 
Chapter 3) the brain, thymus, spleen, pituitary and adrenal glands were collected and 
stored in 10% neutral buffered formalin.  The tissues were then embedded in paraffin 
wax, sections cut at 3µm and stained for light microscopy.  Additional sections of 
pituitary were cut at 5μm for evaluation of ACTH, PRL, TSH, LH and FSH by 
immunohistochemistry. 
 
4.2 Results  
A) WT mice 
Microscopic changes were observed in the spleen, thymus and adrenal glands of WT 
mice 4h after administration of LPS and are detailed in Table 4.1 and Figures 4.1-6.  
 
In the spleen, LPS increased the incidence of lymphoid cell apoptosis (pyknotic nuclei 
with apoptotic bodies) in 4/6 (compared to 1/6 in saline-treated WT mice) and 
increased extramedullary erythropoiesis (consisting in an increased amount of 
immature haematopoietic cells) in 6/6 LPS-treated animals (Table 4.1).  Lymphoid 
necrosis (5/6) and cortical hypertrophy (increased thickening of the cortical layer 
containing a larger number of cells, 2/6) were seen in the thymus of LPS-treated 
animals (Table 4.1).  In the adrenal glands, slight to moderate inflammatory cell 
infiltration (predominantly PMNs with occasional monocytes) was evident in the 
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cortex and medulla (including vascular lumen) in 6/6 LPS-treated animals.  In 
addition, cortical vacuolation (an index of lipid droplets removed upon fixation) was 
reduced in 5/6 LPS-treated animals (Table 4.1). 
 
 SALINE LPS 
 
Number of animals examined 
 
 
6 
 
6 
Spleen   
White pulp, mainly germinal centres, lymphoid cell 
apoptosis 
 - minimal 
 
 
1 
 
 
4 
Extramedullary erythropoiesis 
 - minimal 
 - mild 
 
 
0 
0 
 
5 
1 
Thymus   
Lymphoid necrosis 
 - minimal 
 - mild 
 
0 
0 
 
4 
1 
Cortical hypertrophy 
 
0 2 
Brain   
No Abnormality Detected 
 
6 6 
Pituitary gland   
No Abnormality Detected 
 
6 6 
Adrenal gland   
Inflammatory cell infiltrate 
 - slight 
 - moderate 
 
0 
0 
 
3 
3 
Decreased vacuolation in cortex 
 
0 5 
 
Table 4.1:  Effect of i.p. LPS administration on the morphology of the spleen, 
thymus, brain, pituitary and adrenal glands from WT mice.  LPS (500µg/kg) or 
saline (both at 2.5ml/kg, i.p.) were administered to WT mice and tissues removed, 
fixed in 10% neutral buffered formalin, embedded in paraffin wax, sections cut (3µm) 
and stained with H&E for evaluation by light microscopy (n = 6/group).  Values 
represent the number of animals in which the finding was observed.    
 
It was not possible to differentiate the subpopulation of PMNs that had infiltrated the 
adrenal glands with standard H&E staining.  Therefore, the staining procedure was 
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modified to include May Grunwald Giemsa stain, however, this still did not clearly 
identify the different PMNs.  Therefore, the protocol for H&E staining was modified 
to identify cells of an eosinophilic appearance in an attempt to identify the PMNs.  
The most prominent feature of neutrophils is their highly lobulated nucleus (which 
stains darkly with haematoxylin, the basic dye, and contrasts with the salmon pink 
appearance of the cytoplasm stained by both elements of H&E).  Neutrophils and 
eosinophils can be differentiated by increasing the contact time with, and acidity of, 
eosin (an acidic dye).  Eosin stains the membrane-bound cytoplasmic granules which 
contains a variety of hydrolytic enzymes such as histamine in eosinophils, giving a 
bright red appearance (Burkitt et al., 2006).  Therefore, sections from the LPS-treated 
animals (where inflammatory cell infiltration was observed) were stained with this 
modified H&E staining method.  In all animals inflammatory cell infiltration within 
the adrenal cortex and medulla was predominantly eosinophilic PMNs, with 
occasional monocytes and neutrophilic PMNs.  The primary leukocyte within the 
cortex was considered to be the eosinophil.   
 
No microscopic changes were observed in the pituitary gland or brain 4h after 
treatment with LPS.   
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(A) SAL (B) LPS 
 
 
 
 
 
Figure 4.1: Histology of the adrenal glands from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The adrenal glands were removed 4h later, processed and stained with H&E. (A) shows normal tissue appearance within 
the cortex (as indicated by arrow) in saline treated animals, whilst (B) shows the decreased vacuolation (as indicated by arrow) in the cortex, 
predominantly the zona fasciculata and glomerulosa in LPS-treated mice (x20). Note leukocyte infiltration in (B), shown in Figure 4.2 at higher 
magnification.  The images shown are representative of the results described for all affected animals. 
100 µ m 
100 µ m 
100 µ m 
100 µ m 
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(A) LPS (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: Histology of the adrenal glands from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The adrenal glands were removed 4h later, processed and stained with H&E.  In LPS-treated WT mice, a mixed 
inflammatory cell population was observed, (A) shows two monocytes (as indicated by arrows) and (B) shows (as indicated by arrows) an 
eosinophil (Eo) and neutrophil (Ne), both with lobular nucleus, however eosinophils were frequently seen unlike neutrophils and monocytes that 
were only occasional seen (x60).  In SAL-treated mice, no inflammatory cell infiltration was seen in any animal, see Figure 4.1.  The images 
shown are representative of the results described for all affected animals.   
Ne 
Eo 
  201 
(A) SAL (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Histology of the thymus from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline (both at 
2.5ml/kg, i.p.).  The thymus was removed 4h later, processed and stained with H&E. (A) shows normal cellular distribution within the cortex 
(shown by arrow) in saline treated animals, whilst (B) shows cortical hypertrophy (as indicated by arrow) that was seen in the thymus from LPS-
treated mice, considered minimal (x20).  The images shown are representative of the results described for all affected animals. 
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(A) SAL (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Histology of the thymus from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline (both at 
2.5ml/kg, i.p.).  The thymus was removed 4h later, processed and stained with H&E. (A) shows normal appearance in saline treated animals, 
whilst (B) shows (as indicated by arrow) lymphoid necrosis (x60).  The images shown are representative of the results described for all affected 
animals. 
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(A) SAL (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Histology of the spleen from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline (both at 
2.5ml/kg, i.p.).  The spleen was removed 4h later, processed and stained with H&E. (A) shows normal tissue appearance within the cortex in 
saline treated animals, whilst (B) shows extramedullary haematopoiesis (as indicated by arrow) in tissue from LPS-treated mice (x60).  The 
images shown are representative of the results described for all affected animals. 
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(A) SAL (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Histology of the pituitary gland from WT mice injected (i.p.) with LPS.  WT mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was collected after 4h, processed and stained with H&E. (A) and (B) show tissue appearance within 
the (i) pars nervosa, (ii) pars intermedia and (iii) pars distalis in (A) saline and (B) LPS treated animals (x20).  The images shown are 
representative of the results described for all affected animals. 
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B) ANXA1
-/-
 Mice 
 WT ANXA1
-/-
 
 SALINE LPS SALINE LPS 
 
Number of animals examined 
 
 
6 
 
6 
 
6 
 
6 
Spleen     
No Abnormality Detected 5 0 5 0 
White pulp, mainly germinal centres, 
lymphoid cell apoptosis 
 - minimal 
 
 
1 
 
 
4 
 
 
0 
 
 
4 
Extramedullary erythropoiesis 
 - minimal 
 - mild 
 
0 
0 
 
5 
1 
 
1 
0 
 
5 
0 
Thymus     
No Abnormality Detected 6 1 6 2
A
 
Lymphoid necrosis 
 - minimal 
 - mild 
 
0 
0 
 
4 
1 
 
0 
0 
 
3 
0 
Brain     
No Abnormality Detected 
 
6 6 6 6 
Pituitary gland     
No Abnormality Detected 
 
6 6 6 6 
Adrenal gland     
No Abnormality Detected 6 0 6 0 
Inflammatory cell infiltrate 
 - slight 
 - moderate 
 
0 
0 
 
3 
3 
 
0 
0 
 
5 
0 
Decreased vacuolation in cortex 
 
0 5 0 1 
A Sample missing from one LPS-treated ANXA1
-/-
 mouse. 
 
Table 4.2:  Effect of i.p. LPS administration on the morphology of the spleen, 
thymus, brain, pituitary and adrenal glands from WT and ANXA1
-/-
 mice.  Mice 
were treated with LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.).  Tissues were 
removed 4h later, fixed in 10% neutral buffered formalin, embedded in paraffin wax, 
sections cut (3µm) and stained with H&E for evaluation by light microscopy (n = 
6/group). Values in table represent number of animals with finding.  Values represent 
the number of animals in which the finding was observed. 
 
LPS (500µg/kg; 2.5ml/kg, i.p.) induced microscopic changes in the spleen, thymus 
and adrenal glands of WT and ANXA1
-/-
 mice (Table 4.2; Figures 4.7-8).  As in the 
WTs, LPS increased the incidence of lymphoid cell apoptosis (4/6 mice vs. 0/6 in 
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saline-treated controls) and extramedullary erythropoiesis (5/6 animals vs. 1/6 saline 
controls) in the spleen of ANXA1
-/-
 mice, Table 4.2).  Thymic lymphoid necrosis was 
also evident in LPS-treated WT (5/6) and ANXA1
-/-
 (3/5) animals (Table 4.2).  No 
microscopic changes were detected in the pituitary gland (Figure 4.8) or brain 4h of 
WT or ANXA1
-/-
 animals after treatment with LPS (Table 4.2).  By contrast, in both 
mouse strains, inflammatory cells (predominantly eosinophils but also occasional 
monocytes and neutrophilic PMNs) were evident in the adrenal gland (cortex and 
medulla) of LPS treated WT and ANXA1
-/-
 mice (Figures 4.7, Table 4.2).  LPS also 
reduced vacuolation in 5/6 WT mice; however only 1/6 ANXA1
-/- 
mice responded to 
LPS with a decrease in vacuolation (Table 4.2). 
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(A) LPS (B) LPS 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Histology of the adrenal glands from ANXA1
-/-
 mice injected (i.p.) with LPS.  ANXA1
-/-
 mice were treated with LPS (500µg/kg) 
or saline (both at 2.5ml/kg, i.p.).  The adrenal glands were removed after 4h, processed and stained with H&E. (A) shows mixed inflammatory 
cell population in the vasculature of the medulla that was not present in SAL-treated, whilst (B) shows an eosinophil (as indicated by arrow, Eo) 
and a neutrophil (as indicated by arrow, Ne), however eosinophils were frequently seen unlike neutrophils (x60).  For comparison with WT 
mice, see Figure 4.1-2.  The images shown are representative of the results described for all affected animals.  
Eo 
Ne 
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(A) SAL (B) LPS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Histology of the pituitary gland from ANXA1
-/-
 mice injected (i.p.) with LPS.  ANXA1
-/-
 mice were treated with LPS 
(500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The pituitary gland was collected after 4h, processed and stained with H&E. (A) and (B) show 
normal tissue appearance within the (i) pars nervosa, (ii) pars intermedia and (iii) pars distalis in both (A) saline and (B) LPS treated animals 
(x20).  The images shown are representative of the results described for all affected animals. 
i 
ii 
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i 
ii iii 
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C) WT (Fpr2
+/+
) and Fpr2
-/-
 mice 
 Fpr2
+/+
 Fpr2
-/-
 
 SALINE LPS SALINE LPS 
Number of animals examined 3 3 2 3 
Spleen     
No Abnormality Detected 3 0 2 1 
White pulp, mainly germinal 
centres, lymphoid cell apoptosis 
 - minimal 
 
 
0 
 
 
0 
 
 
0 
 
 
1 
Extramedullary haematopoiesis 
 - minimal 
 
0 
 
3 
 
0 
 
1 
Thymus     
No Abnormality Detected 0 1 2 2 
Lymphoid necrosis 
 - minimal 
 
0 
 
1 
 
0 
 
1 
Cortical hypertrophy 0 1 0 0 
Brain     
No Abnormality Detected 3 3 2 3 
Pituitary gland     
No Abnormality Detected 3 3 2 2
a
 
FSH – pars distalis 3 3 2 2 
LH – pars distalis 3 3 2 2 
TSH – pars distalis* 3 3 2 2 
ACTH – pars distalis 3 3 2 2 
PRL – pars distalis 3 3 2 2 
Adrenal gland     
No Abnormality Detected 3 0 2 0 
Inflammatory cell infiltrate 
 - slight 
 
0 
 
3 
 
0 
 
3 
Decreased vacuolation in cortex 0 2 0 0 
    a=no sample 
Table 4.3:  Effect of i.p. LPS administration on the morphology of the spleen, 
thymus, brain, pituitary and adrenal glands of Fpr2
+/+
 (control) and Fpr2
-/-
 mice.  
Fpr2
+/+
 or Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline (both at 2.5ml/kg, 
i.p.).  Tissues removed 4h later, fixed in 10% neutral buffered formalin, embedded in 
paraffin wax, sections cut at 3µm (H&E) or 5µm (immunohistochemistry) for 
evaluation by light microscopy (n = 3/group). The pituitary gland was immunostained 
for ACTH, PRL, TSH, FSH and LH.  * Intense TSH staining was observed in the 
anterior pituitary gland of Fpr2
-/-
 mice.  
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LPS (500µg/kg; 2.5ml/kg, i.p.) induced microscopic changes in the spleen, thymus 
and adrenal glands of Fpr2
+/+
 or Fpr2
-/-
 mice (Table 4.3; Figures 4.9-10).  In the 
spleen, LPS increased the incidence of lymphoid cell apoptosis in 0/3 Fpr2
+/+
 and 1/3 
Fpr2
-/-
 mice and caused extramedullary erythropoiesis in 3/3 Fpr2
+/+
 and 1/3 Fpr2
-/-
 
mice.  Thymic lymphoid necrosis was seen in 1/3 Fpr2
+/+
 and 1/3 Fpr2
-/-
 LPS-treated 
mice.  In the adrenal gland, LPS decreased cortical vacuolation in the controls but not 
in Fpr2-null mice.  It also induced inflammatory cell infiltration in the cortex and 
medulla of mice of both strains.  Initial studies indicated the infiltrating cells were 
predominantly PMNs with occasional monocytes.  However, using the modified H&E 
staining to differentiate between neutrophils and eosinophils, it became apparent that 
the cells were mainly eosinophilic PMNs with occasional monocytes and neutrophilic 
PMNs.  In addition, a visual assessment, performed blind, indicated that the 
cytoplasm of eosinophils from LPS-treated Fpr2
-/-
 mice stains a darker red than that of 
corresponding cells in LPS-treated Fpr2
+/+ 
mice.  This should be further substantiated 
with appropriate stains and greater number of animals in case it was related to the 
particular sections.   
 
No microscopic changes were detected in the pituitary gland or in the brain of Fpr2
+/+
 
or Fpr2
-/-
 mice 4h after treatment with LPS.  Similarly, while ACTH (Figures 4.11-
12), PRL (Figures 4.13-14), TSH (Figures 4.15-16), LH (Figures 4.19-20) and FSH 
(Figures 4.17-18) were readily all detectable by immunostaining in the pars distalis of 
both Fpr2
+/+
 and Fpr2
-/-
 mice, with the exception of TSH, there were no obvious 
differences between Fpr2
+/+
 or Fpr2
-/-
 saline treated animals, or between Fpr2
-/-
 saline 
or Fpr2
-/-
 LPS-treated mice.  In LPS-treated Fpr2
-/-
 mice (Figure 4.16), the TSH signal 
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appeared stronger than that in the saline-treated Fpr2
-/-
 mice or Fpr2
+/+
 mice treated 
with either saline or LPS (Figure 4.15). 
 
The Fpr2
-/-
 mice contain a GFP in-frame insertion within the promoter region to 
enable the visualisation of GFP expression in place of Fpr2 expression. However, it 
was not possible to visualise GFP in frozen sections of brain, spleen, thymus, pituitary 
and adrenal glands from both control and treated (4h after LPS) Fpr2
-/-
 mice (data not 
shown).  Initial attempts used fluorescent microscopy, and subsequently an anti-GFP 
followed by a secondary antibody (biotinylated anti-rabbit).  A further attempt using a 
fluorophore labelled anti-GFP antibody was also unsuccessful.  Therefore, it is 
unclear as to whether the methodology or strength of expression of the reporter gene 
was the cause for a lack of detection.  Whilst GFP expression offers many advantages 
over LacZ, such as the potential for use of non-terminal visualisation of expression 
(Hadjantonakis & Nagy, 2001), the absence of a control tissue from the Fpr2
-/-
 meant 
that method validation was trial and error.  However, using Fpr2
-/-
 mice (of the same 
derivation) Dufton et al. (2009), were able to detect the expression of GFP in bone 
marrow macrophages using flow cytometry and in granulocytes taken from acute 
inflammatory cell populations derived in vivo (Dufton et al., 2009).  This data is the 
first successful identification of GFP from these mice, suggesting that it is functional 
and detection methods for microscopic evaluation require further validation.  Whilst 
not included in this thesis as is preliminary data, GFP has been detected in the adrenal 
cortex from Fpr2
-/-
 mice using alternative fixation technique (formalin fixation) as 
well as primary antibody, followed by DAB, then counterstained with haematoxylin 
(Naughton et al., unpublished). 
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(A) Fpr2
+/+
 mice (B) Fpr2
-/-
 mice 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Histology of the adrenal glands from Fpr2
+/+
 or Fpr2
-/-
 mice injected (i.p.) with LPS.  Fpr2
+/+ 
and Fpr2
-/-
 mice were treated with 
LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The adrenal glands were removed after 4h, processed and stained with H&E. The 
inflammatory response (as indicated by arrows) within the vessels of the medulla are shown in (A) Fpr2
+/+
 mice and (B) Fpr2
-/-
 mice treated with 
LPS (x20).  The images shown are representative of the results described for all affected animals. 
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(A) Fpr2
+/+
 mice (B) Fpr2
-/-
 mice 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Histology of the adrenal glands from Fpr2
+/+
 or Fpr2
-/-
 mice injected (i.p.) with LPS.  Fpr2
+/+ 
and Fpr2
-/-
 mice were treated 
with LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The adrenal glands were removed after 4h, processed and stained with H&E. The 
leukocytes (as indicated by arrows) within the cortex are shown in (A) for Fpr2
+/+
 mice and (B) for Fpr2
-/-
 mice treated with LPS (x60).  The 
images shown are representative of the results described for all affected animals. 
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(A) IHC for ACTH (B) IHC control for ACTH (primary antibody free) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11:  Immunostaining for ACTH in the pituitary gland from Fpr2
+/+
 mice.  Fpr2
+/+
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for ACTH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) show positive staining for ACTH (brown) within the pars distalis of saline-treated Fpr2
+/+
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for ACTH (B) IHC control for ACTH (primary antibody free) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12:  Immunostaining for ACTH in the pituitary gland from Fpr2
-/-
 mice.  Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for ACTH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for ACTH (brown) within the pars distalis of saline-treated Fpr2
-/-
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for PRL (B) IHC control for PRL (primary antibody free) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13:  Immunostaining for PRL in the pituitary gland from Fpr2
+/+
 mice.  Fpr2
+/+
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for PRL using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for PRL (brown) within the pars distalis of LPS-treated Fpr2
+/+
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for PRL (B) IHC control for PRL (primary antibody free) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14:  Immunostaining for PRL in the pituitary gland from Fpr2
-/-
 mice.  Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for PRL using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for PRL (brown) within the pars distalis of LPS-treated Fpr2
-/-
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for TSH (B) IHC control for TSH (primary antibody free) 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Immunostaining for TSH in the pituitary gland from Fpr2
+/+
 mice.  Fpr2
+/+ 
mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for TSH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for TSH (brown) within the pars distalis of LPS-treated Fpr2
+/+
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for TSH (B) IHC control for TSH (primary antibody free) 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Immunostaining for TSH in the pituitary gland from Fpr2
-/-
 mice.  Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for TSH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for TSH (brown) within the pars distalis of LPS-treated Fpr2
-/-
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  In all three Fpr2
-/-
 mice there was a stronger signal for TSH and this was comparable to 
both SAL-treated Fpr2
+/+
 and Fpr2
-/-
 mice (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for FSH (B) IHC control for FSH (primary antibody free) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Immunostaining for FSH in the pituitary gland from Fpr2
+/+
 mice.  Fpr2
+/+
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for FSH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for FSH (brown) within the pars distalis of LPS-treated Fpr2
+/+
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for FSH (B) IHC control for FSH (primary antibody free) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
Figure 4.18: Immunostaining for FSH in the pituitary gland from Fpr2
-/-
 mice.  Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for FSH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for FSH (brown) within the pars distalis of LPS-treated Fpr2
-/-
 mice, whilst (B) 
shows control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for LH (B) IHC control for LH (primary antibody free) 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19:  Immunostaining for LH in the pituitary gland from Fpr2
+/+
 mice.  Fpr2
+/+
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for LH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for LH (brown) within the pars distalis of LPS-treated Fpr2
+/+
 mice, whilst (B) shows 
control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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(A) IHC for LH (B) IHC control for LH (primary antibody free) 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20:  Immunostaining for LH in the pituitary gland from Fpr2
-/-
 mice.  Fpr2
-/-
 mice were treated with LPS (500µg/kg) or saline 
(both at 2.5ml/kg, i.p.).  The pituitary gland was removed after 4h, processed and stained for LH using immunohistochemistry (DAB with 
haematoxylin counterstaining). (A) shows positive staining for LH (brown) within the pars distalis of LPS-treated Fpr2
-/-
 mice, whilst (B) shows 
control (primary antibody free) sections (x60).  The images shown are representative of the results described for all affected animals. 
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D) Effect of ACTH on the release of CORT from adrenals collected after LPS 
injection 
The adrenal glands were removed from WT mice 4h after administration of LPS 
(500µg/kg) or saline (both at 2.5ml/kg, i.p.) and, following cell dispersion were 
incubated in the presence and absence of ACTH to assess the influence of the toxin on 
adrenal functionality with respect to CORT release. 
 
 
Figure 4.21:  Effect of ACTH1-24 on the release of CORT from dispersed murine 
adrenal cells removed from WT mice 4h after administration of saline or LPS.  
The adrenal glands were removed from WT mice 4h after administration of LPS 
(500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The dispersed cells were incubated 
(1x10
6
 cells/ml) with ACTH1-24 (Sigma, 0-10nM) for 2h and the supernatant analysed 
for CORT by EIA. Each value represents the mean ± SEM, n=3-5 
wells/concentration, adrenals collected from 15 WT mice/group.  **P<0.01 one-way 
ANOVA with Dunnett‘s post hoc test. 
 
Cells from saline-treated WT mice responded to ACTH1-24 (Sigma) with 
concentrated-related increases in CORT release. Significant effects (vs. untreated 
controls) were observed at concentrations of 0.001µM, 0.01µM, 0.1µM (P<0.05), 
1µM (P<0.01) and 10µM (P<0.01), being 2.8-fold greater than non-stimulated cells 
(Figure 4.21).  However, adrenal cells from LPS-treated WT mice failed to respond to 
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ACTH with an increase in CORT release at any concentration of the peptide tested.  
This data was repeated in a subsequent experiment using different animals given 
saline or LPS as described previously.   
 
4.3 Discussion  
The data described in the previous chapter demonstrate statistically significant 
increases in the murine FPRs (Fpr1, Fpr2 and Fpr3) and ANXA1 in the spleen, 
pituitary and adrenal glands of normal mice following intra-peritoneal administration 
of LPS (500µg/kg).  As the cells expressing the FPRs within the brain-pituitary-
adrenal axis have not yet been identified and FPRs (as well as ANXA1) are expressed 
mainly by cells of the immune system, we explored the possibility that the increase in 
FPR expression in the pituitary and adrenal glands of LPS-treated mice may be 
associated with an inflammatory response.  These studies also provided an 
opportunity to explore the impact of this low dose of LPS on the general histology of 
the tissues at a time-point when changes in FPR and ANXA1 gene expression were 
maximal (4h).  In addition, the same assessment was extended to ANXA1
-/-
 and 
Fpr2
-/-
 mice to gain some insight to the roles of ANXA1 and FPR2 on the observed 
changes.  Due to the mixed genetic background of the Fpr2
-/-
 mice colony (<12 
generation), Fpr2
+/+ 
mice from the same colony were used as WT controls.   
 
The dose of LPS used in our experiments (500µg/kg, i.p.) was sufficient to cause 
HPA-activation but below those used in mice to model the pathology seen in patients 
with severe sepsis where doses approximately 20 to 30-fold higher are used (O'Malley 
et al., 1998; Xu et al., 2009a).  In severe sepsis in both man and experimental animals, 
multiple organ failure can occur.  This is characterised by the sequential functional 
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collapse of different organ systems due to an uncontrolled host inflammatory response 
(O'Malley et al., 1998).  In mice, the inflammatory response induced by LPS is 
characterised by the release of pro-inflammatory cytokines, expression of TLR4 by 
endothelial cells (Dauphinee & Karsan, 2006), adhesion of activated leukocytes to the 
vasculature and degenerative changes in many tissues, most notable the lung, liver, 
spleen and intestine (O'Malley et al., 1998).  Although we used a relatively low dose 
of LPS in the present study, it was sufficient to induce cytokine release, activate the 
HPA axis and cause morphological changes in the spleen, thymus and adrenal gland, 
although not in the brain or pituitary gland.       
 
4.1 Effects of LPS treatment on histology of spleen 
The spleen is composed mainly of two types of tissue, the white and red pulp. The 
white pulp consists of lymphoid tissue and is responsible for the organ‘s 
immunological function, whilst the red pulp contains large numbers of 
sinuses/sinusoids filled with blood and acts primarily to remove old or damaged red 
blood cells as well as a serving as a storage reservoir for blood (Greaves, 2000a).  In 
the present study, LPS induced lymphoid apoptosis (programmed cell death), typified 
by pyknotic nuclei with apoptotic bodies in all animals, irrespective of genotype.  
Using higher doses of LPS (15mg/kg), O‘Malley et al., (1998) have described 
additional changes including splenitis, splenic lymphoid hyperplasia and splenic 
lymphoid necrosis 24h after treatment.  In an alternative model of mouse sepsis (cecal 
ligation and puncture), apoptotic lymphoid cells (as pyknotic or with fragmented 
nuclei) were also described in the spleen (Hotchkiss et al., 1997).  Our finding of 
lymphoid apoptosis 4h after injection of LPS was not surprising as prior to this time-
point increases in CORT and pro-apoptotic cytokines (including TNFα and IL-1β) 
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were evident.  It is unlikely that IL-1β was responsible for the induction of apoptosis 
as when live E.coli was given to IL-1β null mice, splenic lymphocyte apoptosis was 
still observed (Sarkar et al., 2006).  As both TNFα and GCs (CORT) were raised by 
LPS, it is feasible that both contributed to the induction of apoptosis, acting via 
different mechanisms.  TNFα binds to the TNF receptor 1 or 2 (Oberholzer et al., 
2001), but mediates its pro-apoptotic actions through TNF receptor 1 (Micheau & 
Tschopp, 2003) with subsequent activation of caspase-8 (Badiola et al., 2009) or 
caspase-2 (Duan & Dixit, 1997), leading to apoptosis.  GCs act via a different 
mechanism involving GR-mediated increases in caspase-9 and caspase-10, not 
caspase-8, in GC-induced apoptosis (Planey et al., 2003).  Furthermore, in either 
sepsis (man) or endotoxaemia (rat), other apoptotic inducing factors have been 
reported such as raised intracellular free Ca
2+
 in lymphocytes (Zaloga et al., 1993) and 
enhanced production of oxygen free radicals by macrophages (Bautista et al., 1990).   
 
Several lines of evidence led us to question whether the LPS-induced increases in 
expression of FPRs and ANXA1 contribute to the increased apoptosis observed in the 
lymphoid tissue.  ANXA1 accelerates the process of apoptosis in human neutrophils 
(Solito et al., 2003a), whereas serum amyloid A (an acute phase protein and FPR 
ligand) rescues human neutrophils from apoptosis, an effect which is reversed by the 
FPR ligands, LXA4 and 15-epi-LXA4, (El Kebir et al., 2007) which prevent 
mitochondrial dysfunction and the subsequent activation of caspase-3 (El Kebir et al., 
2008).  Our data argue against a role for ANXA1 or FPR2 in the apoptotic response to 
LPS as splenic tissue from LPS-treated ANXA1- and Fpr2-null mice was 
indistinguishable from that of the corresponding WT groups.  However, we cannot 
preclude the possibility that a compensatory mechanism has developed in these 
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genetically modified strains, nor can we make any conclusions about the roles of Fpr1 
and Fpr3. 
 
In addition to apoptosis, extramedullary haematopoiesis (development and growth of 
haematopoietic tissue outside the bone marrow) was also prominent in the spleen of 
LPS-treated mice.  Erythropoiesis is associated with both increases in GCs (O'Malley 
et al., 1998) and changes in cytokines such as TNFα (Marino et al., 1997).  The 
effects of GCs on erythropoiesis are well characterised.  GCs enhance the formation 
of murine erythroid colonies (Golde et al., 1976) and increase proliferation of 
erythroid cells (Udupa et al., 1986).  Stress also induces erythropoiesis, particularly in 
the spleen of mice (Broudy et al., 1996) and rats (Ou et al., 1980).  Humans with 
adrenal deficiency due to Addison‘s disease frequently suffer from anaemia, whilst 
subjects with Cushing‘s disease, with high GC levels, have elevated red cell count 
(Miller & Tyrell, 1995).  The role of cytokines in extramedullary haematopoiesis 
within the spleen is unclear although there is good evidence that TNFα is involved.  
For example, TNF
-/-
 mice, unlike WT controls, do not develop extramedullary splenic 
haematopoiesis when treated with C. parvum or endotoxins of other origins (Kindler 
et al., 1989; Flynn et al., 1995; Marino et al., 1997).  Similarly, WT mice treated with 
an anti-TNF anti-serum do not develop extramedullary haematopoiesis (Kindler et al., 
1989; Flynn et al., 1995).  Thus, it is possible that the LPS-induced extramedullary 
haematopoiesis observed in the current study is due, at least in part, to the increased 
circulating levels of TNFα and CORT.   
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4.2 Effects of LPS treatment on histology of thymus 
The thymus consists of two lobes (cortex and medulla) enclosed in a capsule and is 
further divided internally into many lobules.  It is primarily responsible for the 
maturation and differentiation of T-lymphocytes derived in the bone marrow 
(Greaves, 2000a).  As reported previously, (Rowlands et al., 1965; O'Malley et al., 
1998) LPS induced lymphoid necrosis in the thymus.  This response is often 
associated with apoptosis, as with the lymphoid tissue in the spleen.  Apoptosis is a 
normal process in the thymus which permits deselection of non optimal thymocytes 
and frequently occurs during periods of immune stimulation (Thorbecke et al., 1994; 
Lindhout & de Groot, 1995).  The LPS-induced thymic necrosis reported here may be 
explained by changes in cytokines and/or the increase in GCs (Norimatsu et al., 1995; 
Levin et al., 1999), as discussed previously for the spleen.  In addition, it may due in 
part to the generation of reactive oxygen species (ROS) released from leukocytes in 
response to LPS and oxidative damage (Nowak et al., 1993).  This is supported by 
evidence that pre-treatment with an NADPH oxidase inhibitor or the free radical 
scavenger, NAO, prevents the necrotic response to LPS in the thymus (Lomnitski et 
al., 2000).   
 
LPS also induced cortical hypertrophy in the thymus.  This was surprising given that 
both acute and chronic stress are well known to reduce thymus size, a phenomenon 
often termed stress-induced thymic involution (Gruver & Sempowski, 2008), and is 
explained by an acute loss of mature cortical thymocytes (expressing cell surface 
receptors CD4 and CD8) due to apoptosis and a reduced output of naïve T cells to the 
periphery (Thorbecke et al., 1994).  Had later time-points been evaluated, it is 
possible that atrophy of the cortex would develop, as reported in BALB/c mice which 
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develop severe thymic atrophy 3 days after administration of LPS [100µg/mice i.p.; 
approximately 5mg/kg, (Hick et al., 2006)].   
 
In line with data on the spleen, deletion of ANXA1
-/- 
or Fpr2
-/-
 had no obvious effects 
on the morphology of the thymus, nor did it modify the thymic responses to LPS.  
Together these data suggest that changes in GCs or cytokines may underpin the 
morphological responses to LPS and that these changes are independent of ANXA1 
and Fpr2. 
 
4.3 Effects of LPS treatment on histology of brain 
There were no obvious morphological changes in the brains (rostral, mid and caudal 
sections) from WT, ANXA1
-/-
, Fpr2
+/+
 or Fpr2
-/-
 mice 4h after treatment with LPS.  
The lack of detectable microscopic changes in the brain is not surprising as while LPS 
(S. typhimurium)-treated rats at a similar dose (500μg/kg) showed mild astrocytic, 
perivascular oedema in the microvasculature (Wright et al., 2007), these 
ultrastructural changes were detected by electron microscopy and would almost 
certainly not be detectable with the less powerful light microscopy used in the present 
study.  Nonetheless, leakage of LPS into the brain may lead to a centrally-mediated 
inflammatory response through its actions on TLR4 on microglia, astrocytes as well 
as the endothelium (Caso et al., 2007).  Moreover, when given i.c.v., LPS causes 
neutrophil infiltration in the brain parenchyma of mice (Zhou et al., 2006).  The 
absence of microscopic changes reported here may reflect the low dose of LPS 
administered which may be insufficient to compromise the blood brain barrier (BBB) 
and, thus, to allow LPS to lead into the brain.  Similarly, in the study performed by 
Wright et al., (2007) the BBB appeared to be intact as particles of lanthanum nitrate, 
Chapter 4 
 231 
an ionic tracer used to evaluate the integrity of the BBB, were not detected in either 
the endothelial cell cytoplasm or the perivascular space, but retained within the 
microvessel lumen of LPS-treated rats (Wright et al., 2007).   
 
LPS has been shown to affect the BBB indirectly and directly by acting on the 
endothelium (Verma et al., 2006; Jaeger et al., 2009).  The indirect effects of LPS are 
due in part to pro-inflammatory cytokines (TNFα, IL-1α, IL-1β and IL-6) released in 
the periphery which transfer an inflammatory signal to the brain by increasing the 
permeability of the BBB causing leakage, facilitating cytokine transfer across the 
BBB and activating ascending neural pathways (Gaykema et al., 1995).  There is also 
limited evidence for specific systems which transport cytokines across the BBB 
(Banks et al., 1991; Banks et al., 2001; Pan et al., 2007), as shown for example by 
detection of blood-borne radiolabelled murine TNFα in the brain parenchyma and 
cerebrospinal fluid (Pan & Kastin, 2001).  Further studies using endocytosis inhibitors 
and IL-1 receptor-blocking antibodies in co-cultures of porcine brain microvascular 
endothelial cells and astrocytes (to mimic the BBB), suggest that IL-1β transport may 
be mediated through a type II IL-1 receptor dependent mechanism and not by 
adsorptive-mediated endocytosis (Skinner et al., 2009).  LPS may also modulate BBB 
function, as P-glycoprotein (a transporter which is present in the BBB) is inhibited by 
LPS and activated by TNFα (Hartz et al., 2006; Bauer et al., 2007).  Additionally, 
transport of amyloid beta to the brain by the receptor for advanced glycation end 
products (RAGE) is increased by LPS, whilst brain-to-blood transport of amyloid 
protein is decreased, raising the possibility that inflammation may potentially enhance 
the development or progression of Alzheimer‘s disease (Banks & Erickson, 2010).  
LPS may also modify tight junction regulation in the BBB as in vitro it decreases 
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transendothelial electrical resistance in concentrations as low as 1µg/ml (Dohgu & 
Banks, 2008).  
 
The absence of inflammatory cell infiltration in the brain of LPS-treated animals 
reported in the present study contrasts with that seen after i.c.v. administration of LPS 
(Zhou et al., 2006) and suggests that despite the increase in systemic cytokines or 
GCs induced by i.p. treatment with LPS the BBB remains intact 4h after treatment.    
 
The lack of changes in the brain of ANXA1
-/-
 and Fpr2
-/-
 mice treated with LPS 
suggests that the BBB in these animals is similar to WT mice and that deletion of 
ANXA1 or Fpr2 does not affect the permeability of the BBB 4h after treatment with 
this low dose of LPS. 
 
4.4 Effects of LPS treatment on the histology of the pituitary gland 
As with the brain but in contrast to other peripheral tissues studied, no microscopic 
changes were seen in pituitary tissue (pars distalis, pars intermedia or pars nervosa) 
from LPS-treated mice.  Nonetheless, as described in Chapter 3, LPS caused marked 
effects on pituitary gene expression, an effect which may be mediated by direct 
effects of LPS on the folliculo-stellate or endocrine cells, both of which are known to 
express members of the TLR family (Tierney et al., 2005).  In support of this concept, 
LPS, and indeed pro-inflammatory cytokines released by LPS into the systemic 
circulation, would be expected to have ready access to the pituitary cells.  The 
pituitary gland is external to the BBB and its cells are thus not protected from small 
proteins and sugars in the way that the brain‘s neurons are.  The anterior pituitary lobe 
does not have a direct arterial supply but is, nonetheless, highly vascularised, 
receiving its blood directly from the hypothalamic median eminence area via the 
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specialised hypothalamo-hypophyseal portal system, itself fed by a branch of the 
internal carotid artery.  However, our finding that LPS, albeit in a low dose, did not 
cause leukocyte infiltration in the pituitary suggests that this gland, unlike the adrenal 
and other tissues [e.g. mesentery (Gavins et al., 2009)], is protected from the 
potentially harmful effects of infiltrating leukocytes which could cause tissue damage 
and compromise the critical homeostatic role of the organ.  The mechanism by which 
this protection is afforded is unclear but may reflect some degree of specialisation of 
these cells, perhaps relating to the expression by the vascular cells of adhesion 
molecules or other substances critical to leukocyte migration.  It seems unlikely that 
either ANXA1 or Fpr2 is important in this regard as LPS also failed to induce 
leukocyte infiltration in the pituitary gland in ANXA1 and Fpr2-null mice. 
 
4.5 Effects of ANXA1 and Fpr2 gene deletion on immunohistochemical features 
of the endocrine cells in the anterior pituitary gland 
As part of the phenotypic assessment of the recently derived ANXA1
-/-
 and Fpr2
-/-
 
mice, immunostaining for ACTH, PRL, TSH, LH and FSH in the anterior pituitary 
gland was performed in control and LPS-treated mice of both strains and compared to 
the corresponding controls (WT and Fpr2
+/+
).  The analysis was qualitative and not 
designed to provide a quantitative assessment of either the relative proportions of each 
of the sub-types of endocrine cells or the intensity of expression of the various protein 
hormones.  ACTH, PRL, TSH, LH and FSH positive cells were all identified in 
pituitary tissue from all four mouse strains, with no discernable between-strain 
differences.  In addition, there were no obvious qualitative effects of LPS on the 
distribution of the various populations.  However, the TSH signal appeared stronger in 
LPS-treated Fpr2
-/-
 mice than that in the saline-treated Fpr2
-/-
 mice or Fpr2
+/+
 mice 
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treated with either saline or LPS.  These data are potentially interesting and, if 
confirmed by quantitative methods, this would suggest that IL-1β-mediated LPS-
induced release of TSH (Wassen et al., 1996) is dependent upon Fpr2 gene.  To the 
best of our knowledge, this is the first evidence to suggest a role for Fpr2 in the 
regulation of TSH release.  However, thyrotrophs express ANXA1 binding sites 
(Christian et al., 1997) and ANXA1 has a role in mediating the inhibitory effects of 
GCs on TSH secretion (Taylor et al., 1995).  Whether these binding sites correspond 
with Fpr2 remains to be determined but in this context it is interesting to note that in 
Fpr2-null mice, which express GFP as a reporter gene, LPS induces GFP staining in 
all endocrine subtypes of the pituitary gland, including thyrotrophs (Naughton et al., 
unpublished).  Further studies are now underway to determine the functional effects of 
Fpr2 gene deletion on pituitary hormone secretion (Naughton et al., in progress). 
 
Our finding that ANXA1 gene deletion has no obvious qualitative effects on the 
pituitary endocrine cell population contrasts with previous studies based on 
quantitative light- and electron microscopic techniques which demonstrated marked, 
gender-specific effects of ANXA1 gene deletion on pituitary morphology.  These 
studies indicated that the lactotrophs from male, but not female, ANXA1-null mice, 
show increased in ultrastructural activity [defined as increased margination of 
secretory granules to the plasma membrane and increased amounts of rough 
endoplasmic reticulum, (Afzal et al., 2006)] as also do the somatotrophs (Afzal et al., 
2006) and gonadotrophs (Wain et al., 2004).  By contrast, the number of secretory 
granules is reduced in the corticotrophs of male but not female ANXA1-null mice 
(Morris et al., 2006).  The morphological changes in the lactotrophs of ANXA1-null 
mice are associated with significant, sex specific functional changes.  Thus the 
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pituitary prolactin content is decreased and plasma prolactin is increased in male 
ANXA1-null mice; no such changes are evident in the female, but mice of both sexes 
show gender- and tissue-specific changes in the sensitivity of the lactotrophs and 
hypothalamic dopaminergic pathways to oestrogens and androgens (Cover et al., 
2004; Cover et al., 2005).  However, despite the morphological changes in the 
corticotrophs reported by Morris et al., (2006), the HPA response to immune 
challenge and GCs are unaffected by ANXA1 gene deletion, indicating that the 
knockout mouse has compensated effectively for the gene loss (John et al., 2003).  
 
4.6 Effects of LPS treatment on histology of adrenal gland 
The present data show that LPS induces leukocytic (predominantly eosinophilic) 
infiltration in the adrenal gland together with decreased vacuolation in the 
steroidogenic cells of the cortex. The LPS-induced cellular infiltration was unaffected 
by ANXA1 or Fpr2 gene deletion.  By contrast, deletion of either gene attenuated the 
LPS-induced decrease in vacuolation.  Together, these findings suggest that (a) the 
adrenal gland is an important target for LPS, inducing local inflammation and 
decreasing the steroidogenic potential of the tissue and (b) the effects of LPS on 
steroidogenesis are at least partially dependent on ANXA1 and Fpr2 but that neither 
protein contributes to the cellular infiltration induced by the toxin. 
 
LPS-induced leukocyte infiltration. 
These studies were carried out to explore the possibility that the LPS-induced increase 
in ANXA1, Fpr1, Fpr2 and Fpr3 expression in the adrenal is a consequence of 
leukocytes expressing these genes infiltrating the adrenal tissue.  Our hypothesis was 
supported by evidence that leukocytes, in particular neutrophils and monocytes, 
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invade other tissues as part of an inflammatory response to LPS (Bone, 1991) and that 
these cells express the genes of interest in abundance (Ye et al., 2009).  
 
Analysis of control tissue 
Previous studies have described resident population of immune cells, particularly 
macrophages, in the adrenal gland.  For example, Hume et al., (1984) identified an 
abundant population of F4/80 positive cells, presumed to be macrophages, within the 
adrenal cortex and medulla of mice.  Within the cortex, the cells were most abundant 
in the zona glomerulosa where they appeared to line the vascular sinuses or to be 
wrapped around capillaries and a smaller population was evident in the zona 
fasciculata (Hume et al., 1984).  Resident macrophages have also been reported in the 
human adrenal cortex (Gonzalez-Hernandez et al., 1994), localised mainly to the 
inner adrenocortical zone and shown to express TNFα (Gonzalez-Hernandez et al., 
1996), IL-1 (Gonzalez-Hernandez et al., 1995) and IL-6 (Path et al., 1997).  In light of 
these reports, an important part of our study was to examine and quantify the resident 
population of immune cells in adrenal glands from control (saline-treated) mice so as 
to interpret data from the LPS-treated group.  However, in stark contrast to the 
previous reports, we were unable to detect resident macrophages or other cells of 
immunological lineage in adrenal tissue from the controls.  Nor did we observe such 
cells in adrenal tissue from saline-treated ANXA1-null mice or Fpr2-null mice.  We 
therefore concluded that any cells of immunological lineage observed in adrenal tissue 
from LPS-treated animals had entered the adrenal gland as a consequence of the 
actions of the toxin. 
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Leukocyte migration 
The ability of tissues to recruit leukocytes from the blood when exposed to infection 
or other toxic insults is remarkable.  The initial host response to bacterial infections, 
as mimicked by injection of LPS, is executed through pattern recognition receptors, 
primarily TLR4, that are expressed on neutrophils (Lien et al., 2000).  Neutrophils are 
the first cells to infiltrate sites of bacterial infection.  They are ideally designed to 
counter the effects of pathogenic bacteria because they store proteolytic enzymes, 
secrete pro-inflammatory molecules (e.g. cytokines, eicosanoids) and produce ROS 
rapidly (Brown et al., 2006).  However, in addition, the substances released by the 
infiltrating cells may cause localised tissue damage and compromise function (Brown 
et al., 2006).  Neutrophil recruitment is followed by invasion of other immune cells 
particularly monocytes which are attracted by chemokines, such as monocyte 
chemotactic protein 1 [MCP-1, (Thompson et al., 2008)].  Monocytes clear the 
invading leukocytes through apoptosis and ingestion, and also remove other debris as 
part of the resolution of acute inflammation (Bellingan et al., 1996).  Eosinophils are 
generally considered to be the predominant inflammatory cells associated with 
allergic asthma and parasitic infections.  However, in line with our observations, 
recent data suggests they may also be involved with the innate immune response to 
bacterial infection (Hogan et al., 2008). 
 
While leukocyte migration has been studied extensively in many models of 
inflammation, few workers have examined the phenomenon in endocrine tissues.  One 
group however, examined the effects of two successive doses of LPS (10 mg/kg, i.p. 
on days 1 & 8) on adrenal histology in the rat, making observations 24h after the 
second injection.  The data showed sinusoidal PMN infiltration in the medulla, but not 
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the cortex, together with evidence of medullary necrosis and decreased vacuolation in 
both the medulla and the zona fasciculata (Lomnitski et al., 2000).  These findings 
contrast with the present data which provided clear evidence for leukocytic 
infiltration, predominantly eosinophilic with occasional neutrophils and monocytes in 
both the cortex and the medulla 4h after LPS treatment.  These differences may be 
species related or due to the different time course of the study.  Indeed, one major 
limitation of our study is the fact we examined the tissue at only one time point after 
LPS administration.  
 
The presence of only occasional neutrophils in the adrenal tissue from LPS treated 
animals in our study was surprising.  In mouse models of peritonitis, Hurst et al., 
(2001) have shown that IL-6 and its soluble receptor (sIL-6R) contribute to cessation 
of neutrophil recruitment and the attraction of monocytes through control of CXC and 
CC chemokine expression (Hurst et al., 2001).  In our study plasma IL-6 was maximal 
2h after injection of LPS (P<0.01) but had declined to the control value by 4h.  In the 
light of these data it is conceivable that maximal neutrophil infiltration occurred 
before our 4h time point and that the occasional neutrophils we saw were residual 
from an earlier time point.  Nonetheless, an interesting correlation can be made 
between the inflammatory cell infiltration seen in the adrenal in our experiment and 
that seen in the pleura of mice given LPS intra-thoracically [i.t., (Bozza et al., 1994)].  
When LPS is given i.t. (250ng/cavity) to rats, eosinophil migration (maximal at 48h) 
is preceded by a huge neutrophil influx (4h) and accompanied by monocyte invasion 
[maximal at 48h, (Bozza et al., 1994)]. More importantly, whilst the neutrophil 
migration was acute, the recruitment of eosinophils was long-lasting and dependent 
on the dose of LPS administered (Bozza et al., 1994).  Although the time-course of 
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events in the adrenal gland appears to be different, this study is in line with the 
premise that the 4h time-point we chose for tissue evaluation is the point at which 
neutrophil and monocyte recruitment has declined and eosinophil recruitment is 
ongoing.  In the absence of data on leukocyte trafficking in the adrenal gland, nothing 
is currently known about the mechanisms by which eosinophils are recruited to this 
tissue.  LPS-induced pleural eosinophil accumulation has been shown to be dependent 
on lymphocytes and tissue macrophages (Bozza et al., 1994).  In a recent study, 
Penido et al., (2001) showed that LPS-induced eosinophil migration into the mouse 
pleural cavity is unaffected by anti-murine eotaxin and anti-murine RANTES 
antibodies and by a CC chemokine neutralising protein and concluded that the 
eosinophil infiltration is independent of eotaxin, RANTES and CC chemokines.  
However, they also provided evidence for a role of G protein coupled CCR3 receptor.   
 
Both ANXA1 and Fpr2 are implicated in the processes of leukocyte migration in 
conditions of inflammation.  ANXA1 is mobilised to the outer cell surface when 
neutrophils adhere to the endothelium.  Furthermore, treatment of mice with ANXA1 
or the peptide ANXA1Ac2-26 during a systemic inflammatory response is associated 
with a detachment of adherent neutrophils from the vascular wall in the mesentery and 
a consequent reduction in neutrophil infiltration (Lim et al., 1998).  Similar effects of 
ANXA1Ac2-26 have been reported in Fpr1
-/-
 mice, where the actions of the peptide are 
blocked by Boc2 [an Fpr1 and Fpr2 antagonist at concentrations used, (Gavins et al., 
2003)] suggesting that the anti-migratory actions of ANXA1Ac2-26 are mediated 
through another FPR, possibly Fpr2.  With regard to eosinophil migration, LXA4, a 
selective Fpr2 ligand, modulates eosinophil migration, causing concentration-
dependent inhibition of cell migration induced by fMLP (Soyombo et al., 1994).  In 
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addition, LXA4 inhibits the granulocyte macrophage colony stimulating factor 
(GM-CSF) stimulated secretion by eosinophils of pro-inflammatory cytokines and 
modifies the cell surface protein composition (Starosta, 2009).  As human eosinophils 
express FPR1 and FPR2, but not FPR3, (Svensson 2007) and LXA4 is selective for 
FPR2 and has only a very low affinity for FPR1 (Ye et al., 2009), it is likely that the 
effects of LXA4 on human eosinophil migration are mediated through FPR2.  In the 
light of the evidence that ANXA1 and Fpr2 contribute to the processes involved in 
neutrophil migration in the mouse and that FPR2 is implicated in eosinophil migration 
in man, our finding that neither ANXA1 nor Fpr2 gene deletion influence 
inflammatory cell infiltration in the adrenal gland was surprising.  It may be that these 
mice developed an effective compensatory mechanism or that the mechanisms 
governing leukocyte infiltration in the adrenal gland differ from those described in 
other tissues.  Alternatively, effects of the genes might be observed if higher doses of 
LPS were used, in line with those employed previously (Damazo et al., 2005).  
Therefore, it is unclear from these data whether the increased expression in mRNAs 
for ANXA1 and FPRs evident in the adrenal gland after LPS treatment is a reflection 
of expression of the genes by native adrenal cells or by invading inflammatory cells 
present in the tissue at the time of sampling. 
 
Role of infiltrating leukocytes 
As detailed earlier, this study was undertaken to explore the possibility that infiltrating 
inflammatory cells were the source of the LPS-induced increase in expression of 
ANXA1, Fpr1, Fpr2 and Fpr3 in the adrenal gland.  Human and murine neutrophils, 
eosinophils, monocytes and macrophages all express high levels of ANXA1 (Perretti 
& D'Acquisto, 2009).  As discussed in the introduction, our understanding of the 
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expression pattern of the FPRs in murine leukocytes is limited due to the lack of 
specific antibodies.  However, there is evidence that PMNs, monocytes and dendritic 
cells all express Fpr1 and that neutrophils also express Fpr‘s.  Fpr3 expression has 
been described only for mixed populations of leukocytes (see Chapter 1).  However, 
taking an orthological approach we can consider the profile of FPR receptor 
expression in human leukocytes to help explain our data.  Human neutrophils express 
FPR1 and FPR2, both of which are considered important for cellular recognition of 
chemotactic peptides (Ye & Boulay, 1997).  FPR3 transcripts have not been identified 
in neutrophils (Murphy et al., 1992), but are expressed (along with FPR1 and FPR2) 
by monocytes, circulating precursors of macrophages and dendritic cells (Yang et al., 
2001).  The cellular expression of FPR2 and FPR1 declines, in the process of human 
monocyte differentiation into dendritic cells [although this differs in mice where Fpr1 
expression is maintained, (Lee et al., 2004)], and FPR3 is considered the predominant 
FPR in mature dendritic cells.  However, FPR2 expression levels remain unchanged 
when monocytes differentiate into macrophages (Yang et al., 2002; Migeotte et al., 
2005).  Human eosinophils express FPR1 and FPR2 but not FPR3 (Svensson et al., 
2009).  Taken together these finding raise the possibility that the increased expression 
of Fpr1 and Fpr2 may indeed be due in part to the infiltration of eosinophils and to a 
lesser extent possibly also neutrophils and monocytes. 
 
The extent to which the infiltrating eosinophils impact on the functional integrity of 
the adrenal is unclear.  Activated eosinophils secrete antibacterial proteins that include 
major basic protein, eosinophil cationic protein (ECP), eosinophil derived neurotoxin 
(EDN) and eosinophil peroxidase (EP) that are capable of inducing tissue damage and 
dysfunction (Rothenberg & Hogan, 2006; Linch et al., 2009).  Thus, the infiltration of 
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eosinophils into the adrenal glands at an early stage of bacterial infection may lead to 
adrenal dysfunction caused by oxidative stress from the eosinophilic cytotoxic 
proteins that reduces the capability of the adrenal cortex to synthesise or release GCs.  
Interestingly, GCs are considered the most effective treatment for eosinophilia 
through their anti-inflammatory effects on various cytokines, chemokines, including 
eotaxin (Rothenberg & Hogan, 2006) and RANTES (Banerjee et al., 2008).  It is 
possible that by inhibiting eosinophil function and preventing degranulation during 
bacterial infection, adrenal function may improve during sepsis.   
 
There is evidence that certain pro-inflammatory mediators have direct effects on 
steroidogenesis such as IL-6 (Path et al., 1996), TNFα (Mikhaylova et al., 2007),  
defensins (Zhu & Solomon, 1992), AA metabolites (Wang et al. 2000a), particularly 
the leukotrienes (Jones et al., 1987).  Furthermore, while we are not aware of any 
studies in which the potential effects of eosinophils or neutrophils on steroidogenesis 
have been examined, there is evidence that cytokines released from monocytes 
stimulate the release of cortisol from human adrenal cells (Whitcomb et al., 1988).  It 
is therefore possible that the infiltrating cells, particularly monocytes, observed in the 
adrenal cortex following LPS treatment serve to modulate steroidogenesis and thus 
contribute to the observed increase in circulating CORT.  Alternatively, they may play 
a key role in removing cells damaged as a result of LPS. 
 
Effects of LPS on vacuolation in the steroidogenic cells 
In line with the data of Lomnitski et al., (2000) we also observed a striking decrease 
in vacuolation in the steroidogenic cells of the cortex in LPS-treated animals.  In 
addition, the cytoplasmic volume of the cells was reduced.  Together, these data 
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suggest that steroidogenesis is impaired 4h after the administration of LPS, a finding 
confirmed by our in vitro study which showed that the ability of adrenal cells from 
LPS-treated mice to respond to ACTH with an increase in CORT output is severely 
compromised.  Evidence that the decrease in cytoplasmic volume is a consequence of 
increased CORT secretion is provided by studies which demonstrate that acute 
administration of ACTH reduces the lipid volume in the cells of all three cortical 
zones and increases in volume of dense bodies in the cells of the zona fasciculata and 
zona reticularis in rabbits (Mazzocchi et al., 1979).  Indeed, reduced vacuolation has 
been described as a morphological adaptation to stress (Pellegrini et al., 1998).  
Further support of this concept is provided by evidence that cytoplasmic vacuolation 
in the zona fasciculata is reduced in rats 24h after treatment with a dose of LPS 
considerably higher than that used in our study (Lomnitski et al., 2000).  One possible 
explanation for the decreased vacuolation and loss of response to ACTH is a decrease 
in the amount of substrate available for steroidogenesis.  In support of this concept, 
LPS has also been shown to influence the expression of StAR, the protein that 
facilitates the transport of cholesterol into the mitochondria in steroidogenesis.  LPS 
(200μg/mouse, i.p.) increases StAR mRNA and protein; its effects that are maximal at 
8h and still evident at 24h and the rise in StAR may thus compensate for the initial 
loss of cholesterol suggested by our study.  Interestingly, while LPS augmented StAR, 
it had no effect on expression of the mRNAs for the steroidogenic enzymes P450scc, 
3β-hydroxysteroid dehydrogenase or P450c17 (Hales et al., 2000), further supporting 
the concept of a compensatory action.  While cholesterol depletion would explain the 
decrease in vacuolation, other data suggest that the concurrent loss of sensitivity to 
ACTH may also be related to alterations in ACTH binding.  Enriquez de Salamanca et 
al., (2005) evaluated the effects of ACTH (0.01–100ng/ml) and LPS (0–250μg/ml) on 
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ACTH binding using an in vitro preparation of fasciculata-reticularis cells.  Their data 
showed that ACTH treatment (4 days) increased the ACTH specific binding in a 
concentration-dependent way while LPS (1-10μg/ml) produced a significant 
concentration-dependent reduction in ACTH binding.  Furthermore, in ex vivo 
experiments on isolated adrenocortical cells, the secretion of CORT induced by 
ACTH (>0.1ng/ml) was inhibited by LPS (10 μg/ml over 24h).  Moreover, LPS also 
caused a small reduction in the ability of dibutyryl cAMP to induce CORT synthesis 
but did not affect the response to pregnenolone, suggesting that the effects of LPS are 
targeted principally at a point before the formation of cAMP in the signal transduction 
cascade and may be explained by a reduction in the binding of ACTH to its receptors 
(De Salamanca & Garcia, 2005).   
 
Our data, like those of Lomnitski et al., (2000) suggest that acute treatment with LPS 
leads to rapid impairment of adrenocortical function and indicate that this may be 
explained both by desensitisation of the ACTH receptor and loss of the cholesterol, 
which may be compensated for rapidly by induction of StAR synthesis.  These 
findings raised the questions as to whether a similar loss of adrenal sensitivity is 
evident in animals exposed to repeated stress over a short time period (<1day).  The 
published data appear inconsistent in this regard.  Thus, when immobilisation, electric 
shock and forced running stressors were applied over various intervals up to 24h, the 
increase in the concentrations of pituitary cAMP and plasma ACTH and CORT 
induced by the final stress were comparable in magnitude to those induced by the 
initial stress (Dallman & Jones, 1973; Kant et al., 1988; Andres et al., 1999).  By 
contrast, in a series of experiments in rats in which repeated forced running was used 
as a stressor (15min, followed by 45min recovery repeated four times) and plasma 
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ACTH and CORT were measured during each recovery period (when plasma CORT 
would be expected to be maximal), the concentrations of plasma CORT attained after 
the second, third and fourth stressors were lower than that reached after the initial 
stress of the initial recovery period whilst the ACTH response was sustained 
suggesting that the adrenal gland had become desensitised to ACTH (Kant et al., 
1988). 
 
Adrenal insufficiency has been noted in patients with sepsis (Maxime et al., 2009), 
although not to the best of our knowledge in the initial stages.  Furthermore, while 
there is evidence of adaptation of the HPA axis in conditions of chronic or repeated 
stress, we are not aware of any reported chronic stress paradigms in which GC 
secretion is impaired due to primary adrenal failure as would appear to be the case in 
our study.  Our data and those generated by others (Grinevich et al., 2001; Urbach-
Ross & Kusnecov, 2007) differ from those generated following non inflammatory 
stressors (Ulrich-Lai et al., 2006), suggesting that exposure to endotoxin leads to an 
impairment of the HPA function similar to ‗adrenal insufficiency‘ seen in patients 
with sepsis (Maxime et al., 2009).  They further suggest that this is due both 
desensitisation of the steroidogenic cells to ACTH and cholesterol depletion which 
may be mediated by direct actions of LPS on the adrenal and/or by infiltrating 
leukocyte infiltration. 
 
The LPS-induced decrease in vacuolation was very much less pronounced in 
ANXA1-null mice, compared to saline-treated and LPS-treated WTs, yet these mice 
respond to LPS with a normal increase in ACTH and CORT release (John et al., 
2003); in addition, Fpr2 gene deletion also attenuated the LPS-induced decrease in 
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vacuolation.  The observation that ANXA1 gene deletion attenuates the LPS-induced 
loss of vacuolation is surprising in the light of findings that ANXA1 suppresses 
ACTH-driven steroidogenesis (Davies et al., 2007).  It is possible that a subtle 
difference in steroidogenesis brought about by gene deletion leads to a greater 
capacity of adrenocortical cells from ANXA1 null mice to release CORT that was not 
detectable by histological evaluation and requires further investigation, perhaps using 
ex vivo assessments.  Alternatively, it may reflect effects of ANXA1 gene deletion on 
the mevalonate pathway that produces cholesterol.  In support of this concept, 
lovastatin, an inhibitor of HMG-coenzyme A (the rate limiting enzyme in the 
mevalonate pathway), prevents the LPS-induced translocation of phosphorylated 
ANXA1 to the cell surface in a folliculo-stellate cell line (TtT/GF, Solito et al., 2006).  
The effects of lovastatin were overcome by mevalonic acid (the product of HMG-
coenzyme A) and 2-hydroxymyristic acid (an inhibitor of myristoylation), but not 
cholesterol (Solito et al., 2006), raising the possibility that ANXA1 is an alternative 
substrate in the mevalonic pathway.  In this event, deletion of ANXA1 might lead to 
enhanced synthesis of cholesterol, and this would require further investigation.   
 
Fpr2
-/-
 mice also differed from WT in their response to LPS, with the vacuolation 
within the adrenal cortex being comparable to saline treated-mice.  As discussed 
previously, ANXA1 is considered to be a second messenger for the negative feedback 
effects of GCs in the anterior pituitary, and John et al., (2007) hypothesised that these 
may be mediated through an FPR receptor, possibly Fpr2.  It is feasible that if these 
effects are mediated through Fpr2, gene deletion will remove an element of the 
negative feedback control of ACTH release from the anterior pituitary gland, leading 
to increased basal and stress-induced levels of ACTH which would be expected to 
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increase the steroidogenic capability of the adrenal cortex (Ulrich-Lai et al., 2006).  
Alternatively, as suggested by our gene expression data, Fpr2 may be present within 
the adrenal cortex, and deletion of this gene may affect the synthesis and/or release of 
GCs in either normal or stressed conditions.  Given that ANXA1 depresses 
steroidogenesis (Davies et al., 2007) and has been shown to act via Fpr2 in other 
tissues, these findings are difficult to reconcile.  However, the data in Chapter 6 reveal 
that a non-selective FPR antagonist inhibits ACTH driven CORT release from 
adrenocortical cells, thus raising the possibly that an FPR-mediated mechanism exerts 
a tonic, positive effect on steroidogenesis.  Phenotypic analysis of the newly 
generated Fpr2-null mice offers an exciting opportunity to explore further the role of 
this receptor with the HPA axis. 
 
Conclusions 
We therefore suggest that the effects of LPS treatment on the steroidogenic cells 
within the adrenal gland may be attributed to direct effects LPS and/or infiltrating 
leukocytes and that the up-regulation of mRNAs for ANXA1 and FPRs may be 
dependent on these leukocytes.  The next chapter explores further the role of the 
infiltrating leukocytes in mediating the adrenal responses to LPS.   
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CHAPTER 5         
EXPRESSION OF FORMYL PEPTIDE RECEPTORS IN 
THE ADRENAL GLAND OF PMN-DEPLETED MICE 
5.1 Introduction and Methods 
The data in the previous two chapters demonstrates that LPS exerts profound effects 
on the adrenal gland, producing alterations in both gene expression and cellular 
morphology.  LPS thus induced up-regulation of the genes encoding the murine FPRs 
(Fpr1, Fpr2 and Fpr3) and ANXA1 together with infiltration of inflammatory cells 
into the adrenal tissue and decreased vacuolation in the steroidogenic cells.  Our 
histological studies suggested that 4h after injection of LPS the invading cells were 
mainly eosinophils with occasional neutrophils and monocytes.   
 
It was unclear from these data whether the LPS-induced up-regulation in Fpr1, Fpr2, 
Fpr3 and ANXA1 in the adrenal gland was a consequence of direct actions of the 
toxin, or mediators released in response to it, on the adrenal cells, or whether it was 
secondary to the infiltration of leukocytes known to be LPS-sensitive and to express 
these genes.  Previous studies (Davies et al., 2007) have localised ANXA1 to the 
outer region of the adrenal cortex.  However, the identity and location of the cells 
which express FPRs are unknown and investigations are limited by the current lack of 
reliable antibodies against the various members of the FPR family for IHC.  Our 
attempt to identify Fpr2 expressing cells using GFP as a surrogate were not 
successful, as discussed in Chapter 4.   
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Therefore, the aim of the experiments described in this chapter was to examine the 
effects of PMN depletion on the changes in gene expression (ANXA1, Fpr1, Fpr2 and 
Fpr3) and cellular morphology in the adrenal glands induced by administration of LPS 
(i.p.) and to make parallel measurements of plasma cytokines and serum CORT.  WT 
mice were treated with anti-mouse PMN serum (10ml/kg, i.p.) or an equivalent 
volume of IgG matched control serum (10ml/kg, i.p.) on two consecutive occasions 
(24h apart).  LPS (500μg/kg) or a corresponding volume of the saline vehicle (both at 
2.5ml/kg, i.p.) was administered 24h after the second injection and the animals were 
killed 4h later.  Blood was collected for analysis of cytokines (TNFα, IL-1β, IL-6, 
IL-10, IL-4, VEGF, RANTES, IFNγ, IL-17 and eotaxin) and CORT.  After perfusion, 
the adrenal gland and spleen (control tissue) were collected for analysis of gene 
expression (ANXA1, Fpr1, Fpr2, Fpr3, GAPDH, β-actin and β-2M) and cellular 
morphology. 
 
5.2 Results 
A) Confirmation of PMN depletion in WT mice given anti-mouse PMN serum 
Mice treated with anti-mouse PMN serum for two days showed a significant reduction 
(approximately 80%, P<0.01) in the number of circulating PMNs (neutrophils, 
basophils and eosinophils) vs. controls, highlighting the efficacy of the anti-PMN 
antiserum (Figure 5.1).  It should be noted that whilst the serum is referred to as an 
anti-PMN serum, circulating neutrophils were decreased by ~85% (from 1.75x10
3/μl 
to 0.28x10
3/μl), while basophil and eosinophil counts were low <0.12x103/μl both 
before and after anti-PMN serum was given.  
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Figure 5.1:  Effects of anti-mouse PMN serum on PMN count in WT mice.  Anti-
mouse PMN serum or IgG matched serum (10ml/kg, i.p.) diluted 1:10 in saline was 
administered to WT mice (n=6/group) once daily for two days.  Blood samples were 
collected into EDTA (for total white cell count) and for blood smears (for differential 
cell count) prior to injection of serum on Day 1 and prior to injection of Saline or LPS 
on Day 3 for assessment of PMN (neutrophils, basophils and eosinophils) count.  
Values are mean ± SEM from 6 mice. **P<0.01 (Students t-test). 
 
B) CORT response of PMN-depleted WT mice given saline or LPS  
Treatment of mice pre-treated with either the control serum or anti-PMN serum with 
LPS (500µg/kg, 2.5ml/kg, i.p.) caused a significant increase (3.3-fold, P<0.01) in 
serum CORT concentrations 4h after treatment (Figure 5.2) when compared to saline 
treated controls (Figure 5.2).  There was no difference in the magnitude of the CORT 
response to LPS in mice treated with anti-PMN serum vs. the IgG-matched control 
serum (P>0.05, Figure 5.2).   
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Figure 5.2:  Effects of LPS administration on the serum CORT concentration in 
PMN depleted WT mice.  Serum samples were collected by cardiac puncture 4h 
after the administration of LPS (500µg/kg) or saline (both at 2.5ml/kg i.p.) to PMN 
depleted WT mice of IgG-treated controls for the analysis of CORT by enzyme 
immunoassay.  PMNs were depleted through pre-treatment with an anti-mouse PMN 
serum (10ml/kg, i.p.) diluted 1:10 in saline for two days prior to injection with LPS. 
IgG matched serum controls were also included (10ml/kg, i.p.).  Values are mean ± 
SEM of n = 6 mice per group.  **P<0.01 vs. saline-treated (one way ANOVA).  
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C) Assessment of plasma cytokines following intra-peritoneal administration of 
LPS in PMN-depleted WT mice  
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Figure 5.3:  Effects of LPS administration on the plasma concentrations of 
TNFα, IL-1β, IL-6 and IL-10 in PMN depleted WT mice.  Plasma samples were 
collected by cardiac puncture 4h after the administration of LPS (500µg/kg) or saline 
(both at 2.5ml/kg i.p.) to PMN depleted or IgG-treated WT mice for the analysis of  
(A) TNFα, (B) IL-1β (C) IL-6 or (D) IL-10 by Luminex xMAP technology.  PMNs 
were depleted through pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) 
diluted 1:10 in saline for two days prior to injection with LPS. IgG matched serum 
controls were also included (10ml/kg, i.p.).  Values are mean ± SEM of n = 6 mice per 
group.  **P<0.01, *P<0.05 vs. saline-treated or vs. serum-treated (one-way ANOVA 
followed by Dunnett‘s test). NS, not significant.  Note: Values for IL-6 from LPS 
treated animals were greater than the maximum concentration used from the standard 
curve and were arbitrarily assigned the maximum 10,000pg/ml, therefore, values may 
be greater. 
 
LPS also caused marked changes in the plasma cytokine profile within 4h of injection 
in mice treated with the anti-mouse PMN serum or the control serum (Figure 5.3).  
Significant increases in the plasma concentrations of TNFα were seen in both IgG 
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(17-fold, P<0.01) and anti-mouse PMN (13-fold, P<0.01) serum-treated mice, 
compared to time-matched saline-treated controls (Figure 5.3A).  Resting plasma 
IL-1β was increased in mice treated with IgG vs. untreated controls but no further 
increase was evident in these animals following treatment with LPS.  By contrast 
PMN depletion had no effect on the resting plasma IL-1β concentration vs. controls 
but facilitated a marked increase in the release of this cytokine in response to LPS 
(6-fold, P<0.01, Figure 5.3B) vs. the corresponding IgG controls (1.9-fold, P<0.05; 
Figure 5.3B).  Plasma concentrations of IL-6 were significantly increased (P<0.01) in 
both LPS-treated groups of mice vs. the saline-treated controls (Figure 5.3C), so much 
so that the values exceeded the maximum concentration used in the standard curve 
(value was 99.9% of actual 10000pg/ml) and were arbitrarily assigned a value of 
>9999-10000pg/ml.  Basal levels of IL-6 were at the lower end of the standard curve, 
indicating the remarkable increase in the release of this cytokine following 
administration of LPS (Figure 5.3C).  LPS also induced statistically significant 
increases in the plasma concentrations of IL-10 in both groups of mice but the 
response in those treated with the anti-mouse PMN serum (215-fold, P<0.01, Figure 
5.3D) was larger (2.2-fold, P<0.01) than that of the IgG-treated controls (35-fold, 
P<0.01, Figure 5.3D).  
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Figure 5.4:  Effects of LPS administration on the plasma concentrations of IL-4, 
eotaxin, IFNγ and RANTES in PMN depleted WT mice.  Plasma samples were 
collected by cardiac puncture 4h after the administration of LPS (500µg/kg) or saline 
(both at 2.5ml/kg i.p.) to PMN depleted or IgG-treated WT mice for the analysis of 
(A) IL-4, (B) Eotaxin (C) IFNγ or (D) RANTES by Luminex xMAP technology.  
PMNs were depleted through pre-treatment with an anti-mouse PMN serum (10ml/kg, 
i.p.) for two days prior to injection with LPS.  IgG matched serum controls were also 
included (10ml/kg, i.p.).  Values are mean ± SEM of n = 6 mice per group.  **P<0.01, 
*P<0.05 vs. saline-treated or vs. serum-treated (one-way ANOVA followed by 
Dunnett‘s test).  NS, not significant. Values for RANTES from LPS treated animals 
and eotaxin from anti-PMN/LPS animals were greater than the maximum acceptable 
concentration used from the standard curve and were arbitrarily assigned the 
maximum >400 and >2000pg/ml, respectively, therefore, values may be greater. 
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LPS had no effect on the plasma concentrations of IL-4 (Figure 5.4A) or eotaxin 
(Figure 5.4B), although it should be stated that all values for eotaxin exceeded the 
highest value on the standard curve.  By contrast, LPS increased the plasma 
concentrations of IFNγ (P<0.05, Figure 5.4C) and RANTES (Figure 5.4D, P<0.01) in 
mice treated with either the anti-PMN antiserum or the control serum; there were no 
significant differences between the two groups in the magnitude of the IFNγ (Figure 
5.4C) and RANTES (Figure 5.4D) responses (P>0.05). However, as for IL-6, the 
LPS-induced increases in RANTES were substantive, so much so that the values 
exceeded the maximum concentration in the standard curve (value was 91% of actual 
400pg/ml) and were arbitrarily assigned a value of >399-400pg/ml.  Hence any 
differences between the treatment groups may have been masked.   
 
In anti-PMN serum treated mice, there was a statistically significant increase in serum 
IL-17, compared to saline treated controls (3.2-fold, P<0.01, Figure 5.5A).  However, 
this was not reflected in LPS-treated mice given the control serum which showed a 
great deal of inter-animal variability and an apparent 9.6-fold increase which failed to 
reach statistical significance (P>0.05, Figure 5.5A).  Plasma VEGF concentrations in 
mice treated with the control serum were unaffected by LPS.  However, the toxin 
caused a significant increase in plasma VEGF in mice treated with the anti-PMN 
serum group (P<0.01, Figure 5.5B) 
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Figure 5.5:  Effects of LPS administration on plasma concentrations of IL-17 and 
VEGF in PMN depleted WT mice.  Plasma samples were collected by cardiac 
puncture 4h after the administration of LPS (500µg/kg) or saline (both at 2.5ml/kg 
i.p.) to PMN depleted and IgG-treated WT mice for the analysis of (A) IL-17 or (B) 
VEGF by Luminex xMAP technology.  PMNs were depleted through pre-treatment 
with an anti-mouse PMN serum (10ml/kg, i.p.) for two days prior to injection with 
LPS. IgG matched serum controls were also included (10ml/kg, i.p.).  Values are 
mean ± SEM of n = 6 mice per group.  **P<0.01, *P<0.05 vs. saline-treated or vs. 
serum-treated (one-way ANOVA followed by Dunnett‘s test).  NS, not significant.  
 
C) Effects of LPS on the cellular morphology of the spleen and adrenal gland in 
mice treated with anti-mouse PMN serum or the IgG matched control serum 
LPS (500µg/kg; 2.5ml/kg, i.p.) induced microscopic changes in the spleen and adrenal 
glands of WT mice pre-treated with the anti-mouse PMN serum or the IgG matched 
control serum (Table 5.1).  When compared to those seen in IgG matched control 
animals given LPS and those described in Chapter 4, subtle differences were observed 
in both the spleen and adrenal glands of mice depleted of PMNs.  In the spleen, PMN 
depletion exaggerated the change induced by LPS.  Thus, in the white pulp there was 
an increased incidence of lymphoid cell apoptosis (consisting of pyknotic nuclei with 
apoptotic bodies) in 3/4 mice treated with anti-mouse PMN-serum mice whereas only 
3/6 mice treated with the control serum showed this pathology.  LPS triggered 
lymphocyte apoptosis in the red-pulp only of 3/4 mice treated with the anti-mouse 
PMN serum but not in animals treated with the control serum while LPS induced 
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extramedullary haematopoiesis was identified in all animals treated with the anti-
mouse PMN serum-treated mice versus 5/6 IgG matched controls.   
 
 IgG Matched 
Serum 
Anti-mouse PMN 
Serum 
 SALINE LPS SALINE LPS 
 
Spleen 
Number of animals examined 
 
 
 
6 
 
 
6 
 
 
6 
 
 
4
A
 
White pulp, mainly germinal 
centres, lymphoid cell apoptosis 
 - minimal 
 - mild 
 
 
0 
0 
 
 
2 
1 
 
 
1 
0 
 
 
2 
1 
Lymphocyte apoptosis in red 
pulp 
 - mild 
 
 
0 
 
 
0 
 
 
0 
 
 
3 
     
Extramedullary haematopoiesis 
 - minimal 
 - mild 
 
1 
0 
 
2 
3 
 
0 
0 
 
1 
3 
Adrenal gland     
Number of animals examined 
 
6 6 6 6 
Inflammatory cell infiltrate 
 - minimal 
 - slight 
 - moderate 
 
0 
0 
0 
 
0 
1 
4 
 
0 
0 
0 
 
4 
0 
0 
Decreased vacuolation in cortex 
 
0 5 1 6 
 
Table 5.1: Effect of i.p. LPS administration on the morphology of the spleen and 
adrenal glands from normal and PMN depleted WT mice.  LPS (500µg/kg) or 
saline (both at 2.5ml/kg, i.p.) was administered to PMN depleted and IgG-treated WT 
mice.  4h after injection, tissues were removed, fixed in 10% neutral buffered 
formalin, embedded in paraffin wax, sections cut (3µm) and stained with H&E for 
evaluation by light microscopy (n = 6/group).  PMNs were depleted through 
pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) for two days prior to 
injection with LPS. IgG matched serum controls were also included (10ml/kg, i.p.). 
A: two samples missing.  Values represent the number of animals in which the finding 
was observed.  
 
LPS caused inflammatory cell infiltration in the cortex and medulla and decreased 
vacuolation in 5/6 IgG matched controls vs. the corresponding saline-treated controls 
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(Table 5.1).  The invading cells were predominantly eosinophilic PMNs, with 
occasional monocytes and neutrophilic PMNs and the severity of the response was 
comparable to that observed previously in WT mice (see Chapter 4).  In addition, 
occasional lymphocytes were observed in the lumen of the medullary blood vessels.  
The failure of 1/6 mice treated with the control serum to respond to LPS was quite 
remarkable.  Sections taken from this animal were indistinguishable from those of 
saline-treated controls in terms of both infiltrating cells and vacuolation.  As this 
animal failed to release CORT or cytokines when challenged with LPS it was likely 
that the toxin was not administered correctly and therefore this animal was 
subsequently removed from the analysis. 
 
In complete contrast to mice treated with IgG-serum, LPS failed to cause 
inflammatory cell infiltration in the adrenal cortex or medulla in two of the six PMN-
depleted animals studied and in four animals the cell infiltration was minimal (and in 
one animal only detectable in one of the two adrenal glands).  Again, the invading 
cells were predominantly eosinophilic PMNs, with occasional monocytes and 
neutrophilic PMNs spread throughout the gland with occasional lymphocytes in the 
lumen of the medullary vessels.  However, these changes were minimal when 
compared to those observed in mice treated with the control serum and also those 
noted previously in WT mice (Chapter 4).  However, despite the impairment of 
inflammatory cell infiltration, the decrease in vacuolation induced by LPS was 
maintained in PMN-depleted mice. 
.  
  259 
(A) IgG and LPS (B) Anti-mouse PMN and LPS 
 
 
 
 
 
 
 
 
 
 
Figure 5.6: Effects of i.p. administration of LPS on the adrenal glands from normal and PMN-depleted WT mice.  PMN depleted WT 
mice were treated with LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The adrenal glands were removed after 4h, processed and stained with 
H&E. (A) shows the presence of leukocytes in the vasculature of the medulla (as indicated by arrow) in IgG-control serum treated WT mice 
compared to (B) in LPS-treated mice that showed the absence or only the occasional leukocyte (as indicated by arrow) with PMN depletion 
(x60).  The images shown are representative of the results described for all affected animals.   
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(A) IgG and LPS (B) Anti-mouse PMN and LPS 
 
 
 
 
 
 
 
 
 
 
Figure 5.7:  Effects of i.p. administration of LPS on the adrenal glands from normal and PMN-depleted WT mice.  PMN depleted WT 
mice were treated with LPS (500µg/kg) or saline (both at 2.5ml/kg, i.p.).  The adrenal glands were removed after 4h, processed and stained with 
H&E.  (A) shows the presence of eosinophils (indicated by arrow) in the cortex in LPS-treated IgG-matched WT mice, whilst (B) shows a lack 
of inflammatory cell infiltrate in the cortex of PMN depleted WT mice given LPS (x60).  The images shown are representative of the results 
described for all affected animals.   
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(D) Changes in gene expression in the adrenal gland and spleen induced by intra-
peritoneal administration of LPS. 
Mice pre-treated with anti-PMN antiserum or equivalent volume of the control IgG 
were treated with LPS (500µg/kg, i.p.) or saline (both at 2.5ml/kg, i.p.).  Four hours 
later the animals were killed, perfused, the spleen and adrenal glands collected and 
analysed by qRT-PCR for expression of mRNAs for murine Fpr1, Fpr2, Fpr3, 
ANXA1 as well as endogenous controls (GAPDH, β-actin and β-2M). 
 
As before, all endogenous controls used were assessed for independence from 
treatment using the CEF (Product) and β-actin was considered the most suitable and 
was used as the normaliser and covariate for statistical analysis by ANCOVA.  
 
Figures 5.8-11 demonstrate the effects of LPS vs. saline on the expression of mRNAs 
for Fpr1, Fpr2, Fpr3, and ANXA1 in the adrenal gland and spleen from anti-mouse 
PMN-serum and IgG-matched serum control mice.  Administration of LPS 
(500µg/kg, 2.5ml/kg i.p.) to IgG matched serum treated mice caused significant 
increases vs. saline in the expression of mRNAs for Fpr1 (2.1-fold; P<0.01, Figure 
5.8A), Fpr2 (2.9-fold; P<0.01, Figure 5.9A) and Fpr3 (from an adjusted mean value of 
0.1 to 2.4; P<0.01, Figure 5.10A), but not ANXA1 in the adrenal glands (Figure 
5.11A).  Increases in Fpr1 (1.10-fold; P<0.05, Figure 5.8B) and Fpr2 (1.31-fold; 
P<0.05, Figure 5.9B), vs. saline controls, but not Fpr3 (Figure 5.10B) or ANXA1 
(Figure 5.11B) were also seen in the spleen.  By contrast, LPS had no effect on the 
expression of the Fpr1 (Figure 5.8A) or Fpr3 (Figure 5.10A) and also failed to 
influence ANXA1 expression (Figure 5.11A) in the adrenal gland of PMN-depleted 
mice, although, as in mice treated with the control serum, it increased Fpr2 expression 
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(2.9-fold; P<0.01, Figure 5.9A).  Similarly, LPS increased expression of Fpr2 mRNA 
in the spleen of PMN-depleted mice (1.26-fold; P<0.05 vs. time-matched saline 
controls, Figure 5.9B) but failed to influence the expression of Fpr1 (Figure 5.8B), 
Fpr3 (Figure 5.10B) or ANXA1 (Figure 5.11B). 
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Figure 5.8:  Effect of i.p. administration of LPS on the expression of Fpr1 mRNA 
in adrenal gland and spleen in PMN depleted WT mice.  LPS (500µg/kg) or saline 
(both at 2.5ml/kg i.p.) were given to PMN depleted or IgG-treated WT mice (n = 
6/group) and (A) adrenal glands and (B) spleen were removed after 4h.  Fpr1 mRNA 
was quantified by qRT-PCR (mean adjusted to β-actin ± SEM).  PMNs were depleted 
through pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) for two days 
prior to injection with LPS. IgG matched serum controls were also included (10ml/kg, 
i.p.).  *P<0.05, **P<0.01 vs. IgG controls (ANCOVA followed by Dunnett‘s test after 
log transformation of normalised data).  NS, not significant. 
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Figure 5.9:  Effect of i.p. administration of LPS on the expression of Fpr2 mRNA 
in adrenal gland and spleen in PMN depleted WT mice.  LPS (500µg/kg) or saline 
(both at 2.5ml/kg i.p.) were given to PMN depleted or IgG-treated WT mice (n = 
6/group) and (A) adrenal glands and (B) spleen were removed after 4h.  Fpr2 mRNA 
was quantified by qRT-PCR (mean adjusted to β-actin ± SEM).  PMNs were depleted 
through pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) for two days 
prior to injection with LPS. IgG matched serum controls were also included (10ml/kg, 
i.p.).  **P<0.01 vs. IgG controls (ANCOVA followed by Dunnett‘s test after log 
transformation of normalised data). 
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Figure 5.10:  Effect of i.p. administration of LPS on the expression of Fpr3 
mRNA in adrenal gland and spleen in PMN depleted WT mice.  LPS (500µg/kg) 
or saline (both at 2.5ml/kg i.p.) were given to PMN depleted or IgG-treated WT mice 
(n = 6/group) and (A) adrenal glands and (B) spleen were removed after 4h.  Fpr3 
mRNA was quantified by qRT-PCR (mean adjusted to β-actin ± SEM).  PMNs were 
depleted through pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) for two 
days prior to injection with LPS. IgG matched serum controls were also included 
(10ml/kg, i.p.).  **P<0.01 vs. IgG controls (ANCOVA followed by Dunnett‘s test 
after log transformation of normalised data).  NS, not significant.  mRNA was 
assessed using primers and probe labelled Fpr3_Rep.   
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Figure 5.11:  Effect of i.p. administration of LPS on the expression of ANXA1 
mRNA in adrenal gland and spleen in PMN depleted WT mice.  LPS (500µg/kg) 
or saline (both at 2.5ml/kg i.p.) were given to PMN depleted or IgG-treated WT mice 
(n = 6/group) and (A) adrenal glands and (B) spleen were removed after 4h.  ANXA1 
mRNA was quantified by qRT-PCR (mean adjusted to β-actin ± SEM).  PMNs were 
depleted through pre-treatment with an anti-mouse PMN serum (10ml/kg, i.p.) for two 
days prior to injection with LPS. IgG matched serum controls were also included 
(10ml/kg, i.p.). 
   
5.3 Discussion 
The data show that treatment with anti-PMN serum is an effective means of reducing 
the number of circulating leukocytes, with a reduction of some 80% in the blood cell 
count 24h after the second injection of the serum.  They also show that PMN 
depletion impairs the LPS-induced infiltration of leukocytes into the adrenal gland 
and prevents the increase in expression of Fpr1 and Fpr3 mRNAs induced by the 
toxin without affecting the rise in Fpr2 mRNA.  A similar pattern of gene expression 
was evident in spleen, although in this tissue, PMN depletion augmented the cellular 
response to LPS with evidence of increased apoptosis in the red and white pulp.  On 
the other hand, PMN depletion did not influence the HPA response to LPS, as 
evidenced by the rise in serum CORT, nor did it influence the LPS-induced decrease 
in vacuolation of the steroidogenic cells. 
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5.3.1 Effects of PMN depletion on the LPS-induced alterations in adrenal 
morphology and function 
PMN depletion effectively attenuated the LPS-induced inflammatory cell infiltration 
into the adrenal gland.  However, occasional lymphocytes were observed in the 
vascular lumen, perhaps reflecting a minimal response involving lymphocytes which 
may reflect an increased leukocyte count induced by the release of pro-inflammatory 
cytokines (Chapter 4).  Strikingly, PMN depletion prevented the LPS induction of 
Fpr1 and Fpr3 mRNAs in the adrenal gland, a finding that supported our hypothesis 
that the infiltrating cells are responsible for the up-regulation of these genes in the 
adrenal cortex.  Further support for this hypothesis is provided by evidence that 
murine PMNs and monocytes express Fpr1 (Ye et al., 2009) and that FPR1 
expression in human PMNs is increased by LPS (Mandal & Hamilton, 2007).  The 
finding that PMN depletion also prevented LPS-induced Fpr3 expression in the 
adrenal may well reflect the propensity of eosinophils and monocyte to express this 
gene.  While data on murine eosinophils are lacking, FPR3 is expressed by human 
eosinophils (Svensson et al., 2009), monocytes (Durstin et al., 1994) and dendritic 
cells (Yang et al., 2002), but not by neutrophils  (Murphy et al., 1992). 
 
Given that FPR2 is expressed in abundance by human neutrophils and monocytes, our 
finding that PMN-depletion prevented the LPS-induced induction of Fpr2 mRNA in 
the adrenal gland is surprising and leads us to conclude that induction in control mice 
treated with LPS reflects expression by native adrenal cells.  Support for this view lies 
in the evidence that ANXA1, a ligand for Fpr2, suppresses ACTH-driven 
steroidogenesis in rodent adrenal tissue (Davies et al., 2007).  However, as FPR2 is 
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expressed by human lymphocytes (Ye et al., 2009) and it is therefore possible that the 
increased expression of Fpr2 was due, at least in part to the presence of these cells. 
 
A surprising finding was the failure of LPS to induce ANXA1 expression in PMN-
depleted mice or the IgG treated controls.  ANXA1 expression is increased in 
conditions of immune challenge and it is therefore possible that the administration of 
IgG and anti-PMN themselves augmented ANXA1 expression and masked any effects 
of LPS.  An additional study in which ANXA1 mRNA expression in these two groups 
of mice is compared with that of the untreated controls is needed to answer this 
question. 
 
Despite the changes in inflammatory cell infiltration and gene expression caused by 
PMN depletion, the steroidogenic response to LPS was unaffected by treatment with 
anti-PMN serum.  Thus the LPS-induced increase in serum CORT and decrease in 
vacuolation were both maintained in the PMN-depleted mice.  These findings support 
the premise that the activation of the HPA axis induced by i.p. injection of LPS is 
independent of circulating PMNs and is effected mainly by cytokines released by 
peritoneal macrophages which trigger a vagally mediated neuroendocrine reflex and 
also by direct effects of LPS and pro-inflammatory cytokines on the endothelial cells 
of the BBB, the pituitary gland and, possibly, the adrenal cortex (Szafarczyk et al., 
1985; Gaykema et al., 1995; Turnbull & Rivier, 1999; Mulla & Buckingham, 1999; 
Blatteis et al., 2005; Anand et al., 2007). 
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5.3.2 Effects of PMN-depletion on the LPS-induced changes morphology and 
gene expression spleen 
PMN depletion appeared to exacerbate the LPS-induced changes seen previously 
(Chapter 4) in the spleen.  There was a greater incidence and severity of lymphoid cell 
apoptosis in the white pulp as well as lymphocyte apoptosis in the red pulp, not seen 
previously.  It is likely that these increases are a reflection of an exaggerated 
lymphocytic response to the dose of LPS, in the absence of neutrophils.  It is not clear 
if the LPS-induced apoptosis is beneficial or detrimental to host survival.  The loss of 
lymphocytes may lead to an impaired inflammatory response and a reduction in the 
pro-inflammatory cytokines (Moldawer, 1999) or may be detrimental as lymphocyte 
apoptosis will invariably lead to immunosuppression (Cheadle et al., 1993; Rajan & 
Sleigh, 1997).  The greater severity of lymphocyte apoptosis in the spleen and a loss 
of lymphocytes in sepsis may also be associated with its pathogenesis (Hotchkiss et 
al., 2001).  As before, extramedullary haematopoiesis was evident in the spleen and 
may be mediated by the concurrent rise in serum CORT (Chapter 4) which may also 
have contributed to the apoptotic process (Oberholzer et al., 2001).  These 
morphological changes may also be due to the increased release of IL-1β, as these 
pro-apoptotic cytokines are able to induce lymphopenia in rats (Ulich et al., 1987). 
 
Surprisingly, and as in the adrenal gland, the LPS-induced increase in Fpr1 and Fpr3 
mRNAs in the spleen was ablated by PMN depletion, suggesting that PMNs have an 
important role in regulating this response, even though they were not identified 
microscopically in the spleen of saline or IgG-treated controls.  Nonetheless, the 
spleen has been shown consistently to express mRNAs for Fpr1, Fpr2 and Fpr3  (Le et 
al., 2002; Wang & Ye, 2002; Devosse et al., 2009).  The finding that the LPS-induced 
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increase in Fpr2 expression was maintained in PMN-depleted animals may reflect the 
sustained presence of lymphocytes (Ye et al., 2009), which were unaffected by 
treatment.  As in the adrenal gland, LPS failed to induce ANXA1 expression in the 
spleen in IgG- and anti-PMN-treated mice, perhaps because both treatments elicited 
an immunological response that would be expected to increase the levels of ANXA1, 
an anti-inflammatory mediator (Perretti, 2003), and may therefore mask any response 
to LPS. 
 
5.3.3 Effects of PMN depletion on the LPS-induced changes in circulating 
cytokines and chemokines  
Treatment with both IgG and anti-PMN serum to mice failed to elicit any changes in 
plasma cytokines in the control group.  This suggests that neither IgG nor the anti-
PMN serum elicited an inflammatory response (based on the cytokines assessed) or 
the delay between treatment and collection of blood was sufficient for any response to 
subside. 
 
In IgG-treated mice, LPS injection led to increases in the pro-inflammatory cytokines 
(TNFα, IL-6, RANTES and IFNγ) as well as a compensatory increase in the anti-
inflammatory cytokine, IL-10.  It was however, surprising that both IL-4 and eotaxin 
were unchanged as these are chemoattractants for eosinophils (Dubois & Bruijnzeel, 
1994; Pease & Williams, 2001), considered the principal leukocyte in the adrenal 
gland at this time-point.  It may be that eotaxin does not influence LPS-induced 
eosinophil accumulation, as LPS-induced eosinophil infiltration into the pleura has 
been shown to be independent of eotaxin (Penido et al., 2001).  An assessment of 
plasma vs. tissue concentration of these cytokines would confirm that the LPS-
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induced eosinophil migration in the adrenal gland is similar to that for the pleura 
(Penido et al., 2001).  IFNγ, an important mediator/regulator of LPS-induced 
inflammation (Heremans 1987), was unaffected but the high variability (two animals 
having high concentrations) and that previously increases were shown between 6.5-
10h after LPS injection (Amiot et al., 1997) may account for this variability in 
response. 
 
We did note differences between IgG- and anti-PMN-treated mice given LPS after 4h 
with IL-1β and concomitant increase in IL-10.  Elevations in the pro-inflammatory 
cytokines have been reported for neutropenic mice challenged with differing 
endotoxins (Netea et al., 1997), in particular TNFα, IL-1α, IL-1β and IL-6, and that 
the absence of PMNs leads to an increase in pro-inflammatory cytokines that may be 
detrimental to the host.  However, IL-1β has been shown to be protective against 
infection, especially in neutropenic mice (Van't Wout et al., 1988).  It should be noted 
that whilst TNFα and IL-6 were increased in anti-PMN mice after 4h, there was no 
distinguishable difference to IgG-serum treated mice.  However, that this data differed 
to that obtained previously at 4h (Chapter 3, no increases at 4h), may have been due to 
the immune complexes in both serums that can activate complement components, 
leading to an exacerbated response in both groups of animals after LPS, as seen 
previously (Richard et al., 2000).  The lack of change in IFNγ is probably more 
reflection of a lack of neutrophils that release IFNγ upon degranulation (Ethuin et al., 
2004).  The change in VEGF, a potent proangiogenic cytokine, is not considered to be 
of relevance as it was highly variable and close to the limit of detection and 
comparable to IgG matched controls.    
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We have shown in mice depleted of PMNs, LPS still induced increases in CORT, pro-
inflammatory cytokines and reduced vacuolation in the adrenal gland indicating a full 
stress response.  Furthermore, we were able to dramatically reduce the inflammatory 
cell infiltration in the adrenal cortex and show an up-regulation of mRNA for Fpr2 
only occurred (Fpr1 and Fpr3 unaffected) in LPS treated mice.  Whilst in the spleen, 
changes were similar to those seen before suggesting that LPS-induced lymphocyte 
apoptosis is independent of PMNs, yet like the adrenal gland, only mRNA for Fpr2 
was up-regulated.  Therefore, it would be intriguing to assess the effects of ligands for 
Fpr2 on the release of CORT ex vivo. 
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CHAPTER 6         
EFFECTS OF FORMYL PEPTIDE RECEPTOR LIGANDS 
ON CORTICOSTERONE RELEASE FROM DISPERSED 
ADRENAL CELLS 
6.1 Introduction and Methods 
Our data have shown that central or peripheral administration of LPS causes 
up-regulation of the mRNAs for Fpr1, Fpr2 and Fpr3 in the pituitary and adrenal 
glands.  They also revealed that intra-peritoneal administration of LPS induces 
inflammatory cell infiltration, predominantly eosinophilic, in the adrenal gland but not 
in the pituitary gland together with a decrease in vacuolation of the steroidogenic cells 
and an apparent decrease in the sensitivity of the cells to ACTH.  The LPS-induced 
infiltration of inflammatory cells and up-regulation of Fpr1 and Fpr3 expression was 
dependent on circulating PMNs and thus prevented by PMN depletion.  By contrast, 
PMN depletion had no effect on the LPS-induced decrease in vacuolation and up-
regulation of Fpr2 mRNA expression.  These findings suggest that Fpr2 expressed 
within the adrenal may have a role in the regulation of adrenal function and raises the 
possibility that the inhibitory effects of ANXA1 on ACTH stimulated CORT 
secretion described by Davies et al., (2007) is mediated by this receptor.  To test this 
hypothesis, the effects of various FPR ligands on resting and ACTH-stimulated 
CORT secretion by dispersed adrenal cells maintained in vitro in static conditions 
were examined using the methods described in Chapter 2 (Cover et al., 2001).  The 
results presented in this section describe, firstly, preliminary experiments designed to 
determine the optimal concentration of ACTH to use and, secondly, the effects of 
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graded concentrations of various FPR ligands (ANXA1Ac2-26, fMLP, Boc2 and 
WRW4) in the absence or presence of ACTH.  As these experiments relied on the 
number of adrenocortical cells yielded from a set number of animals (age and weight 
matched), normal variability in achievable cell count was expected.  As described in 
the methods, the number of wells/concentration was adjusted in real-time to ensure 
that the quality of the experiment was not affected.  Ideally, the number of animals 
would be increased, however, as the initial investigations were exploratory, the 
number of animals were kept to a minimum for ethical reasons and experiments were 
run between 3-5 wells/treatment.  If a positive response to treatment was observed, 
the experiment was repeated with a new batch of animals, drug preparations and 
CORT EIA kit to confirm treatment-related effect. 
 
6.2 Results  
Incubation of dispersed adrenal cells (1x10
6
 cells/ml) with ACTH1-24 (Sigma 0-
100nM, 2h) caused concentration-related increases in CORT with maximal responses 
occurring at concentrations >1nM ACTH (Figure 6.1).  Therefore, a concentration of 
1nM ACTH1-24 was selected for all future experiments.      
 
It should be noted that during the course of these experiments, it was found that the 
Sigma ACTH preparation (which was supplied in a freeze dried form, dissolved in-
house in sterile water and stored in aliquots of 10μM at -20°C) was unreliable as the 
freeze-thaw cycle appeared to influence the biological activity of the peptide.  
Accordingly, an alternative preparation made for clinical use, tetracosactide 
(ACTH1-24, supplied as vials of 1mg/ml tetracosactide acetate, Alliance 
Pharmaceuticals, Hammersmith Hospital Pharmacy), was used.  Subsequent 
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experiments showed that the bioactivity of the preparations was comparable, as 
indexed by the degree of CORT release from dispersed adrenal cells.  Details of the 
preparation used for each experiment are provided in the results section.   
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Figure 6.1:  Effect of ACTH1-24 on the release of CORT from dispersed murine 
adrenal cells.  The cells (1x10
6
cells/ml) were incubated with ACTH1-24 (Sigma) at 
concentrations of 0-100nM for 2h and the supernatant analysed for CORT by EIA.  
Each value represents the mean ± SEM, n=5 wells/concentration, adrenals collected 
from 12 WT mice.  **P<0.01 vs. untreated controls, one-way ANOVA with 
Dunnett‘s post hoc test. 
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Figure 6.2:  Effect of ANXA1Ac2-26 on basal and ACTH1-24 stimulated release of 
CORT from dispersed murine adrenal cells.  The dispersed cells were incubated 
(1x10
6
 cells/ml) with ACTH1-24 (Sigma, 1nM) +/- ANXA1Ac2-26 (0-30μM) for 2h and 
the supernatant analysed for CORT by EIA.  Each value represents the mean ± SEM, 
n=5 wells/concentration, adrenals collected from 12 WT mice.  **P<0.01 vs. ACTH, 
++P<0.01 vs. untreated, Two-way ANOVA with Bonferroni post-hoc tests.   
 
Incubation of dispersed adrenal cells (1x10
6
 cells/ml) with ANXA1Ac2-26 +/-(10 and 
30 µM, 2h) caused a significant decrease in the release of CORT induced by 
ACTH1-24 (Sigma, 1nM, P<0.01, n=5) without affecting the basal release of the steroid 
(Figure 6.2).   
 
Figure 6.3 shows the effects of a non-selective FPR agonist, fMLP, on ACTH1-24 
(Sigma, 1nM)-stimulated CORT release.  fMLP (0-100µM) had no effect on resting 
CORT release.  However, it reduced ACTH-stimulated CORT release in 
concentrations of 1µM (17%; P<0.05) and 10µM (31%; P<0.05).  By contrast, a 
higher concentration of fMLP (100µM) was without effect (Figure 6.3). 
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Figure 6.3:  Effect of fMLP on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells.  The dispersed cells were incubated (1x10
6
 
cells/ml) with ACTH1-24 (Sigma, 1nM) +/- fMLP (0-100μM) for 2h and the 
supernatant analysed for CORT by EIA.  Each value represents the mean ± SEM, n=4 
wells/concentration, adrenals collected from 12 WT mice.  ++P<0.01 vs. untreated, 
P<0.05 vs. ACTH, Kruskal-Wallace with Dunn‘s post-hoc test.  
 
 
An apparently similar profile of data was obtained in a second experiment but in this 
case the response to ACTH1-24 (tetracosactide, 1nM) stimulated CORT release 
obtained with 1µM (32%) or 10µM (32%) fMLP did not reach significance.  It is 
probably due to two wells in this experiment showing a poor response to ACTH, with 
lower than expected CORT release (Figure 6.4).   
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Figure 6.4:  Effect of fMLP on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells.  The dispersed cells were incubated (1x10
6
 
cells/ml) with ACTH1-24 (tetracosactide, 1nM) +/- fMLP (0-100μM) for 2h and the 
supernatant analysed for CORT by EIA.  Each value represents the mean ± SEM, n=3 
wells/concentration, adrenals collected from 12 WT mice.  +P<0.05 vs. untreated, 
Kruskal-Wallace with Dunn‘s post-hoc test. 
 
In concentrations up to 10µM, the selective Fpr2/3 antagonist, WRW4, had no effect 
on the release of CORT from dispersed adrenal cells in the presence or absence of 
ACTH1-24 (tetracosactide; 1nM, Figure 6.5).  However, Boc2 (an antagonist showing 
selectivity for Fpr1 at the concentrations used), caused a statistically significant 
decrease in ACTH-stimulated CORT release at concentrations of 3µM (46%; P<0.05) 
and 10µM (69%; P<0.05, Figure 6.6).  There were no differences in cell viability (as 
measured by Trypan blue exclusion) at the end of the 2h incubation period.  For both 
experiments conducted with WRW4 and Boc2, a higher adrenal cell count (2x10
6
 
cells/ml) was used. 
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Figure 6.5:  Effect of WRW4 on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells.  The dispersed cells were incubated (1x10
6
 
cells/ml) with ACTH1-24 (tetracosactide, 1nM +/- WRW4 (0-10μM) for 2h and the 
supernatant analysed for CORT by EIA.  Each value represents the mean ± SEM, n=3 
wells/concentration, adrenals collected from 15 WT mice.  +P<0.05 vs. untreated, 
Kruskal-Wallace with Dunn‘s post-hoc test. 
 
 
 
Figure 6.6:  Effect of Boc2 on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells.  The dispersed cells were incubated (1x10
6
 
cells/ml) with ACTH1-24 (tetracosactide, 1nM) +/- Boc2 (0-10μM) for 2h and the 
supernatant analysed for CORT by EIA.  Each value represents the mean ± SEM, n=4 
wells/concentration, adrenals collected from 15 WT mice.  *P<0.05, **P<0.01 
++P<0.01 vs. untreated, **P<0.01; NS = not statistically different (P>0.05) 
Kruskal-Wallace with Dunn‘s post-hoc test. 
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Subsequent experiments (Figures 6.7 and 6.8) tested the ability of Boc2 (0, 1, 3 and 
10µM) and WRW4 (0, 0.1, 1 and 10µM) to reverse the inhibitory effects of 
ANXA1Ac2-26 on ACTH-driven CORT secretion, using a concentration of 10µM 
ANXA1Ac2-26 (previously shown to be the lowest effective concentration; Figure 6.1).  
The number of wells/plate is a limiting factor in the experimental design; hence, as to 
obtain a group size sufficient for statistical analysis, wells with Boc2, WRW4 and 
ANXA1Ac2-26 alone were not included in the experiment as each has consistently 
failed to influence CORT release alone in multiple experiments at multiple 
concentrations, with the concentration of CORT always either below or at the lowest 
level of quantification.   
 
In contrast to our previous experiment ANXA1Ac2-26 failed to inhibit the secretory 
response to ACTH1-24 (tetracosactide, 1nM).  The reason for this is unclear but may 
reflect differences in the potency of ANXA1Ac2-26 as the peptide used in this 
experiment came from a different batch from that used previously.  The lack of effect 
could not be linked to poor cell viability as the cells responded readily to ACTH and 
cell viability was >97% after the incubation period when assessed by the Trypan blue 
exclusion test.  However, Boc2 caused a highly significant reduction in ACTH 
stimulated CORT release in the presence and absence of ANXA1Ac2-26 (P<0.01, 
Figure 6.7).    
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Figure 6.7:  Effect of Boc2 on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells +/-10µM ANXA1Ac2-26.  The cells were 
dispersed and incubated (1x10
6
 cells/ml) with ACTH1-24 (Tetracosactide, 1nM), +/- 
Boc2 (0-10μM), +/- ANXA1Ac2-26 (10µM) for 2h and the supernatant analysed for 
CORT by EIA.  Each value represents the mean ± SEM, n=4 wells/concentration, 
adrenals collected from 15 WT mice.  ++P<0.01 vs. untreated, *P<0.05 Kruskal-
Wallace with Dunn‘s post-hoc test. 
 
 
In the experiment with WRW4, ANXA1Ac2-26 (10µM) also failed to reduce ACTH-
stimulated CORT release as the apparent reduction (31%) in steroid release did not 
reach significance (P>0.05).  WRW4 (0.01-1µM) did not modify the response to 
ANXA1Ac2-26 (µM Figure 6.8).   
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Figure 6.8:  Effect of WRW4 on basal and ACTH1-24 stimulated release of CORT 
from dispersed murine adrenal cells +/-10 µM ANXA1Ac2-26.  The dispersed cells 
were incubated (1x10
6
 cells/ml) with ACTH1-24 (Tetracosactide, 1nM) at 1nM, +/- 
WRW4 (0-1μM), +/- ANXA1Ac2-26 (10µM) for 2h and the supernatant analysed for 
CORT by EIA.  Each value represents the mean ± SEM, n=4 wells/concentration, 
adrenals collected from 15 WT mice. ++P<0.01 vs. untreated, NS = Not statistically 
different (P>0.05), Kruskal-Wallace with Dunn‘s post-hoc test.  
 
 
 
6.3 Discussion  
Here we have shown that the ACTH-stimulated release of CORT in primary adrenal 
cell culture is partially inhibited in the presence of the peptide ANXA1Ac2-26 (an 
agonist that does not differentiate between Fpr1, Fpr2 and Fpr3) and fMLP which is a 
selective Fpr1 agonist at low concentrations [Kd 0.53-24nM, (Ye et al., 2009)] but 
which also interacts with Fpr2 at considerably higher concentrations [Kd 430nM, 
(Quehenberger et al., 1993)].  However, WRW4 (a selective Fpr2 antagonist) had no 
effect on CORT release.  By contrast, Boc2 (an antagonist showing selectivity for 
Fpr1 at the concentrations used) reproducibly decreased ACTH-stimulated release of 
CORT in a concentration-dependent way, suggesting an Fpr1-mediated tonic 
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stimulatory effect on ACTH stimulated steroidogenesis.  Together these data further 
support a complex role for these receptors within the adrenal gland in modulating the 
stimulatory effects of ACTH. 
 
The FPR family respond to ANXA1 and various ANXA1 peptides in rodents and man 
(John et al., 2007).  In humans, ANXA1Ac2-26 binds to and activates FPR1, FPR2 and 
FPR3 (Gavins et al., 2007).  In ligand competition binding experiments, the EC50 
values for FPR1 and FPR2 are 1.4 and 1.8μM, respectively (Hayhoe et al., 2006).  
Using HEK293 cells transfected with human FPRs, ANXA1Ac2-26 binds to both FPR1 
and FPR2 receptors with an approximate EC50 of 1µM (Gavins et al., 2007) while 
Perretti et al., (2002) showed ANXA1Ac2-26 to have an IC50 of ~0.3μM in HEK293 
transfected with FPR2.  In the present study ANXA1Ac2-26 caused a significant 
reduction in the ACTH-stimulated release of CORT from adrenocortical cells, thus 
confirming the finding of Davies et al., (2007), who showed ANXA1Ac2-26 to be 
effective at concentrations >0.3µM (Figure 6.10).  In our experiment the peptide was 
active at a relatively high concentration only (10µM), a difference that may reflect the 
potency of the peptide batch or different experimental conditions (i.e. 1x10
6
 cells/ml 
per well in 96-well plate vs. 50,000 cells/ml per well in 24-well cell culture plates in 
Davies et al., 2007).   
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Figure 6.9:  Effect of ANXA1Ac2-26 on basal 100pM ACTH stimulated release of 
CORT from dispersed adrenal cells.  Effect of ANXA1Ac2-26 (0.003-30 μM) on 
basal and ACTH (100 pM) stimulated CORT release. Open circles=ACTH1-24-
stimulated groups +/-ANXA1Ac2-26; filled circles=basal groups +/-ANXA1Ac2-26. 
Boiled ANXA1Ac2-26 controls are shown: open triangles=ACTH1-24 stimulated groups 
+/-boiled ANXA1Ac2-26; closed triangles=basal groups +/- boiled ANXA1Ac2-26. Each 
value represents the mean ±SEM, n=6 wells. *P<0.05, **P<0.01 vs. ACTH1-24-alone 
control; ##P<0.01 vs. corresponding ACTH1-24 free control, ANOVA plus Duncan‘s 
test (Davies et al., 2007). Typical data are shown from three replicate experiments. 
 
We also showed that fMLP reduced ACTH-stimulated release of CORT at 
concentrations of 1 and 10μM.  Fpr1 exists in two binding forms that have a low (Kd 
24nM) and high (Kd 0.53nM) affinity for fMLP and this receptor is activated by 
concentrations of fMLP in the nM region (Ye et al., 2009).  By contrast, FPR2 has 
only a very low affinity for fMLP [Kd 430nM, (Quehenberger et al., 1993)] and thus 
is effective at this receptor only at high concentrations [>10μM, (Murphy et al., 
1992)].  John et al., (2007) showed in anterior pituitary segments that fMLP blocks 
forskolin-stimulated ACTH release at high (1-100μM), but not low (10 and 100nM) 
concentrations (John et al., 2007).  The lower concentrations used would have been 
expected to elicit a response at Fpr1 only as they activate these receptors to induce 
degranulation of human neutrophils (Schiffman et al., 1975; Marasco et al., 1984). 
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Furthermore, Chiang et al., (2006) suggest that FPR2 does not effectively respond to 
fMLP in vitro or in vivo unless cells are exposed to higher concentrations [>1mM, 
(Chiang et al., 2006)].  Hence, John et al., (2007) concluded on the basis of these and 
other data that Fpr2 is responsible for the blockade of forskolin-stimulated ACTH 
release from the pituitary gland.  By analogy, our finding that ACTH-stimulated 
CORT release from adrenocortical cells was blocked by ANXA1Ac2-26, [supported the 
findings of Davies et al., (2007)], and by high, but not low, concentrations of fMLP, 
indicate these effects may be Fpr2-mediated.   
 
If the decrease in ACTH-stimulated CORT release from adrenocortical cells was 
mediated through Fpr2, it was perplexing that WRW4 failed to inhibit the release of 
CORT.  WRW4 peptide is a potent antagonist of FPR2 with an IC50 of 0.23μM (Bae 
et al., 2004) and a Kd of 0.32nM (Zhou et al., 2007).  Unfortunately, in this study the 
apparent inhibitory effects of ANXA1Ac2-26, on ACTH-stimulated CORT release did 
not reach significance and hence the data are hard to interpret.  However, unlike 
Boc2, WRW4 failed to influence resting CORT release, suggesting Fpr2 does not 
contribute to the regulation of the basal release of CORT. 
 
When Boc2 is used at high concentrations it inhibits FPR2 [100μM, (Gavins et al., 
2003)].  However, in lower concentrations it is considered to be selective for Fpr1 
(Stenfeldt et al., 2007).  We used Boc2 at a concentration of 10μM, which is close to 
the IC50 [0.26μM, (Ye et al., 2009)] which would be expected to be selective for Fpr1.  
Our finding that Boc2 reproducibly reduced ACTH-stimulated CORT release may 
suggest that the response may be a tonic Fpr1-mediated stimulatory effect on 
steroidogenesis and this interesting possibility warrants further investigation. 
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Ligands for Fpr1 include bacterial (formylated peptides), viral (non-formyl peptides) 
or host derived (annexin A1 and other ANXA1 derived peptides) peptides, (Ye et al., 
2009).  Previously it has been shown that whilst both ANXA1Ac2-26 and ANXA1Ac1-50 
inhibited forskolin-evoked ACTH and prolactin release from anterior pituitary 
segments ex vivo, their effects lacked the potency and full efficacy of the parent 
molecule ANXA11-346 (John et al., 2002).  Therefore, the inhibitory effects on ACTH-
stimulated release of CORT seen with ANXA1Ac2-26 and at lower doses by Davies et 
al., (2007) may actually have been greater if we had used the full-length ANXA1.  An 
inhibitory effect of ANXA1 in the adrenal gland similar to that seen in the 
hypothalamus (Loxley et al., 1993) may also be associated to IL-6, as its receptors are 
present in the adrenal cortex (Path et al., 1997) and it has been shown to stimulate 
CORT release (Salas et al., 1990).  However, the effects of Boc2 and fMLP suggest 
that ANXA1 may be mediating an effect on steroidogenesis through an FPR, possibly 
Fpr1 or Fpr2 and additional experiments are required to clarify its role within the 
adrenal gland, perhaps using both Fpr1- and Fpr2-null mice and ligands for these 
receptors. 
 
It is unclear as to which intracellular signalling pathways are affected in response to 
ANXA1 or Boc2 at the receptor level.  In a corticotroph-like cell line (AtT20), the 
release of ACTH through exocytosis was shown to be by enhancement of actin 
polymerisation through the Rho kinase (ROCK) signalling pathway (McArthur et al., 
2009).  There is also other data that suggests ANXA1 is more effective in suppressing 
cAMP mediated exocytotic responses rather than phospholipase C, and the disruption 
of the signalling cascade occurs at a point distal to Ca
2+
 entry which is required for 
vesicle fusion (John et al., 2004).  ACTH-stimulated CORT secretion from the 
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adrenal cortical cells occurs not through exocytosis but by rapid diffusion following 
conversion of cholesterol to pregnenolone, the rate limiting step in steroidogenesis.  
Hence the mechanism by which ANXA1 blocks CORT release may differ from that 
used by the pituitary corticotrophs (McArthur et al., 2009).  ACTH acts through a 
specific GPCR increasing levels of cAMP inducing cholesterol transport into 
mitochondria and steroidogenesis as well the subsequent transcription of genes 
encoding the enzymes required to synthesise CORT through increased activity of 
protein kinase A, which phosphorylates transcriptional regulatory factors (Wang et 
al., 2000).  The short incubation period (2h) used in these experiments suggests that 
ANXA1 may inhibit the synthesis of CORT through the cAMP pathway.  However, 
that vacuolation of the steroidogenic cells in ANXA1- and Fpr2-null mice differed 
from WT may be indicative of an effect of ANXA1/FPRs on cholesterol transport or 
storage.  Further experiments would be required to explore this aspect.  Alternatively, 
the effects on steroidogenesis may be comparable to leptin, which acts through the 
MAPK pathway to downregulate cAMP-induced StAR protein expression and 
progesterone production (Lin et al., 2009).  F2L, considered an agonist for human 
FPR3 and Fpr2  (Gao et al., 2007), triggers intracellular Ca
2+
 release,
 
inhibition 
through Gi of cAMP accumulation, and phosphorylation of ERK1/2 MAPKs (Ye et 
al., 2009).  More recently it has been shown that F2L may modulate multiple 
members of the FPR family (Ye et al., 2009), therefore it would be prudent to assess 
F2L in the functional adrenal cell experiments.  
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GENERAL DISCUSSION 
ANXA1, an anti-inflammatory protein, is an important mediator of the regulatory 
effects of GCs within the neuroendocrine and host defence systems.  Recent data 
suggest that ANXA1 acts as a second messenger in the negative feedback effects of 
GCs in the release of ACTH and that this may be mediated by an FPR, possibly Fpr2 
or Fpr3 (John et al., 2007).  Using in vitro and in vivo techniques we have shown that 
ANXA1 and the FPRs may act at the adrenal level as an interface between the 
immune and endocrine system in mediating the body‘s response to an immune 
stressor (LPS).  We have shown that LPS causes a prompt rise in CORT release, thus 
confirming many previous reports, and that this is coupled with increased expression 
of ANXA1, Fpr1, Fpr2 and Fpr3 in both the pituitary and the adrenal gland.  Our data 
also show that adrenal function is compromised within 4h of low dose of an endotoxin 
with impaired steroidogenesis, due to loss of sensitivity to ACTH and substrate 
depletion, and the potentially cytotoxic actions of infiltrating inflammatory cells.  
These data suggest that the adrenal insufficiency seen in up to 76% of patients with 
sepsis who were unable to respond to exogenous corticotrophin may reflect an 
impaired adrenal reserve (Annane, 2002; Annane et al., 2006) that may be due to a 
direct effect of LPS on the adrenal gland and that ANXA1 and the FPRs may play a 
key role in this immune-endocrine interface. 
 
When endotoxin, LPS, is given intra-peritoneally at low doses to mice, peritoneal 
macrophages release eicosanoids and pro-inflammatory cytokines that stimulate the 
hypothalamus, through the vagal afferent pathway and subsequent stimulation of the 
ventral noradrenergic bundle, to release CRH and subsequently ACTH and CORT 
(Gaykema et al., 1995).  The dose of LPS (500μg/kg) we used was 20-30-fold lower 
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than that used in mouse models of sepsis (O'Malley et al., 1998; Xu et al., 2009a) yet 
sufficient enough to increase pro-inflammatory cytokines and CORT in mice.  In the 
pituitary gland, taken from mice given this low dose of LPS, mRNAs for ANXA1 and 
the FPRs were increased, and at maximal up-regulation (4h after treatment) the 
pituitary gland showed no microscopic changes supporting the data generated by John 
et al., (2007) that ANXA1 and the Fpr‘s play an important role in mediating the 
regulatory effects of glucocorticoids within the neuroendocrine system.  Whilst there 
were no changes in mRNA for these genes within the hippocampus and 
hypothalamus, increased expression of ANXA1 and the Fpr‘s was seen in the adrenal 
gland of LPS-treated mice.  Microscopic evaluation of the adrenal gland after 4h 
showed leukocyte infiltration, predominantly eosinophils with occasional neutrophils 
and monocytes similar to that described in the pleura of mice after intra-thoracic 
injection of LPS where an initial infiltration of neutrophils followed by eosinophils 
and monocytes was described (Bozza et al., 1994).  In addition, LPS reduced the 
vacuolation in the steroidogenic cells and decreased the sensitivity of the cells to 
stimulation with ACTH, suggesting that the initial increase in CORT release may be 
followed by a refractory period in which the capacity of the adrenal to release CORT 
is compromised.    
 
Treatment of mice with an anti-PMN serum prevented the LPS-induced infiltration of 
leukocytes into the adrenal gland without affecting the decrease in vacuolation or the 
rise in circulating CORT caused by the toxin, suggesting that the invading cells do not 
contribute the change steroidogenesis.  They may however account for the LPS-
induced up-regulation of mRNAs for ANXA1, Fpr1 and Fpr3 as treatment with anti-
PMN serum prevented these responses.  By contrast, the toxin-induced rise in Fpr2 
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mRNA was independent of the leukocyte status; similarly the cytokine profile was 
largely unaffected by PMN depletion. 
 
LPS-induced leukocyte infiltration in the adrenal gland in ANXA1- and Fpr2-null 
mice was comparable to that in WT controls suggesting that neither ANXA1 nor Fpr2 
is involved in the recruitment of these cells.  However, the LPS-induced loss of 
vacuolation in the steroidogenic cells evident in WT was prevented by ANXA1- or 
Fpr2-gene deletion, suggesting a role for both genes in the regulation of 
steroidogenesis.  Studies in ANXA1-null mice are in accord with these data (Davies et 
al., 2007) as also is the report that ANXA1Ac2-26 inhibits ACTH-driven CORT release 
in vitro (Davies et al., 2007).  Our ex vivo finding that both ANXA1Ac2-26 and fMLP 
partially inhibit ACTH-stimulated release of CORT from adrenocortical cells accords 
with this view and, as the effective concentrations of fMLP are in the μM range, 
suggest the effect is mediated via Fpr2.  Interestingly, we also found the selective 
Fpr1 antagonist, Boc2, elicits an inhibitory effect on ACTH-driven steroidogenesis at 
low concentrations which led us to suggest an opposing Fpr1-mediated tonic 
stimulatory effect may also operate.  Whilst further investigation at the adrenal level 
is required to tease out the functional effects of ANXA1 and the role of the FPRs in 
effects on steroidogenesis, it is clear that infiltrating leukocytes affect steroidogenesis 
and that this may be mediated through Fpr1 or Fpr2, and that this may depend on the 
immune stressor, which for LPS, appears to be Fpr2.  
  
During an inflammatory response there is the activation of endothelial cells and 
infiltration of leukocytes.  Within the adrenal gland it is likely there will be activation 
of endothelial cells following LPS that may activate PLA2 leading to the release of 
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AA (Bogatcheva et al., 2005), subsequent production of lipoxygenase products (Fiore 
& Serhan, 1990) as well as cytotoxic substances from eosinophils and neutrophils, all 
of which may influence the response of adrenocortical cells to ACTH.  An important 
anti-inflammatory effect of GCs is the inhibition of AA release from phospholipids by 
PLA2 (Vishwanath et al., 1993).  Interestingly, in human umbilical vein endothelial 
cells, ANXA1 was shown to inhibit the release of cPLA2 and thus inhibiting the 
release of AA (Herbert et al., 2007), suggesting that ANXA1 may mediate the 
inhibitory effects of GCs via AA.  During inflammation, activated leukocytes (via 5-
LO interaction) can also produce the anti-inflammatory lipoxins through LTA4, 
normally associated with the production of pro-inflammatory leukotrienes, via platelet 
12-LO or conversion of 15s-hydroxyl-5,8,11-cis—13-trans-eicosatetraenoic acid 
(15S-H(p)ETE) released from epithelial cells to produce LXA4 and LXB4 (Serhan, 
1997).  The multi-cellular responses of LXA4 are mediated through FPR2 which has 
the ability to interact with a wide panel of small peptides/proteins ending in a diverse 
signalling cascade (Chiang et al., 2006).  Based on the plethora of tissues that LXA4 
exerts function on, it is no surprise that we are still discovering roles for the lipoxins 
with their effects, mediated through the FPRs (high affinity for Fpr2), likely to lead to 
diverse cellular signalling as part of a cross-talk between the tissue and the immune 
system (Chiang et al., 2006).  For example in peridontitis, LXA4 reduces PMN 
mediated tissue damage, whilst in the kidney, by reducing leukocyte rolling and 
adherence as well as PMN recruitment (Chiang et al., 2006).  In a series of similar 
experiments investigating the release of CORT using the isolated rat adrenal cell 
system, AA was shown to inhibit the release of CORT (Jones et al., 1987).  Pre-
incubation with Leukotriene A4 (LTA4) and lipoxygenase products 15-
hydroxyeicosatetraenoic acid (HETE) and 5-HETE resulted in significant inhibitions 
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of CORT production in response to ACTH (Jones et al., 1987).  The effect of AA may 
actually have been associated with the metabolism of AA, as adrenal glomerulosa 
cells have been shown to metabolise exogenous AA to HETE (Campbell et al., 1991).  
AA is a polyunsaturated fatty acid that serves as a precursor for prostaglandins, 
prostacyclins, thromboxanes, epoxins, endocannabinoids, leukotrienes and lipoxins 
(Malcher-Lopes & Buzzi, 2009).  The role of AA in steroidogenesis is well 
established in that it is essential for steroid production and StAR protein expression 
(Wang et al., 2000) and it is likely that the inhibition of CORT in this experiment was 
mediated through this pathway as leukotrienes and lipoxins are biologically active 
metabolites derived from AA, which is released from cell membrane phospholipids by 
the action of PLA2 (Brink et al., 2003).  However, the mechanism of action through 
which AA acts on steroidogenic cells has not yet been fully elucidated.   
 
However it is clear that there is a link between ANXA1 and the FPRs at the adrenal-
immune interface and further work is required to investigate the effects of other 
ligands such as LXA4 and F2L on adrenal cells in both WT and Fpr2
-/-
 mice and 
characterise the signalling cascade following inhibition of ACTH-stimulated CORT 
release with these ligands.  This research could advance the understanding of the 
immune-endocrine interface as well as provide new drugs to improve adrenal 
responsiveness that may help in the outcome during late sepsis.   
 
Based on the data captured in this thesis, in conjunction with published data, it is 
likely that during an inflammatory response, such as infection, activation of the innate 
immune system, increase in leukocytes, endothelial activation and pro-inflammatory 
mediators lead to the release of anti-inflammatory mediators, that inhibit the release 
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of CORT in the adrenal gland, so as to inhibit the release of GCs during 
inflammation.  With a better understanding of the ligands for the FPRs, development 
of more appropriate antibodies and utilising the phenotype of transgenic colonies for 
both FPR2 and ANXA1, it is hoped that further research can build on the data 
presented in this thesis to characterise their role within the adrenal gland.  These data 
can also translate to the clinical setting and serve to assist the research and 
development of novel drugs for immune-mediated disease by elucidating the role of 
GCs in the resolution of inflammation. 
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CONCLUSIONS 
Annexin A1 (ANXA1), an anti-inflammatory protein, is an important mediator of the 
regulatory effects of glucocorticoids (GCs) within the neuroendocrine and host 
defence systems.  Recent data suggests its actions are mediated via formyl peptide 
receptors (FPRs).  In the present study, in vitro and in vivo methods have been used to 
investigate the role of ANXA1 and the FPRs within the HPA axis in response to an 
immune stressor.   
 
Our evaluation of gene expression and histology for the pituitary gland continue to 
support a role for ANXA1 and the FPRs in mediating the inhibitory effects of GCs 
within the pituitary gland, suggesting that LPS has a pleiotropic effect on the role of 
FPRs in both endocrine and non-endocrine cells that should be further investigated.  
 
The precise roles of ANXA1, Fpr1 and Fpr2 within the spleen remain to be defined, 
as they may be associated with the effects of GCs on the lymphocyte population in 
response to LPS.  The finding that expression of Fpr3 was unaffected by LPS requires 
further investigation, but it is likely that Fpr3 has no role within the spleen. 
 
The results presented in this thesis have shown that ANXA1 and the FPRs play an 
important role within the adrenal gland in mediating the release of GCs in response to 
an immune stressor and adrenal function is compromised following a low dose of an 
endotoxin with impaired steroidogenesis.  The precise role of ANXA1 and the FPRs 
in the adrenal gland remains to be defined, but it would appear that ANXA1 and Fpr2 
do not mediate leukocyte infiltration but more likely the regulation of steroidogenesis 
in response to an endotoxin.  This is further supported by the effects of the peptide 
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ANXA1Ac2-26 and fMLP in partially inhibiting ACTH-stimulated release of CORT 
from adrenocortical cells at concentrations suggestive that the effect is mediated via 
Fpr2.  Whilst the increase in mRNA for Fpr1 following an endotoxin was dependent 
of invading leukocytes, the selective Fpr1 antagonist, Boc2, showed an inhibitory 
effect on ACTH-driven steroidogenesis at low concentrations which led us to suggest 
there may be an opposing Fpr1-mediated tonic stimulatory effect.   
 
These data raise the possibility that adrenal function may be compromised in 
endotoxaemia both through impaired steroidogenesis, due to substrate depletion, and 
the cytotoxic actions of infiltrating inflammatory cells.  The roles of ANXA1 and 
Fpr2 in modulating steroidogenesis require further investigation, along with the 
unexplored roles of Fpr1 and Fpr3 in the adrenal cortex.  
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SUMMARY 
1. Using two different techniques to detect gene expression (ISH and qRT-PCR), 
mRNA for V1b was detected in the hippocampus from untreated WT mice. 
Peripheral administration (i.p.) of LPS to stimulate the HPA axis showed up-
regulation of mRNA for V1b in the hippocampus 2h after treatment and was 
comparable to saline-treated controls >4h.  Central administration (i.c.v.) of 
LPS causes neuroinflammation followed by HPA-activation and this led to a 
down-regulation of mRNA for V1b in the hippocampus.  No changes in 
mRNA for V1b were seen in the anterior pituitary gland.  The opposing 
changes in hippocampal V1b receptor expression following peripheral and 
central administration of LPS suggest that this V1b receptor population may 
be particularly plastic in conditions of stress.   
 
2.  Using ISH, mRNA for Fpr1 or Fpr3 was not detected in the brain (all major 
regions) from untreated WT mice.  Very low levels of mRNA for Fpr2 were 
detected in the hippocampus, dentate gyrus and cerebellum from untreated 
WT mice, also detectable in hippocampus using qRT-PCR.  No mRNA for 
Fpr1, Fpr2 or Fpr3 was detected in the hypothalamus with ISH.  
 
3. Using qRT-PCR to assess mRNA for Fpr1, Fpr2, Fpr3 and ANXA1 in the 
hippocampus, HPA axis and spleen the rank order of mRNA expression in 
untreated WT mice are: 
  Fpr1: spleen>hypothalamus>hippocampus>adrenal>pituitary 
 Fpr2: spleen>hypothalamus>adrenal>hippocampus> pituitary 
  Fpr3: spleen>hypothalamus>hippocampus>adrenal>pituitary 
  ANXA1: spleen>adrenal>hypothalamus>hippocampus>pituitary 
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4. Peripheral administration (i.p.) of LPS to stimulate the HPA axis in WT mice 
caused a significant increase in serum CORT concentrations between 2h and 
4h, being maximal at 4h when compared to corresponding saline treated 
controls.  
 
5. When LPS (i.p.) was given to WT mice, there were increases in plasma 
concentrations of TNFα (2h), IL-1α (2h), IL-1β (2h) and IL-6 (2h) when 
assessed using ELISA and compared to corresponding saline treated controls.  
Additional investigations using the Luminex xMAP platform showed 
increases in IL-10 and RANTES at 2h compared to time-matched saline 
controls.  No changes in IL-4, IFNγ, IL-17, VEGF or eotaxin were evident at 
this time-point. 
 
6. Peripheral administration (i.p.) of LPS to WT mice led to an up-regulation of 
mRNA for Fpr1, Fpr2 and Fpr3 in the pituitary (2-4h) and adrenal (2-8h) 
glands. By 24h mRNA for all FPRs were comparable to corresponding saline 
treated controls after 24h.  Up-regulation of mRNA for Fpr1 and Fpr2 were 
also seen in the spleen after 4h only vs. time-matched saline controls.  In the 
hypothalamus a small but significant increase in Fpr1 mRNA was apparent 8h 
after LPS injection when compared to time-matched saline-treated control 
 
7. LPS (i.p.) also caused an up-regulation of mRNA for ANXA1 in WT mice in 
the pituitary (2h) and adrenal glands (2-4h), comparable in both tissues 
thereafter.  
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8.  WT mice were given LPS (i.c.v.), which causes both neuroinflammation and 
HPA-activation, and evaluated for gene expression (qRT-PCR) over a 24h 
period.  Up-regulation of mRNA for Fpr1 was seen in the hypothalamus (8h), 
pituitary (4-8h) and adrenal (2-8h) glands.  Up-regulation of mRNA for Fpr2 
and Fpr3 was seen in the pituitary (4-8h) and adrenal (2-8h) glands.  No 
significant changes in Fpr2 and Fpr3 gene expression were evident in the 
hippocampus or hypothalamus of the LPS-treated animals.  ANXA1 mRNA 
expression in the hippocampus, hypothalamus and adrenal gland was not 
affected by central LPS treatment.  However, ANXA1 mRNA in the pituitary 
gland was increased (2 and 8h) after LPS treatment, when compared to time-
matched saline treated controls. 
 
9. Peripheral administration (i.p.) of LPS to WT mice causes microscopic 
changes in the spleen (increased incidence of lymphoid cell apoptosis and 
extramedullary haematopoiesis), thymus (lymphoid necrosis and cortical 
hypertrophy) and adrenal glands (inflammatory cell infiltration and decreased 
cortical vacuolation), 4h after treatment when compared with saline-treated 
controls.  No microscopic changes were detected in the pituitary gland or brain 
4h after treatment with LPS. 
 
10. Microscopic evaluation of the adrenals glands with a modified H&E stain 
from WT mice given LPS (i.p.) further characterised the inflammatory 
changes in the adrenal glands. The severity was considered slight to moderate, 
described as mixed inflammatory cell infiltration within the cortex and 
medulla, predominantly eosinophils with occasional monocytes and 
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neutrophils.  The primary inflammatory cell was considered to be the 
eosinophil.  
 
11. The adrenal glands were removed for primary tissue culture experiments from 
WT mice given saline or LPS, 4h after treatment. Cells from saline-treated 
WT mice responded to ACTH with concentrated-related increases in CORT 
release. Significant effects (vs. untreated controls) were observed at 
concentrations of 0.001µM, 0.01µM, 0.1µM, 1µM and 10µM.  However, 
adrenal cells from LPS-treated WT mice failed to respond to ACTH with an 
increase in CORT release at any concentration of the peptide tested.     
 
12.  Microscopic evaluation of Fpr2
-/-
 and ANXA1
-/-
 mice showed changes in the 
spleen, thymus and adrenal glands 4h after LPS-treatment that were 
comparable to their WT counterparts.  One exception was the adrenal cortex, 
as both Fpr2
-/-
 and ANXA1
-/-
 mice appeared to have normal cortical 
vacuolation when compared to LPS-treated WT controls.  Again, no 
microscopic changes detected in the pituitary gland or in the brain, 4h after 
treatment with LPS. 
 
13. No microscopic changes were detected in the pituitary gland or in the brain of 
Fpr2
+/+
 or Fpr2
-/-
 mice 4h after treatment with LPS.  Similarly, while ACTH, 
PRL, TSH, LH and FSH were readily all detectable by immunostaining in the 
pars distalis of both Fpr2
+/+
 and Fpr2
-/-
 mice, with the exception of TSH, there 
were no obvious differences between Fpr2
+/+
 or Fpr2
-/-
 saline treated animals, 
or between Fpr2
-/-
 saline or Fpr2
-/-
 LPS-treated mice.  In LPS-treated Fpr2
-/-
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mice, the TSH signal appeared stronger than that in the saline-treated Fpr2
-/-
 
mice or Fpr2
+/+
 mice treated with either saline or LPS. 
 
14. The Fpr2
-/-
 mice contain a GFP in-frame insertion within the promoter region 
to enable the visualisation of GFP expression in place of Fpr2 expression. 
However, it was not possible to visualise GFP in frozen sections of brain, 
spleen, thymus, pituitary and adrenal glands from both control and treated (4h 
after LPS) Fpr2
-/-
 mice.  Continued evaluation of the adrenal glands is on-
going and preliminary detection of GFP in the adrenal cortex using a different 
fixation (formalin) and primary antibody is evident (Naughton et al., personal 
communication).   
 
15.  When WT mice were given rabbit polyclonal antibodies against murine PMNs 
over two days (i.p.) there was a depletion (Day 3) of circulating PMNs by 
approximately 80% when compared to pre-treatment (Day 1).    
 
16. In PMN-depleted mice given LPS (i.p.) increases in CORT concentrations 
were apparent when compared to PMN-depleted mice given saline.  There 
were no differences between IgG-matched control WT mice given LPS and 
PMN-depleted mice.  
 
17.  In both normal (IgG-matched) and PMN-depleted WT mice, there were 
increases in the plasma cytokines after 4h, compared to saline treated controls 
(evaluated using Luminex xMap platform).  Plasma concentrations were 
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increased for TNFα, IL-6, IL-10 and RANTES in all LPS-treated groups.  No 
changes in IL-4, IL-17 or eotaxin were observed. 
 
18.  In PMN-depleted WT mice only, IL-1β plasma concentrations were increased 
compared to saline-treated controls.  A greater increase in IL-10 was seen in 
PMN-depleted mice not controls given LPS.  Concentrations of IFNγ were 
increased in IgG-matched LPS-treated controls, unlike their PMN-depleted 
counterparts. 
 
19. LPS (500µg/kg; 2.5ml/kg, i.p.) induced microscopic changes in the spleen of 
WT mice pre-treated with the anti-mouse PMN serum or the IgG matched 
control serum.  In the spleen, PMN depletion exaggerated the change induced 
by LPS.  Thus, in the white pulp there was an increased incidence of lymphoid 
cell apoptosis (consisting of pyknotic nuclei with apoptotic bodies) with anti-
mouse PMN-serum mice whereas fewer mice treated with the control serum 
showed this pathology.  LPS triggered lymphocyte apoptosis in the red-pulp 
only of mice treated with the anti-mouse PMN serum but not in animals 
treated with the control serum while LPS induced extramedullary 
haematopoiesis was identified in all animals treated LPS.   
 
20. Inflammatory cell infiltration was completely absent or minimal in the adrenal 
glands from PMN-depleted mice compared to IgG-matched controls 4h after 
treatment with LPS.  In addition, there was a decrease in cortical vacuolation,  
in all LPS-treated animals.   
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21.  In PMN depleted mice given LPS, up-regulation of mRNA for Fpr2 in the 
adrenal gland was seen, whereas in control mice, up-regulation of mRNA for 
Fpr1, Fpr2 and Fpr3 were observed, and comparable to data generated 
previously with WT mice.  In PMN-depleted mice, an up-regulation of mRNA 
for Fpr2 was seen in the spleen only, with no changes in Fpr1.  Fpr3 was 
unaffected in the spleen as before. 
 
22. In primary tissue culture experiments, Incubation of dispersed adrenal cells 
(1x10
6
 cells/ml) with ACTH1-24 (Sigma 0-100nM, 2h) caused concentration-
related increases in CORT with maximal responses occurring at 
concentrations >1nM ACTH. 
 
23. When the peptide ANXA1Ac2-26 (3, 10 and 30µM) was co-administered with 
ACTH1-24 (1nM) to adrenal cells for 2h, there were decreases in the release of 
CORT at concentrations of 10 and 30µM. 
 
24. fMLP (0.1, 1, 10 and 100µM) was co-administered with ACTH1-24 (1nM) to 
adrenal cells and inhibited the stimulated CORT release at 1 and 10µM, but 
not at 0.1 or 100µM.    
 
25. Boc2 (0, 3, and 10µM) was co-administered with ACTH1-24 (1nM) to adrenal 
cells and inhibited the stimulated CORT release at 10µM. 
 
26. For WRW4, the concentration of ANXA1Ac2-26 at 10µM did not elicit a 
statistically significant reduction in CORT in this experiment. 
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